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Breast cancer (BC) is the most common cancer among women and leading contributor 
to cancer mortality, hence constitutes a major public health issue worldwide. In 
Scotland, over 4,000 women are diagnosed with BC every year and around a 1,000 die 
from this disease. Monitoring incidence, mortality and survival trends is key for 
surveillance of disease progression. BC is heterogeneous, with multiple subtypes 
defined by molecular markers, such as the oestrogen receptor (ER), that have different 
aetiology, targeted treatments and prognosis, yet standard reporting of incidence and 
mortality rates is not usually done using tumour marker data. The Scottish Cancer 
Registry was the first registry in the UK to collect molecular marker data and therefore, 
constitutes an excellent opportunity to explore incidence and survival trends over time 
by molecular subtypes. This PhD aims to describe temporal trends in BC incidence 
and survival by molecular subtypes in Scotland to inform public health prevention 
programmes, diagnostic and therapeutic services. 
Methods:  
A systematic review was conducted to determine the extent of available data on BC 
incidence trends by ER in population-based studies of women of European ancestry. 
In addition, the Scottish Cancer registry data on over 72,000 women diagnosed with 
incident primary BC from 1997 to 2016 (the focus of most analyses for this 
dissertation) was used to describe trends in incidence and survival in Scotland. Age-
standardised incidence rates (ASiR) and age-specific incidence were estimated by BC 
subtype after imputation of molecular marker data. Joinpoint regression and age-
period-cohort (APC) models were used to assess whether significant differences were 
observed in incidence trends by ER, the human epidermal growth factor receptor 2 
(HER2) and the immunohistochemistry (IHC) defined molecular subtypes. Kaplan-
Meier (KM) estimates and traditional and extended Cox proportional hazards models 
were computed to assess breast cancer specific survival (BCSS) by BC subtypes. 
Sensitivity analysis was carried out to compare results for the Cox models from 
complete case analysis (CCA) and multiple imputation analysis (MIA). The effect of 
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individual, tumour characteristics and treatments on BCSS for each subtype was also 
investigated. Trends in 5-year survival by age, grade and stage characteristics for the 
different subtypes (ER+ and ER-) were investigated to identify the characteristics of 
women showing greatest and lowest improvements over time. Other causes of death 
were also explored and cumulative incidence functions (CIF) were investigated. 
Results:  
The systematic review showed that ER+ BC incidence increased and ER- BC 
incidence decreased in the last four decades (EAPCs ranging from 0.8% to 3% for ER+ 
tumours and -2.1% to -3.4% for ER- tumours) and that the rise in overall incidence 
trends is mainly driven by increases of ER+ tumours in women of screening age. In 
Scotland, BC incidence rates showed the same divergent pattern between ER+ and 
ER- tumours observed in other countries. ER+ tumour incidence increased by 0.4% 
per year from 1997 to 2011 and increases were mainly among routinely screened 
women aged 50 to 69 years. In contrast, ER- tumour incidence decreased among all 
ages by -2.5% per year over the study period. Apart from the period effects observed, 
APC models showed that older cohorts of women born in 1912-1940 had lower 
incidence rate ratios (IRR) for ER+ tumours, and younger cohort of women born in 
1960-1986 had lower IRR for ER- tumours, compared to women from the 1941-1959 
birth cohorts. Results for the IHC defined subtypes showed that luminal A tumours, 
that account for more than half of all tumours, had similar patterns to those observed 
for ER+ tumours, with increases until 2011. In contrast, luminal B tumours declined 
over time, particularly in women over 50 years of age. There was no clear trend for 
HER2-enriched or triple negative breast cancers (TNBC) overall but TNBC tumours 
seemed to increase in younger women aged 20 to 49 years. 
BCSS also differed between subtypes with ER+ tumours having better survival than 
ER- tumours, luminal A tumours having the best survival of all IHC defined subtypes 
and TNBC having the worst survival. Age, grade, stage, screening and surgery were 
the most important prognostic factors irrespective of tumour subtype, with women who 
had older age, higher grade, stages III-IV, tumours not screen detected and who did 
not have surgery having worse survival. Deprivation was also associated with lower 
BCSS, with women living in the most deprived areas of Scotland having increased 
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BC-specific mortality when compared to women in the least deprived areas and this 
relationship was observed for all subtypes with slightly higher HR for HER2-enriched 
subtypes (but wider CI). Five-year BCSS trends showed improvements in the last two 
decades, especially for women aged 50 to 69 years. The greatest gains in survival were 
seeing in women with advanced tumours (high grade or stage III-IV tumours) and ER- 
tumours seemed to have greatest improvements than ER+ tumours, although their 
survival remained lower than for ER+ tumours. The improvements observed for 
women with high grade and stage III-IV tumours were observed in both screen and not 
screen detected tumours but the rise was sharper amongst women with screen detected 
tumours. Women younger than 50 years showed similar improvements than those 
observed in women aged 50 to 69 years. Older women aged 70 years or more showed 
no consistent survival improvements over time and over 50% of women in that age 
had a primary cause of death other than BC with cardiovascular diseases (CVD) being 
a major contributor (22% of all deaths). 
Conclusions:  
This project is the first in the UK to describe incidence and survival trends by 
molecular subtypes of BC using population-based data. Divergent incidence trends 
found in Scotland are similar to those observed in other countries and confirm different 
aetiology of BC molecular subtypes. Increases in the incidence of hormone sensitive 
tumours are likely to be driven by the implementation of mammographic screening 
programmes, population aging and changes in risk factors (RFs) that have differential 
effects on the subtypes, such as, reproductive factors and obesity. Survival 
improvements in Scotland are likely due to multiple contributors with two major 
factors such as screening and the improvement and development of new treatments 
likely playing a role. This PhD has allowed us to further understand disease 
progression of the different subtypes in Scotland and has identified groups of women 
(those with advanced tumour characteristics, living in the most deprived regions of 
Scotland or women aged 70 years or older) with lower survival and/or lower 
improvements in survival trends that could benefit from further prevention and 
treatment programmes. This PhD also highlights the importance of monitoring future 
























Lay summary  
 
BC is the most common cancer in women worldwide and a major cause of mortality. 
In Scotland, almost 4,000 new BC cases are diagnosed every year and around 1,000 
women die from this disease. BC is not a single disease but rather multiple diseases, 
with BC subtypes defined depending on the presence of tumour markers. Oestrogen 
and progesterone receptors (ER and PR) and other substances such as the human 
epidermal growth factor 2 (HER2) are such tumour markers that have been the target 
of different therapies. The Scottish Cancer Registry has been collecting data on ER 
status since 1997 and on PR and HER2 from 2009. However, national official statistics 
do not report the number of new cases or deaths by these markers but overall. This 
PhD aims to describe trends of new cases and survival by BC subtypes in Scotland for 
the last two decades. Monitoring these trends can improve our understanding of the 
different subtypes and identify groups of women that might benefit from more 
treatment options or programmes aimed to reduce the individual risk of having BC.  
Previous research from other countries have shown that tumours that are ER+ have 
been increasing in recent decades, especially amongst women of screening age, while 
ER- tumours are declining. In Scotland, we observed similar trends likely due to 
multiple factors. For example, the adoption of a national screening programme for 
women aged 50 to 69 years may have contributed to the increases observed in ER+ 
tumours as these tumours are more likely to be diagnosed through screening than ER- 
tumours.  
Survival after a BC diagnosis also differed by subtype and women with ER+ tumours 
had better survival than those diagnosed with ER- tumours. Age, tumour grade, tumour 
stage, method of detection and surgery were the most important factors in survival 
regardless of tumour subtype. Women aged 70 years or more, women with higher 
grade tumours, stages III-IV tumours and non-screen detected tumours and who did 
not have surgery had worse survival. Deprivation was also an important factor for 
survival in all subtypes with women in the most deprived areas having worse survival 
than women living in the least deprived areas of Scotland. BC survival improved over 
time, especially for women younger than 70 years with more advanced diseases (high 
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grade tumours and stage III-IV tumours) and the improvements were greatest amongst 
women with ER- tumours, which is a very positive outcome as those subtypes have 
less treatment options available. The improvements observed for advanced tumours 
were greater amongst screen detected tumours which might indicate the positive effect 
of screening on survival. Older women aged 70 years or more showed no consistent 
improvements in survival over time and over 50% of them died from causes other than 
BC, with CVDs being the most common cause.  
This project is the first in the UK to describe trends at the population level in new BC 
cases and survival by molecular subtypes of BC. The trends found in Scotland 
highlight that BCs are different diseases and that those women having worst outcomes 
(older age, living in most deprived areas or with more advanced tumours) will further 
benefit from new treatments personalised to their disease or from prevention 
programmes. This PhD also highlights the importance of future monitoring of number 
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During this thesis I aim to investigate BC incidence and survival trends by molecular 
subtypes defined using routinely collected immunohistochemistry (IHC) molecular 
marker data in Scotland to identify subgroups of women with increasing incidence 
and/or worse outcomes to inform clinical planning and cancer control programmes.  
Chapter 1 of this thesis gives an overview of BC epidemiology and how the use of 
molecular subtypes has evolved over time and informed BC treatments. In Chapter 2, 
contemporary incidence trends of BC in European ancestry populations are described 
by oestrogen receptor (ER), the first targeted receptor discovered for BC. Results from 
the systematic review show divergent trends by ER status in most countries with 
available data and provides an important context to compare and contrast with the data 
from Scotland. Further, if differences between countries are observed, it provides 
potential hypotheses on which factors might cause incidence or survival differences.  
In Chapter 3, BC incidence trends in Scotland by ER and by IHC defined molecular 
subtypes are presented. Joinpoint regression analysis, which gives an overall estimate 
of the direction of the trend and defines probable time points at which there is a change 
in trend and APC models, used to determine whether the observed trends are due to 
age, period or cohort effects, were performed. This chapter presents, for the first time 
in the UK, population-based BC incidence by molecular subtypes and highlights the 
importance of using individual and molecular tumour markers to assess incidence 
trends for cancer surveillance.  
Chapter 4 presents survival analysis by different molecular subtypes of BC and shows 
clear differences in prognosis and the importance of other characteristics such as age, 
grade and stage in survival. This chapter also presents survival trends by method of 
detection, for which data is not collected in most cancer registries, and by deprivation 
which is an important risk factor for worse prognosis in Scotland. Survival trends for 
combinations of the most important prognostic factors are presented along with trends 
for treatment use within the Scottish population of women diagnosed with BC.  
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Chapter 5 provides a general discussion of the PhD summarizing the key findings and 
its contribution to the literature, strengths and limitations of the PhD and future 




Chapter 1 Background 
1.1 Natural history of breast cancer 
1.1.1 Anatomy of the breast 
The human breast consists of a combination of stromal and epithelial elements (Figure 
1.1). The stroma is responsible for the structure of the breast, surrounds the mammary 
gland and provides important growth factor signalling for breast development [1]. It is 
composed of adipose and connective tissue, blood and lymphatic vessels. The 
epithelial elements and functional units of the breast are the terminal duct lobular units 
(TDLU). TDLUs are also the predominant source of breast cancers. TDLUs are 
composed of a terminal duct and its lobules [2]. The lobules or milk glands are 
responsible for the production of milk. The ducts are also called milk conduits and 
their main purpose is to carry the milk from the lobules to the nipple for discharge [3]. 
The ducts are small conduits that grow following a tree branching pattern during 
puberty and end in oval shaped glands called lobes [4]. The human breast has 12 to 20 
lobes and each lobe is composed of lobules.  
Figure 1.1 Anatomy of the female breast 
 
Figure taken from American Cancer Society webpage: What is breast cancer? [5] 
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The breast undergoes various developmental stages over the course of a woman’s life. 
At birth, men and women’s breasts are similar consisting of a primitive mammary 
gland, but with puberty the breast of a woman starts to differentiate and the primitive 
terminals grow into secondary branches due to the influence of ovarian hormones. At 
this stage, the fatty tissue and areola also grow leading to an increase in size of the 
breast. In an adult woman, breast changes occur with every menstrual cycle. The 
ovarian hormones (oestrogen and progesterone) stimulate the growth of the TDLUs 
and the breast changes in texture and size in preparation for pregnancy. If pregnancy 
takes place, the TDLUs continue to grow and more lobules are formed to allow for 
lactation. On the contrary, if there is no pregnancy, the breast will recover its size and 
the process will start again with the next cycle. After pregnancy, once the woman stops 
breastfeeding, apoptosis of the epithelial cells cause regression  of the TDLUs to its 
pre-pregnancy state in a process called involution [6]. During menopause, circulating 
hormone levels decrease dramatically producing changes in the breasts. The drop of 
oestrogen leads to loss of elasticity of the connective tissue that shrinks and loses its 
shape.  
The breast also contains ligaments, nerves, lymph vessels, lymph nodes and blood 
vessels. Lymph nodes are collections of immune cells that play a major role in the 
spread of the disease to other parts of the body. Lymph nodes are connected by lymph 
vessels throughout the body forming a network called the lymphatic system. 
Cancerous cells from the breast infiltrate the lymph vessels and travel to the nearest 
lymph nodes where they start to grow [3]. When lymph nodes around the breast 
contain tumour cells, it is more likely that the disease may affect other parts of the 
body. Patients diagnosed with BC undergo a sentinel lymph node biopsy to test if the 
closest lymph node to the tumour contains cancerous cells.  
1.1.2 Precursor lesions 
Most BCs originate in the epithelial cells of the breast, specifically in the TDLUs [7], 
and are classified as carcinomas. Rarely (<1%) they can have their origin in the bone 
tissue near the breast (sarcomas). Carcinomas are divided in two major subtypes based 
on its histology. The first of those subtypes are the in situ or non-invasive carcinomas.  
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In situ or non-invasive BCs are pre-invasive lesions similar to the invasive BCs and 
they account for approximately 15-25% of all cases diagnosed [8, 9]. In non-invasive 
breast tumours the malignant cells are confined and do not invade the stroma. They 
are classified as ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). 
This distinction does not depend on the tissue of origin, as most carcinomas in the 
breast arise from the TDLU [7], but on the difference in structure, function and 
chemical composition of the cells [10]. DCIS is the most common type of non-invasive 
precursor lesion of invasive BC and presence of DCIS is associated with a 2 to 8-fold 
increased risk of invasive BC [11, 12], especially within the 5 to 10 years after 
diagnosis [13]. In contrast to DCIS, whether LCIS is a precursor lesion is inconclusive: 
LCIS carries a smaller risk of recurrence and is usually considered a marker of risk of 
invasive BC and not a precursor lesion [14]. However, LCIS has been associated with 
risk of bilateral involvement and a population-based study by Li et al. on 4490 LCIS 
patients suggested that it might be a precursor lesion of invasive lobular cancer [12]  
Precursor lesions are considered to increase the risk of progression to invasive BC. 
Apart from DCIS, benign breast diseases (BBD) are also considered precursor lesions. 
Atypical ductal hyperplasia (ADH) is the most important of BBD as it is associated 
with a 4- fold increase in risk of invasive BC [15]. In the natural history of BC, TDLUs 
can transform into premalignant lesions (ADH and DCIS) and invasive BC (Figure 
1.2). 
 
Figure adapted from [16] 
 
Terminal duct 
lobular unit (TDLU) 
Atypical ductal 
hyperplasia (ADH) 








1.1.3 Invasive breast cancer 
BC originates in the breast tissue when cells in this region start to grow abnormally 
forming a tumour. The abnormal growth of the cells is consequence of mutations and 
other molecular abnormalities responsible for cell growth. Healthy cells undergo a 
process of cell regeneration in which they replace themselves with new cells. In cancer 
cells, the process of cell division and growth is altered from normal process of cell 
division (homeostasis), and cancerous cells keep dividing without control forming a 
tumour. The tumour is considered a cancer or malignant when the abnormal breast 
cells start to invade other surrounding tissues in the gland and when it reaches even 
more distant areas of the body is called metastasis.  
Precursor lesions (ADH and DCIS) may infiltrate the surrounding stroma of the breast 
and become malignant tumours (Figure 1.2), termed invasive BC. Invasive BC is a 
heterogeneous group of tumours of which the most common is the “invasive carcinoma 
of no special type” (NST) that accounts for 75 to 80% of all invasive carcinomas [4]. 
NST tumours were previously known as invasive ductal carcinomas [6]. The second 
most common invasive carcinoma is the invasive lobular carcinoma that accounts for 
5 to 15% of all the cases and is considered a “special type” because of its distinct 
morphology and clinical behaviour. Other “special types” are mucinous carcinoma, 
adenoid cystic carcinoma, medullary carcinoma, tubular carcinoma, papillary 
carcinoma and metaplastic carcinomas [4]. These ‘special types’ tumours usually have 
a good prognosis.  
 
1.2 Epidemiology of breast cancer 
1.2.1 Incidence rates of BC 
BC is the most common cancer diagnosed in women (Figure 1.3) in 156 countries 
(75%) [17]. In 2017, 1.9 million women were estimated to have been diagnosed with 
BC (24% of all cancer cases) [18]. BC incidence has increased considerably in recent 
decades worldwide. The implementation and improvement of enhanced screening 
regimens in high-income countries (HIC) and changes in risk factors (RF) experienced 
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in recent decades likely contributed to the increased incidence. Since cancer is a 
disease associated with advanced age, with increased longevity, incidence rates are 
expected to continue increasing. By 2030 it is estimated that incidence rates of cancer 
will increase by 68% worldwide and BC incidence by 2% annually in HIC [19].  
 
Figure 1.3 Most common cancer per country in women of all ages, estimated age-
standardised incidence rate (World) in 2018 
 
 
BC incidence rates differ considerably between countries, with Western and Northern 
European countries, North America and Australia/New Zealand having the highest 
incidence rates in the world [age-standardised incidence rate (ASiR) =113 women per 
100,000 in Belgium (1st ranked country), ASiR =109 in Luxembourg (2nd ), ASiR =95 
in Australia (7th ), ASiR =94 in the UK (8th) and ASiR =85 in the USA (22nd)] and 
Shout-East Asia (ASiR =27) and Africa (ASiR =35) having the lowest incidence [17, 
18].  
The higher incidence of BC in HIC is associated with the introduction of screening 
programmes and with increased prevalence of BC RFs, such as, obesity and changes 
in reproductive factors [4]. However, in the last two decades, the increase in BC 
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incidence in some HICs has started to decrease or has remained stable due to plateaus 
in screening [20] and incidence increases have been larger in low-and-middle-income 
countries (LMIC) with approximately a 5% rise each year [10]. For example, rural 
areas of China have seen their ASiR increase by 8% each year [21] and BC in urban 
areas of India has overtaken cervical cancer as the most common cancer in women 
[22]. Cancer registry data from Uganda and Algeria, report doubling of incidence rates 
in the last 20 years, and BC is becoming more prevalent in Africa [23]. It is estimated 
that, in the next decade, 19.7 million BC cases will be diagnosed worldwide, of which 
10.6 million (54%) will be in LMICs [17, 24].  
All these examples support that demographic changes (including improved longevity, 
prevention and diagnostic tools and survival from infectious diseases) and the adoption 
of lifestyle factors associated with BC, such as delayed childbearing, obesity and 
increased smoking and alcohol consumption may contribute to the increases in LMICs 
[25]. Hence, BC is a major global public health problem that needs new strategies for 
prevention to combat the increasing risk in incidence and improved access to targeted 
treatments to improve survival [26]. 
1.2.2 Mortality rates of BC  
BC mortality rates have been decreasing since the 1990s particularly in HICs (Figure 
1.4) due to improved surveillance, the introduction of screening programmes and the 
development of targeted treatments [27]. However, BC mortality is still the leading 
cause of mortality amongst women in 104 (50%) countries worldwide and over 
600,000 women were thought to have died from the disease in 2017 [18]. Further, BC 















1.3 Risk factors associated with breast cancer 
BC is associated with multiple RFs [28, 29]. While BC can affect men and women, it 
is very rare for men (only <1% of all BCs in the UK [30]. Hence, below I summarise 
the established RFs for female BC identified by reviewing breast cancer reports 
convened from expert panels from the World Cancer Research Fund (WCRF), the 
International Agency for Research on Cancer (IARC) and the American Association 
for Cancer Research (AACR). 
1.3.1 Age 
The risk of BC rises with increasing age. Evaluation of age-specific incidence rates 
show a log linear relationship until the age of menopause (approximately 50 years) 
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when incidence rates slow down. In 1983, Pike et al. suggested that the relationship 
between BC incidence and age was closely related to the rate of breast tissue aging, 
which was not chronological but biological –related to the breast tissue changes in 
response to different hormone exposures during the lifecourse of a woman including 
reproductive factors (e.g. menarche, parity and menopause) during the reproductive 
life of a woman. Hence, these data supported a relationship to hormone exposures [31]. 
Pike et al also suggested that the role of hormones in the breast tissue was an important 
factor in the development of BC, which has been supported with further evidence 
evaluating circulating hormones [32].  
1.3.2 Height 
Higher adult height has been associated with an increased risk of BC in many 
systematic reviews and meta-analysis of epidemiological studies [33-36] with most 
reviews reporting a linear dose-response relationship. A recent study reporting results 
from a meta-analysis of 26 prospective studies found that for every 10 cm increase in 
height, the risk of breast cancer increased by 17% (95% CI from 15% to 19%) for all 
the combination of all studies [37]. This study also conducted a mendelian 
randomisation (MR) analysis in two consortiums aimed to determine the causal 
relationship between height and breast cancer risk using an instrument with 168 height 
associated variants. They found an OR of BC of 1.22 (95% CI = 1.13 to 1.32) in the 
first consortium and 1.21 (95% CI = 1.05 to 1.39) in the second consortium per 10 cm 
increase in genetically predicted height. 
1.3.3 Breast density 
Breast density measures the macroscopic composition of the breast tissue, which can 
be visualised radiographically and assessed routinely through mammographic 
screening. Women with dense breasts have a greater ratio of fibroglandular tissue 
(stromal and epithelial) to fatty tissue. Breast cancers arise predominantly from 
epithelial cells, but a challenge to breast cancer early detection has been noted 
especially for women with dense breast tissue. This is because cancerous tissue and 
dense tissue both appear as a solid white area, it makes reading of the mammograms 
more difficult which can lead to a delayed diagnosis of BC especially for younger 
women where density is higher. However, breast density is not only associated with 
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delayed diagnosis but also with an increased risk of BC [38]. A systematic review and 
meta-analysis with over 14,000 cases and over 200,000 controls from 42 studies found 
that women with a percentage density of 5% to 24%, 25% to 49%, 50% to 74%, and 
≥75% had a pooled RR of 1.8 (95% CI: 1.5 to 2.2), 2.1 (1.7 to 2.6), 2.9 (2.5 to 3.4), 
and 4.6 (3.6 to 5.9) respectively compared to women with a breast density of less than 
5% [39]. Therefore, breast density has been established as one of the strongest risk 
factors of BC and research is now focusing on whether breast density should be 
considered for screening stratification via a risk prediction model.  
1.3.4 Family history and genetic factors 
A meta-analysis of 74 studies, found that family history of BC is associated with a 2-
fold increased risk of the disease [RR = 1.9 (95% CI, 1.7 to 2.0)], and this risk is higher 
if BC occurs in a first-degree relative compared to a second-degree relative [40]. It is 
estimated that 5 to 10% of BC cases have a strong genetic predisposition with 4-5% 
caused by high penetrance genes [41]. Historically, high risk variants in BRCA1 and 
BRCA2 were the most studied, and a meta-analysis of the penetrance of mutations 
carriers for BC estimated that a woman at 70 years of age with a mutation in BRCA1 
has a cumulative risk of BC of 57% (95% CI, 47% to 66%), and for mutations in 
BRCA2, of 49% (95% CI, 40% to 57%) [42]. Other moderate penetrance genes, 
including TP53, CHD1, NF1, PALB2, ATM, CHECK2, PTEN and NBN that 
contribute to the heritability of BC have also been identified [43].  
In more recent years, genome-wide association studies (GWAS) have identified a 
substantial number of single-nucleotide polymorphisms (SNPs) associated with BC 
risk, which along with other known variants explain about 41% of the familial relative 
risk [44], hence much of the genetic contribution to breast cancer risk still remains 
unknown.  
In 2017, utilising data from 68 individual studies included in the Breast Cancer 
Association Consortium (BCAC) and the Discovery, Biology and Risk of Inherited 
Variants in Breast Cancer Consortium (DRIVE), Michailidou et al. published a GWAS 
study in which they identified 65 new loci associated with BC risk, more 
predominantly with ER+ subtype [44]. This study constituted a major development for 
BC susceptibility as the new identified loci accounted for 44% of the known genetic 
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susceptibility from all SNPs identified to that date. More recently, Milne et al. 
identified a further 10 variants and replicated the associations observed in previous 
studies for ER- tumours confirming 125 variants associated with ER- BC risk, which 
account for 16% of the familial relative risk for this subtype [45]. The number of loci 
identified is likely to increase in the following years, as new insights into the genetic 
susceptibility of BC would be useful to implement risks scores for personalised 
screening and prevention.  
1.3.5 Reproductive factors 
1.3.5.1 Age at menarche and age at menopause 
Early age at menarche and late age at menopause have been associated with an 
increased risk of BC. A meta-analysis of 117 epidemiological studies in over 100,000 
women diagnosed with BC showed that women with younger age at menarche had 
their risk of BC increased by 1.05 (95% CI=1.04 to 1.06) for every year younger [46]. 
This study also found that a delay in menopause was also associated with an increased 
BC risk, with a pooled estimate of 1.029 (95% CI; 1.025 to 1.032) for every year older 
at menopause. They also reported that menopausal status had a differential effect in 
risk, with premenopausal women having an increased risk of 1.4 (95% CI: 1.3 to 1.5) 
at age 45-54 years compared to postmenopausal women of the same age. Both RFs 
have been related to a longer exposure to hormones (especially oestrogen) and to a 
higher number of menstrual cycles during a woman’s life.  
1.3.5.2 Age at first birth and number of live births 
Older age at first live birth has been associated with an increased risk of BC. Data from 
several studies (including a meta-analysis of 8 studies from Nordic countries) showed 
an increased risk for women aged 35 years or older at the time of their first birth 
compared to women aged 20 years or younger [28, 47]. This relationship may have to 
do with the changes that occur in the breast tissue during pregnancy, time at which the 
breast reaches its full maturity. Colditz et al. created a multiple birth model based on 
Pike’s model [31] that shows that pregnancy has a dual effect on the risk of BC- the 
first live birth has an adverse effect when it occurs but it decreases the risk later in life, 
as it is associated with a decline of tissue aging [48]. Further, tissue aging decreases 
with each consecutive live birth and the shorter the time between births the lower the 
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rate of tissue aging and risk of BC. Therefore, the number of births, the age at each 
birth and the time between births also have an effect on risk. The model by Colditz et 
al showed that nulliparous women have an increased risk of BC compared to women 
that have multiple children at a younger age. In contrast, having one birth at the age of 
35 years or older carries a higher risk of developing BC in the future than not having 
children [48]. 
1.3.5.3 Breastfeeding 
Breastfeeding is a protective factor for BC. A recent study from the Collaborative 
Group on Hormonal Factors in Breast Cancer using data from 47 epidemiological 
studies in 30 countries, reported a 4.3% (95% CI: 2.9 to 5.8) decrease in the relative 
risk (RR) of BC for every 12 months of breastfeeding for women that breastfed 
compared to women who never breastfed [49]. 
1.3.6 Oral contraceptives 
Oral contraceptives (OC) have been used for decades and their use has been associated 
with a small increased risk of BC. Data from 54 studies, showed that women using OC 
had a small increased risk of BC at the time of use and up to 10 years after cessation 
compared to non-users (RR ranging from 1.24 (95% CI: 1.15 to 1.33) for current users 
to 1.07 (95% CI: 1.02 to 1.13) for 5-9 years after cessation) [50]. A more recent 
population-based study in Denmark found an increased RR of 1.2 (95% CI: 1.14 to 
1.26) among current users compared to non-users and this increase was higher with a 
prolonged use of OC (ranging from 1.09 (95% CI: 0.96 to 1.23) for less than a year of 
use to 1.38 (95% CI: 1.26 to 1.51) for more than 10 years of use) [51]. However, the 
association between BC risk and OC depends on the concentration of hormones used. 
A population-based case-control study by Althuis et al. found a higher RR of BC for 
users taking OC with high concentrations of oestradiol [RR=2.0 (95% CI: 1.2 to 3.2)] 
than users taking OC with a low dose [RR=1.3 (95% CI: 0.9 to 1.7)] compared to non-
users [52]. A report from the Nurses’ Health Study II in over 110,000 nurses showed 
that current OC users risk of BC was as high as 3.1 times (95% CI: 2.0 to 4.7) that in 
non-users if they were in the estradiol and levonorgestrel combination [53]. 
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1.3.7 Postmenopausal hormones 
Postmenopausal hormone therapy use, also known as hormone replacement therapy or 
menopausal hormone therapy (MHT) was introduced in the UK in 1965 and has been 
associated with an increased risk of BC. The Women’s Health Initiative (WHI) study 
was a randomised controlled trial (RCT) in the US that aimed to determine the 
relationship between MHT use and risk of multiple diseases. The results from the WHI 
study were published in 2002 concluding that MHT, especially oestrogen plus 
progestin use, increased the risk of heart disease and BC [54]. In the UK, the Million 
Women study confirmed the results from the WHI study when they found that current 
MHT users had a higher risk of BC than never users (RR=1.7, 95% CI: 1.6 to 1.8) 
[55]. The increase differed depending on the hormone combination, with women in 
the oestrogen-progestogen group having a higher increase in incidence than women in 
the oestrogen only group. The publication of these studies had an impact on MHT use 
that started to decrease shortly after and, as a consequence, incidence of BC declined 
in most Western countries [56-62]. The Collaborative Group on Hormonal Factors in 
Breast Cancer reviewed all the evidence from prospective cohort and randomised 
studies on the type and timing of MHT use. This study confirmed the results from WHI 
and the Million Women study and estimated that a causal relationship would result in 
1 in 50 women using daily oestrogen-progestogen preparations from the age of 50 and 
for 5 years would develop BC and 1 in 70 for those using oestrogen and intermittent 
progestogen and 1 in 200 for those using oestrogen only [63].  
1.3.8 Obesity, BMI and diet 
Epidemiological studies have established that obesity is a RF for BC, however, this 
relationship seems to differ according to menopausal status. Results from the Million 
Women study showed that a 10 units increase in body mass index (BMI) was 
associated with an increased RR of 1.40 (95%CI: 1.31 to 1.49) for BC, but only among 
postmenopausal women [64]. A more recent meta-analysis of 31 studies found a 
weaker but statistically significant association (RR=1.12, 95% CI: 1.08 to 1.16) 
between a 5 kg/m2 increase in BMI and postmenopausal BC but an inverse association 
with premenopausal BC (RR=0.92, 95% CI: 0.88 to 0.97) [65, 66]. Apart from BMI, 
other measures of obesity, such as central obesity and weight gain during adulthood 
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have also been associated with BC risk. For example, a cohort study and a case-control 
study in the US reported that weight gain after the age of 18 years was associated with 
increased BC incidence after menopause [67, 68]. A more recent study using data from 
the Nurses’s Health Study, found increased risk of BC after menopause amongst 
women with long-term increased weight after the age of 18 years both pre and post 
menopause, but there was no association with premenopausal BC [69]. 
The role of diet in BC risk has also been investigated but evidence is less conclusive 
than for BMI and other obesity measures. A recent review of 32 studies found that the 
Western dietary pattern was associated with an increased risk (RR=1.20, 95% CI: 1.06 
to 1.35) of BC in postmenopausal women but not in premenopausal women. In 
contrast, premenopausal women with healthy dietary patterns had a decreased risk of 
BC (RR=0.77, 95% CI: 0.61 to 0.98) [70]. Individual dietary items have also been 
identified: dietary fibre, fruit, vegetables and whole grains [71-73] are associated with 
a decreased risk of BC whereas processed meats are associated with an increased risk 
[74]. However, associations of BC and diet are still limited and more evidence is 
needed, especially as diet is one of the only modifiable RFs associated with BC and 
hence, could be a target for prevention.  
1.3.9 Physical activity 
The positive effect of physical activity in reducing the risk of BC and helping women 
diagnosed with BC to recover quickly has been widely established. A continuous 
project from the WCRF with data from 126 observational cohort studies in over 22,000 
premenopausal and over 100,000 postmenopausal women diagnosed with BC, recently 
reported that vigorous physical activity was inversely associated with pre and 
postmenopausal BC risk [RR=0.79 (95% CI: 0.69 to 0.71) for premenopausal and 
RR=0.90 (95% CI: 0.85 to 0.95) for postmenopausal women] [75]. This systematic 
review and meta-analysis also found that increasing sitting time in postmenopausal 
women was associate with a 20% (95% CI: 0 to 44%) higher BC risk and that walking 
did not showed a positive effect for either premenopausal or postmenopausal women 
in terms of reduced risk of BC.  
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1.3.10 Alcohol and smoking 
A causal relationship between alcohol consumption and BC has been established [76]. 
A recent meta-analysis of 22 prospective cohort studies found a dose-response 
relationship between total alcohol consumption and wine consumption and BC risk, 
with an increase of 10g per day of total alcohol or wine associated with increases in 
BC risk by 11% (95% CI: 8% to 13%) and 9% (95% CI: 4% to 14%) respectively [77]. 
This association has been established in both pre and postmenopausal women and data 
from two cohort studies conducted in nurses in the US supports an association between 
alcohol consumption in early life (teenager and young adult years) and risk of BC later 
in life [78, 79].  
Alcohol consumption and smoking are highly correlated factors and determining the 
causal relationship of smoking and BC risk has been difficult due to the effects of time 
of exposure, the role of alcohol as a confounder or effect modifier and the possible 
effect of menopausal status [80]. A study with pooled data from 14 cohort studies in 
36,000 invasive BCs found that smoking was associated with BC risk, particularly if 
it was initiated before a first full-term pregnancy and regardless of alcohol intake [81].  
1.3.11 Socioeconomic status 
BC has been labelled as a “welfare disease” since incidence increases with higher 
socioeconomic status (SES), especially education [82]. A recent meta-analysis of 25 
European studies found a 25% (95% CI: 17% to 32%) increase in incidence of BC in 
women with higher SES [83]. However, this association was no longer significant after 
adjustment for other RFs, supporting the idea that women in different socioeconomic 
classes may have distinct reproductive and lifestyle factors and a different uptake of 
screening programmes that influence their risk of BC. Apart from education, other 
socioeconomic measures, such as, individual measures of occupation, education or 
income, or area-based indices of deprivation have also been investigated in relation to 
BC incidence. For example, using an area-based measure of deprivation, the Scottish 
Index of Multiple Deprivation (SIMD), Brown et al found higher incidence rates in 
women in the least deprived areas of Scotland compared to women in the most 
deprived and they postulated that reproductive factors, especially age at first birth, may 
be responsible for the higher incidence seen in affluent women [84]. In contrast to the 
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increased risk of BC in women with high SES, BC mortality rates are higher amongst 
women with low SES, known as the BC paradox which has been hypothesised to be 
related to screening uptake. A recent review of 13 studies from 7 European countries 
reported that women in most deprived areas were less likely to attend BC screening 
than women in the least deprived areas [85].  
1.4 Breast cancer subtypes 
BC is heterogeneous, with different subtypes that can be considered as biologically 
different diseases. While there are many different ways to try to classify homogenous 
subtypes of BC, for the purposes of this dissertation, I will primarily focus on the key 
endocrine hormone receptor for oestrogen and progesterone, and on the human 
epidermal growth factor receptor 2 (HER2).  
1.4.1 Oestrogen receptor and progesterone receptor 
Ovarian hormones, particularly oestrogen and progesterone have been historically 
associated with BC. In 1895, Beatson performed the first oophorectomy in a woman 
with BC and discovered that the tumour completely remitted when the ovaries of the 
woman were removed [86]. The procedure stopped the production of oestrogen in the 
ovaries and led to the idea that BC was associated with the circulation of hormones, 
especially oestrogens.  
Oestrogens are hormones produced in the ovaries involved in the regulation of the 
reproductive system of women. They are present in the breast and can enter the cells 
and bind to the oestrogen receptor (ER). This binding activates cell proliferation and 
growth. Therefore, when the binding takes place in a BC cell, it can lead to the 
formation of a tumour. Breast tumours that express oestrogen are called oestrogen 
receptor positive (ER+) and they account for three out of every four invasive tumours, 
and those that don’t express oestrogen are called oestrogen receptor negative (ER-). 
Another important hormone associated with BC is progesterone. Progesterone receptor 
(PR) status is highly correlated with ER status. PR synthesis is regulated by oestrogen 
and therefore, the presence of PR indicates the presence of ER in breast tumours [87]. 
For that reason, measuring both gives a better indication of whether patients may 
respond to hormone therapy (HT). The majority of ER+ tumours are also PR+ and 
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survival is higher when the tumour expresses both hormone receptors than when the 
tumour expresses only one or neither receptor [87, 88]. 
ER and PR status are usually investigated when a woman is diagnosed with BC, as 
they are important markers for treatment decision and prognosis. In the early 70s, the 
US and some European countries started measuring ER and PR status using 
immunohistochemistry (IHC).  
1.4.2 Human epidermal growth factor receptor 2  
In the 1990s, with advances in molecular technologies, HER2 was discovered and it 
was observed that women with tumours that overexpress HER2 had worse overall and 
relapse-free survival than women who did not overexpress this marker [6, 89, 90]. 
HER2 positivity prevalence ranges from 12-30% [91-93] depending on the 
characteristics of the population and since its discovery, targeted treatments have been 
developed, such as, Trastuzumab significantly improving survival for both early stage 
and metastatic patients [94-96]. 
1.4.3 Molecular subtypes of breast cancer 
Perou et al.[97] published in 2000 the seminal paper that defined the intrinsic 
molecular subtypes of BC that classified tumours in four subtypes based on their gene 
expression patterns, ER+/luminal-like, basal-like, HER2+ and normal breast. This 
study also showed for the first time that ER- tumours, as defined clinically, comprise 
at least two biologically different subtypes: basal-like and HER2+ tumours. Since the 
development of the molecular subtype classification, BC subtypes have been used for 
treatment guidance, especially for adjuvant therapy, and for risk stratification of 
patients [98]. However, genetic expression profiling is a costly technique and hence, 
not available for most tumours diagnosed in clinical practice. For that reason, in recent 
years research efforts have been focused in the use of IHC clinically available markers 
(ER, PR, HER2 and the tumour proliferation marker Ki-67) as surrogates for the 
intrinsic subtypes of BC. In 2011, the St. Gallen International Expert Consensus [99] 
highlighted the need of a simplified classification of BC subtypes based on 
clinicopathological markers that could be adopted in clinical practice to aid treatment 
management of patients. Based on Cheang et al. [100] classification they proposed the 
following surrogate definitions (Table 1.1).  
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Table 1.1 Surrogate definitions of intrinsic subtypes of breast cancer using IHC 



















Luminal B Luminal B-like 
(HER2-) 





 Luminal B-like 
(HER2+) 
ER and/or PR 
positive 





ER and PR 
negative 
Positive Any 41-69% 
Basal-like Triple 
Negative 
ER and PR 
negative 
Negative Any 80% 
ER=oestrogen receptor, PR= progesterone receptor, HER2= human epidermal growth factor 2, Ki-67=marker of 
proliferation Ki-67, IHC= immunohistochemistry. Table modified from St.Gallen Consensus 2011 [99] *Column 
from [101] 
 
In 2013, the panel voted to change the Ki-67 threshold to >=20% indicating “high” 
proliferation. Based on the study by Prat et al. [102] the panel also suggested that PR 
had the ability to distinguish between luminal A and luminal B-like tumours, and that 
a PR threshold of >=20% could be used to differentiate luminal A-like of luminal B-
like (HER2-) tumours [103]. In the proposed classification Ki-67 had an important role 
in distinguishing between luminal A- like and luminal B-like tumours, but as this 
marker is not routinely collected, they suggested that other measures of proliferation 
such as grade could be used instead [99, 104]. One year later, a study in over 9,000 
women by Maissonneuve et al. [105] proposed an updated definition of the intrinsic 
molecular subtypes based on an intermediate cut-off for Ki-67 and the use of PR as a 
prognostic factor only for tumours with intermediate Ki-67. This classification 
maximises the number of tumours classified as luminal A-like for which chemotherapy 
can be omitted. This study also found that women with high grade luminal A-like 
tumours had similar prognosis than women with luminal B-like tumours, suggesting 
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that grade might be a useful factor to differentiate between luminal A- like and luminal 
B-like tumours. A study by Ehinger et al. [106] investigating the role of grade in the 
subtype classification showed that patients with ER+/HER2- low grade tumours had 
similar prognosis to luminal A-like tumours whereas prognosis in patients with 
ER+/HER2- high grade tumours was more similar to that in patients with luminal -B 
like tumours. Further, the study by Lundgren et al. [107] looking at the agreement 
between the intrinsic molecular subtypes and their surrogate classification showed that 
using grade to further identify luminal A and luminal B- like tumours improved 
agreement to 80% in comparison with the original St.Gallen classification or that 
proposed for Maissonneuve et al. with agreement rates of 62 and 66% respectively. 
The agreement between the molecular subtypes and its surrogates using IHC markers 
have been seen to differ depending on the subtype (last column, Table 1.1). TNBC 
have been shown to be a good surrogate for basal-like tumours with 80% of all basal-
like tumours found to be TNBC [101, 108]. However, tumours classified as HER2-
enriched by IHC markers show a lower agreement rate with the corresponding 
molecular subtype with only 41 to 69% estimated to match [109, 110]. 
 
1.4.4 Risk factors differences by molecular subtypes 
The RFs noted above (section 1.3), have been more consistently associated with 
ER+/luminal tumours than with ER-/HER2-enriched or TNBC, for which fewer RFs 
have been identified. ER+ tumours have been associated with reproductive factors (age 
at menarche, age at menopause, age at first birth, number of births and breastfeeding) 
and MHT use [111-114]. In contrast, ER- tumours have been more consistently 
associated with genetic RFs. For example, BRCA1 mutation carrier status is 
significantly associated with risk of ER- tumours compared to ER+ tumours [115]. 
Data support aetiologic heterogeneity by molecular subtypes with differential patterns 
for some RFs. 
This section 1.4.4 highlights some of the RFs associated with ER+/luminal and ER-
/HER2-enriched or TNBC. A more detailed summary of the established RFs can be 
found in a recent edition of cancer epidemiology and prevention, 4th edition [6] and 
Table 1.2 from [116]. 
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Luminal A Luminal B HER2-
overexpressing 
Triple Negative 
Younger age at 
menarche 
+ + + unk + + + 
Greater parity − − − unk unk + + 
Older age at first birth + + unk unk unk 
Breastfeeding − − − − unk − − − 
Older age at menopause + + unk unk + 
Greater BMI 
(premenopausal) 
− unk unk + 
Greater BMI 
(postmenopausal) 
unk unk unk unk 
Family history + + + + + + + + + + 
Alcohol use + unk + unk 
Use of oral 
contraceptives 
− unk unk + 
MHT use + + unk unk unk 
+++ Consistent evidence of a positive association, ++ probable positive association, + possible positive association. 
Minuses indicate similar consistency of negative associations. ER=oestrogen receptor, HER2= human epidermal 
growth factor 2, BMI= body mass index MHT=menopausal hormone therapy, unk=unknown. Table from [116] 
 
 
1.4.5 Breast cancer treatment by subtype 
Apart from tumour characteristics, such as size, grade and stage, hormone receptor 
status and HER2 status are essential for determining treatment plans, as the different 
subtypes of BC respond differently to the available treatments. Most primary breast 
tumours are treated with surgery, chemotherapy and radiotherapy. However, BC 
treatment usually involves multiple treatment methods and women may also receive 
therapy according to their hormone receptor status and/or HER2 status. 
ER+ breast tumours are usually treated with anti-oestrogen therapy, also known as 
endocrine therapy or hormone therapy (HT). Anti-oestrogen therapies for the treatment 
and prevention of BC have been used for decades, and have considerably improved 
prognosis and reduced the likelihood of recurrence [117].  
Table 1.3 presents a summary of the most important treatments developed to target ER 




Table 1.3 Therapies targeted to ER and HER2 receptors most commonly used for pre 
and/or postmenopausal women and date of approval 
Treatment Targeted 
receptor 





































Trastuzumab (Herceptin) HER2 Both (pre and post) 1998 
ER=oestrogen receptor, HER2= human epidermal growth factor 2, SERM= selective oestrogen receptor modulator 
 
Tamoxifen, a selective ER modulator (SERM), was the first anti-oestrogen therapy. 
Developed in 1977, tamoxifen acts by blocking the binding of oestrogen to the ER of 
the BC cells and therefore, preventing growth and proliferation of ER+ breast tumours 
[118]. Tamoxifen was first approved for the treatment of advanced BC but has been 
since used as adjuvant therapy for the treatment of primary BC. Treatment with 
tamoxifen is sometimes combined with chemotherapy, especially in women with 
higher risk of recurrence, as combined treatment is more effective than tamoxifen 
alone [119]. This treatment usually lasts for many years since the benefit is greater in 
women treated for 5 years compared to women treated for 1 or 2 years. A RCT from 
the early breast cancer trialists’ collaborative group found a reduction in recurrence 
and mortality of 47% (SD 3) and 26% (SD 4) respectively for women treated for 5 
years, almost double the reduction found for women treated for 1 or 2 years [117]. 
However, the long periods of tamoxifen use in women with BC may lead to the 
development of drug resistance. Further, tamoxifen has been found to be associated 
with an increased risk of endometrial cancer in postmenopausal women and 
thromboembolism [120]. In contrast, tamoxifen use for the treatment of BC in 
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premenopausal women is not associated with adverse risk. Although the benefits of 
this drug in postmenopausal women are considered to outweigh its harms, other 
hormone therapies with lower side effects have been developed over time. For 
example, raloxifene, another SERM produced to treat osteoporosis, has been seen to 
reduce the risk of BC by 50% (95% CI: 29% to 85%) and, in contrast to tamoxifen, it 
may be associated with a decreased risk of endometrial cancer [121]. Fulvestrant, an 
ER antagonist to treat metastatic postmenopausal women with ER+ breast tumours, 
was also developed in the early 2000s. Compare to tamoxifen, fulvestrant decreases 
PR expression while maintaining the same levels of efficacy and tolerance as 
tamoxifen [122].  
In the last 20 years, aromatase inhibitors (AI) are increasingly being used to treat BC. 
AI indirectly target the ER by inactivating the aromatase enzyme responsible for the 
conversion of androgen to oestrogen and, therefore, decreasing the levels of circulating 
oestrogen. Formestane was the first AI tested in clinical trials in women who had 
relapsed after being treated with tamoxifen or other available treatments. AI are as 
effective as tamoxifen and the third generation (anastrozole, letrozole and exemestane) 
have been found to be better than tamoxifen as first line treatment for advanced 
cancers. A trial comparing letrozole and tamoxifen found that letrozole was associated 
with longer time to disease progression, longer time to treatment failure and better 
overall response rate than tamoxifen in postmenopausal women with advance disease 
[123]. Several studies have also reported the efficacy of AI for treatment of early BC 
in postmenopausal women with ER+/PR+ cancers. The Arimidex, Tamoxifen, Alone 
or in Combination (ATAC) trial reported that adjuvant treatment with anastrozole was 
better than treatment with tamoxifen or combined treatments for hormone receptor 
positive women, and that anastrozole treatment had a longer effect in tumour reduction 
than tamoxifen [124]. Another trial reported that treatment with exemestane after two 
to three years of tamoxifen use, reduced the risk of disease compared to five years of 
treatment with tamoxifen [125].  
In addition, AI are well tolerated, with fewer side effects than tamoxifen. Results from 
the ATAC trial suggests that women treated with anastrozole had lower incidence of 
vaginal bleeding and discharge, thromboembolism, hot flashes and endometrial cancer 
but higher incidence of fractures and musculoskeletal disorders than women treated 
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with tamoxifen [124]. For all these reasons, AI are now challenging the use of 
tamoxifen as the current adjuvant endocrine therapy standard for ER+ breast tumours. 
However, AI are not indicated for premenopausal women. Further, women with ER-
negative or PR-negative tumours are unresponsive to both AI and tamoxifen.  
HER2 status has also been an important indicator for treatment in the last years. 
Approximately 12-30% of breast tumours overexpress HER2 [91-93], these tumours 
are generally more aggressive and sometimes they cannot be treated with 
chemotherapy [90]. For that reason, anti-HER2 therapy specifically targeted to these 
tumours has been an important treatment development in the last years. Trastuzumab 
(Herceptin), the first anti-HER2 drug, was approved in 1998 and launched in 2006 in 
the UK. Trastuzumab is the primary anti-HER2 therapy that improves overall survival 
(OS) in women with early and advanced disease that overexpresses HER2.  
HT is used for ER+ tumours, however, only 5% of ER- tumours respond to anti-
oestrogen therapy [126] explaining why they are not usually treated with this kind of 
therapy. ER-negative tumours have limited treatment options, usually surgery and 
chemotherapy. Research is now focused on developing new treatments for advanced 
BCs and the more aggressive subtypes and using genetic molecular profiling to 
develop personalised therapies [127].  
1.5 Breast cancer screening 
Early detection of BC allows earlier treatment and therefore, it is associated with a 
decreased risk of mortality regardless of lead time bias. In a recent meta-analysis of 11 
RCTs, participants in the screening programme showed a 20% (95% CI: 11% to 27%) 
reduction in mortality compared to those in the control group [128]. Mammography is 
the most widely used method for early detection of BC and most countries have 
implemented mammographic screening programs. In Scotland, a national 
mammographic screening programme was established in 1988 and women aged 50 to 
70 years old are invited to have a routine screen every three years. Women over 70 
years of age are able to make appointments for continued screening. 
Although mammographic screening and early detection programs for BC have 
substantial benefits, they are also associated with some harms. A recent independent 
review by Marmot et al investigated the potential benefits and harms of BC screening 
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[129]. Marmot et al. reported that the main harm of BC screening was overdiagnosis, 
which consists of the detection of a tumour that would not have been detected 
otherwise during a woman’s lifetime. Based on three RCTs, the review estimated that 
the frequency of overdiagnosis was 19% (95% CI: 15% to 23%) for a woman invited 
to screening during the period of the screening programme. Evidence from 
observational studies estimated overdiagnosis ranging from 0 to 37% [129]. The main 
consequences of overdiagnosis are that women become patients; they may receive 
unnecessary treatment, suffer from physical and psychological distress and have 
poorer quality of life due to the diagnosis. Further, women may have a false-positive 
mammogram result. A systematic review by Bond et al. [130] found that women with 
a false-positive result may have psychological distress for a long period of time (up to 
three years after the mammogram). Besides, a false-positive result may also have a 
negative effect in the likelihood of a woman returning for screening in the next round 
[130]. 
BC screening has an effect on incidence and therefore it should be considered when 
looking at incidence rates of BC. A UK study looking at the effect of mammographic 
screening on BC incidence reported a long-term increase in incidence of BC for 
women who attended screening compared to women who did not attend [131]. In the 
US, screening mammography has also been associated with a 2-fold increased 
incidence of early-stage breast tumours but not with the incidence of advanced tumours 
that decreased by 8% [132].  
A reduction of advanced BC incidence in screened populations compared to non-
screened populations is an indicator of the effectiveness of a mammographic screening 
programme. Autier et al, reported that, in general, trends in advanced BC incidence in 
areas with sustained mammographic screening (7 to 15 years of screening) did not 
change over time [133]. New evidence suggests that the decrease in mortality in 
countries with BC screening programmes, is mostly due to an improvement in patient 
treatments and not to mammographic screening [134]. Autier et al concluded that new 
methods for BC screening should be implemented in order to decrease mortality and 
minimise the harms of mammographic screening [134].  
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1.6 Justification for this PhD project and aims 
BC incidence has been shown to differ by ER status in limited studies in the last three 
decades. ER represents an important target for responsiveness to anti-oestrogen 
therapy and aetiologic differences by RFs. Few countries collect data on ER status and 
other molecular markers routinely. In Scotland, ER data were collected on BCs from 
1997-present, representing the longest duration of data collection in the UK, since 
Wales does not hold any data on ER, Northern Ireland holds data from around 2008, 
and England holds data from about 2009. For that reason, the Cancer Registry data 
from Scotland provides a unique resource for the analysis of longer-term temporal 
trends of BC by ER status and molecular subtypes in the UK. Only one article has 
looked at the incidence of BC by ER status in Scotland from 1997 to 2007 and 
therefore, current trends by ER and the molecular subtypes of BC are unknown.  
The literature review will describe the temporal trends of BC incidence by ER status 
observed in countries with European ancestry populations and will help identify the 
gaps in the literature and provide comparison data for the trends in Scotland. Further, 
the analysis of the temporal trends in Scotland will help us understand if there are 
differences in incidence and survival by molecular subtypes and investigate the 
underlying RFs associated with the observed trends. It may also shed some light about 
the specific characteristics of the women who are at greater risk of developing 
aggressive tumours and have worse prognosis therefore, more likely to benefit from 
prevention, screening or treatment interventions.  
ER and HER2 status in BC is essential for treatment decisions and therefore, knowing 
the evolution over time of the different BC subtypes and predicting future incidence 
patterns will help to allocate resources for treatment and prevention programmes, as 
well as inform policy.  
Therefore, the overall aims for this project are: 
 To systematically identify population-based studies in incidence trends by ER 
status that can be used as a comparison for the trends observed in Scotland 
 To describe temporal incidence and survival trends of BC by molecular 
subtypes in Scotland 
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 To identify subgroups of women with increased incidence risk and worse 






Chapter 2 Literature Review 
2.1 Background 
This chapter relates to the first aim of the PhD: to perform a systematic search of the 
literature on trends of incidence of BC by ER status in Europe, US, Canada, Australia 
and New Zealand. 
In order to know how many high-income countries were collecting ER data in their 
cancer registries, I contacted the cancer registries (national or regional) in 47 countries: 
43 countries with European ancestry majority populations in the WHO European 
region, Canada, the US, Australia and New Zealand. The full list of countries can be 
found Appendix A.1.  
Of the 47 cancer registries contacted only registries from 16 countries (34%) collected 
ER status data (Figure 2.1). Six countries (Bulgaria, Denmark, Ireland, Iceland, New 
Zealand and Norway) were collecting ER status in their national cancer registries and 
ten countries (Australia, Canada, France, Germany, Italy, Spain, Sweden, Switzerland, 
the UK and the US) in some of their regional registries. Twenty-one countries (45%) 
were not collecting ER data and 10 countries (21%) did not answer my query. 
 
Figure 2.1 Cancer registries in high-income countries collecting ER status 
 
Figure created with mapchart.net  
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Apart from the limited information about ER status in the cancer registries of HIC, to 
my knowledge this is the first systematic review on incidence of BC by ER status. For 
those reasons, the objective of this systematic review is to describe temporal trends of 
BC incidence by ER status in HIC and to determine if data support the hypothesis that 
incidence trends by ER status have changed over time.  
2.2 Methods  
2.2.1 Search strategy 
An electronic literature review search on MEDLINE, EMBASE and Web of Science 
core collection was conducted, using a combination of MeSH and keywords for ‘breast 
cancer’, ‘incidence’ and ‘oestrogen receptor’. The search strategy was devised with 
advice from librarians at the University of Edinburgh and is available in Appendix 
A.2. The search was restricted to English articles in humans published up to January 
2018. In addition to the online search, cancer registries for all the WHO European area 
countries with European ancestry majority populations (43 countries), the US, Canada, 
Australia and New Zealand were contacted, when possible, to request information on 
ER status and published articles looking at BC incidence by ER status. The publication 
sections and library resources from individual cancer registries webpages, IARC and 
major cancer association webpages were also searched for publicly available reports. 
The bibliographies of the selected articles were reviewed and relevant studies included 
in the final selection. 
2.2.2 Inclusion criteria 
Studies were selected if they reported incidence of invasive female BC stratified by 
ER status. Additionally, study data had to come from population-based or cancer 
registries of countries with a majority of European ancestry populations. Reviews, 
editorial comments with no additional data reported, conference or meeting abstracts, 
or studies with duplicate populations were excluded. Studies reporting only incidence 
rates in men or reporting incidence rates for a subgroup (other than ER status) or by 
age at diagnosis instead of year of diagnosis were also excluded. Additional inclusion 
criteria are reported in Appendix A.3. 
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2.2.3 Screening, selection and data extraction 
Record screening was based on title and/or abstract review. A second pass screening 
was performed on abstracts and/or full texts where eligibility was uncertain. During 
the data extraction phase, information on country, data source, study start and end year, 
number of cases, number (%) of cases with ER status, women’s age, categories of BC 
subtypes reported in the study, year at which collection of ER, PR and HER2 status 
started and information on screening was extracted (Table 2.1). The outcomes for each 
study were also extracted and are presented in Figure 2.3 and Table 2.2 (overall 
incidence rates) and Table 2.3 (age-specific incidence rates). Results were summarised 
using narrative synthesis.  
2.3 Results 
The initial search identified 5413 articles, 1976 from Medline, 1795 from Embase, 
1609 from Web of Science, 31 from individual cancer registries and IARC webpages 
and two from bibliographic references of the selected articles. After 1572 duplicate 
articles were excluded, 3841 articles remained for title and/or abstract screening. 
During the screening phase, 3648 articles were excluded because they were not 
relevant. Therefore, a total of 193 articles were retrieved for full-text assessment. Of 
these, 179 were excluded as they did not fulfil the inclusion criteria (Figure 2.2) and 
14 articles were selected [135-148]. These 14 studies presented data from eight 
countries: Denmark (n=2), France (n=1), Germany (n=1), Ireland (n=1), Norway 
(n=1), Scotland (n=1), Sweden (n=1) and the US (n=6). The studies were published 
between 2007 and 2017 and reported incidence trends from 1980 to 2013. Study 
sample sizes ranged from more than half million women for the US articles using 
Surveillance, Epidemiology and End Results (SEER) data to 3,792 cases for the French 
study from Fontenoy et al [139]. The percentage of total BC cases that had available 
ER status ranged from 71% to 94% and there was variability between years in some 
studies. Nine studies reported incident BC cases in women of all ages and five studies 
looked only at women aged 50 years or older. There was also variability in the 
hormonal status reported by studies: 11 studies reported incidence by ER status, five 
reported incidence by joint ER/PR status and one reported incidence by ER/HER2 
combination. Seven countries had a national or regional screening programme 
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implemented (Appendix A.4), with women aged 50 years or older screened every two 
to three years. In the US, no national or regional screening programme has been 
implemented but women aged 40 to more than 75 years may still be screened every 
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database searching  
Medline (n= 1,976) 
Embase (n= 1,795) 




























Additional records identified 
through other sources:  
 
Cancer registries/IARC (n= 31) 
Bibliographic references (n= 2) 
Records screened  
(n= 3,841) 
Records excluded  
(n= 3,648) 
Articles excluded (n= 179) for 
the following reasons:  
Do not report BC incidence 
stratified by ER (n= 90) 
Comments/letters with no 
additional data (n= 22) 
Duplicate data (n= 14) 
Conference abstract (n= 13) 
Not primary BC or subgroup 
(n= 10) 
Reviews (n= 9) 
Do not report trends by year 
of diagnosis (n= 7) 
Studies are not population-
based (n= 7) 
Do not report incidence (n= 6) 
Full-text not available (n= 1) 
 
Studies included in 
narrative synthesis  
(n= 14) 







Figure 2.2 Study selection flow diagram for breast cancer incidence by ER status 
31 
 
Table 2.1 Characteristics of the studies included in the review of breast cancer incidence by ER status organised by study period start 
year (page 1 of 3) 







































1980 2006 7,386 81% in 1989 
and 99% in 
2006.  






No 40 to 75+ years, 
every 1-2 years 
Jemal et al 
(2007) 
USA SEER 9 1990 2003 394,891  NR 40 years 
or older 








No 40 to 75+ years, 






1990 2004 NR 83% in San 
Francisco 
Bay Area 
and 71% in 
the rest of 
California. 
<40 to 70+ 
years 








No 40 to 75+ years, 
every 1-2 years 
Anderson et 
al. (2011) 
USA SEER 13 1992 2008 429,757 358,624 
(83%) 
30 to 84 
years 




since 1990.  
No 40 to 75+ years, 
every 1-2 years 
Anderson et 
al (2013) 





1993 2010 62,549 57,587 
(92%) 
30 to 84 
years 





Yes (1991) 50 to 69 years, 
every 2 years 
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Table 2.1 (continued) Characteristics of the studies included in the review of breast cancer incidence by ER status organised by study 
period start year (page 2 of 3) 
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implementa
tion) 






Denmark DBCG and Danish 
cancer registry 






ER+, ER- and 
unknown. 
ER status since 
1977.  
Yes (1991) 50 to 69 years, 
every 2 years 
Hofvind et 
al. (2012) 
Norway NBCSP and 
Norwegian 
Cancer registry 








Yes (1996) 50 to 69 years, 
every 2 years 
Sharpe et 
al. (2010) 
Scotland Scottish Cancer 
Registry 
1997 2005 NR NR 50 to 74 
years 
ER status: 
ER+, ER- and 
unknown. 
ER status since 
1997. 
Yes (1988) 50 to 70, every 
3 years 
Lambe et al. 
(2010) 





1997 2007 NR 89% 50-59 
years 
ER status: 










Yes (1986) 40 to 74 years, 
every 18 
months (age 
40 to 49) and 









1998 2007 50,378 85% -93%  50 to 70+ 
years 
ER/PR status: 









Yes (2002) 50 to 69 years, 
every 2 years 
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Table 2.1 (continued) Characteristics of the studies included in the review of breast cancer incidence by ER status organised by study 
period start year (page 3 of 3) 






















? (Year of 
implementa
tion) 




Hou et al. 
(2013) 








ER status since 
1990.  
No 40 to 75+ years, 
every 1-2 years 
DeSantis et 
al. (2011) 
USA SEER 12 2000 2007 NR Ranging 
from 82% 
in 2000 to 
93% in 
2007. 






ER status since 
1990. 
No 40 to 75+ years, 
every 1-2 years 
Fontenoy et 
al. (2010) 




2003 2007 3,792 3,555 
(94%) 












Yes (1989) 50 to 74 years, 
every 2 years 
Mullooly et 
al. (2017) 
Ireland NCRI 2004 2013 24,845 23,425 
(94%) 














Yes (2000) 50 to 64 years, 
every 2 years 
Abbreviations: DBCG= Danish Breast Cancer Cooperative Group, ER= Oestrogen receptor, HER2= human epidermal growth factor receptor 2, NBCSP= Norwegian Breast Cancer 
Screening Programme, NCRI= National Cancer Registry of Ireland, NR= Not reported, PR= Progesterone receptor, SEER= Surveillance, Epidemiology and End Results, USA=United 
States of America. 
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2.3.1 Overall incidence trends by ER 
The outcome data for the seven studies reporting overall rates is summarised in Figure 
2.3 and Table 2.2. Outcome measures reported among the studies were age-
standardised incidence rates (ASiR) and/or estimated annual percentage change 
(EAPC). ASiR are the gold standard to report incidence rates that account for the age 
structure of the population, therefore allowing for comparison between populations. 
The EAPC is a popular method of trend analysis and estimates the annual percentage 
change for ASiR assuming a constant rate of change over time (linearity) [149]. 
Seven studies from three countries (US, Denmark and Ireland) reported overall 
incidence trends by ER status [135, 136, 138, 140, 143, 144, 146] for women of all 
ages. These studies show that ER+ BC incidence increased and ER- BC incidence 
decreased overall between 1980 and 2013 (Figure 2.3). However, incidence rates by 
ER status fluctuated between time periods.  
2.3.1.1 Studies with trends estimated using joinpoint regression analysis 
Four of the seven studies [138, 140, 143, 144] (all from the US) used joinpoint 
regression analysis to investigate whether changes in BC incidence were observed at 
any time point and EAPC for periods when linear trends were observed. Joinpoint 
regression analysis is used when the overall trend in incidence is not constant over the 
entire period of time (nonlinearity). Glass et al, using data from the Kaiser Permanente 
Northwest (KPNW) registry, reported an increase in incidence of BC from 1980 to 
2001, and a subsequent annual decrease of 2.7% until 2006. In contrast, ER- tumours 
incidence rates decreased from 1980 to 2006 and the decrease was especially sharp 
from 1999 to 2006 (9.8% annual decrease) [140]. That same year another two studies 
were published in the US with similar results but for different populations. Jemal et al 
explored further the temporal incidence trends in the nine oldest SEER cancer registry 
areas looking particularly at age and ER status [143]. Their findings were consistent 
with those reported by Glass et al. ER+ rates increased 3% annually (95% CI: 2.0% to 
3.9%) from 1990 to 2000. and decreased by 9.1% from 2002 to 2003. ER- rates 
decreased 1.1% (95% CI: 0.6% to 1.7%) per year from 1990 to 2003. Keegan et al 
looked at changes in BC incidence in the San Francisco bay area, known for having 
one of the highest rates of BC in the world, in comparison with the rest of women in 
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California [144]. Incidence rates of ER+ and ER- breast tumours followed the same 
pattern than those observed in the SEER and KPNW populations, with ER+ increasing 
and ER- decreasing. A decrease in ER+ incidence was also observed in the San 
Francisco bay area and the rest of California after 2001-2002. The most recent study 
by DeSantis et al. also found a decrease in the incidence of ER+ tumours after 2000 
but incidence rates started to slightly increase from 2003 to 2007 (0.8% annually, p 
value=0.18). ER- tumour incidence decreased for the whole study period [138]. 
2.3.1.2 Studies with trends estimated using APC models 
The other three studies [135, 136, 146] reported the annual percentage change for the 
whole study period for three countries: the US, Denmark and Ireland. ER+ BC 
incidence increased over time in all countries, with an annual percentage change 
ranging from 0.1% in the US [135] to 3% in Denmark [136], and ER- incidence 
decreased (EAPC range: -2% in the US [135] to -3.4% in Ireland [146]). The incidence 
of ER+ tumours fluctuated, especially in the US where, in general, ER+ incidence 
increased from 1980 until the early 2000s when it fell sharply [135, 140, 143, 144]. In 
contrast with the decrease observed in the US, in Denmark, ER+ incidence rates 
remained constant from 2002 to 2007 and increased again after that time. 
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Figure 2.3 Summary of age standardised incidence rates of BC by ER status for all the studies reporting overall rates 
 
Figure has been calculated using ASiR and EAPCs reported in the individual studies and found in Error! Not a valid bookmark self-reference. and is presented in the log scale. ASiR=Age 
standardised incidence rate, EAPC=estimated annual percentage change, ER= oestrogen receptor, USA=United States of America. Dotted line represents year 2000, around the time of 
the publication of the WHI study. Rates from DeSantis et al. not presented as they did not report overall incidence rates by ER status only EAPCs.  
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Table 2.2 Age-standardised incidence and estimated annual percentage change in incidence of BC by ER status for seven studies reporting 
overall rates organised by study date and time periods (page 1 of 2) 
Study and 
country 
Overall estimates by time period 
1980-1989 1990-1998 1999-2002 2003-2007 2008-2013 




ER+= 5.0% (3.7, 14.4) 
from 1980 to 1983, 
18.9% (0.1, 41.2) from 
1983 to 1986.  
ER-= -2.1% (-3.2, -1.0) 
from 1980 to 1995 
EAPC: 
ER+= 2.1% (1.2, 2.9) 
from 1986 to 2001. 
ER-= 3.7% (-9.0, 18.1) 
from 1995 to 1999. 
 
ASiR: 
ER-= 24.0 in 2002-2003. 
EAPC: 
ER+= -2.7% (-6.4, 1.1) from 2001 to 2006 
ER-= -9.8% (-12.8, -6.6) from 1999 to 2006. 
ASiR: 




Jemal et al 
(2007), 
USA 
 EAPC:  
ER+=3% (2.0, 3.9) from 
1990 to 2000. 
ER-=-1.1% (-0.6, -1.7) 
from 1990 to 2003,  
EAPC:  
ER+=-9.1% from 2002 to 2003. 






San Francisco Bay 
area: ER+=6.9% (3.0, 
10.8) from 1992 to 
1996, 0.2% (-2.3, 2.9) 
from 1996 to 2002  
ER-=-2.1% (-2.9, -1.4) 
from 1992 to 2004. 
The rest of California: 
ER+=4.5% (3.7, 5.4) 
from 1992 to 2001  
ER-=-0.6% (-1.3, 0.2) 
from 1992 to 2004. 
ASiR: 
San Francisco Bay area: ER+/PR+=96.0 from 2001 to 
2002. ER+/PR-=19.5 from 2001 to 2002. ER-/PR+=2.3 
from 2001 to 2002. ER-/PR-=21.6 from 2001 to 2002. 
The rest of California: ER+/PR+=76.0 from 2001 to 
2002. ER+/PR-=15.9 from 2001 to 2002. ER-/PR+=1.9 
from 2001 to 2002. ER-/PR-=20.5 from 2001 to 2002  
EAPC: 
San Francisco Bay area: ER+= -10.4% (-20.2, 0.7) 
from 2002 to 2004.ER-=-2.1% (-2.9, -1.4) from 1992 
to 2004. The rest of California: ER+= -7.3% (-11.2, 
3.2) from 2001 to 2004. ER-=-0.6% (-1.3, 0.2) from 
1992 to 2004 
ASiR: 
San Francisco Bay area: ER+/PR+= 
83.7 from 2003 to 2004. ER+/PR-
= 15.3 from 2003 to 2004. ER-
/PR+= 1.0 from 2003 to 2004. 
ER-/PR-= 20.3 from 2003 to 2004/ 
The rest of California: ER+/PR+= 
65.9 from 2003 to 2004. ER+/PR-
= 14.1 from 2003 to 2004. ER-
/PR+= 1.3 from 2003 to 2004. ER-




Table 2.2 (continued) Age-standardised incidence and estimated annual percentage change in incidence of BC by ER status for seven studies 
reporting overall rates organised by study date and time periods (page 2 of 2) 
Study and country Overall estimates by time period 
1980 -1989 1990-1998 1999-2002 2003-2007 2008-2013 
Anderson et al. 
(2011), USA 
 ASiR: in figure. EAPC: ER-=-1.95% (-2.12, -1.79)  
Anderson et al 
(2013), Denmark 
 ASiR: ER+=rose from 155 to 206 in 2007. ER-=fell from 48 to 37 during the study period (1993 to 2010). 
EAPC: ER+= 3.0% (2.8, 3.3), ER-=-2.1% (-2.5, -1.6). 
DeSantis et al. (2011), 
USA 





Mullooly et al. 
(2017), Ireland 
   ASiR: in figure.  
EAPC: ER+=2.2% (1.0, 3.5), ER-=-3.4% (-5.1, -
1.8), ER+/HER2-=2.9% (1.3, 4.4), ER+/HER2+=-
1.6% (-4.3, 1.3), ER-/HER2+=-4.6% (-6.5, -2.6), 
ER-/HER2-=-3.0% (-4.9, -1.1). 
Abbreviations: ASiR= age-standardised incidence rate, EAPC= estimated annual percentage change, ER= Oestrogen receptor, PR= Progesterone receptor, USA=United States of America. 










2.3.2 Incidence trends by ER between pre and postmenopausal women 
Nine studies reported incidence trends for women in all age groups and six studies for 
women aged 50 years or older (Table 2.1). One study defined postmenopausal status 
as not having menstrual bleeding for the past year [137]. In the rest of studies reporting 
menopausal status, age was used as a proxy, with 50 years being the cut-off point for 
menopausal status, i.e. women age<50 years are considered premenopausal and 
women aged 50 years or older are considered postmenopausal. 
2.3.2.1 Results from studies reporting pre and postmenopausal incidence rates by ER.  
Age specific estimates of incidence by ER status for pre and postmenopausal women 
are summarised in Table 2.3. Of the 11 studies presenting age-specific incidence rates, 
five reported incidence for pre and postmenopausal women [135, 137, 138, 142, 146] 
and their results are summarised below by country.  
US 
Anderson et al. showed that the increase in incidence of ER+ tumours from 1992 to 
2008 in the US, was higher in women of 50+ years of age than in women of 30 to 49 
years of age [135]. In contrast, annual declines in ER- incidence were more marked in 
the younger than the older age group (2.4% vs 1.4% annually). SEER data from 18 
registries for the years 2000 to 2009, found an increasing trend of ER+ incidence for 
the premenopausal age groups (20-39 and 40- 49 years ) [142]. For women >=50 years 
of age ER+ incidence decreased from 2000 to 2004 and started to increase again in 
2005. ER- incidence decreased for all age groups, irrespective of menopausal status 
but the decrease was most marked in women aged 50 to 69 years (4.5% per year). 
DeSantis et al. reported that ER+ breast tumours in US women significantly increased 
2.7% per year from 2003 to 2007 for women aged 40 to 49 years and there was a trend 
towards an increase for women aged 30 to 39 years [138]. For postmenopausal women, 
there was a slight decrease of 0.3% per year for the age groups from 50 to 59 and 70 
or more, and an increase of 1.6% for women aged 60 to 69, none of these time trends 
were statistically significant. The ER- incidence trend was consistent with previous 
studies showing a decrease for all age groups. The decrease was higher among women 





A study in Denmark by Bigaard et al.[137] found that postmenopausal women had a 
similar increase in incidence of ER+ tumours (2% per year, 95% CI: 1.1 to 2.8), than 
women younger than 35 years (2.2%, 95% CI:-0.4 to 4.8). They also found a 
significant increase in ER+ incidence for premenopausal women aged more than 35 
years from 1996 to 2002 that levelled off after that time up to 2007. ER- incidence 
decreased for the whole study period for women aged 35 to 49 years and for 
postmenopausal women by 4.5% (95 % CI =-6.5 to -2.5) and 3% (95 % CI =-4.3 to -
1.7) per year respectively, but increased for women younger than 35 years (1.4%, 95% 
CI: -2.8 to 5.7), however it was not statistically significant. 
Ireland 
In Ireland, ER+ incidence increased and ER- incidence decreased for all age groups 
from 2004 to 2013 [146]. However, the drop in incidence of ER- tumours was higher 
for premenopausal women aged 30 to 49 years (-3.1%, 95% CI: -4.5 to -1.7) and for 
postmenopausal women aged more than 65 years (-4.2%, 95% CI: -5.8 to -2.5). 
2.3.2.2 Results from studies reporting only postmenopausal incidence rates by ER.  
The other six studies presented incidence trends for post-menopausal women only 
[139, 141, 143, 145, 147, 148] and their results are summarised below by country. 
Norway 
A study from Norway by Hofvind et al. [141] showed that the incidence of hormone 
receptor positive tumours (ER+/PR+) increased for all age groups during the study 
period, incidence in women aged 55 to 59 years peaked in 2002 and this trend was not 
observed for the rest of age groups.  
Scotland 
In Scotland, Sharpe et al investigated trends in BC incidence by ER status using 
Scottish cancer registry data [148]. They found that ER+ incidence increased for 
postmenopausal women from 1997 to 2000, after which a sharp decrease in incidence 
took place and this was most marked in women aged 50 to 64 years (11.2% decrease 
from 2000 to 2005). This decrease was also observed in women aged 65 to 74 years 
but it was smaller and only lasted until 2002 when the incidence of ER+ tumours 
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started to increase again. ER- incidence decreased by 44.3% from 1997 to 2005 in 
women aged 50 to 64 years and remained constant in women aged 65 to 74 years.  
Sweden 
Another study using data from three regional population-based cancer registries in 
Sweden [145] reported similar results to those seen in Norway and Scotland. In 
postmenopausal women aged 50 to 59 years, ER+ incidence increased from 1997 to 
2003 and decreased from 2003 to 2007, while ER- incidence slightly decreased. The 
time at which ER+ incidence trend changed was later than in Scotland but more similar 
to Norway.  
Germany 
In Germany, Rusner et al [147] EAPC in BC incidence by ER status for data from 3 
regional registries. The results for this German study were different to those observed 
in the rest of the countries with no clear evidence of an ER+/PR+ incidence increase 
from 1998 to 2007, except for women aged 70 years or more in the Munich area for 
whom ER+/PR+ incidence rose 2.4% per year (95% CI: 1.7 to 3.2). ER-/PR-, ER+/PR- 
and ER-/PR+ incidence remained constant.  
France 
The last study reporting incidence trends by ER status for postmenopausal women 
used data from the Loire-Atlantique region in France and reported a sharp decrease in 
incidence of ER+/PR+ tumours from 2003 to 2006 (EAPC=-12.2% , 95% CI: -17.2 to 
-6.8) [139]. ER-/PR- tumours were also observed to decrease for this time period but 
not statistically significant. 
 
Overall, the literature supports higher annual increase in incidence of ER+ tumours 
among postmenopausal women than among premenopausal women, however 
postmenopausal women also experienced a more marked decrease around the early 
2000s. ER- incidence fell in most studies and the decrease was not consistently 




Table 2.3 Age-specific incidence and annual percentage change in incidence of breast cancer for studies reporting age specific rates 
(n=11) (page 1 of 2) 
 
Study and country 
Age-specific estimates 
Pre-menopausal Post-menopausal 
Jemal et al (2007) , USA NR 50 to 69 years: Much larger decrease from 2002 to 2003 in 
ER+/PR+ tumours than in ER-/PR- tumours.  
65 to 69 years: ER+=-20% from 2002 to 2003. ER-=2% from 
2002 to 2003.   
Anderson et al. (2011) , USA 30 to 49 years: ER+=1.2% (1.0, 1.3), ER-= -2.4% (-2.66, 
-2.18%). 
50 to 84 years: ER+=high (driving the overall pattern), ER-=-
1.35% (-1.52, -1.19). 
Bigaard et al (2012), Denmark Younger than 35 years: ER+= 2.2% (-0.4, 4.8). ER-=1.4% 
(-2.8, 5.7). Premenopausal, >35 years: ER+= 10.4% 
(7.3, 13.6) from 1996 to 2002 and -3.4% (-6.6, -0.1) 
from 2003 to 2007. ER-=-4.5% (-6.5, -2.5). 
Postmenopausal: ER+= 2.0% (1.1, 2.8). ER-=-3.0% (-4.3, -1.7). 
Hofvind et al. (2012), Norway NR 50 to 54 years: ER+/PR+=increased slowly (no peak) from 
1996 to 2009. 
55 to 59 years: ER+/PR+=increased. Peaked in 2002 with 280 
women per 100,000 cases. Decreased after 2002.  
60 to 64 years: ER+/PR+=increased from 1996 to 2009. 
Sharpe et al. (2010), Scotland NR Overall percentage change: 
50 to 64 years: ER+=31.5% from 1997 to 2000 and -11.2% 
from 2000 to 2005. ER-=-44.3% from 1997 to 2005.  
65 to 74 years: ER+=30.4% from 1997 to 2000, -4.1% from 
2000 to 2002 and 41.3% from 2002 to 2005. ER-=constant. 
Lambe et al. (2010), Sweden NR 50 to 59 years: ER+=increase from 1997 to 2003 and decrease 






Table 2.3 (continued) Age-specific incidence and annual percentage change in incidence of breast cancer for studies reporting age 
specific rates (n=11) (page 2 of 2) 
 
Study and country 
Age-specific estimates 
Pre-menopausal Post-menopausal 
Rusner et al. (2012), Germany NR 50 to 69 years: Brandenburg: ER+/PR+=constant, Munich: 
ER+/PR+=constant, Saarland: ER+/PR+=constant. 
70 years or older: Brandenburg: ER+/PR+=constant, Munich: 
ER+/PR+=2.4% (1.7, 3.2), Saarland: ER+/PR+=constant. 
ER-/PR- and mixed tumours did not reveal obvious pattern 
neither. 
Hou et al.(2013) , USA 20-39 years: ER+=1.8%. ER-=-1.8%. 
40-49 years: ER+=1.5%. ER-=-3.0%. 
 
50-69 years: ER+=-4.8% from 2000 to 2004 and 1.4% from 
2004 to 2009. ER-=-4.5%. 
70 years or older: ER+=-3.3% from 2000 to 2004 and 1.6% 
from 2004 to 2009. ER-=-2.1%. 
DeSantis et al. (2011) , USA 30 to 39 years: ER+=1.5%. ER-=-3.1%. 
40 to 49 years: ER+=2.7%. ER-=-5.7%. 
 
50 to 59 years: ER+=-0.3%. ER-=-4.9%. 
60 to 69 years: ER+=1.6%. ER-=-2.3%. 
70+ years: ER+=-0.3%. ER-=-0.9%. 
Fontenoy et al. (2010), France NR 50 to 64 years: ER+/PR+=-12.2% (-17.2, -6.8), ER-/PR-=-6.9% 
(-17.2, 4.7), ER+/PR-=0.1% (-10.5, 12.0), ER-/PR+ =25.5% (-
14.5, 84.3). 
Mullooly et al. (2017), Ireland 30 to 49 years: ER+=1.2% (-1.4, 3.9) 
ER-=-3.1% (-4.5,-1.7) 
 
50 to 64 years: ER+=3.0% (-1.4, 7.6), ER-=-3.4% (-7.1, 0.6) 
65 years or older: ER+=2.0% (0.0, 4.0), ER-=-4.2% (-5.8, -2.5) 
Estimates are estimated annual percentage change (EAPC) unless stated otherwise. Significant results in bold. ER= Oestrogen receptor, NR= Not reported, PR= Progesterone 





2.3.3 Incidence trends by ER before and after WHI 
As explained in section 1.3, MHT use has been associated with an increased risk of 
BC, especially for ER+ tumours. Whether incidence trends by ER changed after the 
publication of the Women’s Health Initiative study (WHI) in 2002 was evaluated in 
12 studies. These studies provide evidence that ER+ incidence decreased after the 
results of the WHI study and this was observed in different countries (Table 2.2).  
In the US, all studies reported decreases in ER+ incidence in the early 2000s [135, 138, 
140, 142-144]. Some studies also showed that this drop was higher in postmenopausal 
women [136, 138, 142]. There was variability between studies in the year at which the 
incidence of ER+ tumours started to decline and some estimates did not reach 
significance. Studies also suggest that the decrease stopped around 2006 and ER+ 
incidence started increasing again after that time [138, 142]. 
In other countries, a drop in ER+ breast tumours around the time of the publication of 
the results of the WHI study has also been reported. The highest decrease was observed 
in France where ER+/PR+ incidence drop by 12.2% (95% CI: -17.2 to -6.8) annually 
from 2003 to 2007 [139]. In Norway, the decrease was only observed for the incidence 
of ER+/PR+ tumours in women aged 55 to 59 but not for women aged 50 to 54 or 
older than 60 years of age [141]. The study by Sharpe et al. reported a decrease in ER+ 
incidence in Scotland for all postmenopausal women that was especially sharp (11.2% 
per year) for women aged 50 to 64 years [148]. However, this drop in incidence in 
Scotland started in 2000, before the publication of the WHI results. In Sweden, ER+ 
incidence also decreased from 2003 to 2007 for women aged 50 to 59 years [145].  
In contrast with these results, Bigaard et al found that in Denmark the decrease in 
incidence of ER+ breast tumours after 2002 was only observed for premenopausal 
women aged 35 years or older, whereas in postmenopausal women the incidence of 
ER+ tumours increased significantly after 2002 [137]. A more recent study in 







2.4.1 Summary of key findings 
This review of 14 studies in 8 countries showed that overall ER+ BC incidence have 
increased and ER- BC incidence have decreased in the last four decades, with EAPCs 
ranging from 0.8% to 3% for ER+ tumours and -2.1% to -3.4% for ER- tumours. The 
results also show that the increasing overall trend is mainly driven by the increase of 
ER+ cancer incidence since they account for around 75% of the total BC cases and 
ER- cancer incidence is decreasing. It is reassuring to note declining incidence of ER- 
tumours, as these tumours are usually more aggressive and have worse prognosis than 
ER+ subtypes.  
A possible explanation for the divergent patterns observed between subtypes may be 
changes in RFs that have different effects on risk of ER+ and ER- tumours. HR+ 
tumours have been associated with reproductive factors and postmenopausal obesity 
[150]. Reproductive patterns have considerably changed over time, especially in HIC 
where women are having less children and at an older age than in the past, both factors 
associated with an increased risk of ER+ tumours. Obesity has also been associated 
with an increased risk of ER+ tumours in postmenopausal women but not in 
premenopausal women. Obesity prevalence is increasing worldwide with the latest 
estimates reporting an increase in obesity prevalence from 6 to 15% in women between 
1975 and 2014 [151]. If obesity rates continue to rise this could result in an increased 
incidence of ER+ tumours. Age could also contribute to the increase in incidence since 
people are living longer and most breast tumours are diagnosed at an older age.  
Another factor likely important for the increase in incidence of ER+ tumours, is 
mammographic screening, implemented in all the countries from which the papers for 
the review were identified during the 80s, 90s and 2000s. Improvement in screening 
such as the change from analogue to digital mammography, and the extension of 
mammographic screening invitation to older women may have also contributed to the 
increases observed. 
The literature supports that, in general, postmenopausal women had a higher increase 
in incidence of ER+ tumours than premenopausal women. Declines in ER- incidence 
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were similar across all age groups. The greater annual increase in incidence observed 
for postmenopausal women compared to pre-menopausal women has been 
hypothesised to be in part related to MHT use. In fact, the reviewed studies showed 
that although overall ER+ incidence increased over time, around the early 2000s most 
countries experienced a decrease in ER+ tumour incidence that coincides with the 
publication of the results of the WHI study that linked MHT use to an increased risk 
of BC. Most countries reported a decrease in postmenopausal ER+ tumours that was 
especially high in France (12.2% annual decrease from 2003 to 2006) and in the US. 
Studies with more recent data suggest that ER+ incidence rates increased again after 
2006. 
This review also indicates that there is a gap in the literature in the incidence trends by 
ER for the last decade, with only one study showing incidence trends by ER up to 2013 
[146] this is possibly due to the introduction of PR and HER2 as molecular markers 
and the use of the intrinsic subtypes or its surrogates IHC markers to estimate recent 
BC incidence trends. In addition, cancer registries from at least 16 HIC with European 
ancestry populations are collecting ER status routinely but only eight countries have 
actually published the observed incidence rates by ER status. For the remaining eight 
countries, incidence trends by ER status remain unknown or unpublished. Although 
the studies included in this literature review are only from HIC with majority European 
ancestry populations, the divergent pattern by ER may be observed worldwide and for 
other ethnicities since overall BC incidence is also on the rise in LMIC. In fact, this 
divergent pattern has been observed for other ethnic groups in the US [142].  
2.4.2 Limitations of the systematic review  
2.4.2.1 Limitations related to the studies included in the review. 
The studies included are mainly descriptive and with high quality data but bias or 
confounding may be present. Ascertainment bias could occur as BC diagnosis criteria 
have changed over time, along with ER/PR measurement techniques. For example, in 
the US, the cut-off value for classifying a tumour as ER+ changed from 10% to 1% 
which may have reduced the number of tumours classified as ER- and therefore may 
have had an effect on the trends observed [152]. Missing ER status was a limitation in 
all studies and ranged between 29% and 6%. Three studies [135, 136, 146] used 
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imputation techniques to adjust for missing ER and HER2 status and reported that 
ignoring missing molecular marker data could result on biased rates especially in the 
early years for which missing molecular marker data was higher. The definition of a 
BC and the selection of BC cases used for computing incidence trends are likely to 
differ between countries. Population estimates, usually based on Census figures, are 
prone to bias and may underestimate the number of people in each age group and, as 
a result, overestimate BC incidence rates. The use of number of tumours instead of 
number of persons as the numerator of the incidence rates might overestimate BC 
incidence rates too. Furthermore, interpretation of these results is limited since the 
studies included in the review use population aggregated data and there is restricted or 
no information on mammographic screening, MHT use and other RFs that could 
contribute to the incidence trends observed. Future studies should examine the possible 
reasons for the divergent pattern of ER+ and ER- tumours and look for RFs associated 
with each of these subtypes. 
2.4.2.2 Limitations related to the methodology used to conduct the systematic review 
The systematic review consisted on a narrative synthesis of the BC incidence trends 
by ER status and meta-analysis to estimate the pooled incidence rate per 100,000 
women by ER was not conducted as this was not the main purpose of the review. The 
main aim was to find how many countries in the world were collecting BC molecular 
marker data routinely on their cancer registries and to compare the rates by ER status 
between countries. Further, only seven studies were found to report overall BC 
incidence trends by ER status and heterogeneity between studies was high, including: 
different methodology to calculate the standardised rates, different time periods 
presented and different age groups of women; for that reason, some of the time periods 
had very limited information and summarising the results with a pooled estimate was 
not deem to be adequate. Another reason was the fact that most studies did not report 
ASiR for all years and to estimate the ASIR I had to rely on visually inspecting the 
graphs of the trends to estimate approximate rates- given that some graphs were on the 
log scale this was difficult to do. Lastly, five of the seven studies that reported overall 
rates were from the US and given the large sample size of these studies (over 400,000 
women) in comparison with the European studies the pooled estimate would be 
reflecting the trends in the US and not for all countries.  
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Another limitation of the systematic review was that no standardised quality 
assessment method, such as the commonly used Newcastle-Ottawa scale (NOS), was 
used to review the quality of the studies included in the review. Data from all studies, 
except for that in Glass et al. [140], which comes from KPNW (a large prepaid US 
health plan), came from regional or national cancer registries of HIC with European 
ancestry populations and was deem to have a good quality both in terms of 
completeness and accuracy.  
Further, another limitation was the focus on studies that were written or translated into 
English. However, I did a thorough search for any reports published in the websites of 
the cancer registries for all European ancestry countries and used google translate to 
translate the original reports that were not in English and did not find any report 
presenting incidence by ER status so this limitation is not likely to have excluded any 
additional articles. Finally, the systematic review was conducted by one reviewer 
(single screening) due to time constraints instead of the international standard of two 
reviewers (double screening).  
2.5 Conclusion  
This systematic review showed that BC incidence differed by ER status in most 
countries with available data and that increases in recent decades are driven by 
increases of ER+ tumours which constitute the majority of BCs. The review suggests 
that molecular marker data is still limited in many countries and that future reporting 
of trends should be done by ER given the heterogeneity of BCs. Further, it describes 
international BC trends by ER status that will be compared during this PhD to the 
observed trends in Scotland, allowing to further generate hypothesis about the factors 
that might be driving the trends. 
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Chapter 3 Breast cancer incidence trends by molecular 
subtypes 
3.1 Background 
Numbers of incident breast tumours continue to increase due to population aging and 
the implementation of mammographic screening programmes in the UK [153] and 
other HIC [154]. The increase in obesity prevalence and changes in major RFs for BC, 
such as, changes in reproductive factors, may have also contributed to the increases in 
incidence observed in recent decades [155]. 
Recent changes in the prevalence of RFs that may have differential effects in the 
incidence trends, such as, obesity, alcohol consumption and reproductive factors may 
have had different effects on different subtypes of BC. Further, the literature conducted 
in Chapter 2 provides evidence that incidence patterns differ by BC subtypes with 
countries like the US, Denmark and Ireland reporting divergent incidence trends by 
ER status, with incidence increasing for ER+ tumours and decreasing for ER- tumours. 
I hypothesise that similar incidence trends may be observed in Scotland.  
This chapter aims to describe temporal trends of BC in Scotland by ER status, HER2 
status and the combination of ER, PR and HER2 used as a proxy for the intrinsic 
molecular subtypes derived from genetic profiling. I will also investigate the role of 
mammographic screening as a possible driver that may be affecting the observed 
trends and contrast the results with those already observed in other countries. 
3.2 Hypotheses 
The hypotheses that will be explored in this chapter of the PhD are: 
 Incidence trends may differ between molecular subtypes of BC and similar 
trends to those observed in other countries are also likely to be seen in Scotland 
due to similar RFs patterns.  
 Incidence trends may have changed over time. Increases are expected due to 
period effects, as the introduction of mammographic screening, and cohort 
effects, such as, changes in reproductive factors patterns, especially for 
hormone sensitive breast tumours.  
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 Increasing age is strongly associated with an increased risk of BC. However, 
age might have a different effect in incidence depending on the BC subtype.  
 Screening is associated with increasing incidence of BC but it might have a 
differential effect in incidence for the different molecular subtypes.  
 
3.3 Methods  
3.3.1 Scottish cancer registry data  
The data used for this PhD project have been obtained from Information Services 
Division (ISD) of the NHS National Services Scotland, the national organisation in 
Scotland for health information and intelligence that provides statistical services. ISD 
holds the Scottish Cancer Registry (also known as SMR06) that contains person and 
tumour based records that are created by linkage of hospital administration records, 
screening datasets, death registration data, private hospitals data and community 
prescribing records [156].  
The Scottish Cancer Registry was established in 1958, with electronic data available 
from 1981 and it holds over 1.8 million records, covering all Scottish residents that 
have ever been diagnosed with cancer. In Scotland, the use of the patient Community 
Health Index (CHI), that uniquely identifies all Scottish residents registered with a 
general practitioner (GP), increases the ability to link the cancer data to hospital 
admissions and death registration data. For that reason, coverage of the Scottish cancer 
registry is high with an overall estimate of ascertainment of BC cases that exceeds the 
98% and that is independent of age [157].  
An anonymized dataset derived from SMR06 containing all primary invasive BCs 
from 1997 (the most recent year for which ER data is available) to 2016 was requested. 
The governance process consisted of an application to access the data submitted to the 
Public Benefit and Privacy Panel (PBPP) that contained a thorough explanation of the 
research project and how the data would be used. Data access was granted by PBPP 
and available from April 2018 through the National Services Scotland (NSS) National 
Safe Haven secure environment. The SMR06 variables requested and included in the 
dataset are shown in Table 3.1 along with a description of data completeness.  
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Table 3.1 Variables included in the requested SMR06 dataset of primary breast cancer 
among women in Scotland for 1997-2016 with completeness rate 
Variable included in the dataset requested to ISD Completeness 
Individual characteristics 
Age at diagnosis 
Scottish health board 








Date of diagnosis 
Date of registration 
Tumour morphology 
Tumour grade  
Clinical TNM classification 
T stage (clinical) 
N stage (clinical) 
M stage(clinical) 
Pathological TNM classification^ 
T stage (pathological) 





Number of positive nodes 







































Date of death 





*Variables registered since 2009 for which no data are available for previous years. ^Pathological TNM stage 
available from 2005. Percentage based on available years. ER=Oestrogen receptor, HER2= human Epidermal 
Growth Factor 2, PR= Progesterone receptor, SIMD= Scottish Index of Multiple Deprivation, TNM= tumour, nodes 










3.3.1.1 Individual characteristics 
Age at diagnosis was recorded for all women and age at death was extracted from age 
at diagnosis and date of death. Age at diagnosis was further stratified in three 
categories based on the age at which women are routinely invited for mammography 
screening in Scotland: women aged less than 50 years, women aged 50 to 69 years 
(approximate ages at which women are routinely screened) and women aged 70 years 
or older (usually not screened unless they request it). Throughout this thesis the term 
age is related to age at diagnosis of BC.  
The Scottish health board in which a woman resided at the time of diagnosis was 
recorded for all women. There are 14 NHS health boards in Scotland (NHS Ayrshire 
and Arran, NHS Borders, NHS Dumfries and Galloway, NHS Western Isles, NHS 
Fife, NHS Forth Valley, NHS Grampian, NHS Greater Glasgow and Clyde, NHS 
Highland, NHS Lanarkshire, NHS Lothian, NHS Orkney, NHS Shetland, NHS 
Tayside). The NHS health boards were further classified in larger Scottish regions: 
North region comprising NHS Western Isles, NHS Grampian, NHS Highland, NHS 
Orkney, NHS Shetland and NHS Tayside; South-East region comprising NHS 
Borders, NHS Dumfries and Galloway, NHS Fife and NHS Lothian; and West region 
comprising NHS Ayrshire and Arran, NHS Forth Valley, NHS Greater Glasgow and 
Clyde and NHS Lanarkshire.  
The Scottish Index of multiple Deprivation (SIMD) is an area-based measure of 
deprivation based on 7 domains: income, employment, health, education, crime, access 
to services and housing. SIMD ranks the 6,976 data zones in Scotland from the most 
deprived to the least deprived area and decile and quintiles of all areas are derived from 
them. SIMD is often expressed in quintiles or deciles and I will use SIMD quintile as 
measure of deprivation throughout the PhD thesis and compare women in the 20% 
most deprived areas (quintile 1) with women in the 20% least deprived areas (quintile 
5). SIMD was available for all women within the cancer registry with a Scottish 
postcode. Several SIMD versions (SIMD 2004, 2006, 2009, 2012 and 2016) were 
available for our study period from 1997 to 2016. The most appropriate SIMD version 
for each year of diagnosis was selected as recommended in the deprivation guidance 
for analysts [158] and a unique quintile was used for each woman throughout the PhD.  
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The Charlson Comorbidity Index is a measure used to classify people with respect 
to their comorbid conditions that might influence mortality risk. The measure consists 
on a weighted index that takes into account the number of comorbidities and the 
severity of each comorbidity [159]. The original index developed by Charlson et al. 
defined 30 clinically important comorbidities but has been adapted for the different 
versions of the ICD codes. In 2004, an Australian version of the Charlson index 
adapted the score to include 17 comorbidities weighted from (1=least severe to 6=most 
severe) using ICD10 codes. The 17 scores (weight) are: acute myocardial infarction 
(1), congestive heart failure (1), peripheral vascular disease (1), cerebral vascular 
accident (1), dementia (1), pulmonary disease (1), connective tissue disorder (1), 
peptic ulcer (1), liver disease (1), diabetes (1), diabetes with complications (2), 
paraplegia (2), renal disease (2), cancer (2), metastatic cancer (3), severe liver disease 
(3) and HIV (6) [160]. The final score is then calculated by adding each of the 
individual comorbidities (with their weights) for an individual patient. In Scotland, the 
score is included within the SMR01- General/acute inpatient and day case records to 
establish a prior morbidity weighting and used as a proxy for co-morbidity. The score 
is calculated by looking back at 1 and 5 years before the patient’s most recent 
admission [161].  
3.3.1.2 Molecular markers  
Oestrogen receptor (ER) status is available since 1997 for all invasive tumours 
diagnosed histologically, through biopsy, surgical excision or histology of nodes or 
metastases. The method used to assign ER status (positive or negative) to a tumour 
was the Allred score system. The scores are summed to give a maximum of eight 
depending on the combination of scores assigned following immunohistochemical 
staining for the proportion of cells that stain positively and the intensity of staining 
[162]. A score of 0-1 indicates a negative result and a score of 2-8 indicates a positive 
result, with higher score indicating a stronger positive result. ER status can also be 
recorded as a value from which the status is derived depending on the assay method. 
The three most common assay methods used and how they classify the tumours as ER 
positive and ER negative are given in Table 3.2. 
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Table 3.2 Assay methods for the classification of tumours depending on their ER 
status 
Assay method ER positive ER negative 
DCC >=20fmols ER/mg protein <20 fmols ER/mg protein 
EIA >=20fmols ER/mg protein <20 fmols ER/mg protein 
ERICA >=10% positive staining <10% positive staining 
DCC= dextran-coated charcoal assay, EIA= Enzyme immunoassay, ER=oestrogen receptor, ERICA= oestrogen 
receptor immunocytochemical assay, fmols=femtomoles, mg= milligram 
 
Progesterone receptor status was measured using the same method as the ER and 
data are available from 2009. HER2 status, or the over-expression of HER2 receptors 
in a tumour cell, was measured from 2009 using IHC HER2 receptor test. This test 
shows how much of the HER2 protein is present in a tumour cell. When the result is 
borderline, the fluorescence in-situ hybridisation (FISH) test is carried out to confirm 
the result.  
 
3.3.1.3 Breast cancer subtype definition 
ER, PR and HER2 combinations were used as a proxy for the classification of 
molecular BCs through genetic profiling known as intrinsic molecular subtypes of BC 
[97]. ER and PR were combined as hormone receptor status and defined as hormone 
receptor positive (HR+) if either ER or PR were positive, hormone receptor negative 
(HR-) if ER and PR were negative or one of them was negative and the other had 
unknown status, and hormone receptor unknown if ER and PR were unknown. HER2 
was defined as HER2+, HER2- or HER2 unknown.  
The combinations of ER/PR (hormone receptors) and HER2 status were used as 
surrogates for the molecular classification as defined according to the St Gallen 2011 
consensus (Table 1.1 in Chapter 1) with a full description in Appendix B.1. 
HR+/HER2- tumours will be defined as luminal A, HR+/HER2+ as luminal B, HR-
/HER2+ as HER2-enriched and HR-/HER2- as triple negative breast cancers (TNBC) 
throughout the dissertation.  
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Ki-67 a marker for tumour proliferation is not currently recorded in the Scottish cancer 
registry, which is why grade was used to further differentiate luminal A and luminal 
B tumours. Luminal A tumours with high grade were reclassified as luminal B tumours 
and sensitivity analysis is presented.  
 
3.3.1.4 Other tumour characteristics definitions 
For each woman with a BC diagnosis, the registry collects tumour information on 
tumour grade (low grade or well differentiated, medium grade or moderately well 
differentiated, high grade or poorly differentiated and unknown grade), tumour size 
in centimetres (cm) (categorised into <1cm, 1-2cm, more than 2 cm and unknown), 
nodal status (positive, negative or unknown), the number of positive nodes detected 
and the method of first detection (screen-detected, not screened detected and 
unknown).  
Clinical and pathological TNM stage is also recorded as individual T, N and M stage 
variables. Clinical TNM stage was available for all study period and pathological TNM 
stage was only available from 2005. As a general principle, pathological TNM stage 
was prioritised over clinical stage as it tends to be more accurate. However, there were 
some exceptions: 
 M stage which is based on clinical examination and imaging was prioritised 
over pathological except when clinical stage was unknown or when 
pathological stage indicated metastasis (stage IV) and clinical stage did not. M 
status was often unknown or not recorded and, in this case, I assumed that no 
metastasis was present. 
 If the woman had neoadjuvant therapy (radiotherapy, chemotherapy or HT) at 
least 4 weeks before surgery, the clinical stage was prioritised. 
 Stage T4 which indicates primary tumour involvement of chest wall or skin is 
often obvious at clinical examination, for that reason if clinical T stage was T4 




Following the rules above and using pathological tumour size and the number of 
positive nodes variables to complete missing pathological T and N variables a final 
TNM stage variable was derived. The full algorithm followed to derive TNM stage 
from clinical and pathological TNM stage records is presented in Appendix B.2. and 
categorised as I, IIA, IIB, IIIA, IIIB, IIIC and IV following the American Joint 
Committee on Cancer (AJCC) 8th Edition Cancer Staging manual [163]. 
 
3.3.2 Selection of population 
The original SMR06 dataset obtained from ISD contained all tumour registrations for 
individual people with a primary BC (including in situ tumours in the breast and in 
other organs, and malignant cancers in other organs). The dataset contained 91,735 
registered cancers in 74,324 people diagnosed between 1997 and 2016. Some of these 
tumours were not relevant to the primary analysis for this PhD (calculating incidence 
rates of female invasive BC) and therefore, the original dataset was modified to create 
the study cohort following the steps described below and illustrated in Figure 3.1 for 
numbers of tumours and in Figure 3.2 for numbers of people: 
1. Exclusion of men 
2. Exclusion of women with other primary malignant cancer prior to BC 
diagnosis and exclusion of all other primary malignant entries 
3. Exclusion of records of in situ or benign tumours in other organs  












Figure 3.1 Flowchart of the selection of female invasive breast cancers based on 
number of tumours 
 
 
Total number of tumour records 
          n=91,735 
 
Tumour records in men 
n=550 
 
Tumour records in women 
n= 91,185 
 
Tumour records of in situ 




Tumour records in women without 
history of other primary malignant 




All tumour records in 
women with other primary 
malignant cancer prior to 
breast cancer diagnosis 
and exclusion of all other 
primary malignant entries 
n=10,798 
Tumour records of in situ 
or unknown behaviour 
tumours of the breast  
n=1,466 
 
Invasive breast cancer tumour records in women 
without history of other primary malignant cancer 
prior to breast cancer 
n= 76,048 
 
Single invasive breast cancers 
records in women  
n=68,564 
 
Multiple records of invasive 
























After the exclusion of tumours that were not relevant for our primary analysis, 76,048 
invasive BCs in 72,217 women remained in the dataset (Figure 3.1 and Figure 3.2).  
By convention incidence rates computed by ISD-NHS Scotland, the Office for 
National Statistics for the UK and international agencies are tumour based rather than 
on an individual subject basis. I compared incidence rates reported by ISD (tumour 
based) with incidence rates based on a single incident case of BC per woman, the 
approach I used for my analysis. The final selection procedure to select only one 
Number of people with one or more 






Number of women with one or more 
breast cancer tumour records  
n= 73,926 
 
Women with other primary 
malignancy prior to invasive 
breast cancer diagnosis  
 
n=1,709 
Number of women with one or more 
invasive breast cancer records and no 
previous history of other primary 
malignant cancer prior to breast cancer 
n= 72,217 




Women with multiple 
invasive breast tumours 
n=3,653 
 
Figure 3.2 Flowchart of the selection of the study cohort based on number of people 
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invasive BC per woman was established as follows: when a woman was diagnosed 
with multiple invasive BCs and the time of diagnosis between cancers was more than 
6 months, the first primary invasive BC per woman was selected. If the diagnosis of 
the multiple invasive BCs was within 6 months, the more advanced invasive cancer 
was selected as the incident cancer using criteria based on grade and nodal status. A 
scoring system that established an individual score for each invasive lesion was created 
(Table 3.3). 
Table 3.3 Scoring system to select the more advanced invasive breast cancer based 
on grade and nodal status 
Score Grade Nodal Status 
1 I-Well differentiated Positive 
2 I-Well differentiated Negative 
3 II- Moderately differentiated Positive 
4 II- Moderately differentiated Negative 
5 III-Poorly differentiated Positive 
6 III-Poorly differentiated Negative 
 
The score was only computed when both measurements (grade and nodal status) were 
available. The invasive BC with the highest score was selected for each woman. If the 
scores were the same, ER status was further investigated. If one or more of the scores 
could not be computed due to missing data, the record with a valid score was selected. 
In the case that all scores were missing the individual variables were investigated 
following the same order (grade, nodal status and ER). A full flowchart of the selection 
of the primary invasive BC for women with two invasive lesions is included in 
Appendix B.3. For those women with more than two invasive BCs recorded, the 
selection was performed manually using the same procedure. All stages of the 




3.3.3 Statistical Analysis 
3.3.3.1 Incidence rates 
ASiR of BC were computed for all women by ER, HER2 and IHC defined molecular 
subtypes using ER/PR/HER2 combinations. Counts of BCs based on a single incident 
case for each woman (as described in the previous section 3.3.2) for each age and year 
of diagnosis were calculated and used as the numerator in the ASiR. The population 
estimates used as the denominator to compute the incidence rates were mid-year 
population estimates for each age and year of diagnosis obtained from the National 
Records of Scotland [165]. These estimates are derived from decennial census data 
with adjustment for population changes in intervening years and for under-numeration 
(estimated coverage was 94% in the 2011 Census) [166]. Incidence rates were 
standardised using the direct method to the European standard population (2013) in 5-
year age groups. 
Age-specific rates for each age group (<50, 50 to 69 and 70 years or older) by ER, 
HER2 and IHC defined subtypes were also calculated with age stratification based on 
the age at which women are routinely invited for screening. Age at menopause is not 
recorded in the cancer registry, but as the mean age of menopause in the UK is 51 
years [167] women aged less than 50 years can be considered as premenopausal and 
women aged 50 or older can be considered as postmenopausal. 
To describe differences between the incidence rates in this study (computed on the 
basis of one tumour per woman) and those estimated by ISD (computed on a tumour 
basis), I also calculated incidence rates for the study on a tumour basis. I used the total 
number of invasive breast tumours diagnosed from 1997 to 2016, without excluding 
women who had another primary tumour before BC diagnosis for this calculation.  
3.3.3.2 Dealing with missing tumour marker status 
Although, completeness of ER status data in the cancer registry was relatively good 
(missingness= 8% for ER status from 1997 to 2016) missing ER status varied by age 
and by calendar year which, if not taken into account, could lead to biased estimates 
of the rates. The number and percentage of BC cases with missing ER status declined 
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over time from over 600 cases (20%) in 1997 to less than 100 (2%) in 2016 (Figure 
3.3). 
Figure 3.3 Number and percentage of breast cancer cases with ER unknown status in 
Scotland from 1997 to 2016 
 
There was a clear relationship between missing ER status and age at diagnosis, with 
older women being more likely to have an unknown ER status. Fourteen percent of 
women aged 70 years or older had missing ER status compared to 5% of women aged 
less than 70 years with missing ER status from 1997 to 2016. The percentage of women 
having missing ER status declined over time and was more pronounced for women 
aged 70 years or older (Figure 3.4). 
Figure 3.4 Percentage of women diagnosed with BC in Scotland from 1997 to 2016 





























































To correct ER+ and ER- counts for missing ER status, a simple method of multiple 
imputation (MI) developed by Anderson et al [135] was used. For each age 𝑎 and 
calendar year 𝑦: 
𝑇𝑎𝑦 = 𝑃𝑎𝑦 + 𝑁𝑎𝑦 + 𝑀𝑎𝑦 
with 𝑇𝑎𝑦 being the total number of incident cases for each age 𝑎 and calendar year 𝑦, 
𝑃𝑎𝑦the observed number of ER positive counts, 𝑁𝑎𝑦 the observed number of ER 
negative counts and 𝑀𝑎𝑦 the observed number of missing ER counts.  
The model assumes that ER status is missing at random (MAR) within a single age 
and year of diagnosis and that the observed probability of ER+ counts is an unbiased 
estimator of the true probability of ER positive counts in the population. Using the 
observed probability of ER+ counts, 
?̂?𝑎𝑦 = 𝑃𝑎𝑦/(𝑃𝑎𝑦 + 𝑁𝑎𝑦) , 
the corrected ER+, ?̂?𝑎𝑦 , and ER-, ?̂?𝑎𝑦 counts were calculated as follows: 
?̂?𝑎𝑦 = ?̂?𝑎𝑦𝑇𝑎𝑦 
?̂?𝑎𝑦 = 𝑇𝑎𝑦 − ?̂?𝑎𝑦 
If the assumption of MAR is correct, these corrected ER+ and ER- estimates proved 
unbiased estimators of the true ER+ and ER- counts in the population that can be used 
to calculate the age-specific and ASiR over time. An equivalent imputation method 
was used to correct for missing data for HER2 status and for HR/HER2 combinations.  
Other studies have used multiple imputation by chained equations (MICE) models to 
impute missing ER status for BC in cancer registries with both the assumptions of 
MAR [135] and missing not at random (MNAR) [168]. Both studies showed similar 
results irrespective of the assumption but different from a complete case analysis 
(CCA) that would give biased estimates of the rates. For that reason, I have assumed 




3.3.3.3 Joinpoint Regression Analysis 
Overall linear trends for a fixed period of time are frequently summarised using the 
EAPC of the ASiR. EAPC is calculated using a log-linear model that assumes a 
Poisson distribution. Under this model a constant change assumption is presumed, i.e. 
linearity of the rates on the log scale over time [169]. However, incidence rates often 
do not present a linear trend over time and, therefore, it is not reasonable to assume 
that a single EAPC accurately describes time trends. Fay et al. proposed two alternative 
measures to estimate the overall trend: the two point estimator and the adaptive 
estimator [149] when the linear assumption does not hold. 
Kim et al [170] proposed the use of joinpoint regression models, also known as 
piecewise regression, to estimate the points at which there is a change in the incidence 
rates and calculate the EAPC for each identified segment of time. They also proposed 
the use of the average annual percentage change (AAPC) as a better estimator of the 
overall trend over a fixed period of time when there is not a linear trend [171]. The 
AAPC is appropriate even when the model indicates that there are points in time at 
which changes in incidence trends are observed for the specified time interval.  
Joinpoint regression models were fitted for the overall BC incidence rates, for each ER 
and HER2 status and for the IHC defined molecular subtypes. Joinpoint analysis was 
also performed for each marker and combination of markers for three age groups (<50, 
50-69 and 70+ years at diagnosis of BC). A maximum of three joinpoints (time points 
at which there is a change in incidence) were investigated. The simplest joinpoint 
regression model that provided the best fit to the data was selected using the 
permutation test method [170]. This Monte Carlo iterative procedure start by testing 
the null hypothesis of a model with 0 joinpoints versus an alternative hypothesis of a 
model with 3 joinpoints (maximum number of joinpoints previously specified). If the 
null hypothesis is selected the procedure continues by testing it against the alternative 
with 1 less joinpoint and if the alternative hypothesis is selected then it is tested against 
the null with 1 more joinpoint. The procedure continues until all possible hypothesis 
(0 to 3 joinpoints) have been tested sequentially. A total of 4,499 permutations are 
performed and the p value test is adjusted for multiple testing using Bonferroni 
correction [172].  
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The location of the joinpoints within the study period and the final model fitting was 
investigated using Lerman’s grid search method [173] assuming constant variance and 
uncorrelated errors. This method fits a model for each possible position of the 
joinpoint(s) and selects the position(s) that minimises the sum of squared errors (SSE), 
hence, identifying time periods with changes in estimated rates. EAPCs with 95% 
confidence intervals (CI) were calculated and reported for each time period identified 
by the final model, along with AAPC for the whole study period (from 1997 to 2016). 
The parametric method was used to estimate the CI for AAPC and EAPCs. 
Sensitivity analysis was performed for ER+ tumour trends using different model 
selection methods (the Permutation test, the Bayesian Information Criterion (BIC), 
BIC3, and modified BIC) and different errors options (uncorrelated vs autocorrelated). 
Joinpoint regression Software was used for all the analysis [174]. 
3.3.3.4 Age-period-cohort models 
Apart from the classical descriptive approaches described above, age- period and age-
cohort models have frequently been used for surveillance and analysis of disease rates. 
In recent decades, Age-Period-Cohort (APC) models have proved useful to generate 
and test hypothesis for aetiology and prognosis and to estimate age, period and cohorts 
effects, particularly in cancer rates. These three factors are all time-related and can 
serve as estimates of disease risk. Period and cohort effects are usually indicative of 
changes in external exposures, such as implementation of screening programme or 
changes in reproductive factors. 
APC models are based on generalised linear models and describe rates as a product of 
these three factors: age, period and cohort. However, due to the linear relationship 
between the factors, 
𝐶𝑜ℎ𝑜𝑟𝑡 = 𝑃𝑒𝑟𝑖𝑜𝑑 − 𝐴𝑔𝑒 
also known as the “identifiability problem”, the same fitted rates are predicted by many 
different sets of parameters. Hence, the log-linear trends in rates cannot be attributed 
to the influence of age, period or cohort parameters.  
The first approaches used to deal with the identifiability issue consisted on adding 
some constraints to the full APC model [175, 176]. However, these constraints are 
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usually hard to prove and they must be based on biological hypothesis. Many studies 
have tried to address the identifiability issue and methods are summarised in a 2016 
review by Smith and Wakefield [177]. However, Rosenberg et al [178], suggest that 
the identifiability issue has slowed down the use of APC models in epidemiological 
studies although the issue is intrinsic to any time to event analysis of cohort studies. 
They propose a new model [179] that provides a set of estimable functions that are 
closely related to the classical approaches used in cancer surveillance and effective in 
estimating patterns in cancer rates. This model has two key innovations: 1) the cohort 
deviations are weighted to allow cohorts to be followed-up for variable periods of time 
without imposing additional constraints to the model; 2) the age, period and cohort 
deviations that identify the non-linear trend of each effect are estimated using 
decomposition of quadratic components (orthogonal to intercept and the linear trend 
of the effect) and higher-order terms. The quadratic components of the model, or 
“global curvatures” parameters, represent how fast on average the trends in the rates 
are changing and are the main components to identify rate patterns and signals. The 
new method also allows for the estimation of improved functions and hypotheses tests 
that are summarised in Table 3.4 below. 
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Table 3.4 Parameters and estimable functions from APC models and hypothesis test for each estimate (page 1 of 2) 
Type of effect Estimable function Interpretation Hypothesis test 
(null) 
Implications if null 
hypothesis is accepted 
 
Global trend 
Net Drift Annual percentage change of the 
expected age-standardised rates over 
time. Analogue of the EAPC but adjusted 
for cohort effects. Log-linear component 
of the fitted rates. The net drift represents 
the sum of the linear trend from the 
period and cohort effects. 
Net Drift=0 Fitted temporal trends are 






Cross – sectional age 
curve 
Fitted age-specific rates in reference 




are the non-linear 
age effects) 
Fitted cross-sectional curves 
are log-linear. 
Fitted longitudinal curves 
are log-linear. 
The ratio of Longitudinal vs 
Cross-sectional curves is 
constant. 
Longitudinal age curve Fitted age-specific rates in reference 
cohort c0 adjusted for period effects 
Ratio of Longitudinal vs 
Cross-sectional age 
curve 
Quantifies the influence of the Net Drift 





Table 3.4 (continued) Parameters and estimable functions from APC models and hypothesis test for each estimate (page 2 of 2) 
Type of effect Estimable function Interpretation Hypothesis test 
(null) 
Implications if null 





Fitted temporal trends Fitted rates over time in reference age 
group a0 adjusted for cohort effects. 
Analogue to ASR. 
Period 
deviations=0 
Fitted temporal trends and 
period rate ratios are log-
linear. 
PRR Ratio of the age-specific rates in a period 
relative to the reference period (p0) 
All PRR=1 Net Drift is 0 and fitted 







Local drifts Annual percentage change of the 
expected age-specific rates over time. 
Analogue of the EAPC but for each age 
group.  
Local drifts= Net 
drift 
Temporal trends are the 
same in every age group. If 
the local drifts are different 
to the net drift there is 
evidence of cohort effects. 
CRR Ratio of the age-specific rates in a cohort 
relative to the reference cohort (c0) 
All CRR=1 Net Drift is 0 and all local 
drifts are 0. Temporal 
trends are the same in 
every age group. 
CRR= Cohort Rate Ratio, EAPC= Estimated annual percentage change, PRR= Period Rate Ratio. Table modified from [179]
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The new model has two main improvements in comparison with the traditional model: 
1) all parameters are estimable since they are characteristic of the underlying Lexis 
diagram and an age, period and cohort reference groups are selected,  
2) the new hypotheses tests are more robust and they correct for multiple testing.  
Apart from the traditional Wald Chi squared test used in APC models, the new model 
uses Tippett’s method [180] to derive a combination test (testing both quadratic and 
higher order terms) for period and cohort effects. This test combines the Wald test for 
the global curvature and the Wald test for the higher order components into a single p 
value test for the period or cohort effects. The new combination test is more robust and 
useful to capture period or cohort effects that are influencing the observed rates above 
the log-linear trend identified by the net drift. Model fit was checked using the 
deviance residuals of the APC model of each subtype with no systematic patterns 
indicating a good fit and are presented in Appendix Figure B.6, Appendix Figure B.9 
and Appendix Figure B.22 for ER+, ER- and the IHC defined subtypes respectively.  
APC models presented in this chapter are based on the new model developed by 
Rosenberg et al. [179] and further statistical methodology and description of how the 
parameters are derived can be found in the paper. APC models were fitted for the ER+ 
and ER- ASiR calculated after imputation of missing data. I restricted the models to 
women aged 30 to 85 years for consistency with similar estimates from other counties 
and due to small counts in women younger than 30 and older than 85 years. In order 
to obtain stable estimates, single year data was grouped into two-by-two age year and 
time period groups. There were 28 two-year age groups (from 30-31 to 84-85) and ten 
2-year periods (from 1997-1998 to 2015-2016), which covered birth cohorts from 1912 
to 1986. The reference years for the fitted models were identified from the mid-points 
of the available data and were 57 years for age, 2006 for period, and 1949 birth year 
for cohort. 
APC models for HER2 status and the IHC defined molecular subtypes were also 
computed. As data for these markers were only available from 2009 to 2016, count 
data were not grouped as described above but used by individual year for age and time 
period. As for ER models counts were restricted to women aged 30 to 85 years. There 
were 56 one year age groups (from 30 to 85) and eight 1-year periods (from 2009 to 
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2016), which covered birth cohorts from 1924 to 1986. The reference years were 57 
years for age, mid-2012 (2012.5) for period, and 1955 birth year for cohort. All models 
and statistical tests were fitted using R [181] code available from the APC web tool 
developed by the National Cancer Institute (NCI) [182]. P values were deemed 
statistically significant at the 5% level.  
 
3.4 Results 
3.4.1 Overall incidence trends 
A total of 72,217 women were diagnosed with at least one invasive BC between 1997 
and 2016 in Scotland, with approximately 3,000 to 4,000 women registered as having 
an incident BC per year. The overall BC incidence for the final selection of women 
(Figure 3.5, green line) increased over time from 1997 to 2016 but fluctuated during 
those years. From 1997 to 2012, there was a 0.5% annual increase in incidence (95% 
CI: 0.3 to 0.7%). There was a slight decrease observed between 1999 and 2002. After 
2002, BC incidence increased again until 2012. In the last four years, from 2012 to 
2016, a downward trend in incidence (1.3% annual decrease, 95% CI:-2.8 to 0.4%) 
has been observed. 
Overall BC incidence based on a single tumour per woman (Figure 3.5, green line) is 
lower than that based on tumour incidence and there is a less striking increase in BC 
incidence based on data for individual women than that reported by ISD based on 
multiple invasive tumours per woman (Figure 3.5, red line). However, the number of 
invasive tumours recorded per woman did not seem to be responsible for these 
differences, as 6% of women in 1997 and 3% of women in 2016 had secondary 
invasive tumours recorded. Overall BC incidence trends using multiple invasive 
tumours per woman (Figure 3.5, blue line) were also calculated using the same method 





Figure 3.5 Overall age-standardised incidence rates in Scotland from 1997 to 2016 
reported by ISD (based on tumour numerators) and rates calculated for the dataset 
in this study using two methods: tumour based (n=77,841) and person based 
(n=72,217) 
 
Possible differences observed between the rates reported here and those reported by 
ISD reflect both the different calculation procedures (red and blue lines are based on 
tumours and green line in women) and initial definition of the cohort of women (red 
and blue lines include women with other primary tumours and green line exclude 
them) used to compute the incidence rates. The difference between ISD rates (in red) 
and the rates computed for the cohort of women in this dissertation (in blue) using the 
same method (tumours as the denominator for the rates) can be due to the fact that we 
excluded women with previous malignancies of other type. Over 3,500 women had a 
previous malignancy in the cohort (approximately 175 per year), taking into account 
that the difference in the number of women diagnosed every year between the ISD 
cohort and our cohort was between 200-400 women per year, excluding women with 
a previous cancer diagnosis will partially account for the differences observed. Further, 
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cancer registration is a dynamic process and the trends presented by ISD are likely to 
differ from those in other publications even for the same period of time.  
Table 3.5 indicates that both methods (multiple or a single tumour per woman) used 
to estimate incidence rates yielded a population of women with tumours of similar 
characteristics. The differences in tumour characteristics observed between included 
and excluded tumours reflect the selection criteria that aimed to retain the most 
advanced invasive tumour for each woman. 
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Table 3.5 Tumour characteristics of included and excluded tumours for estimates of breast cancer incidence among women in Scotland 
diagnosed between 1997 and 2016 
Tumour characteristic      Tumours excluded   Tumours included            All tumours 
n=5,624 (%) n=72,217 (%) n=77,841 (%) 
TNM Stage I 2,260 (40) 23,554 (33) 25,814 (33) 
 II 1,576 (28)] 25,143 (35) 26,719 (34) 
 III 562 (10) 10,365 (14) 10,927 (14) 
 IV 289 (5) 3,627 (5) 3,916 (5) 
 Unknown 937 (17) 9,528 (13) 10,465 (13) 
Grade Well differentiated 1,075 (19) 8,715 (12) 9,790 (13) 
  Moderately differentiated 2,313 (41) 28,050 (39) 30,363 (39) 
  Poorly differentiated 1,312 (23) 23,525 (33) 24,837 (32) 
  Unknown 924 (17) 11,927 (16) 12,851 (16) 
Nodal status No  2,901 (52) 36,463 (51) 39,364 (50) 
  Yes 1,317 (23) 21,894 (30) 23,211 (30) 
  Unknown 1,406 (25) 13,860 (19) 15,266 (20) 
Tumour size Less than 10mm 1,063 (19) 7,689 (10) 8,752 (11) 
  10-20 mm 1,924 (34) 24,355 (34) 26,279 (34) 
  more than 20mm 1,310 (23) 23,640 (33) 24,950 (32) 
  Unknown 1,327 (24) 16,533 (23) 17,860 (23) 
Screen detected No  4,259 (76) 51,069 (71) 55,328 (71) 
  Yes 1,271 (22) 19,552 (27) 20,823 (27) 
  Unknown 94 (2) 1,596 (2) 1,690 (2) 
ER status Positive 825 (15) 11,726 (16) 12,551 (16) 
  Negative 4,504 (80) 55,144 (76) 59,648 (77) 
  Unknown 295 (5) 5,347 (8) 5,642 (7) 
ER= oestrogen receptor, TNM= tumour, nodes, metastases. 
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Age is one of the most important factors influencing BC incidence rates. In Scotland, 
BC incidence increased with age, with older women having the highest incidence rates 
and over 30% of cases diagnosed in women aged 70 years or older. Figure 3.6 shows 
that incidence rates of BC increase rapidly with age until the approximate age of 
menopause at 50 years. The increase continues but it is moderate from 50 to 70 years 
and rises sharply again after 70 years.  
 
Figure 3.6 Number of breast cancer cases diagnosed and age-specific incidence rates 




3.4.2 Incidence trends by oestrogen receptor status 
3.4.2.1 Women and tumour characteristics by ER status 
Of the 72,217 incident invasive tumours selected that were diagnosed in Scotland from 
1997 to 2016, 76% of them were classified as ER+, 16% as ER- and 8% had unknown 
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Table 3.6 Descriptive characteristics by ER status for all women with an invasive 
breast cancer diagnosed between 1997 and 2016 in Scotland 
Characteristic ER- ER+ ER missing 
  n % n % n % 
  11,726 [16] 55,144 [76] 5,347 [8] 
Age at 
diagnosis 
<50 years 3,196 (27) 10,550 (19) 695 (13) 
50 69 years 5,668 (48) 28,441 (52) 1,580 (30) 
70 years or older 2,862 (24) 16,153 (29) 3,072 (57) 
NHS regions North 3,280 (28) 14,124 (26) 1,307 (24)  
South East 2,782 (24) 15,949 (29) 1,236 (23) 
 





5-Least deprived 2,126 (18) 11,208 (20) 961 (18) 
4 2,348 (20) 11,012 (20) 1,050 (20) 
3 2,380 (20) 11,571 (21) 1,037 (19) 
2 2,431 (21) 11,258 (20) 1,139 (21) 
1-Most deprived 2,440 (21) 10,095 (18) 1,159 (22) 
TNM stage I 2,863 (24) 20,058 (36) 633 (12) 
 II 4,795 (41) 19,470 (35) 878 (16) 
 III 2,200 (19) 7,678 (14) 487 (9) 
 IV 648 (6) 2,492 (5) 487 (9) 
 Unknown 1,220 (10) 5,446 (10) 2,862 (54) 








8,308 (71) 14,586 (26) 642 (12) 
 
Unknown 1,509 (13) 6,536 (12) 3,871 (72) 
Nodal Status No 6,194 (53) 29,400 (53) 869 (16)  
Yes 4,110 (35) 17,369 (31) 415 (8) 
 
Unknown 1,422 (12) 8,375 (15) 4,063 (76) 
Tumour size Less than 10mm 1,017 (9) 6,470 (12) 202 (4) 
 
10 to 20 mm 3,428 (29) 20,449 (37) 478 (9)  
More than 20mm 4,960 (42) 18,168 (33) 512 (10) 
 
Unknown 2,321 (20) 10,057 (18) 4,155 (78) 
Screen 
detected 
No 9,622 (82) 37,400 (68) 4,047 (76) 
Yes 1,943 (17) 17,119 (31) 490 (9)  
Unknown 161 (1) 625 (1) 810 (15) 
HER2 status* Negative 3,050 (69) 20,329 (88) - - 
 
Positive 1,357 (31) 2,844 (12) - - 
PR status* Negative 3,803 (94) 3,036 (16) - - 
 
Positive 226 (6) 15,869 (84) - - 
*Markers only recorded from 2009 to 2016, percentages for those with recorded status. Chi square p value for 
comparison of ER+ and ER- tumours <0.001 for all characteristics. Percentages are given for columns except for 
the total for which row percentages are shown. ER=oestrogen receptor, HER2= human epidermal growth factor 
2, PR= progesterone receptor, TNM= tumour, nodes, metastases.  
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Individual characteristics of women in the cohort showed that over half of breast 
tumours were diagnosed in women aged 50 to 69 years, with a slightly higher 
percentage amongst ER+ tumours than ER- tumours (52% vs 48%). On the contrary, 
the percentage of women <50 years of age who had an ER- tumour was higher than 
the percentage who had an ER+ tumour (27% vs 19%). Tumour characteristics differed 
by ER status, with ER- tumours having characteristics associated with more 
advanced/aggressive disease. ER- tumours had higher grade, higher TNM stage (II and 
III) were more likely to be larger in size and have lymph nodes affected and were less 
likely to be screen detected than ER+ tumours.  
The patterns of other molecular markers also differed by ER status, with ER- tumours 
more likely to be PR negative and HER2 positive than ER+ tumours. In contrast, ER+ 
tumours were more likely to be PR+ and HER2- than ER- tumours. Almost a third of 
ER+ tumours were screen detected compared to only 17% of ER- tumours. In terms 
of social gradient, women with ER- tumours were more likely to be in the most 
deprived quintile than women with ER+ tumours (21% vs 18%).  
As ER status was missing for 8% of the tumours I corrected for missing ER status and 
final numbers of ER+ and ER- tumours are given in Table 3.7 below showing that a 
larger proportion of tumours with missing ER status were imputed as ER+ tumours. 
 
Table 3.7 Number and percentage of breast cancer cases by ER status before and 
after correcting for missing ER status in Scotland, 1997-2016 
ER status Before correction  After correction 
 n %  n % 
ER positive 55,144 76  59,553 82 
ER negative 11,726 16  12,664 18 










3.4.2.2 Incidence rates by ER status and age 
BC incidence increases with age irrespective of ER status, however the pattern 
observed for ER+ and ER- rates is not the same. In Scotland, ER+ rates increase 
rapidly until 50 years of age when the increase by age slows to 70 years of age before 
increasing again at older age (Figure 3.7, red line). Rates of ER- tumours also suffer a 
rapid increase up to 50 years of age but they remain constant after that time (Figure 
3.7, blue line).  
Figure 3.7 Age-specific incidence rates by ER status from 1997 to 2016 in Scotland 
from estimated counts 
 































3.4.2.3 Age-standardised incidence rates by ER status and analysis of trends over time 
using joinpoint regression analysis 
In Scotland, ASiR of ER+ tumours after imputation of missing data increased from 98 
per 100,000 women in 1997 to 113 in 2016 (Figure 3.8, red line). The AAPC estimated 
with joinpoint regression was 0.4% (95% CI: -0.1 to 1%). The increase was 
approximately constant (1.2% increase, 95% CI: 0.8 to 1.5%) from 1997 to 2012 after 
which incidence rates of ER+ tumours decreased by 2.2% annually (95% CI:-4.7 to 
0.4%) (Table 3.8). In contrast, ASiR of ER- tumours decreased consistently over the 
study period (Figure 3.8, blue line), on average by 2.5% per year (95% CI: -3.9 to -
1.1%), and by 11.3% per year (95% CI: -18.9 to -3%) between 1997 and 2000. From 
2000 to 2016, incidence of ER- tumours decreased at 0.7% each year (95% CI: -1.5 to 
0) (Table 3.8).  
Figure 3.8 Age-standardised incidence rates by ER status in Scotland from 1997 to 
2016 with 95% CI after correcting for missing ER status 
 
The effect of using imputation for missing ER status can be observed in Appendix B.4 
were imputed rates of ER+ tumours show more moderate increases than those 
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observed without imputing ER. The effect on ER- tumours is the opposite, showing 
bigger declines in observed compared to imputed analyses, especially for the earlier 
years of the study period.  
Incidence rates by ER status for the three age groups (Figure 3.9) show that the 
increases in incidence observed for ER+ tumours were mainly due to increasing 
incidence in women aged 50 to 69 years. This age group showed consistent increases 
by 0.7% (0.2, 1.3) per year between 1997 and 2011, followed by a decrease of 1.6% (-
1.2, -2.1) per year from 2011 to 2016 (Table 3.8). Younger women aged less than 50 
years also showed increases of 1.1% (0.7, 1.5) per year in ER+ tumours. The decreases 
observed for ER- tumours were consistent for the three age groups but seemed to be 
mainly in early years of the study period for younger women aged less than 50 and 
women older than 70 years (Table 3.8).  
Figure 3.9 Incidence rates of breast cancer in Scotland 1997-2016 by ER status for 3 





Further joinpoint regression graphs and results obtained using the joinpoint 
programme developed by NCI are presented in Appendix B.5. Sensitivity analysis for 
ER+ tumours can be found in Appendix B.6. Sensitivity analysis showed that using an 
uncorrelated or autocorrelated errors models (Appendix Table B.5) did not 
considerably changed the results, a joinpoint was still found at year 2011 or 2012 
(depending on the error model selection) with very similar EAPC estimates for both 
periods (before and after the joinpoint) estimated. The number of joinpoints and the 
trends estimated differed by model selection method (Appendix Table B.6, Appendix 
Table B.7) with permutation method and BIC3 estimating increases in incidence of 
ER+ tumours by 1.2% annually from 1997-2012. BIC method found a significant 
increase between 1999 and 2012 and the modified BIC method an increasing trend for 
the whole study period.
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Table 3.8 Joinpoint regression results for breast cancer incidence rates for women of all ages and for three age groups (20 to 49 years, 
50 to 69 years and 70 years or more) by ER status in Scotland from 1997 to 2016 




















EAPC (95% CI)  
for period before 
joinpoint 
Years           
after 
joinpoint 
EAPC (95% CI) 
for period after 
joinpoint 
Positive  All ages 97.7 112.8 15.1 (13%) 0.4% (-0.1, 1.0) 1997-2012 1.2% (0.8, 1.5) 2012-2016 -2.2 (-4.7, 0.4) 
 20-49 years 41.9 52.1 10.2 (20%) 1.1% (0.7, 1.5) No significant change point identified from 1997-2016 
 50-69 years 192.3 237.4 45.1 (19%) 0.7% (0.2, 1.3) 1997-2011 1.6% (1.2, 2.1) 2011-2016 -1.8 (-3.7, 0.1) 
 70+ years 235.9 234.5 -1.4 (0.6%) 0.1% (-0.3, 0.5) No significant change point identified from 1997-2016 
Negative All ages 35.5 23.1 -12.4 (35%) -2.5% (-3.9, -1.1) 1997-2000 -11.3% (-18.9, -3.0) 2000-2016 -0.7% (-1.5, 0) 
 20-49 years 23.8 15.2 -8.6 (36%) -2.2% (-3.9, -0.6) 1997-2001 -10.3% (-16.8, -3.3) 2001-2016  0% (-1.1, 1.2) 
 50-69 years 64.1 45.5 -18.6 (29%) -1.6% (-2.5, -0.8) No significant change point identified from 1997-2016 
 70+ years 71.8 41.2 -30.6 (43%) -2.4% (-4.2, -0.7) 1997-2003 -7% (-11.4, -2.3) 2003-2016 -0.3% (-1.9, 1.5) 
Bold results are significantly different from 0 (p<0.05). AAPC= average annual percent change, EAPC= estimated annual percentage change, ER=oestrogen receptor. Incidence rates 




3.4.2.4 Age-period-cohort analysis for incidence rates by ER 
APC models by ER status are restricted to women aged 30-85 years (n=67,804) and, 
hence Table 3.9 presents the descriptive characteristics for the population used in APC.  
Table 3.9 Descriptive characteristics of women aged 30 to 85 years diagnosed with 
invasive breast cancer in Scotland and analysed using APC models 







Age 30-49 years  10,379 (20) 3,102 (28) 678 (16)  
50-69 years 28,441 (54) 5,668 (50) 1,580 (38)  




North 13,374 (26) 3,142 (28) 966 (23) 
South East 15,104 (29) 2,644 (24) 954 (23) 































TNM stage I 19,684 (38) 2,813 (25) 578 (14) 
II 18,667 (36) 4,647 (41) 725 (17) 
 III 7,215 (14) 2,083 (19) 391 (9) 
 IV 2,345 (4) 607 (5) 411 (10) 
 Unknown 4,484 (9) 1,083 (10) 2,071 (50) 
Grade I-Well differentiated 8,068 (15) 191 (2) 218 (5)  
II- Moderately 
differentiated 




14,124 (27) 8,031 (71) 597 (14) 
 
Unknown 5,429 (10) 1,373 (12) 2,802 (67) 
Nodal 
Status 
No 29,012 (55) 6,078 (54) 855 (20) 
Yes 17,059 (33) 4,005 (36) 407 (10) 
Unknown 6,324 (12) 1,150 (10) 2,914 (70) 
Screen 
detected 
No 34,729 (66) 9,145 (81) 3,033 (73) 
Yes 17,084 (33) 1,935 (17) 489 (12) 
Unknown 582 (1) 153 (1) 654 (16) 
HER2 
status* 
Negative 19,286 (80) 2,903 (64) 36 (6) 
Positive 2,732 (12) 1,304 (28) 12 (2)  
Unknown 1,995 (8) 362 (8) 584 (92) 
PR status* Negative 2,868 (12) 3,623 (79) <10 (0)  
Positive 15,047 (63) 213 (5) <10 (0)  
Unknown 6,098 (25) 733 (16) 624 (99) 
Tumour 
size 
Less than 10mm 6,424 (12) 1,003 (9) 197 (5) 
10 to 20 mm 20,184 (39) 3,361 (30) 473 (11) 
More than 20mm 17,759 (34) 4,797 (43) 487 (12) 
Unknown 8,028 (15) 2,072 (18) 3,019 (72) 
*Markers collected from 2009. Percentages are by column. ER= oestrogen receptor, HER2= human epidermal 




Net drifts from the final APC model shows that the overall incidence of ER+ tumours 
increased by 0.8% per year (95% CI: 0.6 to 1.0%/year) from 1997 to 2016, whereas 
the incidence of ER- tumours decreased by 1.4% (95% CI: -1.8 to -1.1%/year). Net 
drifts were highly statistically significant for both ER+ (chi square=56.7 with 1df, p 
value<0.0001) and ER- tumours (chi square=71.8 with 1df, p value<0.0001). 
Age effects 
Figure 3.10 presents the fitted longitudinal and cross-sectional age curves from APC 
models that show a similar pattern to the observed for the age-specific incidence rates 
of ER+ and ER- cancers. The longitudinal curve provides a summary measure of the 
age-specific incidence in the reference cohort, while adjusting for period effects. In 
contrast, the cross-sectional age curve is a measure of the age-specific incidence in the 
reference period adjusted for cohort effects.  
Figure 3.10 Longitudinal and cross-sectional age curves of incidence of breast cancer 
in Scotland 1997-2016 by ER status from APC models 
 
Both curves show different patterns for ER+ and ER- tumours. ER+ age specific rates 
sharply increased with age until the approximate age of menopause when there was a 
slight decline, rates increased again until older years. The further increases observed 
after 50 years of age were highest longitudinally (in women born in the same year). 
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ER- age specific incidence showed increases until 50 years of age and then remained 
stable in older ages at diagnosis (for the 2006 reference period) or slightly declined 
(for the 1949 reference cohort). The differences observed between the longitudinal and 
cross-sectional curves is also an indication of the existence of the drift. All hypothesis 
tests for the age deviations (curvature, higher order terms and the combination of both) 
were highly statistically significant for both ER+ (Appendix Table B.9) and ER- 
tumours (Appendix Table B.12) so there is a clear age effect. 
Period effects 
Figure 3.11 shows that temporal trends fitted by the model coincide with the trends 
observed and with the results from joinpoint, with ER+ tumours increasing up to 2012 
and ER- tumours decreasing over time, particularly in earlier years.  





Period rate ratios (PRRs) confirm that incidence of ER+ tumours rose and declined for 
ER- tumours (Figure 3.12). Compared to the reference calendar year (2006), there was 
a lower incidence of ER+ and a higher incidence of ER- rates in earlier years. The 
trends after 2006 do not show a consistent trend for either of the subtypes. The period 
curvature parameters for both ER+ (Appendix Table B.9) and ER- (Appendix Table 
B.12) tumours were highly statistically significant (p<0.001) indicating the existence 
of period effects. The combination test for period effect was also consistent with those 
results for both ER+ (Appendix Table B.10) and ER- (Appendix Table B.13) tumours.  
 
Figure 3.12 Period rate ratios for the incidence rates by ER status in each year of 






CRR curve showed a striking differential pattern between ER+ and ER- tumours 
(Figure 3.13). CRRs ranged from 0.7 (95% CI: 0.6 to 0.9%) for women born in 1913 
to 1.8 (95% CI: 1.0 to 3.1%) for women born in 1985 compared to women born in the 
reference cohort of 1949 for ER+ tumours and from 1.5 (95% CI: 1.0 to 2.3%) for 
women born in 1913 to 0.5 (95% CI: 0.2 to 1.0%) for women born in 1985 for ER- 
tumours.  
Figure 3.13 Cohort rate ratios for the incidence rates for each birth cohort compared 







Cohort effects were also observed in the local drifts patterns (Figure 3.14). The largest 
increases in incidence of ER+ tumours over time was observed in women around 68 
years of age (2% per year, 95% CI: 1.6 to 2.4%], and the largest decline in incidence 
of ER- tumours occurred in women of 52 years (-2.6% per year, 95% CI:--3.2 to -1.9). 
Local drifts were different from the net drift for ER+ tumours (p<0.0001, Appendix 
Table B.9) but did not reach statistical significance for ER- tumours (p=0.062, 
Appendix Table B.12). The combination tests for the cohort effects, although more 
powerful than the Wald tests, showed similar results that were statistically significant 
for ER+ tumours (p<0.0001, Appendix Table B.10) and not significant for ER- 
tumours (p=0.1398, Appendix Table B.13).  

















Net drift= 0.8% per year 
(95% CI: 0.6 to 1.0%/year) 
ER positive 
ER negative 
Net drift= -1.4% per year 





















Additional graphs and all the parameters and hypothesis test results from the APC 
models can be found in Appendix B.7 for ER+ tumours and Appendix B.8 for ER- 
tumours.  
3.4.3 Incidence trends by HER2 status 
Time trend analysis by HER2 and the combination of this marker with other molecular 
markers is limited to years 2009 to 2016 during which 31,099 women were diagnosed 
with invasive BC.  
Table 3.10 presents the distribution of HER2- and HER2+ tumours in Scotland before 
and after the imputation of HER2 status. Eleven percent of all tumours diagnosed 
between 2009 and 2016 had missing HER2 status, with the majority of tumours (three 
in four) being imputed as HER2-. After correcting for HER2 status 85% of women 
had a tumour classified as HER2- and 15% as HER2+. 
Table 3.10 Number and percentage of breast cancer cases by HER2 status before and 
after correcting for missing marker status in Scotland, 2009-2016 
HER2 status Before correction  After correction 
 n %  n % 
HER2 negative 23,420 75  26,357 85 
HER2 positive 4,214 14  4,742 15 






HER2= human epidermal growth factor 2 
 
3.4.3.1 Incidence rates by HER2 status and age 
Age- specific trends by HER2 status showed a similar pattern to those observed for 
ER status (Figure 3.15). Incidence of HER2- tumours rapidly increased until 50 years 
of age, when the increase slows down up to the age of 70 years when incidence 
increases again but less sharp than what was observed in ER+ tumours. The incidence 
of HER2+ tumours increased until 50 years of age when it flattened out as observed 




Figure 3.15 Age-specific incidence rates by HER2 status in Scotland from 2009 to 2016 
 
*Figure is on the natural log scale 
 
3.4.3.2 Age-standardised incidence rates by HER2 status and analysis of trends over time 
using joinpoint regression analysis 
BC incidence trends in Scotland from 2009 to 2016 by HER2 status resembled those 
observed by ER status, with HER2- trends behaving similarly to those observed in 
ER+ and HER2+ as ER- (Figure 3.16). Incidence of HER2- tumours increased by 1.4% 
per year (95% CI: -0.6 to 3.5%/year) from 2009 to 2013, followed by a 2.3% decrease 
per year (95% CI: -5.4 to 0.9%/year) in the most recent years (Table 3.11). However, 
none of those two trends identified reached significance and the most recent declines 
left the rates at levels lower than in 2009. In fact, the AAPC was almost constant for 
HER2- tumours, AAPC=-0.2%/year (-95% CI: 1.3 to 0.9). Incidence rates of HER2+ 
tumours showed a statistically significant decreasing trend over time, with incidence 




























which rates remained constant. AAPC from 2009 to 2016 showed a decreasing trend 
by 2.7%/year but did not reach statistical significance (95%CI: -7.4 to 2.2). A graph 
for the differences in rates for imputed and not imputed counts can be found in 
Appendix B.9. 
Figure 3.16 Incidence rates by HER2 status in Scotland from 2009 to 2016 
 
Incidence rates by HER2 status were similar across age groups. Descriptively, HER2- 
rates in the 50 to 69 years old group showed a similar pattern to the observed for all 
women (Figure 3.17). Joinpoint regression results (Table 3.11) did not suggest any 
significant joinpoint or AAPC estimates for any of the age groups, hence, there were 
no consistent increasing or decreasing patterns observed.  
The declines observed for HER2+ tumours were mainly driven by declines in the 50 
to 69 year age group [-6.4%/year (95% CI: -11.3 to-1.2) from 2009 to 2014] and the 
70 years and older [AAPC=-5.3%/year (95% CI: -9.1 to -1.3)] groups. Incidence rates 
in women aged 20 to 49 years were fairly constant within the study period with 
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AAPC=-0.9%/year (95% CI: -3.3 to 1.6). Further joinpoint results are presented in 
Table 3.11 below. 
 
Figure 3.17 Incidence rates of breast cancer in Scotland 1997-2016 by HER2 status for 





Table 3.11 Joinpoint regression analysis results for breast cancer incidence rates for women of all ages and for three age groups (20 to 
49 years, 50 to 69 years and 70 years or more) by HER2 status in Scotland from 2009 to 2016 
HER2 
status 




















EAPC (95% CI) 
for period before 
joinpoint 
Years           
after 
joinpoint 























-2.3% (-5.4, 0.9) 
 
 20-49 years 52.2 52.6 0.4 (0.8%) 0.9%  
(-0.8, 2.7) 
No significant change point identified from 2009-2016 
 
 50-69 years 241.3 240.6 -0.7 (0.3%) -0.5%  
(-1.8, 0.7) 
No significant change point identified from 2009-2016 
 
 70+ years 250.4 244.7 -5.7 (2.3%) 0.0%  
(-1.3, 1.4) 
No significant change point identified from 2009-2016 
 
          
 
Positive  
All ages 26.4 20.8 -5.6 (21%) -2.7%  
(-7.4, 2.2) 
2009-2014 -6.4%(-11.3, -1.2) 2014-2016 7.2% (-16.4, 37.3) 
 20-49 years 14.9 14.7 -0.2 (1.3%) -0.9%  
(-3.3, 1.6) 
No significant change point identified from 2009-2016 
 
 50-69 years 54.4 42.3 -12.1 (22%) -2.8%  
(-9.0, 3.8) 
2009-2014 -7.9% (-14.5, -0.9) 2014-2016 11.2% (-19.9, 54.2) 
 
 70+ years 49.6 31.5 -18.1 (36%) -5.3%  
(-9.1, -1.3) 
No significant change point identified from 2009-2016 
 
Bold results are significantly different from 0 (p<0.05). AAPC estimated average annual percent change, EAPC estimated annual percentage change, HER2= human 
epidermal growth factor 2. Incidence rates are standardised to the European population. Rates for the age groups are truncated rates for each specific age group.
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3.4.3.3 Age-period-cohort analysis for incidence by HER2 status 
APC models by HER2 status were restricted to rates in women aged 30 to 85 years 
diagnosed in Scotland from 2009 to 2016 (n=29,214). 
Global effect 
Net drifts show that the overall incidence of HER2- tumours remained almost constant 
0.1% per year (95% CI: -0.5 to 0.7%/year) from 2009 to 2016, whereas the incidence 
of HER2+ tumours decreased by 3.3%/year (95% CI: -4.7 to -2.0%/year). These results 
are consistent with those from joinpoint regression and the Wald tests for the net drift 
for HER2- (p value=0.663, Appendix Table B.15) and HER2+ tumours (p 
value<0.00001, Appendix Table B.18). 
Age effects 
Figure 3.18a presents the fitted longitudinal age curves from APC models that show a 
similar pattern to the longitudinal curve by ER status.  
 
Figure 3.18 Longitudinal age curve (a) and ratio between longitudinal and cross-




Incidence increases with age until the approximate age of menopause for HER2- 
tumours. Rates continue to increase after that age at a slower pace and there is an 
important drop in rates after 70 years of age. For HER2+ tumours, longitudinal curve 
is inverse v-shaped with increases until the age of 50 and decreases after.  
The second figure (Figure 3.18b) shows the ratio between the longitudinal and cross-
sectional age curves fitted by APC. The ratio for HER2- tumours show a constant trend 
that is close to 0 and therefore, the longitudinal and cross sectional curves are very 
similar which is also an indication of no net drift. In contrast, the ratio for HER2+ 
tumours ranges from 2.0 (95% CI: 1.3 to 3.2) at 30 years to 0.3 (95% CI: 0.2 to 0.5) at 
85 years.  
Period effects 
PRRs (Figure 3.19) show no clear period differences with the reference period in mid-
2012 for HER2- tumours (p=0.062) and a decreasing trend for HER2+ tumours, with 














Figure 3.19 Period rate ratios for the incidence rates in each year of diagnosis (period) 
compared to the reference year 2006 
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Although there is high uncertainty around the estimates, particularly for HER2+ 
tumours, the Wald tests for period deviations were significant for both subtypes. The 
combination test confirmed that period effects were observed for both ER+ and ER- 
tumours (Appendix B.10 and Appendix B.11). 
Cohort effects 
Figure 3.20 for the CRRs by HER2 status show similar results to those observed for 
ER. However, no consistent effects were observed for HER2-tumours. HER2+ rates 
seemed to be higher in women born in early 30s through the 40s and lower in younger 
women born in the 70s and 80s compare to the referent cohort of women born in 1955. 
Although descriptively the rates did not seem to have clear cohort effects for the 
HER2- tumours, the hypothesis tests for the cohort deviations showed significant 
results for both Wald test (p value=0.004) and the combination test (p value=0.008). 
In contrast, there were no significant cohort effects for HER2+ tumours (Wald test p 

















Figure 3.20 Cohort rate ratios for the incidence rates for each birth cohort compared 




The cohort effects observed for HER2- tumours were observed in the local drifts 
signals (Figure 3.21). Local drifts for the HER2- tumours showed the highest increases 
observed in younger women aged 30-40 years and the highest decreases in women 
aged 60 to 70 years. The pattern for HER2+ tumours did not show any of the age 
groups to be different from the net drift. Hypothesis test for the local drifts was 























Net drift= 0.1% per year 











Net drift= -3.4% per year 
(95% CI: -4.7 to -2.0%/year) 
HER2 positive 













Additional graphs and all the parameters and hypothesis tests results from the APC 
models can be found in Appendix B.10 for HER2- tumours and Appendix B.11 for 
HER2+ tumours. 
 
3.4.4 Incidence trends by IHC defined molecular subtypes 
3.4.4.1 Women and tumour characteristics by molecular subtypes 
Among 31,099 incident invasive tumours selected that were diagnosed in Scotland 
from 2009 to 2016, three in four were luminal tumours with luminal A being the 
majority of them (66% of all tumours) and a further 9% being luminal B. The 
percentage of TNBC was similar to that for luminal B tumours and the least common 
subtype was the HER2-enriched with only 4% of all cases. A further 11% of cases 
could not be classified as any of the subtypes due to missing data.  
Subtypes differed by women and tumour characteristics (Table 3.12). Luminal A, the 
most common subtype, was more common in older women and less common in 
younger than the rest of subtypes. It also had tumour characteristics associated with 
less advanced disease, such as, smaller tumour size, lower grade or fewer tumours with 
affected nodal status. These differences were particularly marked in comparison to 
TNBC that seemed to be the more advanced ones with 79% being poorly differentiated 
and 43% bigger than 20mm. However, the % of women with nodes affected was bigger 
for luminal B and HER2-enriched tumours than for TNBC. Screening also seemed to 
differ by subtype with luminal A being the most screened detected (36%) and TNBC 




Table 3.12 Descriptive characteristics by IHC defined molecular subtype for all women with an invasive breast cancer diagnosed between 
2009 and 2016 in Scotland (n=31,099) 











  n % n % n % n % n % n % 
  20,484 [66] 2,915 [9] 1,288 [4] 2,899 [9] 3,513 [11] 31,099 100 
Age at diagnosis <50 years 3,669 (18) 831 (28) 312 (24) 803 (28) 443 (13) 6,058 (19) 
50 69 years 10,946 (53) 1,426 (49) 654 (51) 1,390 (48) 1,566 (44) 15,982 (51) 
70 years or older 5,869 (29) 658 (23) 322 (25) 706 (24) 1,504 (43) 9,059 (29) 
NHS Scottish 
region 
North 5,410 (26) 790 (27) 333 (26) 772 (27) 790 (23) 8,095 (26) 
South East 5,867 (29) 751 (26) 325 (25) 766 (26) 784 (22) 8,493 (27) 
West 9,207 (45) 1,374 (47) 630 (49) 1,360 (47) 1,939 (55) 14,510 (47) 
Tumour size Less than 10mm 2,874 (14) 304 (10) 169 (13) 283 (10) 363 (10) 3,993 (13)  
10 to 20 mm 7,734 (38) 883 (30) 301 (23) 879 (30) 872 (25) 10,669 (34)  
More than 20mm 6,706 (33) 1,128 (39) 458 (36) 1,248 (43) 712 (43) 10,252 (33)  
Unknown 3,170 (15) 600 (21) 360 (28) 489 (17) 1,566 (17) 6,185 (20) 
Grade I-Well differentiated 3,063 (15) 97 (3) <10 (<1) <40 (1) 345 (10) 3,541 (11)  
II- Moderately differentiated 10,858 (53) 975 (34) 238 (18) 401 (14) 1,151 (33) 13,623 (44)  
III- Poorly differentiated 5,027 (25) 1,554 (53) 886 (69) 2,277 (79) 815 (23) 10,559 (34)  
Unknown 1,536 (7) 289 (10) <200 (12) 189 (6) 1,202 (34) 3,376 (11) 
TNM stage I 8,705 (42) 821 (28) 296 (23) 830 (29) 1,260 (36) 11,912 (38) 
 II 7,307 (36) 1,140 (39) 506 (39) 1,307 (45) 854 (24) 11,114 (36) 
 III 2,241 (11) 487 (17) 259 (20) 424 (15) 318 (9) 3,729 (12) 
 IV 959 (5) 221 (8) 118 (9) 147 (5) 366 (10) 1,811 (6) 
 Unknown 1,272 (6) 246 (8) 109 (8) 191 (7) 715 (20) 2,533 (8) 
Nodal Status No 11,667 (57) 1,464 (50) 626 (49) 1,721 (59) 1,388 (40) 16,866 (54)  
Yes 5,946 (29) 1,083 (37) 496 (38) 907 (31) 610 (17) 9,042 (29)  
Unknown 2,871 (14) 368 (13) 166 (13) 271 (9) 1,515 (43) 5,191 (17) 
Screen detected No 13,069 (64) 2,199 (75) 1,041 (81) 2,394 (83) 2,355 (67) 21,058 (68)  
Yes 7,403 (36) 715 (25) 247 (19) 505 (17) 1,092 (31) 9,962 (32) 
Brackets are row percentages and parenthesis are column percentages. HR= hormone receptor, HER2= human epidermal growth factor 2, NHS= National Health Service, 
PR=progesterone receptor, TNM= tumour, nodes, metastases.  
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After correcting for missing HR/HER2 status (Table 3.13), three in four tumours were 
re-classified as luminal A and a further 11% as luminal B. TNBC constituted another 
11% of all tumours and HER2-enriched was the least likely subtype.  
Table 3.13 Number and percentage of breast cancer cases by IHC defined molecular 
subtype before and after correcting for missing marker status in Scotland, 2009-2016 
Molecular subtype Before correction  After correction 
 n %  n % 
Luminal A 20,484 66  23,093 74 
Luminal B 2,915 9  3,286 11 
HER2-enriched 1,288 4  1,452 5 
Triple Negative 2,899 9  3,268 11 




HER2=human epidermal growth factor 2 
 
3.4.4.2 Incidence rates by molecular subtypes and age 
 
Age- specific trends in BC incidence by molecular subtypes (Figure 3.22) showed a 
different pattern for luminal A tumours than for the rest of molecular subtypes. 
Luminal A age-specific incidence rates had similar patterns those observed for ER+ 
tumours with rapid increases until 50 years of age when rates slightly decline and 
increase again peaking at around 65 and 85 years. The rest of the subtypes showed 
slightly different patterns with incidence increasing until 50 years and remaining 








Figure 3.22 Age-specific rates by IHC defined molecular subtype 
 
*Figure is on the natural log scale 
 
 
3.4.4.3 Age-standardised incidence rates by molecular subtypes and analysis of trends 
over time using joinpoint regression analysis 
Incidence rates for the four molecular subtypes (Figure 3.23) showed that luminal A 
tumours had the highest incidence rates with a similar pattern to the observed for ER+ 
tumours. Incidence of luminal A tumours increased by 4.9% per year (95% CI: -3.9 to 
14.5%/year) from 2009 to 2011, and decreased by 1.7% per year after (95% CI: -3.5 
to 0.2%/year). However, none of those two trends was statistically significant and the 







Figure 3.23 Age-standardised incidence by molecular subtype in Scotland from 1997 
to 2016 with 95% CI after correcting for missing subtype 
 
 
The other subtypes had considerably lower incidence rates and different patterns than 
the luminal A tumours. No significant change point in incidence was identified for 
luminal B or HER2-enriched tumours. HER2-enriched tumours showed a slightly 
decreasing trend overall AAPC=-1.3%/year (95% CI: -6.1 to 3.8) and for each age 
group that did not reach significance. Incidence of luminal B tumours declined overall 
[AAPC=-4.5%/year (95% CI:-7.3 to -1.6)] with declines mainly observed in women 
aged 50-69 years and 70 years or older (Figure 3.24, Table 3.14). TNBC incidence 
decreased in the early years, 2009-2011, but increased after (from 2011 to 2016) with 
and EAPC= 4.5%/year (95% CI: 0.1 to 9). Those increases were mainly observed in 
younger women aged 20-49 years for which AAPC was 4.6%/year (95% CI: 1.2 to 





Figure 3.24 Incidence rates by molecular subtype and age groups (20-49 years, 50-69 
years and 70 years or older) 
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Table 3.14 Joinpoint regression analysis results for breast cancer incidence rates for women of all ages and for three age groups (20 to 
49 years, 50 to 69 years and 70 years or more) by molecular subtypes in Scotland from 2009 to 2016 (page 1 of 2) 
Molecular 
subtype 
























Years           
after 
joinpoint 
EAPC (95% CI) 









2011-2016 -1.7%  
(-3.5, 0.2) 
20-49 years 44.1 42.1 -2 (4.5%) 0.1%  
(-1.5, 1.7) 
No significant change point identified from 2009-2016 
50-69 years 204.9 210.9 6 (2.9%) 0.2%  
(-1.9, 2.2) 
2009-2011 6.6%  
(-3.9, 18.2) 
2011-2016 -2.3%  
(-4.4, -0.1) 
70+ years 224.3 215.8 -8.5 (3.8%) -0.1%  
(-2.4, 2.2) 








All ages 18.9 13.8 -5.1 (27%) -4.5%  
(-7.3, -1.6) 
No significant change point identified from 2009-2016 
20-49 years 10.6 10.4 0.2 (1.9%) -0.9%  
(-2.8, 1.0) 
No significant change point identified from 2009-2016 
50-69 years 36.1 27.6 -8.5 (24%) -5%  
(-8.5, -1.3) 
No significant change point identified from 2009-2016 
70+ years 35.7 20.1 -15.6 (44%) -7.3%  
(-12.6, -1.7) 







Table 3.14 (continued) Joinpoint regression analysis results for breast cancer incidence rates for women of all ages and for three age 
groups (20 to 49 years, 50 to 69 years and 70 years or more) by molecular subtypes in Scotland from 2009 to 2016 (page 2 of 2) 
Molecular 
subtype 
























Years           
after 
joinpoint 
EAPC (95% CI) 






All ages 8.2 7.0 -1.2 (15%) -1.3%  
(-6.1, 3.8) 
No significant change point identified from 2009-2016 
20-49 years 4.3 4.4 0.1 (2.3%) -0.8%  
(-7.3, 6.2) 
No significant change point identified from 2009-2016 
50-69 years 18.2 14.7 -3.5 (19%) -1.6%  
(-7.8, 5.0) 
No significant change point identified from 2009-2016 
70+ years 13.9 11.3 -2.6 (19%) -1.3%  
(-7.8, 5.7) 





All ages 16.1 15.7 -0.4 (2.5%) 0.2%  
(-3.6, 4.1) 
2009-2011 -9.9%  
(-25.5, 8.9) 
2011-2016 4.5%  
(0.1, 9.0) 
20-49 years 8.1 10.4 2.3 (28%) 4.6%  
(1.2, 8.2) 
No significant change point identified from 2009-2016 
50-69 years 36.5 29.8 -6.7 (18%) -1.7%  
(-7.1, 4.1) 
No significant change point identified from 2009-2016 
70+ years 26.8 29.3 2.5 (9.3%) 2.4%  
(-0.7, 5.6) 
No significant change point identified from 2009-2016 
Bold results are significantly different from 0 (p<0.05). AAPC= average annual percent change, EAPC= estimated annual percentage change, HR= hormone receptor, HER2= human 
epidermal growth factor 2. Incidence rates are standardised to the European population. Rates for the age groups are truncated rates for each specific age group. 
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3.4.4.4 Age-period-cohort analysis for incidence by molecular subtypes 
APC models for the molecular subtypes were restricted to women aged 30 to 85 years 
with invasive BC diagnosed between 2009 and 2016 (n=29,214). 
Global effect 
Net drifts for each of the subtypes (Table 3.15) showed very similar results to those 
previously seen using joinpoint regression with only luminal B tumours showing a 
significant declining trend by 4% per year from 2009 to 2016.  
Table 3.15 Net drifts estimated from APC models for each molecular subtype 
Subtype Net Drift Lower CI Upper CI P value 
Luminal A  -0.04 -0.69 0.62 0.906 
Luminal B -4.19 -5.72 -2.63 <0.0001 
HER2-enriched -1.32 -3.63 1.04 0.272 
Triple Negative 0.20 -1.45 1.88 0.813 
CI= confidence interval, HER2=human epidermal growth factor 2. 
 
Age effects 
Fitted longitudinal age curves (Figure 3.25) were similar to age-specific trends in 
Figure 3.22. Further, longitudinal (Figure 3.25) and cross-sectional curves (Appendix 
B.13) for luminal A, HER2-enriched and TNBC had similar patterns suggesting no net 
drift. Luminal B was the only subtype with a clear difference between longitudinal and 
cross sectional curve indicating a significant net drift effect. Age effects were observed 











Figure 3.25 Longitudinal age curve for each molecular subtype 
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The only significant PRRs compared to the reference period in mid-2012 were those 
observed for luminal B tumours between 2012 and 2016 that showed PRRs of around 
0.8 (Figure 3.26). However, period effects were statistically significant only for 










Figure 3.26 Period rate ratio for each molecular subtype 
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CRRs (Figure 3.27) for the molecular subtypes show that luminal B was the only 
subtype with a significant cohort effect with women born in the 1920s and 1930s 
having higher incidence of luminal B tumours in comparison to women born in the 











Figure 3.27 Cohort rate ratio for each molecular subtype 
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Local drifts (Figure 3.28) suggested that the cohort effects observed in the luminal B 
tumours were driven by declines observed in older women aged 60 years or older. 
Local drifts and cohort effects for the rest of the subtypes were not as clear and did not 










Figure 3.28 Local drifts for each molecular subtype 
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All additional graphs, parameters and hypothesis test for the APC models for each 













3.4.5 Sensitivity analysis for luminal tumours 
Luminal tumours are further differentiated using a cell proliferation marker known as 
Ki67. However, routinely collected data from most cancer registry does not include 
this marker. Grade is often used as a marker of cell proliferation, and luminal tumours 
have been further classified using grade. Luminal A tumours with high grade have 
been seen to be more similar in behaviour to luminal B tumours than to luminal A 
tumours of low or middle grade. In this part of the analysis, grade was used as a marker 
for cell proliferation and sensitivity analysis was performed to compare incidence rates 
in luminal A and luminal B tumours with and without the use of grade.  
Table 3.16 presents the distribution of grade between luminal A and luminal B 
tumours. The new classification combined luminal A tumours of high grade (n=5027) 
with the original luminal B tumours of any grade.  
 










Luminal A 3063 (16%) 10858 (57%) 5027 (27%) 
Luminal B 97 (4%) 975 (37%) 1554 (59%) 
Cells represent counts (%) among those with known subtype and grade. 
 
Figure 3.29 shows that luminal A tumours of low/middle grade followed a similar 
pattern in incidence over time to that observed for all luminal A tumours, as they form 







Figure 3.29 Age-standardised incidence rates of luminal tumours classified with and 
without the use of grade 
 
 
When combining luminal A tumours of high grade with luminal B tumours, the 
declines in incidence over time originally observed for luminal B tumours of all grade 
are still observed but with a slightly more marked decline. Joinpoint analysis (Table 
3.17) also shows similar results irrespective of the use of grade to further classify the 
luminal tumours. However, CIs considerably narrow for luminal B tumours as a result 
of larger numerators. Further, increases in incidence trends for luminal A tumours 
(low/middle) grade are now statistically significant amongst women of screening age, 





Table 3.17 Joinpoint regression analysis results for breast cancer incidence rates for women of all ages and for three age groups (20 to 
49 years, 50 to 69 years and 70 years or more) for luminal A and luminal B with and without grade in Scotland from 2009 to 2016 (page 
1 of 2) 
Molecular 
subtype 












2009 to 2016 





















All ages 100.1 99.6 -0.5 (0.5%) 0.1%  
(-1.6, 1.9) 
2009-2011 4.9%  
(-3.9, 14.5) 
2011-2016 -1.7%  
(-3.5, 0.2) 
20-49 years 44.1 42.1 -2 (4.5%) 0.1%  
(-1.5, 1.7) 
No significant change point identified from 2009-2016 
50-69 years 204.9 210.9 6 (2.9%) 0.2%  
(-1.9, 2.2) 
2009-2011 6.6%  
(-3.9, 18.2) 
2011-2016 -2.3%  
(-4.4, -0.1) 
70+ years 224.3 215.8 -8.5 (3.8%) -0.1%  
(-2.4, 2.2) 
2009-2012 3%  
(-3.8, 10.2) 





All ages 71.9 76.4 4.5 (0.6%) 1.1%  
(-0.6, 2.8) 
2009-2011 7.2%  
(-1.4, 16.6) 
2011-2016 -1.3%  
(-3, 0.5) 
20-49 years 27.3 28 0.7 (2.6%) 1.5%  
(-0.6, 3.5) 
No significant change point identified from 2009-2016 
50-69 years 149.2 163.7 14.5 (9.7%) 1.1%  
(0.2, 2.1) 
2009-2011 9.9%  
(4.7, 15.3) 
2011-2016 -2.1%  
(-3.1, -1.2) 
70+ years 169.7 174.2 4.5 (2.7%) 0.8%  
(-2, 3.7) 
2009-2011 6.4%  
(-7.6, 22.5) 
2011-2016 -1.3% 






Table 3.17 (continued) Joinpoint regression analysis results for breast cancer incidence rates for women of all ages and for three age 
groups (20 to 49 years, 50 to 69 years and 70 years or more) for luminal A and luminal B with and without grade in Scotland from 2009 
to 2016 (page 2 of 2) 
Molecular 
subtype 












2009 to 2016 
















(95% CI) for 
period after 
joinpoint 
Luminal B  
(all grade) 
All ages 18.9 13.8 -5.1 (27%) -4.5%  
(-7.3, -1.6) 
No significant change point identified from 2009-2016 
20-49 years 10.6 10.4 0.2 (1.9%) -0.9%  
(-2.8, 1.0) 
No significant change point identified from 2009-2016 
50-69 years 36.1 27.6 -8.5 (24%) -5%  
(-8.5, -1.3) 
No significant change point identified from 2009-2016 
70+ years 35.7 20.1 -15.6 (44%) -7.3%  
(-12.6, -1.7) 
No significant change point identified from 2009-2016 
Luminal B  
(all grade) + 
Luminal A 
(high grade) 
All ages 46.3 37 -9.3 (20%) -3.3% 
(-4.5, -2.1) 
No significant change point identified from 2009-2016 
20-49 years 27.3 24.5 -2.8 (10%) -1.7%  
(-3.6, 0.2) 
No significant change point identified from 2009-2016 
50-69 years 91.8 74.8 -17 (19%) -3.7%  
(-5.8, -1.5) 
No significant change point identified from 2009-2016 
70+ years 89.7 61.4 -28.3 (32%) -4.2%  
(-6.6, -1.9) 
No significant change point identified from 2009-2016 
Bold results are significantly different from 0 (p<0.05). AAPC average annual percent change, EAPC estimated annual percentage change. Joinpoint 
regression was performed using the estimated counts corrected for missing ER and HER2 status, and analysis corrects for multiple testing using 
Bonferroni correction (See methods section).
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3.4.6 Incidence trends by method of detection 
 
Table 3.18 below presents the characteristics of women with screen detected tumours 
and women with non-screen detected tumours that form the dataset for the analysis of 
incidence rates by method of detection.  
Table 3.18 Descriptive characteristics of screen detected and non-screen detected 
tumours in women aged 50 to 69 years (approximate screening age) diagnosed with 
BC in Scotland between 1997 and 2016 (page 1 of 2) 









North 4,527 [49] 4,753 [51] 
South East 4,912 [51] 4,808 [49] 





1997-2001 3,016 [40] 4,548 [60] 
2002-2006 3,685 [46] 4,268 [54] 
2007-2011 5,135 [54] 4,343 [46] 




1-Most deprived 2,830 [44] 3,604 [56] 
2 3,389 [48] 3,627 [52] 
3 3,696 [50] 3,689 [50] 
  4 3,651 [51] 3,507 [49] 
  5-Least deprived 3,567 [50] 3,503 [50] 
Grade I-Well differentiated 3,873 (23) 1,716 (10) 
  II- Moderately differentiated 8,433 (49) 6,531 (36) 
  III- Poorly differentiated 3,696 (22) 7,406 (41) 
  Unknown 1,132 (7) 2,277 (13) 
TNM stage I 10,420 (61) 4,696 (26) 
  II 4,537 (26) 7,127 (40) 
  III 981 (6) 3,190 (18) 
  IV 142 (1) 1,248 (7) 
  Unknown 1,054 (6) 1,669 (9) 
Nodal Status No 12,748 (74) 8,772 (49) 
  Yes 3,769 (22) 6,955 (39) 
  Unknown 617 (4) 2,203 (12) 
Tumour size Less than 10mm 4,273 (25) 1,241 (7) 
  10 to 20 mm 8,453 (49) 6,011 (34) 
  More than 20mm 3,404 (20) 7,479 (42) 





Table 3.18 (continued) Descriptive characteristics of screen detected and non-screen 
detected tumours in women aged 50 to 69 years (approximate screening age) 
diagnosed with BC in Scotland between 1997 and 2016 (page 2 of 2) 





    17,134 [49] 17,930 [51] 
ER status Negative 1,700 (10) 3,897 (22) 
  Positive 15,028 (88) 13,134 (73) 
  Unknown 406 (2) 899 (5) 
PR status* Negative 1,343 (16) 2,144 (29)  
Positive 4,930 (58) 3,548 (48) 
  Unknown 2,273 (27) 1,729 (23) 
HER2 status* Negative 6,799 (80) 5,554 (75) 
  Positive 837 (10) 1,247 (17) 
  Unknown 910 (11) 620 (8) 
Molecular 
subtype* 
Luminal A 5,398 (63) 3,079 (41) 
Luminal B 1,591 (19) 2,300 (31) 
 HER2-enriched 212 (2) 442 (6) 
 Triple Negative 428 (5) 962 (13) 
 Unknown 917 (11) 638 (9) 
*Markers available from 2009. Brackets are row percentages and parenthesis are column percentages. ER= 
oestrogen receptor, HER2= human epidermal growth factor 2, NHS= National Health Service, PR=progesterone 
receptor, TNM= tumour, nodes, metastases. 
 
The distribution of screen and non-screen detected BC tumours was very similar 
amongst the three Scottish regions (roughly 50% screen and 50% non-screen detected) 
but the West region had a lightly higher % of screen detected tumours (53%) than the 
other two regions. The proportion of screen detected tumours increased over time with 
40% of all tumours being screen detected in 1997-2001 and 53% in 2012-2016 period. 
Deprivation was associated with screening with women in the most deprived areas 
being less likely to have screen detected tumours (44%) compared to women in the 
least deprived areas of Scotland (50%).  
Furthermore, screen detected tumours had characteristics of a less aggressive disease 
than tumours that were non-screen detected. They were less likely to be poorly 
differentiated (22% vs 41%), more likely to be stage I (61% vs 26%) and less likely to 
be stage II-IV, less likely to have positive nodal status (22% vs 39%), more likely to 
be smaller than 10mm (25% vs 7%) and more likely to be ER+, PR+ and HER2- than 
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non-screen detected tumours. The distribution of molecular subtypes was also different 
between screen and non-screen detected tumours with a higher % of screen detected 
tumours being luminal A tumours (63% vs 41%), whereas the % of non-screen 
detected tumours that were luminal B, HER2-enriched and TNBC was highest than 
that observed for screen detected tumours.  
Figure 3.30 shows that the incidence of screen detected tumours sharply increased 
from 1997 to 2011 but decreased after that time. In contrast, incidence of non-screen 
detected tumours was constant or slightly declined over the study period.  
Figure 3.30 Incidence by method of detection for women aged 50 to 69 years 
diagnosed in Scotland from 1997 to 2016 
 
Figure 3.31 of the incidence trends by method of detection and ER status shows that 
screen detected ER+ tumours have the same pattern to that observed for all screen 
detected tumours with a rapid increase in incidence whereas ER+ non-screen detected 

































incidence observed for ER- tumours is driven by non-screen detected tumours and ER- 
screen detected tumours show a constant or slightly increasing trend. 
 
Figure 3.31 Incidence by method of detection and ER status in women aged 50 to 69 












Figure 3.32 of the incidence trends by method of detection and IHC defined subtype 
showed that the overall trend observed for luminal A tumours was similar to that 
observed for screen detected tumours. Non-screen detected luminal A tumours also 
showed an increasing trend over time. Although the incidence of luminal B tumours 
was higher for non-screen detected tumours, the pattern observed for all luminal B 
tumours was more similar to that observed for screen detected tumours than for non-
screen detected tumours. HER2-enriched and TNBC incidence by method of detection 
showed that the overall trends were driven by non-screen detected tumours and 


































































Figure 3.32 Trends in incidence by method of detection for each IHC defined 
molecular subtype in women aged 50 to 69 years diagnosed with BC in Scotland from 











3.5.1 Summary of key findings 
In Scotland, trends of BC incidence showed a divergent pattern between ER+ and ER- 
tumours, with increases of ER+ tumours and decreases for ER- tumours for the study 
period from 1997 to 2016. However, incidence of ER+ tumours showed a decreasing 
trend in the last five years (from 2011 to 2016). Increases in incidence of ER+ tumours 
were observed for women of all ages but particularly for women of screening age (50 
to 69 years). In contrast, incidence of ER- tumours declined over time for all age 
groups and the declines were sharpest in early years, between 1997 and 2002. APC 
models results indicated that, in addition to the period effects already described above 
from time trends in ASiR, cohort effects were also observed for ER+ tumours. Women 
born in the 1920s to 1940s had a lower incidence of ER+ breast tumours than women 
born around 1950. There was also a suggestion that younger cohorts born between 
1960s and 1980s had lower incidence of ER- tumours in comparison to those born 
around 1950, however this effect was not statistically significant.  
The analysis of incidence by HER2 status showed similar incidence patterns to those 
observed by ER with HER2- tumour incidence patterns similar to ER+ tumours and 
HER2+ incidence patterns similar to ER- tumours. This was an expected result for 
HER2- tumours as they are mostly ER+ but was unexpected for HER2+ tumours as 
most of them are also ER+ tumours. The limited study period for which HER2 data is 
available in the cancer registry (from 2009 to 2016) influenced the significance of the 
jointpoint and APC results due to lack of power and supported that monitoring HER2 
status by itself does not much more aetiological clues and that its influence on the 
incidence rates is more clear in combination with other molecular subtypes.  
Further analysis of the incidence trends by HER2 in combination with ER and PR 
status as a surrogate for the intrinsic molecular subtypes of BC suggested differences 
in secular incidence trends. Luminal A tumours had similar incidence patterns to those 
observed for ER+ tumours, with increases until 2011 after which incidence declined. 
In contrast, incidence of luminal B tumour declined over time, particularly in women 
over 50 years of age. There was no clear time trend in incidence for HER2-enriched 
tumours but TNBC tumours showed an increasing trend from 2011 that was driven by 
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increases of 4.6% per year (95% CI: 1.2 to 8.2) in younger women aged 20 to 49 years. 
APC model results suggested that incidence of luminal A was influenced by age, 
period and cohort effects but that period effects were the main driver of the changes in 
incidence, hence suggesting screening as a possible factor contributing to the 
increasing trends. For luminal B tumours, there was a significant cohort effect with 
women born in the 1920s and 1930s having higher incidence of luminal B tumours 
than women born in later years, with the largest declines of luminal B tumours 
experienced by women aged 60-70 years old. Sensitivity analysis for incidence of the 
luminal tumours using grade as and additional marker for cell proliferation showed 
results consistent with those previously observed. However, estimates of the annual 
percentage change from joinpoint became more precise due to the larger number of 
luminal B tumours than prior to re-classification of high grade luminal A tumours as 
luminal B.  
3.5.2 Comparison with previous studies and possible explanation for the observed 
trends  
Consistent with previous studies of time trends in BC incidence by ER status in the 
United States for 1980-2008, Denmark for 1993-2010 and Ireland for 2004 to 2013 
[135, 136, 146], incidence trends in Scotland differ by ER status that suggests 
aetiological heterogeneity with distinct patterns by age at diagnosis, year of diagnosis 
and birth cohort. Previous studies showed increases for ER+ tumours that ranged from 
0.1% in the US [135] to 3% in Denmark [136] and decreases for ER- tumours that 
ranged from -2% in the US [135] to -3.4% in Ireland [146]. Although consistent in the 
direction of the trend, differences in the estimates between countries were observed 
that might be related to the different definition of a BC and the use of tumours as the 
basis for the incidence trends in the rest of studies instead of women in our study.  
The declines due to MHT might also be responsible for the differences observed 
between countries. In the United States, the almost constant overall trend for ER+ 
tumours was influenced by periods of increases from 1980 to early 2000s followed by 
the sharp drop in incidence attributed to the declines in MHT use [54, 55] after MHT 
use was found to be associated with an increased risk of BC. In Scotland, the decreases 
in the incidence of ER+ tumours around the year 2000 were previously reported by 
Sharpe et al.[148]. They observed statistically significant declines of 11.2% per year 
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in women aged 50 to 64 years (the screening age range up to 2003) that started in the 
year 2000 and continued up to 2005. Compared to the previous study by Sharpe et al 
[148], this study showed similar but smaller declines in ER+ tumours around the year 
2000. The differences between the two studies in Scotland may have arisen from 
excluding women with a previous malignancy, imputing missing ER marker and 
computing incidence rates with number of women instead of number of tumours as the 
numerator in this analysis. Declines in BC incidence, particularly for ER+ tumours, in 
the early 2000s were also seen in other European countries, such as France [139], 
Sweden [145] and Norway [183]. A recent study of the effect of MHT in BC risk 
suggests a causal association and estimate that approximately one BCs out of 20 
million global BCs since 1990 have been caused by MHT [63]. In Scotland, MHT is 
estimated to account for 2.3% of all BC cases [155].  
After the sudden drop in incidence of ER+ tumours in the early 2000s, a further 
increase in incidence was reported in most countries suggesting other factors might be 
related to the divergent trends observed. Information on the trends observed in the last 
decade is very limited but this study shows, for the first time, recent declines in the 
incidence of ER+ tumours in Scotland that started around the year 2011. In contrast, 
in the US incidence slightly increased by 0.3% per year from 2012 to 2016, mainly for 
local stage and HR+ tumours [184] while rates in Ireland remained stable from 2010 
to 2013 [146]. These more recent declines in ER+ incidence may at least partly be due 
to the achievement of stable uptake rates for screening as they are mainly observed in 
women of screening age from 50 to 69 years [140].  
In Scotland, the mammographic screening programme started in 1988 and was one of 
the first countries in the world to implement a national BC screening programme, 
earlier than Ireland (2000) and Denmark (2010). After the implementation of a 
screening programme, incidence rates of the target disease are expected to rapidly 
increase because prevalent cases are detected and then the effect of the screening 
programme is expected to decline over time until it reaches a plateau. The saturation 
of the screening programme has been previously linked to declines in incidence [135, 
143]. In Scotland, full implementation of the screening programme was completed by 
1991 and uptake has been consistently high with proportions accepting screening over 
75% during the study period. In the last three years of the study period (2013-2016) a 
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slight decrease of 0.6% in uptake has been reported but this is unlikely to have 
contributed to the recent declines in ER+ tumours [185]. This study supports that 
mammographic screening is likely to have contributed to the increases in incidence of 
ER+ tumours from 1997 to 2011. In Scotland, ER+ tumours were more likely to be 
screen detected than ER- tumours (53% vs. 30%) which is consistent with the fact that 
ER- tumours are likely to be detected in younger women who are not screened. The 
APC models showed that the greatest increases were observed among women aged 65 
to 72 years which coincides with the extension of the mammographic programme in 
2003 to include women aged 65 to 70 years of age. Further, additional analysis in 
women of screening age (50 to 69 years) showed that increases in the overall incidence 
of ER+ tumours were driven by increases of screen detected ER+ tumours, whereas 
not screen detected tumours remained constant for the study period which strongly 
suggests the important effect of screening in the increasing trends observed. In 
contrast, ER- tumours were less likely to be screen detected and the overall declining 
trend was more similar to that observed for not screened detected tumours suggesting 
that screening is more likely to detect ER+ than ER- tumours. One possible explanation 
for this could be the rapid cell growth and proliferation of these aggressive subtypes 
that become symptomatic between screening appointments and are known as interval 
breast cancers. Interval breast cancers are more likely to be ER/PR negative [186-188], 
HER2+ [189] and TNBC [187, 190], which could suggest that interval cancers are 
biologically different to screen detected tumours rather than more difficult to detect. 
Other studies suggest that ER- or TNBC interval cancers lack the typical radiological 
features of malignancy seeing in screen detected ER+ tumours [191, 192] and that they 
are associated with a higher breast density which makes them more difficult to be 
screen detected [193]. Future efforts should be considered to improve detection of ER- 
or aggressive tumours subtypes (HER2-enriched, TNBC).  
Apart from screening, other factors may have also contributed to the observed 
divergent trends by ER status. APC models suggest a clear cohort effect for ER+ 
tumours with older generations having a lower risk of ER+ tumours than younger 
generations. Cohort effects are those that affect a whole generation of women, such as, 
changes in reproductive factors and increasing obesity prevalence. The cohort effect 
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found for ER+ cancers in Scotland was also observed in Denmark and Ireland 
suggesting similar RF patterns in these countries.  
Reproductive factors are a likely contributor to the increases in BC incidence amongst 
younger generations. For example, delayed childbearing, younger age at menarche, 
older age at menopause, lack of breastfeeding and nulliparity have been closely related 
to increased risk of ER+ breast tumours [6, 194]. In Scotland, as in many European 
and Western countries, reproductive factors have changed considerably over time. 
Fertility rates have dropped considerably and the number and proportion of nulliparous 
women has increased [14]. Childbirth has also been delayed with women having 
children for the first time at the age of 30.5 years in 2017 compared to an average age 
of 26 years in 1975 [195, 196]. These and other factors, such as earlier age at menarche 
and delayed menopause, may be associated with the gains in incidence of ER+ 
tumours.  
Another likely contributing factor to changes in BC incidence is obesity. Obesity is 
clearly associated with increased risk of BC in postmenopausal women, particularly 
for ER+ tumours [64-66], with limited evidence of an association between obesity and 
reduced risk of BC in premenopausal women that could be at least partly confounded 
by reproductive factors including nulliparity, OC use and oligomenorrhoea [197]. In 
Scotland, overweight and obesity prevalence increased from 52% in 1995 to 63% in 
2008 and then remained approximately stable [198]. Recent obesity prevalence trends 
in Scotland seem to follow similar patterns to those observed for incidence of ER+ 
tumours and estimates from a recent study suggest that obesity and alcohol 
consumption may account for 9% of all BC cases diagnosed in Scotland [155].  
Evidence of the association of established RFs of BC with more aggressive subtypes 
of BC (ER-, HER2-enriched and TNBC) is still very limited and hence investigating 
the RFs that might be driving the observed trends for these subtypes is more difficult 
than for ER+/luminal tumours. There is some evidence of a possible association 
between premenopausal obesity and increased risk of TNBC [150, 199, 200]. In this 
study, increases in TNBC amongst women aged 20 to 49 years were found that could 
be associated with increased premenopausal obesity. Other factor that has been 
associated with a reduced risk of the most aggressive subtypes of BC is breastfeeding, 
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particularly ER- and TNBC [194, 201]. Although, breastfeeding in Scotland remains 
below the recommended proportions, in the last two decades the percentage of babies 
that are being breastfed at 6 to 8 weeks increased from 36% in 2001 to 42% in 2018 
which may have partially contributed to the declines observed for ER- tumours [202].  
3.5.3 Strengths 
3.5.3.1 Scottish cancer registry data 
First, the Scottish cancer registry data presents an excellent opportunity for the analysis 
of incidence trends by ER and other molecular markers. Scotland was the first country 
in the UK to collect data on ER and it has 10 more years of data than other parts of the 
UK. Further, the cancer registry has high quality longitudinal data with a case 
ascertainment over 98%. Overall BC incidence is routinely reported by ISD 
(https://www.isdscotland.org/). However, the heterogeneity observed in BC suggests 
the need for specific monitoring of time trends in incidence for the different subtypes 
of BC as they have different aetiology and prognosis. This could lead to the 
identification of high risk groups of women and to the implementation of new 
prevention and treatment programmes.  
Both statistical modelling techniques used for this part of the PhD (joinpoint analysis 
and APC models) have been successfully used to monitor and summarise cancer rates 
in many countries but I have used them for the first time to analyse UK BC data. Both 
methods are practical and complementary to analyse BC incidence trends. Joinpoint 
modelling is a useful tool for monitoring overall trends and estimate periods of time 
with changes in the rates. However it does not provide any aetiological clue about 
which factors might be driving the observed trends. For that reason, APC models, 
which decompose the trends into age, period and cohort effects are an important 
additional tool to describe the trends and estimate whether changes are related to age, 
period or cohort effects. APC models have been particularly useful to identify further 
signals in incidence and mortality that may be missed by traditional descriptive 
methods and that can lead to further hypotheses to be explored. I used the latest 
joinpoint analysis and APC model tools developed by NCI which are more informative 





The validity of the studies conducted using population-based cancer registry data 
depends on the accuracy and quality of the data collected by the registry and the quality 
control procedures in place [203]. There are three main indicators to evaluate the 
quality of registry data: comparability, completeness, validity or accuracy [204].  
 The comparability of cancer registry data is related to whether the results 
between cancer registries are comparable since the registry follows 
international guidelines in terms of classification and coding of the neoplasms, 
the definition of incidence and data of incidence, the distinction between a 
primary cancer and an extension, recurrence or metastasis of the primary 
cancer. The Scottish cancer registry is considered comparable to other cancer 
registries as it follows the standard classification and coding of disease (the 
International Classification of Disease), and a protocol has been established for 
the definition of incidence and date of incidence [205] which has been recently 
updated to use the European network of cancer registries (ENCR) 
recommended definition of incidence from 2019. One of the main limitations 
for comparability is the recording of multiple tumours. The Scottish cancer 
registry collects all tumours identified in a person but there is no distinction as 
to whether secondary tumours are extensions, metastasis or recurrence from 
the primary tumour and incidence rates reported by ISD are using all tumours 
available. However, this method is also used in most other countries and the 
analysis of incidence in this PhD aimed to correct the overestimation of the 
breast cancer incidence rates due to multiple tumours in the same woman.  
 The completeness is the extent to which the registry is able to ascertain almost 
all cancer cases within the Scottish population. Completeness ensures that 
cancer registrations are highly representative of the general population and that 
estimates of incidence and survival trends are accurate. Case ascertainment or 
completeness in the Scottish cancer registry has been estimated to be very high, 
with over 98% of cases ascertained by the registry [157]. 
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 The accuracy or validity of the data refers to the proportion of cases that truly 
have the characteristics recorded in the registry. Validity of the data can be 
checked by evaluating indicators such as, agreement with medical records, 
histological verification, missing information and internal consistency of the 
records [206]. The accuracy of the Scottish cancer registration has been 
previously estimated to be high with only an approximate 3% of cases showing 
discrepancies between the cancer registry and available medical records [207]. 
In terms of missing information, the registry had low percentages of missing 
data for the molecular markers (approximately 7% for ER status and 11% for 
HER2). However, as observed in Appendix Figure A.1, missing molecular 
marker data can have an important impact in the rates of BC incidence by ER 
status, underestimating the incidence rates of ER+ and ER- tumours, 
particularly for earlier years (when missing molecular marker data was higher). 
Not correcting for missing data could lead to incorrectly estimating a higher 
increasing incidence of ER+ tumours than the one observed and a lower 
declining rate for the ER- tumours. 
Apart from the intrinsic limitations associated with cancer registry data, there were 
other issues particular to the BC data and the analysis of the incidence rates for the 
different molecular subtypes of BC: 
 Molecular data availability for HER2 and PR markers precluded estimation of 
the long term trends in incidence as these markers are only available from 2009 
and therefore, time trends are restricted to seven years of data with the 
additional limitation of relatively high proportions of missing data in the years 
soon after data became available. The results from joinpoint regression and 
APC models for the HER2 alone and the molecular subtypes of BC had 
estimates with wide CIs common for less prevalent subtypes. Future study of 
the incidence by molecular subtypes in Scotland should continue as better 
estimation of trends will be possible once more years of data are available. 
 Individual level data were not available so investigation of possible RFs 
associated with the BC incidence in the study cohort was not possible. 
However, the Scottish cancer registry can be easily linked to other national 
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records datasets, such as maternity and prescription data and future studies 
should look at the effect of those RFs in the observed trends. Another limitation 
of the study is the lack of mRNA expression assays for the classification of the 
molecular subtypes of BC. In this study, markers measured by IHC are used as 
surrogates for the molecular subtypes, which are reasonably good proxies but 
mRNA profiling data would be considered a gold-standard for intrinsic-
subtype classification [208]. 
 As screening mammography was fully implemented during the study period, I 
cannot compare incidence rates before and after the implementation of 
mammographic screening and estimate the impact of screening on the 
incidence rates. However, in order to describe the effect of screening in the 
trends I look at different age groups: women with <50 years (before screening), 
women aged 50 to 69 years (during screening) and women aged 70 years or 
older (after screening). Further, as method of detection is available in the 
cancer registry, incidence trends by method of detection were investigated 
overall and by ER status and IHC defined molecular subtypes. 
3.5.4.2 Statistical analysis 
Imputation of missing molecular markers ER and HER2 is essential to accurately 
estimate BC incidence trends for each molecular subtype. In terms of missing 
information, the registry had low percentages of missing data for the molecular 
markers (approximately 7% for ER status and 11% for HER2). However, as observed 
in Appendix Figure A.1, missing molecular marker data can have an important impact 
in the rates of BC incidence by ER status, underestimating the incidence rates of ER+ 
and ER- tumours, particularly for earlier years (when missing molecular marker data 
was higher). Not correcting for missing data could lead to incorrectly estimating a 
higher increasing incidence of ER+ tumours than the one observed and a lower 
declining rate for the ER- tumours.  
The imputation method assumes that ER and/or HER2 data have the same chance of 
being missing among each cohort of women by year and age at diagnosis. If this 
assumption was wrong, a confounder associated with the molecular markers would 
have to influence whether the markers are tested and recorded. In Scotland, health 
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service guidelines are used to inform investigation and treatment and missing 
molecular data is more likely to reflect administrative omissions, and geographic 
uptake. A more complex imputation model incorporating tumour grade, stage and 
other covariates found that the overall imputed counts were very similar to those 
obtained using the simpler model with only age and year of diagnosis [209]. Therefore, 
redistributing the relatively small percentage of missing molecular data in cases within 
each year and age at diagnosis has been considered an appropriate method to estimate 
incidence trends. Further, previous studies using US, Denmark, and Irish data [135, 
136, 146] have also considered the assumption of the simple imputation model to be 
reasonable and the US study has been compared to previous studies using the same 
SEER data and doing multiple imputation using chained equations giving very similar 
results [61, 210]. 
Joinpoint regression analysis and APC models are both ecological methods and a 
causal relationship between the trends observed and the factors that might be driving 
those trends cannot be established. However, both methods are useful descriptive tools 
to generate hypotheses and estimate the overall increase/decrease in the trends and the 
effect of age, period and cohort effects on the trends. Both methods present limitations 
intrinsic to the use of statistical methods and based on the assumptions for each 
method. Joinpoint regression analysis is based on generalised linear theory and 
assumes that the data follows a Poisson distribution so the results are based on whether 
this assumption can be considered valid or not. Cancer counts are often model 
following a Poisson distribution and Poisson regression has been widely used as an 
appropriate method for the analysis of cancer counts and rates, including breast cancer. 
Another assumption of the joinpoint regression is that the data can be divided into 
subsets and that each subset has its own linear trend with a particular intercept and 
slope, so the model assumes linearity and that the error terms are independent and 
normally distributed [211, 212]. This assumption depends on the actual number of time 
points with count data available as few time points would deem the analysis not 
appropriate. In our study, 20 consecutive years of breast cancer counts were available. 
Another limitation of the joinpoint regression analysis tool is the fact that the final 
model can be calculated using different methods and parameters and hence, the results 
might vary depending on the options selected. For the analysis presented throughout 
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the thesis, the Grid search method was used to calculate the final model with a 
maximum of 3 joinpoints (given that we had 20 years of consecutive data) and 
autocorrelated errors and the permutation test for model selection. Sensitivity analysis 
using a different modelling method to the Grid search method, different model 
selection methods to the permutation test and different error options were performed 
with similar results to the original methods, finding the same number of joinpoints and 
in a similar location. Another limitation of Joinpoint regression is the number of tests 
performed. The permutation method consists on a total of 4,499 permutations but the 
p value test is adjusted for multiple testing using Bonferroni correction [172]. Some 
studies have indicated that Bayesian methodologies can also be applied to joinpoint 
modelling and as they incorporate prior information on the number of joinpoints based 
on information of the counts, they eliminate the issue of multiple testing to find the 
number of joinpoints and its location [213, 214]. However, models such as the ones 
presented here have been seen to provide similar results to Bayesian methods. 
Multiplicity continues to be an issue once you do subgroup analysis and this needs to 
be further corrected doing Bonferroni correction or other multiplicity adjusted 
techniques. 
The main limitation of the APC models is the identifiability constraint which has been 
widely discussed in most APC research [177, 215]. The identifiability problem is 
related to the fact that the rates cannot uniquely be attributed to the effects of age, 
period and cohorts without imposing some additional constraints due to the fact that 
age, period and cohort are associated (cohort=period-age) and hence, co-linear. Those 
additional constraints are usually deem unverifiable and must be carefully selected 
based on information relevant to the study data and its biological hypothesis. However, 
the APC models computed through the dissertation and developed by Rosenberg et al. 
[179] provide a number of estimable functions that do not require additional 
constraints to be imposed since the cohort deviations are weighted to account for the 
variable number of periods that they can be observed. This technique ensures that the 
fitted rates can be expressed in terms of the age, period and cohort effects. Another 
limitation of the APC models is that some of the functions can be hard to interpret, 
however, in the new model the estimable functions are all identifiable and closely 
related to common epidemiological functions. Another limitation specific to the APC 
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model is the limited number of methods used to assess goodness-of-fit. Others have 
propose to use a smooth Gaussian process to model the residuals for each of the 
components [216]. Here, as proposed by the authors of the model used, we graphically 
assessed the residuals to check goodness of fit for each model. Finally, another 
important limitation is that the models do not incorporate established RFs for BC such 
as, reproductive factors and screening that are likely associated with the age, period 
and cohort effects estimated by the models.  
3.6 Conclusion 
BC incidence trends differ by ER status and for molecular subtypes in Scotland and 
showed trends consistent with those observed in other countries. To the best of my 
knowledge, the recent declines in incidence of ER+ tumours from 2011 have not been 
shown in any other country. Another important finding is the increasing trend observed 
for TNBC in young women, which is the subtype with the worst prognosis. This study 
shows that screening is a likely contributor of the increasing trends observed for ER+ 
and luminal tumours and that screening programmes should prioritise detection of the 
more aggressive subtypes that are less likely to be screen detected. New personalised 
screening programmes could be based on polygenic risk scores that stratify women 
according to their BC subtype risk. Additional data, particularly on obesity and 
reproductive factors, are needed to further investigate the RFs associated to the 
observed trends and future monitoring of BC incidence should be done by subtype. 
Apart from differences in incidence, BC subtypes are likely to show survival 







Chapter 4 Survival for the different subtypes of breast cancer and 




According to the latest Globocan estimates, BC is the world’s leading cause of cancer 
mortality among females in over 100 countries [217]. Overall BC mortality trends in 
Scotland and the UK, have seen consistent declines in recent decades [218] and 
predictions for the UK estimate further declines by 36% between 2014 and 2035 [219]. 
However, these data are based on all BCs with limited analysis on mortality trends at the 
population level for subtypes of BC, including trends among different subgroups of 
women with BC based on age and other prognostic tumour characteristics (e.g. grade, 
stage).  
4.1.1 Tools to assess cancer progression 
Along with cancer incidence and survival, mortality rates are important population-based 
tools to estimate cancer progression [220]. Mortality rates are usually estimated using 
number of cancer deaths as the numerator and number of women in the general population 
as the denominator, however, incidence-based mortality (IBM) can also be estimated 
using number of women with breast cancer as the denominator for the rates. A study in 
the US estimating IBM trends overall and by ER status and age at diagnosis found 
clinically and statistically significant BC IBM rates declines between 1990 and 2003 for 
ER+ tumours (limited to women younger than 70 years) but not for ER- tumours [221]. 
Mortality data are usually derived from death certificate records and therefore, 
information on individual and tumour characteristics is generally not available. Linkage 
of death records to population-based cancer registries with incidence data allows the 
estimation of IBM rates by other individual and tumour characteristics and previous 
research has found that IBM rates are comparable to those from death certificate records 
[222]. Given the prognostic importance of molecular markers, trends in BC IBM rates for 




women with specific subtypes or tumour characteristics for which mortality rates are not 
showing improvements and who could be the target of new prevention and treatment 
programmes. However, population-based estimates of IBM rates by molecular subtypes 
require a long follow-up of at least 10-15 years [222] since women who die from BC are 
likely to be diagnosed many years before and hence, available molecular marker data at 
the time of diagnosis is necessary to give reliable long-term IBM rates by molecular 
subtypes. Given the relatively recent routine collection of data on molecular markers in 
the cancer registries (ER from 1997 in Scotland) reliable long-term IBM rates cannot be 
estimated yet. For that reason, most studies investigating BC prognosis by molecular 
subtypes focus on differences in shorter term breast cancer specific survival (BCSS).  
4.1.2 Review of previous studies of BC prognosis by molecular subtypes and important 
prognostic factors  
4.1.2.1 Search terms and inclusion criteria 
A literature search was performed in Medline using the keywords “breast cancer”, 
“survival or prognosis” and “oestrogen receptor or hormone or molecular subtype”. 
Studies were selected if data were female invasive BCs from population-based, cancer 
registries or large epidemiological studies with a majority of European ancestry 
populations. Additionally, they had to report HRs or relative excess risk (RER) for the 
comparison of the molecular subtypes of BC. Table 4.1 summarises the selected studies 
from the USA and Table 4.2 from the studies in Europe. A formal search was not 
conducted to review the prognostic value of the rest of factors. 
4.1.2.2 Studies of BC prognosis by molecular subtypes in the USA.  
Five previous studies in the US have shown that prognosis of BC clearly differs between 
molecular markers (Table 4.1). A large population-based study in over 150,000 women 
diagnosed with BC from 1990 to 2001 using SEER11 data, found that women with 
ER+/PR-, ER-/PR+ and ER-/PR- have significantly lower survival than women with 
ER+/PR+ tumours [223]. A more recent study extended the analysis to more than 400,000 
women in 18 SEER cancer registries and found a 60% (95% CI: 58 to 65%) increase of 




that difference was only observed during the first 5 years after diagnosis [224]. Prognostic 
differences have also been estimated between molecular subtypes (or their IHC 
surrogates), with luminal subtypes having a better prognosis than TNBC or HER2-
enriched subtypes. A recent study in the United States using SEER data from 18 registries 
on over 190k cases of women diagnosed between 2010 and 2013 showed that HR+ (ER+ 
and/or PR+)/HER2- (luminal A) subtype had the best survival followed by HR+/HER2+ 
(luminal B), while TNBC (HR-/HER2-) had the worst survival of all subtypes [225]. 
Evidence of the prognostic differences between subtypes has also been observed in cohort 
studies, such as the Nurses’ Health Study. This study in around 2,000 women diagnosed 
between 1967 and 1997 and followed up to 2007 found that luminal B, HER2-enriched 
and basal-like tumours had hazard ratios (HRs) for BC mortality of 1.90 (95% CI: 1.33 to 
2.71), 1.36 (95% CI: 0.87 to 2.12) and 1.58 (95% CI: 1.05 to 2.39) respectively when 
compared to luminal A subtypes over a median follow up of 15 years [226]. Another 
study, the Carolina Breast Cancer Study, that used immunohistochemical markers to 
subtype more than 1,000 invasive BCs found that only the basal-like subtype was 
associated with a statistically significant HR of 1.7 (95% CI: 1.0 to 2.9 ) of BC mortality 













Confounders adjusted for in the model 
Dunnwald et al. 
[223] 2007, USA 








Age of diagnosis, year of diagnosis, SEER registry, 
race/ethnicity, histologic tumour type, tumour 
size, stage, grade and lymph node status. 
Dawood et al. 
[226] 2011, the 
Nurses’ Health 
Study, USA 










Age at diagnosis, year of diagnosis, BMI at 
diagnosis, tumour grade, stage of disease, 
radiation treatment, chemotherapy and 
hormonal treatment. 















Age at diagnosis, date of diagnosis, and stage at 
diagnosis. 
Ren et al. [224] 
2014, USA 




Age at diagnosis, race, tumour grade, T and N 
stages.  
Howlader et al. 
[225] 2018, USA 








Tumour stage, Bloom-Richardson tumour grade, 
nodal status, surgery, age at diagnosis, SEER 
registry, race/ethnicity, poverty index, urban 
index, insurance status and marital status. 
BMI=Body Mass Index, ER= oestrogen receptor, HER2= human epidermal growth factor 2, HR= hormone receptor, PR=progesterone receptor, SEER= Surveillance, 






4.1.2.3 Studies of BC prognosis by molecular subtypes in Europe.  
European countries have also reported differences in BCSS between molecular subtypes 
(Table 4.2). A study using data from EUROCARE, a database oh high-resolution breast 
cancer studies from registries in Estonia, France, Italy, Spain, the Netherlands and the UK 
reported a pooled relative excess risk (RER) of death of 0.32 (95% CI: 0.24 to 0.43) for 
ER+PR+ compared to ER-PR- tumours. Having one of the molecular markers positive 
(ER+ or PR+) also had a beneficial effect on the risk of death [RER=0.41 (95% CI: 0.28 
to 0.62)]. Apart from the previous study, nine studies from the six countries below 
reported comparisons of BC survival by molecular subtypes in Europe.  
Italy 
Results from a population-based study in Italy [228] in 1,400 women diagnosed during 
the period 2004-2005 showed that 3-year survival rates were highest for luminal A 
tumours and lowest for HER2-enriched tumours, with HRs for luminal B, TNBC and 
HER2+ tumours of 1.65 (95% CI: 1.11 to 2.46), 1.68 (95% CI: 1.04 to 2.72) and 2.18 
(95% CI: 1.28 to 3.70) respectively when adjusted for age and stage. A more recent study 
with population-based data in over 3000 women from 9 Italian cancer registries that 
included the Ki67 marker in the definition of the subtypes found a RERs of death 
significantly greater in the triple-negative and HER2-enriched subtypes when compared 
to luminal A tumours [229].  
Norway 
In Norway, a study in over 20,000 women diagnosed between 2005 and 2015 from the 
national cancer registry, found that TNBC had the highest mortality HR=3.12 (95% CI: 
2.64 to 3.68) compared to luminal A tumours. This study also explored the effect of the 
subtypes on BC specific mortality for three distinct age groups and found increased 
likelihood of breast cancer death (BCD) for young women with luminal A tumours and 
for old women with any subtype compared to women with the same subtype aged 50-69 
years [230]. Previous studies using retrospective data in women diagnosed with BC in 
Norway also showed similar results. Engstrom et al. analysed data in over 900 female BC 




ER, PR, HER2, CK5 and Ki67 markers. They found that luminal A subtype had the best 
BC survival while HER2 and the five negative phenotype had the worst and that the 
differences in BC survival where restricted to the first 5 years after diagnosis with no 
significant differences between the subtypes after that time [231]. These results were 
confirmed by Valla et al [232] in a larger population of BC cases (over 1400).  
Spain 
A study in Spain using data from 10 regional cancer registries in over 3,000 women 
diagnosed in 2005 with a median follow-up time of 5 years, showed an increased RR of 
death in HER2-overexpressed and TNBC of 1.72 (95% CI: 1.15 to 2.57) and 3.16 (95% 
CI: 2.26 to 4.41) respectively compared to ER+ and/or PR+ and HER2- tumours after 
adjusting for age, stage and grade [233].  
Germany  
In Germany, data from the Saarland Cancer registry in over 8000 female invasive BC 
cases diagnosed between 200 and 2009 was assessed for differences in BC prognosis by 
HR and HER2 status separately. The study found a statistically significant RER for HR- 
tumours compared to HR+ tumours [HR= 2.9 (95% CI: 2.3 to 3.7)] but not for HER2 
status alone [HR=0.9 (95% CI: 0.8 to 1.2) for HER2+ compared to HER2-] [234]. 
France 
In France, a population-based study with over 4000 BC cases diagnosed in the Cote d’Or 
region found that ER- and PR- tumours had an increased risk of BC mortality [HR=1.3 
(95% CI: 1.0 to 1.6) for ER- and HR= 1.4 (95% CI: 1.2 to 1.8) for PR-] after adjusting for 
age, number of nodes examined, stage, locoregional extension and multifocality [235].  
Ireland 
In Ireland, a study in over 7000 postmenopausal women aged 50 to 66 years diagnosed 
from 2006 to 2011 and with data ascertained from the National Cancer registry estimated 
that the risk of BC death was 2.0 (95% CI: 1.4 to 2.8) and 3.6 (95% CI: 2.7 to 5.0) times 
higher in women that over-expressed HER2 and with TNBC subtypes compared to the 
risk in women with luminal A tumours and after adjusting for age, tumour grade and stage, 




Table 4.2 Studies from Europe reporting BC survival for the molecular subtypes of BC ordered by country and publication date 
(page 1 of 3). 
Study and country Years of 
diagnosis 
n Breast cancer subtypes categories reported Hazard Ratio 
(95% CI) 
Confounders adjusted 
for in the model 
Allemani et al. [237] 2004, 
EUROCARE high-resolution 
studies (Estonia, France, 
Italy, Spain, Netherlands 
and UK)  
1990–1992  4478  ER/PR status 
ER− and PR− 
ER+ and PR+ 







Age at diagnosis, 
tumour morphology 
and tumour stage.  
Caldarella et al [228] 2011, 
Italy 
2004-2005 1487 Luminal A: ER/PR+ and HER2- 
Luminal B: ER/PR+ and HER2+ 
Triple negative: ER/PR- and HER2- 





T and N status. 
Minicozzi et al. [229] 2013, 
Italy 
2003-2005 3,381  
Luminal A (ER+ and/or PR+, HER2-, low Ki67) 
Luminal B (ER+ and/or PR+, HER2-, high Ki67) 
Luminal-HER2 (ER+ and/or PR+, HER2+, any Ki67) 
Triple-negative (ER-,PR-, HER2-, any Ki67) 




1.9 (1.3–2.9)  
2.7 (1.8–4.1) 
2.3 (1.4–3.6) 





Engstrom et al [231] 2013, 
Norway 
1961-2008 909  
Luminal A 
Luminal B (HER2-) 
Luminal B (HER2+) 
HER2 subtype five negative phenotype (5NP) 







Stage. They also 
present model 
adjusted for age but 






Table 4.2 (continued) Studies from Europe reporting BC survival for the molecular subtypes of BC ordered by country and 
publication date (page 2 of 3). 
Study and country Years of 
diagnosis 
n Breast cancer subtypes categories reported Hazard Ratio 
(95% CI) 
Confounders adjusted 
for in the model 
Valla et al. [232] 2016, 
Norway 
1995-2013 1,423 Luminal A 
Luminal B (HER2-) 
Luminal B (HER2+) 
HER2 type 








Age at diagnosis, stage 
and histopathologic 
grade. 
Johansson et al [230] 
2019, Norway 
2005-2015 21,384 Luminal A-like (ER+PR+HER2-) 
Luminal B-like HER2-negative (ER+PR-HER2-) 




1.7 (1.4, 2.0) 
1.0 (0.8, 1.2) 
1.3 (1.1, 1.7) 
3.1 (2.6, 3.7) 
Age at diagnosis, year of 
diagnosis, tumour grade, 
tumour stage and 
surgery. 
Puig-Vives et al [233] 
2013, Spain 
2005 3480  
ER+ and/or PR+ and HER2- 








3.2 (2.3-4.4)  
2.6 (2.0-3.3) 
Age at diagnosis, stage 








Table 4.2 (continued) Studies from Europe reporting BC survival for the molecular subtypes of BC ordered by country and 
publication date (page 3 of 3). 
Study and country Years of 
diagnosis 




Confounders adjusted for in 
the model 
Holleczek et al [234] 2013, 
Germany 
2000-2009 8571 Hormone receptor status: 
HR+ (ER+PR+) 
HR mixed (ER+ or PR+) 











Age at diagnosis, stage, 
morphology, tumor grade, 
hormone receptor status and 
HER2/neu expression. 
Dabakuyo et al [235] 2008 
France 












Age at diagnosis, year of 
diagnosis, number of nodes 
examined, Stage T and N, ER 
status, PR status, locoregional 
extension and multifocality.  
O’Brien et al. [236] 2018, 
Ireland 
2006–2011 7160 Luminal A 
Luminal B, HER2−  
Luminal B, HER2+  









Age at diagnosis, stage, grade, 
screening, marital status, 
deprivation and co-
morbidities.  
Table presents hazard ratios unless states otherwise (Relative Excess Risk). CI= confidence interval, ER= oestrogen receptor, HER2= human epidermal growth factor 2, 






4.1.2.4 The prognostic effect of other tumour characteristics in relation to the BC subtypes 
The prognostic effect of age and tumour characteristics such as grade and stage in BC has 
been previously described [238, 239], however information on prognosis of combinations 
of age and tumour characteristics by BC molecular subtypes is limited. Several studies 
have shown that young age is an independent prognostic factor in women with luminal 
subtypes but not for HER2-enriched or TNBC [240]. For example, Lian et al, in a 
retrospective study in over 2,000 women with stage I to III BC showed associations of 
young age (<40 years) with luminal A tumours with worse outcomes [disease free survival 
(DFS), distant metastasis free survival (DMFS) and BCSS] compared to older women 
with luminal A tumours [241]. Another study using SEER data with 34,000 women from 
the US evaluating the prognostic effect of age in the molecular subtypes showed that 
women 40 years or older with the HR+/HER2+ subtype had worse OS than women 
younger than 40 years of age. However, in the presence of competing risks, young age at 
diagnosis of BC (<40 years) was only found to be associated with worse BCSS of TNBC 
compared to women diagnosed at 40 years or older [242]. A study in over 4,000 women 
using microarray data found that younger age at diagnosis of BC (< 40 years) was 
associated with poorer recurrence free survival in TNBC but not for HER2-enriched 
tumours when compared to women aged 40 years or more with the same subtypes [243]. 
Prognosis in older women has also been described to differ between subtype, with 
evidence from RCTs on older women with HR+ tumours showing increased hazards of 
BCD in women aged 65 to 74 (HR=1.25, 95% CI: 1.01 to 1.54) and women aged 75 or 
older (HR=1.63, 95% CI: 1.23 to 2.16) compared to women younger than 65 years [244]. 
The importance of stage and grade in prognosis for the different subtypes has been 
described in a few previous studies. The effect of histological grade and molecular 
subtypes in BCSS was evaluated in a recent study in Norway, showing that HER2-
enriched tumours of grade 2 were associated with a 6 times increased BC mortality 
compared to luminal A grade 2 tumours but this association was not observed for grade 3 
tumours which might be due to a small sample sizes for grade 3 tumours [231]. A study 
with over 123,000 women diagnosed with invasive BC from the California Cancer 




a variability in BCSS amongst women with HER2+ tumours between different stages 
[245]. This study also found better survival for all ER+ subtypes than for the ER- subtypes 
irrespective of tumour stage [245]. Method of detection in countries where screening 
mammography is available has been established as an independent prognostic factor for 
BC [246] but statistically significant associations have only been found for luminal A 
subtypes [247].  
4.1.3 Survival chapter layout 
In Scotland, survival analyses based on cancer registry data in women diagnosed with BC 
have been previously published [248] but survival (overall and BC specific) for the 
different hormone subtypes or molecular subtypes has not previously been described using 
population-based cancer registry data. For that reason, this chapter describes trends in 
survival of BC in Scotland by ER status and the IHC defined molecular subtypes of BC. 
I will also investigate the main individual and tumour characteristics associated with 
survival for each ER status and IHC defined molecular subtype. Within the survival 
analysis results, I will describe trends in 5-year BCSS for the different subtypes within the 
different subgroups of key prognostic factors to assess whether survival has improved 
over time in Scotland. This chapter aims to identify high-risk groups of patients with 
worse outcomes that may benefit from further treatment or prevention interventions.  
4.2 Objectives and hypotheses 
Objectives: 
 To determine the association of the different IHC defined subtypes with BCD in 
Scotland 
 To assess the prognostic effect of age, pathologic grade, node status, tumour size 
and stage by molecular subtype 
 To investigate whether time trends in BC survival differ by molecular subtypes 




 To describe characteristics of groups of women diagnosed with BC whose BCSS 
has not improved over time  
Hypotheses: 
BC survival will differ according to ER status and other important individual and tumour 
characteristics, such as, age, stage grade and deprivation. I hypothesise that: 
 ER+ tumours have better prognosis than ER- tumours 
 Luminal A tumours have better prognosis than luminal B, HER2-enriched and 
TNBC  
 BC survival trends have improved in Scotland over time in recent decades and 
may be related to screening and targeted treatment improvements, particularly for 
women with HER2+ tumours  
 Women diagnosed with BC living in least deprived areas of Scotland have better 
prognosis than women living in the most deprived areas and prognosis might 
depend on tumour subtype.  
4.3 Methods 
4.3.1 Study population 
The same population (n= 72,217) used for the analysis of incidence rates was the starting 
point for developing the cohort to investigate survival trends in women diagnosed with 
BC from 1997 to 2016 in Scotland. This cohort included only the first BC diagnosis for 
each woman (see section on incidence). Further exclusion criteria were applied following 
ISD guidelines [249] for survival analyses as described below. 
Women with missing postcode, living outside Scotland or aged more than 99 years were 
excluded from the analysis (n=55). Those women who had missing vital status (n=154) or 
who were diagnosed with BC only from death certificates (n=126) were also excluded 
from the survival analysis. A further 99 women (all with vital status recorded as dead) had 
the same date of incidence and death and therefore, I assumed that their diagnosis was 




total number of excluded cases was 434 (0.6% of the total) and the final population 
consisted of 71,784 women diagnosed from 1997 to 2016 (Table 4.3). 
Table 4.3 Total breast cancer registrations from 1997 to 2016 in Scotland and final 
selection of women for survival analysis with exclusion criteria 
Total registrations from 1997 to 2016 
(after exclusion of multiple tumours)  
72,217 
Excluded from survival analysis  
Missing postcode, living outside Scotland or older than 99 years 55 
Vital status unknown  154 
Death certificate only 126 
Same date of incidence as date of death 99 
Total excluded (% excluded) 434 (0.6%) 
Total included (% included) 71,784 (99.4%) 
4.3.2 Statistical analyses 
4.3.2.1 Outcome definition  
Breast cancer specific survival (BCSS) was the primary outcome of the survival analysis. 
Breast cancer deaths were derived using only the underlying (primary) cause of death as 
recorded in the registry. Date of incidence in the Scottish Registry is normally recorded 
as the date of first consultation or admission at the hospital for that cancer. This date is a 
definite point in time that can be verified from the records and is the most consistent and 
reliable date to use [205]. Duration of follow-up was defined as time from date of 
diagnosis of BC to the first of: date of death from BC, 31st December 2017 for women 
still alive at the end of the study period or embarkation date if women moved from 
Scotland. The 31st of December 2017 was selected, the data was obtained in April of 2018 
and completion of the data for the year 2016 should be the 31st December 2017 in 
accordance with the United Kingdom and Ireland Association of Cancer Registries 
(UKIACR) guidelines. Primary and secondary causes of death are derived from death 




(extended to up to 8 causes in 2013). ISD official statistics use a cause specific death 
variable derived from underlying or primary cause of death with quite a broad selection 
of ICD9 (until 31.12.1999) and ICD10 codes (from 1.1.2000) specific to the disease [249]. 
The approach taken for this analysis is similar to that described by Skyrud et al. [251] in 
that only ICD9 174 and ICD10 C50 codes from primary cause of death were used to derive 
BC specific death. Other primary causes of death were regarded as censored observations 
for the calculation of BCSS. Overall survival (OS) was used as a secondary outcome with 
death from any cause defined as the outcome and censoring at end of follow-up or at 
embarkation. 
4.3.2.2 Breast cancer specific survival analysis by ER status and IHC defined molecular 
subtypes  
Baseline characteristics for all women and by age group are described. No formal tests 
were carried out to look for differences between groups given that large sample sizes 
highly influence the p-value for those type of tests.  
Non- parametric Kaplan-Meier (KM) estimates [252] were used to estimate BCSS and 
OS at 5 and 10 years by ER status. Given the short follow up for the IHC defined molecular 
subtypes (maximum follow up of 8 years) only estimates at 5 years for BCSS and OS were 
computed using the KM method. Five-year survival is a typical endpoint use for 
population cancer statistics and recommended as a quality performance indicator by NHS 
Scotland [253]. The effect of individual and other tumour characteristics and the effect of 
treatments on BCSS was also described using KM curves (Appendix C.5) and compared 
using long rank tests [254]. Five and 10-year BCSS and OS for the combinations of the 
most important prognostic factors (age, grade and stage) by ER and the IHC defined 
molecular subtypes were also estimated.  
BCD was selected as the primary event of interest in the survival analysis, however other 
causes of death that were recorded as primary (underlying) cause for cohort member were 
also described. KM estimates of survival can be biased in the presence of competing risks 
as this method assumes that all events are independent and regards all other events (non 




estimates, I estimated cumulative incidence functions (CIF) for other causes of death 
[including cardiovascular diseases (CVDs)] for the different combinations of age and ER 
status in order to assess whether competing risks were present.  
Traditional Cox proportional hazards models [256] were fitted to investigate the 
association between ER status and IHC defined molecular subtypes (main exposures) and 
BCSS among Scottish women with BC after controlling for other covariates. Hazard Ratio 
(HR) with 95% CI are presented. The proportional hazards (PH) assumption was assessed 
using log-minus-log plots (Appendix Figure C.1) and formally tested for the fully adjusted 
model with ER as the main exposure (Appendix Table C.2) as an example. CCA of ER+ 
and ER- tumours (with ER+ as reference) diagnosed between 1997 and 2016 and CCA of 
IHC defined molecular subtypes (with luminal A tumours as reference) from 2009 are 
presented. The flowchart below (Figure 4.1) summarises the type of analysis and number 
of women for each analysis.  
Figure 4.1 Flowchart of the survival analysis carried out using Cox models for ER status 
and IHC defined molecular subtypes as main exposures 
 
Cox models for ER  status in all 
women diagnosed in Scotland 





1. TVE models,  n=51,140 
2. Stratified Cox models : 
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Cox models for IHC defined 
subtypes in all women diagnosed 









Covariates adjusted for in the models were defined as described in section 3.3.1 of the 
incidence chapter. All confounding factors were included in the models based on clinical 
importance and for consistency with previous literature. Further, univariate models were 
performed to check if they were statistically significant (at the 5% level). As before, IHC 
defined subtypes were defined using grade to further differentiate luminal A and luminal 
B subtypes. Covariates in the models were: year of diagnosis (categorised into four 5- 
calendar year groups: 1997-2001, 2002-2006, 2007-2011 and 2012-2016) for the ER 
models and 2009-2011 and 2012-2016 for the molecular subtypes models, age at diagnosis 
separating those of screening age (<50, 50 to 69 and 70+ years), NHS Scottish region, 
tumour characteristics (grade, TNM stage, and method of detection), treatment regimens 
(surgery, radiotherapy, chemotherapy and HT) and area-based deprivation (SIMD) and 
comorbidity measures (Charlson index of comorbidity). Tumour markers included in the 
molecular subtype definition (ER, PR, HER2 status and grade) were not modelled as 
covariates in the molecular subtype models. Model 0 included the main exposure (ER 
status or the molecular subtypes) unadjusted. Model 1 included model 0 plus age at 
diagnosis, year of diagnosis and NHS Scottish region. Model 2 included model 1 plus 
tumour characteristics. Model 3 included model 2 plus treatment regimens. Lastly, model 
4 included model 3 plus deprivation and comorbidity measures.  
Sensitivity analysis was carried out to investigate alternatives to the traditional Cox 
model when the PH assumption did not hold for ER status and the molecular subtypes. 
The overall HR in a Cox model is estimated over the complete follow-up period, for that 
reason represents an average of all HRs, from very early HRs that affect almost all 
individuals to the HR at the end of the follow up were fewer individuals are still at risk. 
Given that the same weights are given to HRs at any time point, the overall HR is only a 
good estimate when the HR does not change over time. The PH assumption of the 
traditional Cox model implies that the effect of the prognostic factors in the risk (hazard) 
of BCD is constant over time. However, this assumption is often violated in the presence 
of markers for BC [257, 258]. Although a violation of the PH assumption can considerably 
bias [259] the estimates from the Cox model and lead to misleading conclusions, the 




For this study two approaches were taken to investigate alternatives to the Cox model: 
1. An extended Cox regression model with time-varying effects (TVE) [258] for 
those variables for which the PH assumption did not hold was fitted introducing 
the interaction of each one of those variables with follow-up time. A likelihood 
ratio test was used to compare the original Cox model with the TVE model. 
2. Stratified models: two independent models partitioning the follow up time up to 3 
years for model 1 and after 3 years for model 2 were also fitted 
A comparison of the results from the traditional Cox model, the extended model with TVE 
and the stratified models for the fully adjusted (model 4) with ER as the main exposure is 
presented in Appendix C.3. Number of women included in each analysis can be found in 
Figure 4.1. 
4.3.2.3 Dealing with missing covariate data 
MI was performed and findings of CCA models were compared with those of imputed 
models analysis (MIA). The data were assumed to be MAR after checking for missing 
data patterns. Missing covariate data were imputed by chained equation models [261] 
using a model compatible with the analysis model for ER status, PR status, HER2, IHC 
defined molecular subtypes, tumour grade, tumour stage, screening and for the treatment 
regimens (surgery, chemotherapy, radiotherapy and HT). Thirty imputed datasets were 
created using the missing covariate prognostic factors and outcome variables. The 
outcome used was the Nelson-Aalen estimator for time to BCD and a censoring indicator 
as described by White and Royston [262]. Missing values for ER status, PR status, HER2 
status, screening and treatments (binary variables) were imputed from a logistic model 
and missing values for tumour grade and tumour stage (ordinal variable) from an ordinal 
multinomial model. Additionally, the complete variables (age at diagnosis, NHS region, 
year of incidence, SIMD and Charlson comorbidity Index) were included in the 
imputation model. Distributions of imputed variables were checked and compare to 
observed data. Cox regression analysis was performed on each of the 30 imputed datasets 




Comparison of CCA and MIA was restricted to the traditional Cox models for the main 
outcomes (ER and the IHC defined subtypes). MIA was not performed for TVE models 
as imputation of interactions of the covariates with time are computationally intensive, 
particularly within the safe haven environment.  
4.3.2.4 Analysis of the association of other important prognostic factors with breast cancer 
death by molecular subtypes 
To assess the prognostic value of other covariates within each subtype, additional Cox 
regression models were fitted for each ER status and each IHC molecular subtype 
separately. Fitting separate models for each subtype allows adjusting for appropriate 
confounders for that specific subtype, for example, women with ER+ tumours are usually 
treated with HT but women with ER- tumours are not, for that reason, HT was only 
adjusted for in the ER+ and luminal models. Tumour grade was excluded from the luminal 
A and luminal B tumours as it was used to define these subtypes. Separate models of each 
subtype also help with the fundamental assumption from Cox models, the proportionality 
assumption, as no comparison between subtypes is directly estimated. However, other 
covariates can still fail to show proportional hazards over time. For that reason, those 
models for which the PH assumption was violated, were compared to extended Cox 
models with TVE as explained in the sensitivity analysis below.  
4.3.2.5 Trends of breast cancer survival over time for combinations of important prognostic 
factors 
The Cox models showed that the most important prognostic factors of survival for all ER 
subtypes were age, grade and stage. The latest guidance from AJCC TNM stage 
classification (8th edition) [163] highlights the need to use not only TNM stage but to 
incorporate molecular markers (ER, PR, HER2, ki67) and histological grade into the 
staging system to improve prognostic value [264]. I used combinations of age, ER, grade 
and TNM stage to investigate trends in 5-year BCSS and identify the combination of 
characteristics where survival is poorest, that could be targeted in future interventions. 
ER/grade and ER/stage combinations were analysed by age group except for those 




as, ER- low grade tumours with n<50). Further, due to small numbers, grade was 
categorised into 2 groups, low grade (grade I and grade II) and high grade (grade III: 
poorly differentiated) and TNM stages III and IV were collapsed into the same category.  
OS and BCSS probabilities at five years (with 95% CI) for each combination and 
incidence year were calculated using KM and plotted against year of diagnosis to 
graphically assess trends over time. Graphs of survival trends were smoothed using a 
three-year moving average, with incidence year in the graphs representing the middle year 
for that three-year period (for example, year 2000 in the graph represents the average of 
years 1999-2001). Survival probabilities were also calculated for the combinations of 
those four important prognostic factors (age, ER, grade and stage) and method of detection 
to inspect whether survival improvements were related to the tumour being screen 
detected or not.  
Joinpoint regression analysis was used to estimate changes in BCSS probability for each 
combination of tumour factors at 5 years and AAPC is presented (in the graphs) with 95% 
CI for those combinations that showed statistically significant trends over time for the 
whole study period or EAPC for each of the time periods identified through joinpoint. 
Bonferroni correction [265] was used to correct for type I errors resulting from multiple 
Joinpoint regression analyses (one regression for each combination of age, ER status and 
grade/stage). For example, for the combination of ER status and grade for each age group, 




= 0.0056. Complete joinpoint results are presented in Appendix C.10 and 
Appendix C.13. Survival trends for the IHC defined subtypes in combination with age, 
grade and TNM stage are not presented due to small sample sizes for the rare subtypes 
(HER2-enriched and TNBC) and due to the short follow-up (given that molecular 
subtypes are only available from 2009, 5-year BCSS can only be computed from 2009-
2011).  
Given the important effect of treatment regimens in survival and that treatment decisions 
are guided by molecular markers and age, trends in treatments over time are presented by 





4.4.1 Description of the population for survival analysis 
Table 4.4 provides a description of the individual and tumour characteristics by age group 
for the cohort of women diagnosed with BC between 1997 and 2016 in Scotland included 
in the survival analysis.  
Table 4.4 Individual and tumour characteristics for the population of women included in 
the survival analysis by age group (page 1 of 2) 














Region of Scotland     
   North 3,639 (25%) 9,288 (26%) 5,665 (26%) 18,592 (26%) 
   South East 4,020 (28%) 9,769 (27%) 6,044 (28%) 19,833 (28%) 
   West 6,720 (47%) 16,535 (47%) 10,104 (46%) 33,359 (46%) 
Year of diagnosis     
   1997-2001 3,324 (23%) 7,741 (22%) 5,239 (24%) 16,304 (23%) 
   2002-2006 3,543 (25%) 8,319 (23%) 5,427 (25%) 17,289 (24%) 
   2007-2011 3,739 (26%) 9,473 (27%) 5,467 (25%) 18,679 (26%) 
   2012-2016 3,773 (26%) 10,059 (28%) 5,680 (26%) 19,512 (27%) 
SIMD quintile     
   Least deprived 3,218 (23%) 7,570 (21%) 4,101 (19%) 14,889 (21%) 
   4 3,080 (21%) 7,594 (21%) 4,252 (20%) 14,926 (21%) 
   3 2,878 (20%) 7,387 (21%) 4,593 (21%) 14,858 (20%) 
   2 2,726 (19%) 6,803 (19%) 4,729 (21%) 14,258 (20%) 
   Most deprived 2,477 (17%) 6,238 (18%) 4,138 (19%) 12,853 (18%) 
TNM stage 4 
categories 
    
   I 3,851 (27%) 15,576 (44%) 4,682 (22%) 24,109 (34%) 
   II 6,111 (42%) 11,875 (33%) 7,256 (33%) 25,242 (35%) 
   III 2,573 (18%) 4,221 (12%) 3,540 (16%) 10,334 (14%) 
   IV 601 (4%) 1,398 (4%) 1,612 (7%) 3,611 (5%) 
   Unknown 1,243 (9%) 2,522 (7%) 4,723 (22%) 8,488 (12%) 
Tumour grade     
   Grade I 1,196 (8%) 5,625 (16%) 1,863 (8%) 8,684 (12%) 
   Grade II 5,012 (35%) 15,063 (42%) 7,902 (36%) 27,977 (39%) 
   Grade III Poorly 
differentiated 
6,658 (46%) 11,237 (32%) 5,590 (26%) 23,485 (33%) 




Table 4.4 (continued) Individual and tumour characteristics for the population of women 
included in the survival analysis by age group (page 2of 2) 









 [20%] [50%] [30%]  
Tumour size          
(in cm) 
    
   Less than 10mm 1,108 (8%) 5,543 (16%) 1,016 (5%) 7,667 (11%) 
   10 to 20mm 5,034 (35%) 14,571 (41%) 4,698 (22%) 24,303 (34%) 
   More than 20mm 6,164 (43%) 11,014 (31%) 6,404 (29%) 23,582 (33%) 
   Unknown 2,073 (14%) 4,464 (12%) 9,695 (44%) 16,232 (22%) 
Positive nodal 
status? 
    
   Yes 6,216 (43%) 10,858 (30%) 4,769 (22%) 21,843 (30%) 
   No 7,172 (50%) 21,674 (61%) 7,525 (34%) 36,371 (51%) 
   Unknown 991 (7%) 3,060 (9%) 9,519 (44%) 13,570 (19%) 
Diagnosed through 
screening? 
    
   Yes 269 (2%) 17,101 (48%) 2,143 (10%) 19,513 (27%) 
   No 13,786 (96%) 17,877 (50%) 19,138 (88%) 50,801 (71%) 
   Unknown 324 (2%) 614 (2%) 532 (2%) 1,470 (2%) 
ER status     
   Positive 10,505 (73%) 28,385 (80%) 16,113 (74%) 55,003 (77%) 
   Negative 3,188 (22%) 5,655 (16%) 2,855 (13%) 11,698 (16%) 
   Unknown 686 (5%) 1,552 (4%) 2,845 (13%) 5,083 (7%) 
PR status*     
   Positive 3,096 (51%) 8,471 (53%) 4,499 (50%) 16,066 (51%) 
   Negative 1,482 (25%) 3,482 (22%) 1,868 (21%) 6,832 (22%) 
   Unknown 1,458 (24%) 3,997 (25%) 2,612 (29%) 8,067 (26%) 
HER2 status*     
   Positive 1,142 (19%) 2,082 (13%) 981 (11%) 4,205 (14%) 
   Negative 4,466 (74%) 12,337 (77%) 6,571 (73%) 23,374 (75%) 
   Unknown 428 (7%) 1,531 (10%) 1,427 (16%) 3,386 (11%) 
Molecular subtype*    
   Luminal A 2,337 (39%) 8,464 (53%) 4,623 (51%) 15,424 (50%) 
   Luminal B 2,147 (36%) 3,888 (24%) 1,893 (21%) 7,928 (26%) 
   HER2-Enriched 310 (5%) 654 (4%) 321 (4%) 1,285 (4%) 
   Triple Negative 802 (13%) 1,388 (9%) 705 (8%) 2,895 (9%) 
   Unknown 440 (7%) 1,556 (10%) 1,437 (16%) 3,433 (11%) 
*restricted to years 2009 to 2016 (total n=30,965, by age group: <50 years (N=6,036), 50-69 years (N=15,950) and 70 
years or older (N=8,979), parenthesis () are column percentages and brackets [] are row percentages. ER= oestrogen 
receptor, HER2= human epidermal growth factor 2, NHS= National Health Service, PR=progesterone receptor, SIMD= 




The majority, over 75% of tumours in the study population, were ER+ with slightly higher 
proportions of ER+ tumours in women of screening ages 50 to 69 years than in other age 
groups. The most common IHC defined molecular subtype was luminal A for all age 
groups but women aged 50 to 69 years and women aged 70 years or older had a higher % 
of luminal A tumours (53% and 52% respectively) than younger women (39%). Luminal 
B and TNBC were more prevalent in women younger than 50 years compared to older 
women.  
Of the 71,784 women diagnosed with BC between 1997 and 2016 in Scotland with a 
median follow-up of 5.5 years (7.1 years for censored observations) with available 
information on death, 26,280 (37%) died during the study period with a median follow-
up of 3.4 years (Table 4.5). Of those who died, 53% had BC as their primary cause of 
death recorded. However, the proportion of all deaths that were attributed to BC varied 
greatly by age, with 85% of women younger than 50 years dying from BC compared to 
57% and 43% of BCDs in the 50-69 years and 70 years or older groups respectively.  
 
Table 4.5 Breast cancer deaths by age group amongst women with breast cancer 
diagnosed in Scotland from 1997 to 2016 









Breast cancer death     
   No 465 (14%) 3,799 (43%) 8,034 (57%) 12,298 (47%) 
   Yes 2,748 (86%) 5,095 (57%) 6,139 (43%) 13,982 (53%) 
Follow-up time (in years)     
   Median 3.8 4.5 2.8 3.4 
   Q1,Q3 2.0, 7.0 2.0, 8.7 1.0, 6.0 1.4, 7.1 







4.4.2 Does breast cancer survival differ by ER status? 
 
BCSS differed significantly by ER status with women with ER- tumours having lower 
survival than women with ER+ tumours (Figure 4.2).  
Figure 4.2 Kaplan-Meier curves by ER status 
 
 
The difference in BCSS between women with ER+ and ER- tumours was highest during 
the first 5 years of follow-up with 87.4% (95%CI: 87.1 to 87.7) of women with ER+ 
tumours and 70.6% (95%CI: 69.7 to 71.5) of women with ER- tumours surviving 5 years 
(Table 4.6). Survival differences between ER+ and ER- were still notable at 10 years of 
follow-up (14.5% absolute difference between women with ER+ and ER- tumours). 
BCSS declined with age and the difference in survival between women with ER+ and ER- 
tumours was highest in women aged 70 years or older (21.7% difference at 5 years). 




survival at 5 and 10 years (92.1% and 85.8% respectively), in contrast women aged 70 
years or older with ER- tumours had the worst survival of all age and ER combinations.  
Table 4.6 Breast cancer specific survival estimates (in %) at 5 and 10 years after diagnosis 
(with 95% CI) by ER status and age group 
BREAST CANCER 
SPECIFIC SURVIVAL 
<50 YEARS 50-69 YEARS 70 YEARS OR 
OLDER 
TOTAL 
ER+     
cases/deaths 6,691/857 17,511/1,548 6,566/1,973 30,768/4,378 
5-year BCSS (95% CI) 89.2 (88.6, 89.9) 92.1 (91.7, 92.4) 77.1 (76.4, 77.9) 87.4 (87.1, 87.7) 
ER-     
cases/deaths 1,774/587 2,963/944 865/601 5,602/2,132 
5-year BCSS (95% CI) 75.1 (73.5, 76.7) 75.1 (73.9, 76.4) 55.4 (53.4, 57.5) 70.6 (69.7, 71.5) 
% difference at 5 years 









ER+     
cases/deaths 3,678/527 9,165/933 2,330/627 15,173/2087 
10-year BCSS (95% CI) 80.7 (79.8, 81.6) 85.8 (85.2, 86.3) 66.9 (65.9, 67.9) 79.8 (79.3, 80.2) 
ER-     
cases/deaths 1,063/113 1,604/160 327/84 2,994/357 
10-year BCSS (95% CI) 69.6 (67.8, 71.4) 70.4 (69.0, 71.7) 48.8 (46.6, 51.1) 65.3 (64.3, 66.3) 
% difference at 10 years 









BCSS=Breast cancer specific survival, CI= confidence interval, ER= oestrogen receptor.  
Similar patterns in OS at 5 and 10 years between women with ER+ and ER- tumours were 
seen to those observed for BCSS (Appendix C.1). However, OS for women aged 70 years 
or older was 24% lower at 10 years than BCSS (31.8% for ER+ and 24.4% for ER-). 
 
Although overall only 18% of all cases were ER- tumours, they accounted for 31% of the 
total deaths from BC (Table 4.7). Results from Cox models (Figure 4.3) showed that ER- 
tumours had a higher BC specific mortality than ER+ tumours [HR= 1.44 (95% CI: 1.33 
to 1.56)] after adjusting for other tumour characteristics, individual characteristics, 




Figure 4.3 Cox regression model results for the comparison of risk of death from breast 
cancer for ER- tumours and ER+ tumours (as reference) 
 
Footnote: Model 1 was adjusted for age, incidence year and NHS region. Model 2: model 1 + tumour characteristics 
(grade, TNM stage and method of detection. Model 3= model 2 + treatments (surgery, radiotherapy, chemotherapy 
and hormone therapy).  Model 4= model 3 + SIMD and Charlson score index. Models carried out in the complete case 
dataset with n=51,140 women, number of BC deaths=7,592. CI= confidence interval, ER= oestrogen receptor, 
HR=hazard ratio. 
 
Table 4.7 shows all models (from unadjusted to fully adjusted model) and the effect of the 
adjustment of other prognostic factors in BCD in women with ER- tumours compared to 
women with ER+ tumours. Tumour characteristics were the most important prognostic 
factors of BCD and adjusting for these factors (model 2) reduced the HR for BCD for ER- 
compared to ER+ tumours from 2.33 (95% CI: 2.22 to 2.45) to 1.66 (95% CI: 1.57 to 
1.75). Further adjustment for treatments (model 3) reduced the HR to 1.45 (95% CI: 1.34 
to 1.56) and further adjusting for deprivation and comorbidities (model 4) had little effect 




















ER Status        
Positive 42,146 (82%) 5,238 (69%) Ref Ref Ref Ref Ref 
Negative 8,994 (18%) 2,354 (31%) 2.31 (2.20-2.42) 2.33 (2.22-2.45) 1.66 (1.57-1.75) 1.45 (1.34-1.56) 1.44 (1.33-1.56) 
Age        
<50 years 10,886 (21%) 1,823 (24%) 1.37 (1.30-1.45) 1.27 (1.20-1.34) 0.86 (0.81-0.91) 0.89 (0.83-0.94) 0.89 (0.84-0.95) 
50-69 years 27,869 (55%) 3,248 (43%) Ref Ref Ref Ref Ref 
70 years or older 12,385 (24%) 2,521 (33%) 2.23 (2.12-2.35) 2.26 (2.14-2.38) 1.59 (1.51-1.68,) 1.36 (1.27-1.45) 1.36 (1.27-1.45) 
NHS Scottish region        
West 20,738 (41%) 2,800 (37%) Ref Ref Ref Ref Ref 
North 14,545 (28%) 2,388 (31%) 1.20 (1.14-1.27) 1.19 (1.13-1.26) 1.17 (1.11-1.24) 1.07 (1.01-1.13, 
p=0.015) 
1.12 (1.06-1.19) 
South East 15,857 (31%) 2,404 (32%) 1.08 (1.03-1.14, 
p=0.004) 




Year of diagnosis        
1997-2001 10,390 (20%) 2,705 (36%) Ref Ref Ref Ref Ref 
2002-2006 11,077 (22%) 2,209 (29%) 0.84 (0.79-0.89) 0.86 (0.81-0.91) 0.86 (0.81-0.91) 0.79 (0.75-0.84) 0.79 (0.75-0.84) 
2007-2011 13,302 (26%) 1,761 (23%) 0.69 (0.65-0.73) 0.73 (0.68-0.77) 0.72 (0.67-0.76) 0.68 (0.64-0.72) 0.68 (0.64-0.73) 
2012-2016 16,371 (32%) 917 (12%) 0.73 (0.67-0.79) 0.77 (0.71-0.83) 0.80 (0.74-0.87) 0.73 (0.67-0.79) 0.73 (0.67-0.79) 
Grade        
Grade I-(Well) 
differentiated 
7,465 (14%) 351 (5%) Ref  Ref Ref Ref 
Grade II- Moderately 
(well) differentiated 
23,878 (47%) 2,701 (35%) 2.78 (2.49-3.11)  1.86 (1.66-2.08) 1.84 (1.65-2.06) 1.84 (1.64-2.06) 
Grade III-Poorly 
differentiated 
19,797 (39%) 4,540 (60%) 6.08 (5.45-6.78)  3.02 (2.70-3.38) 3.04 (2.71-3.41) 3.02 (2.70-3.39) 
TNM stage        
I 20,598 (40%) 930 (12%) Ref  Ref Ref Ref 
II 20,722 (40%) 2,736 (36%) 2.46 (2.27-2.67)  2.16 (2.00-2.33) 2.12 (1.96-2.29) 2.11 (1.95-2.28) 
III 7,935 (16%) 2,801 (37%) 10.13 (9.21-11.16)  6.33 (5.86-6.84) 5.95 (5.48-6.45) 5.90 (5.44-6.40) 
IV 1,885 (4%) 1,125 (15%) 30.13 (27.61-32.89)  20.94 (19.13-22.91) 11.05 (9.96-12.25) 11.09 (10.00-12.30) 
Screening        
Yes 16,227 (32%) 853 (11%) Ref  Ref Ref Ref 




Table 4.7 (continued) Traditional unadjusted and adjusted models Cox models for the association of ER status with breast cancer 
death (page 2 of 2) 
















       
Yes 48,343 (94%) 6,204 (82%) Ref   Ref Ref 
No 2,797 (6%) 1,388 (18%) 10.17 (9.58-10.78)   4.04 (3.74-4.37) 4.01 (3.70-4.33) 
Radiotherapy        
Yes 35,250 (69%) 4,863 (64%) Ref   Ref  
No 15,890 (31%) 2,729 (36%) 1.25 (1.19-1.31)   1.04 (0.99-1.10, 
p=0.096) 
1.03 (0.98-1.09, p=0.201) 
Chemotherapy        
Yes 20,329 (40%) 4,216 (56%) Ref   Ref Ref 
No 30,811 (60%) 3,376 (44%) 0.55 (0.53-0.58)   0.98 (0.92-1.04, 
p=0.488) 
0.96 (0.90-1.02, p=0.218) 
Hormone therapy        
Yes 40,136 (79%) 5,098 (67%) Ref   Ref Ref 
No 11,004 (21%) 2,494 (33%) 1.97 (1.87-2.06)   1.31 (1.21-1.41) 1.31 (1.21-1.41) 
SIMD quintile        
Least deprived 11,083 (22%) 1,481 (19%) Ref    Ref 
4 11,121 (22%) 1,556 (20%) 1.07 (0.99-1.15, 
p=0.075) 
   1.03 (0.96-1.11, p=0.307) 
3 10,858 (21%) 1,643 (22%) 1.18 (1.10-1.27)    1.12 (1.04-1.20, p=0.002) 
2 9,862 (19%) 1,576 (21%) 1.28 (1.19-1.37)    1.19 (1.11-1.28) 
Most deprived 8,216 (16%) 1,336 (18%) 1.32 (1.23-1.42)    1.24 (1.15-1.34) 
Charlson Score        
Mean (SD) 0.0 (0.3) 0.1 (0.3) 1.34 (1.24-1.44)    1.23 (1.13-1.33) 
Footnote: Model 1 was adjusted for age, incidence year and NHS region. Model 2: model 1 + tumour characteristics (grade, TNM stage and method of detection. Model 
3= model 2 + treatments (surgery, radiotherapy, chemotherapy and hormone therapy). Model 4= model 3 + SIMD and Charlson score index. Models carried out in the 
complete case dataset with n=51,140 women, number of BC deaths=7,592. All HRs were statistically significant at the 0.1% level unless stated otherwise. ER= oestrogen 





Results from the fully adjusted model (model 4) show that all covariates in the model were 
statistically significant independent prognostic factors for BCD, with the exception of 
radiotherapy and chemotherapy. BC mortality was particularly high among women older 
than 70 years (HR= 1.36, 95% CI: 1.27 to 1.45, compared to women aged 50 to 69 years), 
women with grade III tumours (HR= 3.02, 95% CI: 2.70 to 3.39, compared to women with 
grade I tumours), women with stage IV tumours (HR= 11.09, 95% CI: 10.00 to 12.30, 
compared to women with stage I), women with non-screen detected tumours (HR= 1.62, 
95% CI: 1.50 to 1.75, compared to women with screen detected tumours), women who 
did not have surgery (HR= 4.01, 95% CI: 3.70 to 4.33, compared to women who had 
surgery), women who did not received HT (HR= 1.31, 95% CI: 1.21 to 1.41, compared to 
women who received HT), women in the most deprived areas of Scotland (HR= 1.24, 95% 
CI: 1.15 to 1.34, compared to women in the least deprived areas) and women with a higher 
comorbidity index (HR= 1.23, 95% CI: 1.13 to 1.33 per unit increase).  
Log-minus-log plots for all covariates included in the fully adjusted model (model 4) with 
ER status as the main exposure are presented in Appendix Figure C.1 along with formal 
testing of the PH assumption (Appendix Table C.2). Log-minus-log plots showed small 
deviations from proportionality for ER- tumours, grade III, stage IV and the treatment 
variables that were confirmed by the global and individual covariates PH assumption tests. 
Sensitivity analysis  
Extended Cox model with TVEs for the fully adjusted model in Appendix C.3 shows that 
there was a statistically significant interaction of time with ER status [HR for 
time*ER=0.83 (95% CI: 0.81 to 0.85)] indicating that the HR for the comparison of ER- 
and ER+ tumours was not constant over time. Estimates of the HR at different times after 
diagnosis (1, 3, 5 and 10 years) presented in Appendix Table C.4 show that the HR for the 
comparison of women with ER- tumours vs ER+ tumours decreases over time: the risk of 
BCD amongst women with ER- tumours is 2.39, 1.63, 1.12 and 0.43 times that for women 
with ER+ tumours at 1, 3, 5 and 10 years respectively.  
The stratified model for 0 to 3 years of follow-up also shows higher BC mortality amongst 




2.52)] compared to the overall HR from the traditional Cox model. Restricting the follow-
up time to more than 3 years suggested that BC mortality in women with ER- tumours 
was actually lower than for women with ER+ tumours [HR=0.85 (95%CI: 0.76 to 0.96)] 
after adjusting for all other covariates.  
Other tumour characteristics (grade, stage, screening) and treatments (surgery, 
radiotherapy, chemotherapy and HT) also showed non-constant HRs. For example, 
radiotherapy and chemotherapy showed statistically significant results for both TVE 
models and stratified models with a beneficial effect of having these treatments for all 
women that was hidden by the traditional Cox model and that was restricted to early 
follow-up years (up to 3 years). 
4.4.3 Does breast cancer survival differ between IHC defined molecular subtypes? 
Women with luminal A tumours had the best survival of all subtypes, followed by women 
with luminal B tumours and HER2-enriched subtypes (Figure 4.4). Women with a TNBC 
had the worst survival with 72.6% (95% CI: 70.5 to 74.6) of all women with that subtype 
surviving at 5 years, considerably lower than 91.3% (95% CI: 90.1 to 91.9) of women 
with luminal A tumours surviving that time (Table 4.8).  





The differences in survival between the IHC defined subtypes were consistent across the 
three age groups. Women aged less than 50 years and women aged 50 to 69 years had 
very similar BCSS at 5 years within each subtype. However, women aged 70 years or 
older had considerably lower survival than women younger than 70 years of age, 
particularly for the most aggressive HER2-enriched and TNBC subtypes. 
Table 4.8 Breast cancer specific survival estimates (in %) at 5 years after diagnosis (with 
95% CI) by IHC defined molecular subtypes and age group 
IHC defined  
subtype 
<50 YEARS 50- 69 YEARS 70 YEARS OR 
OLDER 
TOTAL 
Luminal A     
cases/deaths 749/75 2,413/183 888/331 4,050/589 
5-year BCSS (95% CI) 93.6 (92.1, 94.9) 95.5 (94.8, 96.0) 81.6 (80.0, 83.1) 91.3 (90.1, 91.9) 
Luminal B     
cases/deaths 679/169 1,176/229 379/242 2,234/640 
5-year BCSS (95% CI) 86.2 (84.2, 88.0) 88.8 (87.5, 90.1) 73.3 (70.5, 75.8) 84.5 (83.5, 85.5) 
HER2-enriched     
cases/deaths 89/29 173/50 49/54 311/133 
5-year BCSS (95% CI) 81.5 (74.9, 86.6) 81.7 (77.4, 85.3) 58.4 (51.1, 65.0) 76.0 (72.7, 78.8) 
Triple Negative     
cases/deaths 187/112 327/155 95/117 609/384 
5-year BCSS (95% CI) 74.5 (70.5, 78.1) 78.6 (75.7, 81.1) 57.4 (52.4, 62.1) 72.6 (70.5, 74.6) 
BCSS= breast cancer specific survival, HER2= human epidermal growth factor 2, IHC= immunohistochemistry. 
OS estimates (Appendix Table C.5) were similar to BCSS estimates for women younger 
than 70 years of age and the differences between subtypes were consistent. For women 
aged 70 years or older OS was considerably lower than BCSS, and the difference was 
more striking between the luminal subtypes. For example, women aged 70 years or more 
with luminal A tumours had a BCSS at 5 years of 81.6% and an OS at 5 years of 58.5%.  
Results from Cox models (Figure 4.5) showed that BCD was significantly higher for 
women with TNBC [HR=3.93 (95% CI: 3.29 to 4.70)] compared to women with luminal 




mortality than women with luminal A tumours after adjustment for other individual and 
tumour characteristics. Adjusting for other characteristics had the largest effect, 
attenuating the HR of BCD for women with HER2-enriched tumours compared to women 
with luminal A tumours from 3.36 (95% CI: 2.86 to 3.95) in the unadjusted model to 1.95 
(95% CI: 1.58 to 2.16) in the fully adjusted model. Full results for all models are presented 
in Table 4.9. The PH assumption held for IHC defined subtypes and for that reason TVE 
models were not used for the models with the molecular subtypes as the main exposure. 
Small deviations from proportionality were observed for other covariates but as I was 
mainly interested in the effect of the subtypes in BCD the traditional Cox model is 
presented and deemed adequate. 
 
Figure 4.5 Unadjusted and fully adjusted Cox regression models results for breast cancer 
death for the IHC defined molecular subtypes with luminal A tumours as the reference 
 
Footnote: Fully adjusted model has age, incidence year, NHS region, tumour characteristics (TNM stage and method 
of detection, treatments (surgery, radiotherapy, chemotherapy and hormone therapy), SIMD and Charlson score 
index. Models carried out in the complete case dataset with n=24,266 women diagnosed between 2009 and 2016, 
number of BC deaths=2,168. CI= confidence interval, HER2= human epidermal growth factor 2, HR=hazard ratio, REF= 




Table 4.9 Traditional unadjusted and adjusted Cox models for the association of IHC defined molecular subtypes with breast 




No deaths (%) Model 0- 
Unadjusted 
Model 1 Model 2 Model 3 Model 4 
 
IHC defined subtype        
Luminal A 13,755 (56%) 723 (33%) Ref Ref Ref Ref Ref 
Luminal B 7,132 (29%) 753 (35%) 1.95 (1.76-2.16) 2.03 (1.83-2.25) 1.71 (1.54-1.89) 2.06 (1.84-2.29) 2.04 (1.83-2.28) 
HER2-enriched 1,140 (4%) 188 (9%) 3.36 (2.86-3.95) 3.48 (2.96-4.09) 2.44 (2.08-2.87) 1.97 (1.60-2.44) 1.95 (1.58-2.41,) 
Triple Negative 2,635 (11%) 504 (23%) 4.09 (3.65-4.58) 4.31 (3.85-4.84) 4.54 (4.03-5.10) 4.02 (3.36-4.80) 3.93 (3.29-4.70) 
Age        






50-69 years 13,332 (54%) 764 (35%) Ref Ref Ref Ref Ref 
70 years or older 6,293 (26%) 963 (45%) 3.19 (2.90-3.50) 3.23 (2.94-3.55) 2.08 (1.88-2.29) 1.49 (1.33-1.66) 1.49 (1.33-1.67) 
NHS Scottish region        
West 11,072 (45%) 962 (44%) Ref Ref Ref Ref Ref 



















Year of diagnosis        
2009-2011 7,425 (30%) 1,005 (46%) Ref Ref Ref Ref Ref 
2012-2016 17,237 (70%) 1,163 (54%) 1.16 (1.06-1.27, 
p=0.003) 
1.15 (1.05-1.27) 1.24 (1.13-1.36) 1.19 (1.08-1.31) 1.19 (1.08-1.31) 
TNM stage        
I 10,081 (41%) 167 (8%) Ref  Ref Ref Ref 
II 9,824 (40%) 622 (29%) 3.92 (3.30-4.65)  2.52 (2.12-3.00) 2.54 (2.12-3.03) 2.51 (2.10-3.00) 
III 3,323 (13%) 631 (29%) 12.33 (10.40-14.62)  7.52 (6.31-8.96) 7.30 (6.09-8.76) 7.26 (6.06-8.71) 
IV 1,434 (6%) 748 (34%) 57.34 (48.46-67.85)  38.12 (32.00-45.41) 14.54 (11.91-17.76) 14.72 (12.05-17.97) 
Screening        
Yes 8,359 (34%) 157 (7%) Ref  Ref Ref Ref 





Table 4.9 (continued) Traditional unadjusted and adjusted Cox models for the association of IHC defined molecular subtypes with 
breast cancer death (page 2 of 2) 




Model 0- Unadjusted Model 1 Model 2 Model 3 Model 4 
Surgery        
Yes 22,178 (90%) 1,212 (56%) Ref   Ref Ref 
No 2,484 (10%) 956 (44%) 13.92 (12.76-15.19)   5.06 (4.43-5.76) 4.98 (4.37-5.68) 
Radiotherapy        
Yes 17,726 (72%) 1,173 (54%) Ref   Ref  
No 6,936 (28%) 995 (46%) 2.48 (2.27-2.69)   1.06 (0.96-1.17, p=0.215) 1.05 (0.95-1.16, p=0.310) 
Chemotherapy        
Yes 9,261 (38%) 1,026 (47%) Ref   Ref Ref 
No 15,401 (62%) 1,142 (53%) 0.71 (0.65-0.77)   1.28 (1.14-1.44) 1.25 (1.11-1.40) 
Hormone therapy        
Yes 19,475 (79%) 1,300 (60%) Ref   Ref Ref 
No 5,187 (21%) 868 (40%) 2.76 (2.54-3.01)   1.84 (1.59-2.14) 1.85 (1.59-2.14) 
SIMD quintile        
Least deprived 5,260 (21%) 399 (18%) Ref    Ref 
4 5,277 (21%) 393 (18%) 0.98 (0.85-1.13, p=0.792)    0.96 (0.83-1.10, p=0.536) 
3 5,126 (21%) 453 (21%) 1.19 (1.04-1.37, p=0.010)    1.11 (0.97-1.27, p=0.136) 
2 4,784 (20%) 478 (22%) 1.39 (1.22-1.59)    1.16 (1.01-1.32, p=0.035) 
Most deprived 4,215 (17%) 445 (21%) 1.49 (1.30-1.71)    1.29 (1.12-1.48) 
Charlson Score        
Mean (SD) 0.0 (0.3) 0.1 (0.3) 1.51 (1.34-1.70)    1.23 (1.08-1.40) 
Footnote: Model 1 was adjusted for age, incidence year and NHS region. Model 2: model 1 + tumour characteristics (grade, TNM stage and method of detection. Model 
3= model 2 + treatments (surgery, radiotherapy, chemotherapy and hormone therapy). Model 4= model 3 + SIMD and Charlson score index. Models carried out in the 
complete case dataset with n=24,662 women, number of BC deaths=2,168. All HRs were statistically significant at the 0.1% level unless stated otherwise. IHC= 
immunohistochemistry, NHS= National Health Service, Ref= reference category, SD= standard deviation, SIMD= Scottish Index of Multiple Deprivation, TNM= tumour, 




4.4.4 Association of other important prognostic factors with breast cancer survival 
within each subtype 
Table 4.10 presents the effect of those covariates in BCD in women with ER+ and ER- 
tumours separately from multivariate Cox regression analysis.  
Table 4.10 Unadjusted and adjusted Cox models results for breast cancer specific 
mortality stratified by ER status (page 1 of 2) 
Characteristic 
ER+ no. cases=42,146  
no. failures=5,238 




HR (95% CI) 
Adjusted  
HR (95% CI) 
Unadjusted 
HR (95% CI) 
Adjusted  
HR (95% CI) 
Age     






50-69 years Ref Ref Ref Ref 
70 years or older 2.35 (2.21-2.50) 1.34 (1.24-1.45) 2.09 (1.90-2.29) 1.30 (1.16-1.46) 
NHS Scottish region     
West Ref Ref Ref Ref 
North 1.18 (1.11-1.26) 1.11 (1.03-1.19, 
p=0.005) 
1.25 (1.14-1.37) 1.13 (1.02-1.25, 
p=0.014) 






Year of diagnosis     
1997-2001 Ref Ref Ref Ref 
2002-2006 0.86 (0.80-0.92) 0.80 (0.74-0.85) 0.89 (0.80-0.99, 
p=0.026) 
0.83 (0.75-0.92) 
2007-2011 0.71 (0.66-0.77) 0.69 (0.64-0.74) 0.74 (0.67-0.83) 0.71 (0.63-0.79) 




Grade     
Grade I-(Well) 
differentiated 
Ref Ref Ref Ref 
Grade II- Moderately 
(well) differentiated 
2.65 (2.37-2.98) 1.80 (1.61-2.02) 3.86 (2.22-6.70) 3.08 (1.77-5.37) 
Poorly differentiated 5.61 (5.01-6.28) 3.14 (2.79-3.53) 4.55 (2.63-7.84) 4.03 (2.33-6.98) 
TNM stage     
I Ref Ref Ref Ref 
II 3.26 (2.99-3.56) 2.20 (2.00-2.42) 2.10 (1.84-2.41) 1.88 (1.63-2.16) 








Screening     
Yes Ref Ref Ref Ref 





Table 4.10 (continued) Unadjusted and adjusted Cox models results for breast cancer 
specific mortality stratified by ER status (page 2 of 2) 
Characteristic 
ER+ no. cases=42,146  
no. failures=5,238 




HR (95% CI) 
Adjusted  
HR (95% CI) 
Unadjusted 
HR (95% CI) 
Adjusted  
HR (95% CI) 
Surgery     
Yes Ref Ref Ref Ref 
No 12.17 (11.36-13.05) 4.55 (4.14-5.00) 13.53 (11.95-
15.31) 
4.41 (3.81-5.10) 
Radiotherapy     
Yes Ref Ref Ref Ref 





Chemotherapy     
Yes Ref Ref Ref Ref 
No 0.55 (0.52-0.58) 0.87 (0.81-0.94) 1.18 (1.08-1.28) 1.28 (1.14-1.43) 
Hormone therapy     
Yes Ref Ref   
No 1.44 (1.31-1.57) 1.50 (1.36-1.64)   
SIMD quintile     
Least deprived Ref Ref Ref Ref 
















2 1.24 (1.14-1.35) 1.18 (1.08-1.28) 1.28 (1.13-1.46) 1.23 (1.08-1.41, 
p=0.002) 
Most deprived 1.30 (1.19-1.42) 1.26 (1.15-1.38) 1.24 (1.08-1.41) 1.20 (1.04-1.38) 
Charlson Score     
Mean (SD) 1.27 (1.14-1.39) 1.17 (1.06-1.30, 
p=0.003) 
1.45 (1.28-1.64) 1.24 (1.09-1.40, 
p=0.001) 
Footnote: Adjusted model includes age, incidence year, NHS region, grade, TNM stage, method of detection, surgery, 
radiotherapy, chemotherapy, hormone therapy (only for ER+ model), SIMD and Charlson score index. Models carried 
out in the complete case dataset separately by ER status. All HRs were statistically significant at the 0.1% level unless 
stated otherwise. CI= confidence interval, ER= oestrogen receptor, HR= hazard ratio, NHS= National Health Service, 
Ref= reference category, SD= standard deviation, SIMD= Scottish Index of Multiple Deprivation, TNM= tumour, nodes, 
metastases.  
 
Results from the Cox models stratified by ER status (Table 4.10) and by the IHC 
defined molecular subtypes (Table 4.12), with follow-up times for each subtype 
presented in Table 4.11, showed that age, grade, stage, detection by screening and 





Table 4.11 Median (IQR) follow-up times for all women and for women with each subtype 
diagnosed in Scotland 
 Median (IQR) follow-up time in 
years 
Diagnosis years 
ER status  1997-2016 
ER+ 5.8 (2.7, 10.6)  
ER- 4.6 (1.8, 10.2)  
IHC defined subtype  2009-2016 
Luminal A 3.2 (1.5, 5.1)  
Luminal B 3.3 (1.6, 5.3)  
HER2-enriched 2.8 (1.2, 4.9)  
Triple Negative 2.6 (1.2, 4.6)  
All women 5.5 (2.3, 10.5) 1997-2016 






Table 4.12 Unadjusted and adjusted Cox models results for breast cancer specific mortality stratified by molecular subtype in 
women diagnosed in Scotland from 2009 to 2016 (page 1 of 2)  
Characteristic 
Luminal A no. cases=13,755 
no. failures=723 
Luminal B no. cases=7,132 
no. failures=753 
HER2-enriched no. cases=1,034  
no. failures=147 




HR (95% CI) 
Adjusted 
HR (95% CI) 
Unadjusted 
HR (95% CI) 
Adjusted 
HR (95% CI) 
Unadjusted 
HR (95% CI) 
Adjusted 
HR (95% CI) 
Unadjusted 
HR (95% CI) 
Adjusted 
HR (95% CI) 
Age         
















50-69 years Ref Ref Ref Ref Ref Ref Ref Ref 
70 years or older 
NHS Scottish region 
4.60 (3.91-5.42) 1.49 (1.23-1.80) 2.62 (2.22-3.09) 1.39 (1.14-1.69, 
p=0.001) 
2.86 (2.01-4.09) 0.72 (0.45-1.16, 
p=0.181) 
2.32 (1.87-2.88) 1.49 (1.15-1.94, 
p=0.003) 
West Ref Ref Ref Ref Ref Ref Ref Ref 














































Grade         
Grade I-(Well) 
differentiated 




Grade II- Moderately 
(well) differentiated 
    Ref Ref Ref Ref 








TNM stage                   I Ref Ref Ref Ref Ref Ref Ref Ref 




2.36 (1.71-3.25) 1.87 (1.34-2.60) 
III 12.51 (9.31-
16.80) 


























Screening               Yes Ref Ref Ref Ref Ref Ref Ref Ref 
No 11.18 (8.39-
14.91) 
2.69 (1.95-3.71) 3.80 (2.94-4.91) 1.71 (1.30-2.25) 3.24 (1.83-5.72) 1.80 (0.98-3.32, 
p=0.058) 




Table 4.12 (continued) Unadjusted and adjusted Cox modes results for breast cancer specific mortality stratified by molecular 
subtype in women diagnosed in Scotland from 2009 to 2016 (page 2 of 2) 
Characteristic 
Luminal A no. cases=13,755 
no. failures=723 
Luminal B no. cases=7,132 
no. failures=753 
HER2-enriched no. cases=1,034   
no. failures=147 




HR (95% CI) 
Adjusted 
HR (95% CI) 
Unadjusted 
HR (95% CI) 
Adjusted 
HR (95% CI) 
Unadjusted 
HR (95% CI) 
Adjusted 
HR (95% CI) 
Unadjusted 
HR (95% CI) 
Adjusted 
HR (95% CI) 
Surgery         














Radiotherapy         
Yes Ref Ref Ref Ref Ref Ref Ref Ref 
No 4.12 (3.55-4.77) 0.82 (0.68-0.98, 
p=0.027) 
1.88 (1.63-2.18) 0.97 (0.82-1.15, 
p=0.745) 
1.89 (1.37-2.61) 1.49 (1.04-2.14, 
p=0.029) 
1.70 (1.40-2.07) 1.28 (1.04-1.59, 
p=0.020) 
Chemotherapy         
Yes Ref Ref Ref Ref Ref Ref Ref Ref 
No 0.64 (0.55-0.76) 0.72 (0.59-0.89, 
p=0.002) 




Hormone therapy         
Yes Ref Ref Ref Ref     
No 1.95 (1.55-2.47) 2.28 (1.78-2.94) 1.90 (1.57-2.30) 1.79 (1.46-2.19)     
SIMD quintile         
Least deprived Ref Ref Ref Ref Ref Ref Ref Ref 






























































Charlson Score         
Mean (SD) 1.41 (1.13-1.76) 1.16 (0.90-1.49) 1.57 (1.30-1.91) 1.28 (1.03-1.58) 2.29 (1.46-3.60) 2.57 (1.47-4.51) 1.33 (1.01-1.75) 1.30 (0.99-1.71) 
Footnote: Adjusted model includes age, incidence year, NHS region, grade (only in the HER2=enriched and TNBC models), TNM stage, method of detection, surgery, 
radiotherapy, chemotherapy, hormone therapy (only for luminal models), SIMD and Charlson score index. Models carried out in the complete case dataset separately by 
molecular subtype. All HRs were statistically significant at the 0.1% level unless stated otherwise. CI= confidence interval, HR= hazard ratio, NHS= National Health Service, 





Older age was associated with higher BCD for all subtypes. Women older than 70 years 
had higher BC-specific mortality when compared to women aged 50 to 69 years for all 
ER status and tumour subtypes except for HER2-enriched tumours (HR=0.72, 95% CI: 
0.45 to 1.16). BC specific mortality differed between the subtypes for women younger 
than 50 years. After adjustment for all other covariates only ER+ and luminal A tumours 
had lower risk of BC mortality when compared to the same subtype in women aged 50 to 
69 years. HER2-enriched subtypes in women younger than 50 years also showed a lower 
risk of BC mortality but HR did not reach statistical significance. Year of diagnosis was 
associated with BC death, with women diagnosed in more recent years, between 2012-
2016, having a lower BC-specific mortality than those diagnosed between 1997 and 2001 
[HR=0.73 for ER+ tumours and 0.83 for ER- tumours] independent of follow-up time. 
Other tumour characteristics 
Grade III- poorly differentiated tumours were associated with higher BC-specific 
mortality than lower grade tumours and the association was stronger for those subtypes 
that did not express ER (HR=4.03, 95% CI: 2.33 to 6.98 for ER- tumours) and those that 
overexpressed HER2 (HR=2.52, 95% CI: 1.48 to 4.28). Higher stage was associated with 
poorer BCSS than for lower stage for all subtypes. Women with stage IV tumours had the 
highest BC-specific mortality that ranged from 10 times (95% CI: 7.8 to 14.8 for luminal 
A tumours) to 19 times (95% CI: 8.2 to 45.9 for HER2-enriched tumours) the mortality 
for a stage I tumour of the same subtype.  
Screen detection showed a consistent inverse association with death across all subtypes 
with women with tumours that were not diagnosed through screening being more likely 
to die from BC (HR=1.66, 95% CI: 1.51 to 1.82 for ER+ tumours and HR=1.60, 95% CI: 
1.37 to 1.86 for ER- tumours). Amongst IHC defined molecular subtypes luminal A 
tumours and TNBC that were not screen detected had the highest increased mortality, 
HR=2.69 (95% CI: 1.95 to 3.71) and 2.34 (95% CI: 1.55 to 3.52) respectively, compared 





Women who did not receive surgery had an increased BC-specific mortality compared to 
those who received surgery that was similar for ER+ and ER- subtypes (HR=4.55, 95% 
CI: 4.14 to 5.00 for ER+ and HR=4.41, 95% CI: 3.81 to 5.10 for ER-). Surgery had a 
greater beneficial effect in luminal A and HER2-enriched tumours with women who did 
not receive surgery having an increase mortality of 8.83 (95% CI: 7.0 to 11.2) and 9.3 
(95% CI: 5.5 to 15.9) times the mortality for those who had surgery. 
The benefit of radiotherapy in women with ER+ tumours and women with luminal A 
tumours was only observed in the unadjusted models but was attenuated after adjustment 
for all other covariates. However, in women with more aggressive subtypes, such as, 
HER2-enriched and TNBC those that did not receive radiotherapy had an HR of 1.49 
(95% CI: 1.04 to 2.14) and 1.28 (95% CI: 1.04 to 1.59) respectively compared to those 
who had radiotherapy.  
The effect of chemotherapy in BCD also differ between subtypes. Women with ER-, 
luminal B and HER2-enriched tumours who did not have chemotherapy had increased 
mortality (HR=1.28, 95% CI: 1.14 to 1.43 for ER-, HR=1.57, 95% CI: 1.30 to 1.91 for 
luminal B and HR=5.66, 95% CI: 3.50 to 9.15 for HER2-enriched) compared to those 
who had chemotherapy. In contrast, chemotherapy had the opposite effect on women with 
ER+ and luminal A tumours and women who did not receive this treatment were less 
likely to die from BC (HR=0.87, 95% CI: 0.81 to 0.94 for ER+ and HR=0.72, 95% CI: 
0.59 to 0.89 for luminal A).  
HT was an important factor for those women with hormone sensitive tumours. Women 
with ER+, luminal A and luminal B tumours who did not receive hormone therapy had 
higher BC-specific mortality compared to those who received HT. (HR=1.5, 95% CI: 1.36 
to 1.64 for ER+, HR=2.28, 95% CI: 1.78 to 2.94 for luminal A and HR=1.79, 95% CI: 






Deprivation and comorbidities  
Deprivation and comorbidities were also associated with BCD amongst all subtypes. 
Women in the most deprived areas of Scotland were more likely to die from BC compared 
to those in the least deprived areas of Scotland (Figure 4.6).  
Figure 4.6 Hazard ratio (with 95% CI) for the association of women in the most deprived 
fifth of areas of Scotland with risk of breast cancer death compared to women in the 
least deprived fifth of areas of Scotland separately by ER status and IHC defined 
molecular subtypes 
 
Footnote: Fully adjusted model includes age, incidence year, NHS region, tumour characteristics (TNM stage and 
method of detection, treatments (surgery, radiotherapy, chemotherapy and hormone therapy), SIMD and Charlson 
comorbidity index. Models carried out separately by subtype with n=42,146 for ER+, n=9,105 for ER-, n=13,755 for 
luminal A, n=7,132 for luminal B, n=1,034 for HER2-enriched and n=2,519 for Triple Negative. CI= confidence interval, 






The increased mortality associated with being in the most deprived compared to the least 
deprived areas was highest amongst women with HER2-enriched tumours for whom the 
risk was doubled. Women in the most deprived areas with ER+, ER- and luminal A 
tumours also had higher mortality compared to women with the same subtype in the least 
deprived areas that ranged from a 20% increase for ER- to 40% increase for luminal A 
tumours. For women with luminal B and TNBC in the most deprived areas there was a 
suggestion of a negative effect of deprivation in survival but the association was no longer 
significant after adjustment for other tumour characteristics.  
 
Sensitivity analysis  
Results for the comparison of traditional Cox models with TVE models that adjust for 
non-proportional hazards are presented in Appendix C.6 for ER+ and ER- tumours and in 
Appendix C.7 for the luminal tumours. The PH assumption for the stratified models for 
HER2-enriched and TNBC held. The effect of screening, stage, grade, radiotherapy, 
chemotherapy and HT in the hazards of BCD decreased over time for ER+ tumours. TVE 
models showed a more plausible results for chemotherapy and radiotherapy that were 
found to have a beneficial effect on survival that was restricted to early years, compared 
to the opposite effect suggested by the traditional Cox model.  
 
4.4.5 Missing data patterns and multiple imputation results 
Patterns of missing data are reported in Table 3.1. Proportions of missing data were 
particularly high for tumour characteristics such as, grade and T, N and M pathological 
and clinical stages. However, the composite TNM stage variable was derived as described 
in Appendix B.2 using other tumour characteristics such us, tumour size and nodal status 
that considerably reduced the amount of missing data (from 50 to 12%). The average 
number of missing variables per woman was low (0.5) but almost 30% of all women 





Table 4.13 Number of missing variables for each woman in the survival dataset 
Number of missing variables Frequency Percentage 
0 51,140 71.2% 
1 12,263 17.1% 
2 4,601 6.4% 
3 2,270 3.2% 
4 562 0.8% 
5 270 0.4% 
6 249 0.4% 
7 268 0.4% 
8 161 0.2% 
 
The correlation of missingness between covariates is presented in Table 4.14. The highest 
correlation was observed amongst the treatment variables, for example between 
chemotherapy and radiotherapy (0.56). Correlation of missingness between tumour 
characteristics was also high, especially between ER status, grade and stage. 
Table 4.14 Correlation of missingness between breast cancer prognostic variables 
 ER status Grade Stage Screening Surgery Radio Chemo 
Grade 0.41       
TNM stage 0.34 0.35      
Screening 0.23 0.14 0.19     
Surgery 0.18 0.14 0.19 0.28    
Radio 0.18 0.09 0.14 0.40 0.34   
Chemo 0.18 0.10 0.14 0.39 0.43 0.56  
HT 0.17 0.07 0.13 0.37 0.27 0.51 0.43 
  Chemo= chemotherapy, HT=hormone therapy, Radio=radiotherapy, TNM= tumour, nodes, metastases. 
 
Descriptive characteristics of the women with complete and incomplete data (Table 4.15) 
were compared to investigate whether data were missing completely at random (MCAR). 
Differences were observed for most characteristics, except for ER status. The percentage 
of women with incomplete data (incomplete cases) was higher in women older than 70 
years, women living in the West of Scotland, women living in the most deprived areas, 
women diagnosed in earlier years, women with stage III and IV tumours, not diagnosed 
through screening and not having surgery, radiation, chemotherapy or HT than in 





Table 4.15 Descriptive characteristics of women with complete and incomplete data 
Characteristic Complete data (N=51,140) Incomplete data (N=20,644) 
Age in years                                     <50 years 10,886 (21%) 3,493 (17%) 
   50-69 years 27,869 (55%) 7,723 (37%) 
   70 years or older 12,385 (24%) 9,428 (46%) 
NHS Scottish region                              North 14,545 (28%) 4,047 (20%) 
   South East 15,857 (31%) 3,976 (19%) 
   West 20,738 (41%) 12,621 (61%) 
Year of diagnosis   
   1997-2001 10,390 (20%) 5,914 (29%) 
   2002-2006 11,077 (22%) 6,212 (30%) 
   2007-2011 13,302 (26%) 5,377 (26%) 
   2012-2016 16,371 (32%) 3,141 (15%) 
ER status   
   Negative 8,994 (18%) 2,704 (17%) 
   Positive 42,146 (82%) 12,857 (83%) 
Tumour grade   
   Grade I- (Well) differentiated 7,465 (15%) 1,219 (14%) 
Grade II- Moderately (well) differentiated 23,878 (47%) 4,099 (46%) 
   Poorly differentiated 19,797 (39%) 3,688 (41%) 
TNM stage   
   I 20,598 (40%) 3,511 (29%) 
   II 20,722 (41%) 4,520 (37%) 
   III 7,935 (15%) 2,399 (20%) 
   IV 1,885 (4%) 1,726 (14%) 
Diagnosed through screening?   
   No 34,913 (68%) 15,888 (83%) 
   Yes 16,227 (32%) 3,286 (17%) 
Surgery   
   No 2,797 (6%) 8,036 (40%) 
   Yes 48,343 (94%) 12,018 (60%) 
Radiation   
   No 15,890 (31%) 10,911 (63%) 
   Yes 35,250 (69%) 6,494 (37%) 
Chemotherapy   
   No 30,811 (60%) 12,717 (67%) 
   Yes 20,329 (40%) 6,147 (33%) 
Hormone therapy   
   No 11,004 (22%) 4,615 (28%) 
   Yes 40,136 (79%) 11,786 (72%) 
SIMD quintile   
   Least deprived 11,083 (22%) 3,806 (18%) 
   4 11,121 (22%) 3,805 (18%) 
   3 10,858 (21%) 4,000 (19%) 
   2 9,862 (19%) 4,396 (21%) 
   Most deprived 8,216 (16%) 4,637 (23%) 
Charlson Comorbidity Index   
   Mean (SD) 0.0 (0.3) 0.1 (0.4) 
ER= oestrogen receptor, NHS=National Health Service, SD= standard deviation, SIMD= Scottish Index of Multiple 




The outcome was also different amongst women with incomplete data with 57% of them 
having died at the end of the study period compared to 28% of women with complete data 
(Table 4.16). Incomplete cases were also more likely to die from BC than those with 
complete data (31% vs 15%). Median follow-up amongst women who died during the 
study period was 4.7 years for women with incomplete data and 5.8 years for women with 
complete data. Missingness was clearly related to individual and tumour characteristics 
and worse outcome was associated with missingness in covariate data, for that reason, 
data were not MCAR.  
Table 4.16 Outcomes and follow-up times for women with complete and incomplete 
data 






Vital status    
   Alive 36,656 (72%) 8,848 (43%) 45,504 (63%) 
   Dead 14,484 (28%) 11,796 (57%) 26,280 (37%) 
Breast cancer death    
   No 43,548 (85%) 14,254 (69%) 57,802 (80.5%) 
   Yes 7,592 (15%) 6,390 (31%) 13,982 (19.5%) 
Follow-up time (in years)    
   Median 5.8 4.7 5.5 
   Q1, Q3 2.7, 10.6 1.6, 10.1 2.3, 10.5 
Q1=quartile 1, Q3=quartile 3 
 
The MAR assumption states that the missing patterns observed depend on the observed 
data but not on the unobserved data. The MAR assumption is an empiric concept and 
therefore, not testable [266]. Further, distinguishing between MAR and MNAR is not 
possible as it depends on non-measured data. Previous studies using BC registry data have 
used MI of missing data under the MAR assumption [267] successfully and sensitivity 
analysis assuming that data was MNAR has shown very similar results [168]. In my study, 
I assumed that a MAR mechanism was more plausible than MNAR as missingness seemed 
to be greatly explained by observed covariates. In order to adjust for MAR data which 




fully adjusted Cox model (model 4) with ER status as the main exposure for the CCA and 
the multiple imputation analysis (MIA) is presented in Table 4.17.  
Table 4.17 Comparison of results from complete case analysis model and multiple 
imputation analysis model (page 1 of 2) 
Characteristic 




 HR (95%CI) HR (95%CI) 
ER Status   
Positive Ref Ref 
Negative 1.44 (1.33-1.56) 1.38 (1.29-1.48) 
Age   
<50 years 0.89 (0.84-0.95) 0.87 (0.83-0.92) 
50-69 years Ref Ref 
70 years or older 1.36 (1.27-1.45) 1.25 (1.19-1.32) 
NHS Scottish region   
West Ref Ref 
North 1.12 (1.06-1.19) 1.11 (1.06-1.16) 
South East 1.01 (0.96-1.07, p=0.665) 0.98 (0.94-1.02, p=0.665) 
Year of diagnosis   
1997-2001 Ref Ref 
2002-2006 0.79 (0.75-0.84) 0.85 (0.82-0.89) 
2007-2011 0.68 (0.64-0.73) 0.70 (0.67-0.74) 
2012-2016 0.73 (0.67-0.79) 0.74 (0.69-0.78) 
Grade   
Grade I-(Well) differentiated Ref Ref 
Grade II- Moderately (well) 
differentiated 
1.84 (1.64-2.06) 1.64. (1.48-1.81) 
Poorly differentiated 3.02 (2.70-3.39) 2.54 (2.30-2.81) 
TNM stage   
I Ref Ref 
II 2.11 (1.95-2.28) 2.21 (2.07-2.37) 
III 5.90 (5.44-6.40) 5.61 (5.23-6.03) 
IV 11.09 (10.00-12.30) 10.22 (9.37-11.16) 
Screening   
Yes Ref Ref 








Table 4.17 (continued) Comparison of results from complete case analysis model and 
multiple imputation analysis model (page 2 of 2) 
Characteristic 




 HR (95%CI) HR (95%CI) 
Surgery   
Yes Ref Ref 
No 4.01 (3.70-4.33) 3.85 (3.64-4.07) 
Radiotherapy   
Yes   
No 1.03 (0.98-1.09, p=0.201) 0.96 (0.92-1.01, p=0.086) 
Chemotherapy   
Yes Ref Ref 
No 0.96 (0.90-1.02, p=0.218) 1.05 (0.99-1.10, p=0.094) 
Hormone therapy   
Yes Ref Ref 
No 1.31 (1.21-1.41) 1.49 (1.40-1.59) 
SIMD quintile   
Least deprived Ref Ref 
4 1.03 (0.96-1.11, p=0.371) 1.04 (0.98-1.11, p=0.371) 
3 1.12 (1.04-1.20, p=0.002) 1.12 (1.06-1.19, p=0.002) 
2 1.19 (1.11-1.28) 1.15 (1.08-1.21) 
Most deprived 1.24 (1.15-1.34) 1.20 (1.13-1.27) 
Charlson Score   
Mean (SD) 1.23 (1.13-1.33) 1.10 (1.04-1.16) 
Both models are fully adjusted and include age, incidence year, NHS region, tumour characteristics (ER status, TNM 
stage and method of detection, treatments (surgery, radiotherapy, chemotherapy and hormone therapy), SIMD and 
Charlson comorbidity index. All HRs were statistically significant at the 0.1% level unless stated otherwise. CI= 
confidence interval, ER= oestrogen receptor, HR= Hazard Ratio, NHS=National Health Service, Ref= reference category, 
SD= standard deviation, SIMD= Scottish Index of Multiple Deprivation, TNM=tumour, node, metastases.  
 
Estimates for the association of BCD with individual and tumour characteristics, were 
similar in the analysis based on imputed data to the CCA. In particular the association of 
the main exposure comparison (ER- vs ER+ tumours) with BCD was very similar in both 
the CCA and the MIA but slightly attenuated. For the rest of covariates estimates were 
slightly lower for age <50 years and age 70 years or older (compared to age 50 to 69 
years), grades II and III (compared to grade I), stages III-IV (compared to stage I), not 
having surgery (compared to having surgery), not having radiotherapy (compared to 
having radiotherapy), living in the 40% most deprived areas (compared to living in the 
20% least deprived areas) and having a higher Charlson comorbidity index, whereas 




2001, stage II (compared to stage I) , having a screen detected tumour (compare to a non-
screen detected tumours), not having chemotherapy (compared to having chemotherapy) 
and not having HT (compared to having HT) were slightly higher for the analysis with 
imputed data. This divergent effect in the HRs is likely reflecting that missingness is 
related to those characteristics for which the effect is attenuated but not so much to those 
characteristics for which the effect is strengthened. MI estimates were all in the same 
direction as those for CCA and imputation did not change the statistical significance of 
any covariate in the model. As expected from the larger sample size, CIs for the estimates 
based on imputed data were narrower than the CI based on CCA and they overlapped 
suggesting only minor differences in the estimates from CCA or MIA.  
Comparison of results from CCA and MIA for the Cox model with IHC defined molecular 
subtypes as the main exposure can be found in Appendix C.8. The association of BCD 
with the molecular subtypes was also slightly attenuated in the analysis with imputed data 
showing higher BC-specific mortality for luminal B, HER2-enriched and TNBC subtypes 
compared to luminal A subtype. CI for the estimates were narrower and overlapped with 
those for the CCA.  
 
4.4.6 Is breast cancer survival improving over time?  
4.4.6.1 Descriptive characteristics by year of diagnosis 
The percentage of breast tumours amongst women younger than 50 years remained 
constant over time at around 20% of all breast tumours diagnosed in Scotland (Table 4.18). 
BCs in women of screening age (50 to 69 years) accounted for a smaller proportion in 
earlier years, 47% in 1997 to 2001, than in more recent years, 52% in 2012-2016. The 







Table 4.18 Description of the most important individual and tumour characteristics 
amongst women with breast cancer by year of diagnosis 
Characteristic 1997-2001 2002-2006 2007-2011 2012-2016 Total 
Age      
<50 years 3,324 (21) 3,543 (21) 3,739 (20) 3,773 (19) 14,379 (20) 
50-69 years 7,741 (47) 8,319 (48) 9,473 (51) 10,059 (52) 35,592 (50) 
70+ years 5,239 (32) 5,427 (31) 5,467 (29) 5,680 (29) 21,813 (30) 
ER status      
Positive 10,978 (78) 13,116 (83) 14,912 (83) 15,997 (84) 55,003 (82) 
Negative 3,037 (22) 2,665 (17) 2,966 (17) 3,030 (16) 11,698 (18) 
Grade      
I- well differentiated 2,143 (19) 2,185 (15) 2,138 (13) 2,218 (13) 8,684 (14) 
II- Moderately 
differentiated 
4,790 (41) 6,580 (46) 7,932 (48) 8,675 (49) 27,977 (47) 
III- Poorly differentiated 4,701 (40) 5,629 (39) 6,562 (39) 6,593 (38) 23,485 (39) 
TNM stage      
I 5,187 (36) 5,178 (35) 6,353 (40) 7,391 (41) 24,109 (38) 
II 5,560 (39) 6,275 (42) 6,223 (39) 7,184 (40) 25,242 (40) 
III 2,958 (20) 2,669 (18) 2,365 (15) 2,342 (13) 10,334 (16) 
IV 710 (5) 666 (5) 1,050 (6) 1,185 (6) 3,611 (6) 
Values in the table are frequency (% by column) amongst women with known characteristics. ER= oestrogen receptor, 
TNM=tumour, node, metastases. 
 
Tumour characteristics also changed with time (Table 4.18). Proportions of women 
diagnosed with an ER+ tumour increased and proportions of ER- tumours declined over 
time. The proportion of grade I and grade III tumours declined over time but the proportion 
of grade II tumours increased from 41% in 1997 to 2001 to 50% in 2012-2016. The 
proportion of early stage tumours (stage I) increased from 1997 to 2016, in contrast a 
considerable decline was observed for stage III tumours (from 21% in 1997 to 2001 to 
13% in 2012-2016). Proportions of stage II and IV tumours remained approximately 







4.4.6.2 Breast cancer specific survival by combinations of age, ER and grade 
BCSS estimates for the combination of ER status and grade for all women and by age 
groups are presented in Table 4.19.  
Table 4.19 Breast cancer specific survival estimates at 5 and 10 years after diagnosis with 
95% CI by ER status and grade (low or high) for all women and by age group 
ER STATUS GRADE <50 YEARS 50-69 YEARS 70 YEARS OR 
OLDER 
TOTAL 
5-year BCSS (95% CI)     
ER+ Low 94.8 (94.1, 95.4) 96.1 (95.8, 96.4) 86.3 (85.4, 87.1) 93.4 (93.1, 93.7)  
High 84.4 (83.1, 85.6) 85.4 (84.4, 86.3) 72.4 (70.7, 74.1) 82.1 (81.4, 82.8) 
ER- Low 81.4 (76.8, 85.2) 83.1 (80.4, 85.5) 68.9 (64.4, 73.0) 78.8 (76.7, 80.8)  
High 75.3 (73.4, 77.1) 75.1 (73.6, 76.5) 56.6 (54.0, 59.2) 71.4 (7.30, 72.5) 
10-year BCSS (95% CI)     
ER+ Low 88.3 (87.2, 89.3) 91.2 (90.6, 91.7) 77.2 (75.9, 78.4) 87.3 (86.9, 87.8)  
High 73.0 (71.3, 74.7) 75.7 (74.4, 77.0) 61.4 (59.2, 63.6) 71.7 (70.7, 72.6) 
ER- Low 72.7 (67.1, 77.4) 76.6 (73.3, 79.5) 61.7 (56.4, 66.4) 71.6 (69.1, 73.9)  
High 70.1 (68.0, 72.0) 70.8 (69.2, 72.4) 50.5 (47.6, 53.3) 66.5 (65.4, 67.7) 
BCSS= breast cancer specific survival, ER=oestrogen receptor. 
Women with ER+, low grade tumours had the best survival at 5 and 10 years after 
diagnosis and women with ER-, high grade tumours the worst survival of all the ER and 
grade combinations. There was a difference of over 20% in absolute survival between 
these two groups of women at both 5 and 10 years after diagnosis. Differences in BCSS 
between ER and grade combinations were consistent across age groups but women older 
than 70 years had considerably worse survival for all combinations than women in 
younger age groups. BCSS at 10 years still differed by ER and grade combinations but 
seem to be very similar for women aged less than 50 years for all combinations except 
ER+, low grade tumours which had better survival than other subgroups.  
4.4.6.3 Breast cancer specific survival by combinations of age, ER and stage 
BCSS by ER status and stage showed that ER+ stage I and II tumours had a survival over 
90% at 5 years and so did ER- stage I tumours. However, BCSS at 5 years for stage III-
IV tumours was considerably worse for both ER+ (65% at 5 years) and ER- (40% at 5 
years) tumours. The same pattern was observed at 10 years after diagnosis with ER- stage 




Differences in BCSS between ER and stage combinations were consistent across age 
groups with ER+, stage I tumours having the best survival and ER-, stage III-IV tumours 
having the worst survival at both 5 and 10 years (Table 4.20). BCSS in women aged <50 
years was very similar to that in women of screening age (50 to 69 years). Women of 
screening age had better survival if they had a low stage tumour irrespective of ER status 
than women younger than 50. The opposite was observed for more advanced stage 
tumours (ER+, stage III-IV tumours and ER-, stage II, III and IV) in women younger than 
50 years who had better survival than women aged 50 to 69 years with the same ER and 
stage combination. Women aged 70 years or older, had considerably lower survival than 
women younger than 70 years of age. 
 
Table 4.20 Breast cancer specific survival estimates at 5 and 10 years after diagnosis with 
95% CI by ER status and TNM stage for all women and by age group 
ER STATUS STAGE <50 YEARS 50-69 YEARS 70 YEARS OR 
OLDER 
TOTAL 
5-year BCSS (95% CI)     
ER+ I 97.9 (97.3, 98.4) 98.7 (98.5, 98.9) 94.6 (93.7, 95.4) 97.9 (97.6, 98.1)  
II 93.2 (92.3, 94.0) 94.0 (93.5, 94.6) 86.3 (85.2, 87.3) 91.7 (91.3, 92.2) 
 III-IV 72.7 (70.6, 74.6) 69.6 (68.0, 71.1) 54.2 (52.4, 56.1) 64.9 (63.9, 65.9) 
ER- I 88.6 (85.8, 90.9) 92.5 (91.0, 93.8) 88.2 (84.4, 91.1) 90.9 (89.7, 92.0)  
II 83.9 (818, 85.8) 81.8 (79.9, 83.4) 67.6 (64.3, 70.7) 79.4 (78.1, 80.6) 
 III-IV 46.6 (42.7, 50.5) 42.8 (39.8, 45.7) 28.7 (25.3, 32.2) 39.6 (37.6, 41.6) 
10-year BCSS (95% CI)     
ER+ I 94.7 (93.6, 95.6) 96.4 (96.0, 96.8) 90.1 (88.7, 91.4) 95.1 (94.7, 95.5)  
II 84.6 (83.2, 85.9) 87.1 (86.1, 87.9) 75.7 (74.1, 77.3) 83.6 (82.9, 84.2) 
 III-IV 58.1 (55.6, 60.4) 53.2 (51.3, 55.1) 39.0 (36.8, 41.2) 49.6 (48.4, 50.9) 
ER- I 85.4 (82.2, 88.1) 88.6 (86.6, 90.2) 82.0 (77.0, 86.0) 86.8 (85.3, 88.2) 
 II 77.3 (74.8, 79.7) 76.7 (74.6, 78.6) 60.9 (57.2, 64.3) 73.5 (72.0, 74.9)  
III-IV 40.7 (36.7, 44.7) 37.4 (34.3, 40.5) 22.0 (18.6, 25.6) 33.9 (31.9, 35.9) 







4.4.6.4 Comparison of breast cancer specific survival and overall survival 
OS probabilities for ER, grade and ER, stage combinations (Appendix C.9) showed the 
same patterns as for BCSS but consistently lower estimates. The difference between OS 
and BCSS for all combinations increased with aged: younger women had very similar OS 
and BCSS irrespective of ER, grade and stage characteristics, while OS for women with 
70 years or older was much lower than BCSS, especially for ER+ tumours with low grade 
or earlier stage.  
4.4.6.5 Time trends in survival by important prognostic factors 
Five-year BCSS probabilities increased over time for ER and grade combinations across 
age groups (Figure 4.7) and estimates from joinpoint regression (Appendix C.10) show 
that women aged 50 to 69 years had the greatest gains in survival over the study period. 
Improvements in survival in women aged 50 to 69 years were highest amongst women 
with high grade tumours and were more striking for ER- tumours (AAPC=1.1%, 95% CI: 
0.8 to 1.5) than for ER+ tumours (AAPC=0.8%, 95% CI: 0.5 to 1.0). Women younger 
than 50 years had improved survival for ER+ high grade tumours (AAPC=0.7%, 95% CI: 
0.4 to 1.0) but no consistent trend in improved survival was observed for ER+ low grade 
tumours.  Survival in women younger than 50 years with ER- high grade tumours slightly 
improved during the study period by 0.5% increase per year (95% CI: 0.1 to 0.8). Five-
year BCSS probabilities for women aged 70 years or older slightly increased in women 
with ER+ high grade tumours (AAPC=0.5%, 95% CI: 0.1 to 0.9) but were constant over 
time with no noticeable gains observed in women with ER+ low grade and ER- high grade 
tumours. Estimates of 5-year OS probabilities by ER and grade for the three age groups 
(Appendix C.11, left column) show the same survival trends patterns than those observed 







Figure 4.7 Trends in 5-year survival probabilities by ER and grade combinations for 
women < 50 years, women aged 50 to 69 years and women aged 70 years or older  
 
Shaded area represents the 95% CI around the BCSS estimate. Year of diagnosis in the graphs represents the middle 




When looking at 5-year BCSS probabilities for the combinations of ER and stage (Figure 
4.8), women aged 50 to 69 years old with advanced tumour stages (III-IV) had the highest 
improvements in survival that were particularly high for ER- tumours for which survival 
increased by 1.4% per year (95% CI: 0.9 to 1.9) over the study period. Survival 
probabilities in women aged 50 to 69 years with ER+ advanced stage tumours only 
improved between years 1997 and 2000, showing no significant trend after that time. 
Stage I and stage II tumours  in women of 50 to 69 years also showed improvements in 
BCSS over time that were higher in ER- tumours than in ER+ tumours of the same stage, 
although the increasing trend observed for ER- stage I tumours was only seen from 1997 
to 2006.  
Survival probabilities amongst women younger than 50 years improved significantly for 
stage II tumours and were higher in ER- tumours (AAPC=0.8%, 95% CI: 0.4 to 1.2) than 
in ER+ tumours (AAPC=0.3%, 95% CI: 0.1 to 0.5). There were no statistically significant 
survival improvements for women aged less than 50 years with stage I or stages III-IV 
tumours over the study period.  
Older women, aged 70 years or more, showed no consistent improvements between ER 
and stage combinations over the study period, except for stage II ER+ tumours that slightly 
increased (AAPC=0.3%, 95% CI: 0.0 to 0.5).  
Five-year OS probabilities by ER and stage for the three age groups (Appendix C.12) 
showed the same survival trends patterns than those observed for BCSS but consistently 









Figure 4.8 Trends in 5- year survival probabilities by ER status and stage combinations for 
the three age groups 
 
Shaded area represents the 95% CI around the BCSS estimate. Year of diagnosis in the graphs represents the middle 
year for that three-year average. AAPC= average annual percent change, EAPC= estimated annual percentage 





4.4.6.6 Was method of detection associated with improved survival? 
BCSS improvements in women of screening age with high grade tumours (both ER+ and 
ER-) were observed regardless of method of detection (Figure 4.9). The increasing 
survival pattern for ER+, high grade tumours was slightly higher for tumours that were 
non-screen detected (AAPC=0.6%, 95% CI: 0.4 to 0.9) than for screen detected tumours 
(AAPC=0.3%, 95% CI: 0.1 to 0.5). ER- high grade screen detected tumours showed the 
greatest improvements in survival between 1999 and 2005 with an average 4.9% increase 
each year (95% CI: 2.1 to 7.7) and no further improvements after that time. BCSS of 
women with ER- high grade tumours that were not screen detected showed a steady 
consistent improvement trend over the study period (AAPC=0.8%, 95% CI: 0.3 to 1.3).  
BCSS trends among women of screening age by ER and stage (Figure 4.10), showed 
improvements in women with ER+ earlier stage tumours (stage I and II) regardless of 
method of detection that were slightly higher for tumours that were not screen detected. 
Women with ER- tumours showed survival improvements for stage I, screen detected 
tumours between 1997 and 2004 (EAPC=1.8%, 95% CI: 0.9 to 2.8) and for stage II non-
screen detected tumours over the study period (AAPC=0.6%, 95% CI: 0.1 to 1.1) and no 
statistically significant trend for stage I non-screen detected and stage II screen detected 
tumours.  
Women of screening age with advanced tumour stages (III-IV) showed improvements in 
BCSS over time for both screen detected and non-screen detected tumours (Figure 4.11). 
ER+ stage III-IV tumours that were screened detected showed a constant 5-year BCSS 
increase over the study period by 1.1%/year (95% CI: 0.4 to 1.8), while the improvements 
in ER+ stage III-IV non-screen detected tumours were only observed between years 1997 
and 2002 (EAPC=3.2%, 95% CI: 1.0 to 5.3), with no significant changes afterwards. 
Improvements in survival for the ER- advanced tumours were observed regardless of 
mode of detection but the rise was sharper amongst women with screen detected tumours 





Figure 4.9 Comparison of trends in 5-year survival probabilities by method of detection in women with breast cancer aged 50 
to 69 years by ER status and grade combinations 
 
Shaded area represents the 95% CI around the BCSS estimate. Year of diagnosis in the graphs represents the middle year for that three-year average. AAPC= average 




Figure 4.10 Comparison of trends in 5-year survival probabilities by method of detection in women with breast cancer aged 
50 to 69 years by ER status and stage (I and II) combinations. 
 
Shaded area represents the 95% CI around the BCSS estimate. Year of diagnosis in the graphs represents the middle year for that three-year average. AAPC= average 




Figure 4.11 Comparison of trends in 5-year survival probabilities by method of detection 
in women with breast cancer aged 50 to 69 years by ER status and stage III-IV 
combinations 
 
Shaded area represents the 95% CI around the BCSS estimate. Year of diagnosis in the graphs represents the middle 
year for that three-year average. AAPC= average annual percent change, EAPC= estimated annual percentage change, 




4.4.7 Competing risk analysis 
  
Primary causes of death amongst women diagnosed with BC in Scotland between 1997 
and 2016 are presented in Table 4.21 overall and for each age group.  
Table 4.21 Primary cause of death amongst women diagnosed with breast cancer in 
Scotland from 1997 to 2016 by age group  









Breast cancer 2,748 (86%) 5,095 (57.3%) 6,139 (43%) 13,982 (53%) 
Other cancer 193 (6%) 1,449 (16.3%) 1,157 (8%) 2,799 (11%) 
CVDs 59 (2%) 916 (10%) 3,098 (22%) 4,073 (16%) 
       Acute Myocardial Infarction 15 (<1%) 242 (3%) 690 (5%) 947 (4%) 
            Ischaemic Heart Disease 10 (<1%) 167 (2%) 499 (4%) 676 (3%) 
   Other heart diseases 19 (<1%) 243 (3%) 745 (5%) 1,007 (4%) 
Stroke and other 15 (<1%) 264 (3%) 1,164 (8%) 1,443 (5%) 
COPD and other respiratory 
diseases 
42 (1%) 440 (5%) 1,141 (8%) 1,623 (6%) 
Alzheimer’s/Dementia 0 (0%) 134 (2%) 1,036 (7%) 1,170 (5%) 
Mental Health (depression, 
alcohol disorders, 
schizophrenia and suicide) 
17 (<1%) 56 (<1%) 21 (<1%) 94 (<1%) 
Diabetes and other endocrine 
diseases 
<10 (<1%) <70 (<1%) 158 (1%) 230 (<1%) 
Miscellaneous 99 (3%) 622 (7%) 1,232 (9%) 1,953 (8%) 
   Accidents 12 (<1%) 54 (<1%) 192 (1%) 258 (1%) 
   Any other cause of death 13 (<1%) 17 (<1%) 18 (<1%) 48 (<1%) 
   Benign neoplasm <10 (<1%) <20 (<1%) 46 (<1%) 70 (<1%) 
   Blood diseases 0 (0%) 11 (<1%) 17 (<1%) 28 (<1%) 
   Digestive system diseases 33 (1%) 270 (3%) 412 (3%) 715 (<1%) 
   Infectious disease 11 (<1%) 73 (<1%) 140 (1%) 224 (<1%) 
   Kidney and genitourinary 
system diseases 
<10 (<1%) <70 (<1%) 243 (2%) 318 (1%) 
   Medical and surgical 
complications 
<10 (<1%) <10 (<1%) 10 (<1%) 21 (<1%) 
   Musculoskeletal system 
diseases 
<10 (<1%) <30 (<1%) 57 (<1%) 81 (<1%) 
   Other endocrine diseases <10 (<1%) <10 (<1%) 36 (<1%) 50 (<1%) 
   Other nervous system 13 (<1%) 88 (1%) 116 (<1%) 217 (<1%) 
   Skin diseases <10 (<1%) <20 (<1%) 27 (<1%) 43 (<1%) 
Unknown 40 (1%) 101 (1%) 145 (1%) 286 (1%) 
Values are frequency (% by column) with some cells showing approximate counts to comply with statistical disclosure. 





Apart from BC, CVD (which includes acute myocardial infarction, ischaemic heart 
disease and stroke), other cancers, COPD and Alzheimer’s disease or dementia were the 
most common primary causes of death in Scottish women diagnosed with BC. There was 
a clear relationship between age and other primary causes of death, with a higher 
proportion of women aged 70 years or older dying from these conditions than the 
proportion observed in women aged less than 70 years. For example, CVDs accounted for 
22% of all deaths in women aged 70 years or older compared to 10% of total deaths in 
women aged 50 to 69 and 2% in women aged less than 50 years.  

















Figure 4.12 Cumulative incidence graph of BC death (breast: red line) and other cause of 




The probability of dying from BC was highest in women aged 70 years or older with ER- 
tumours, but probability of BCD was also high amongst younger women, particularly 
during the first 5 years after BC diagnosis (Figure 4.12, panel b). Women aged less than 
50 years with ER+ tumours had considerably higher probability of dying from BC than 
dying from other causes (Figure 4.12, panel a). In contrast, women with ER+ tumours of 
screening age (50 to 69 years) had a similar probability of dying from BC as from other 
causes and women with ER+ tumours aged 70 years or older had the same probability of 
dying from BC than from other causes during the first 3-4 years after diagnosis and higher 
probability of dying from other causes after that time.  
Figure 4.13 shows that the probability of dying from CVD in women aged 70 years or 
older was higher amongst women with ER+ tumours and represented almost half of the 









Figure 4.13 Cumulative incidence graph of BC death (breast: red line), CVD death (CVD: 
green line) and other cause of death (other: blue line) in women aged 70 years or older 




4.4.8 Trends in BC treatment by age and ER status in Scotland  
 
The majority of women had surgery to remove the tumour (84% of all women) and were 
treated with HT (72%). Radiation and chemotherapy were less common treatments with 
58% and 37% of all women receiving these treatments (Table 4.22). 
Table 4.22 Treatments by age group in women diagnosed with BC in Scotland from 1997 
to 2016 









Surgery     
   Yes 13,753 (96%) 33,509 (94%) 13,099 (60%) 60,361 (84%) 
   No 527 (4%) 1917 (5%) 8,389 (38%) 10,833 (15%) 
   Unknown 99 (<1%) 166 (<1%) 325 (2%) 590 (<1%) 
Radiotherapy     
   Yes 9,906 (69%) 24,164 (68%) 7,674 (35%) 41,744 (58%) 
   No 3,738 (26%) 9,842 (28%) 13,221 (61%) 26,801 (37%) 
   Unknown 735 (5%) 1,586 (4%) 918 (4%) 3,239 (5%) 
Chemotherapy     
   Yes 10,539 (73%) 14,180 (39.8%) 1,757 (8%) 26,476 (37%) 
   No 3,574 (25%) 20,622 (57.9%) 19,332 (89%) 43,528 (61%) 
   Unknown 266 (2%) 790 (2.2%) 724 (3%) 1,780 (2%) 
Hormone therapy     
   Yes 9,298 (65%) 25,953 (72.9%) 16,671 (76%) 51,922 (72%) 
   No 4,065 (28%) 7,583 (21.3%) 3,971 (18%) 15,619 (22%) 
   Unknown 1,016 (7%) 2,056 (5.8%) 1,171 (5%) 4,243 (6%) 
Neoadjuvant therapy     
   No 11,562 (80%) 31,948 (90%) 20,025 (92%) 63,535 (88%) 
   Yes 2,817 (20%) 3,644 (10%) 1,788 (8%) 8,249 (12%) 
Type of neoadjuvant therapy*    
   Chemotherapy alone  2,464 (88%) 2,174 (60%) 204 (11%) 4,842 (59%) 
   HT alone 163 (6%) 1,207 (33%) 1,482 (83%) 2,852 (35%) 
   Radiotherapy alone <10 (<1%) <20 (<1%) 17 (1%) 33 (<1%) 
   Chemotherapy and HT 114 (4%) 140 (4%) 34 (2%) 288 (4%) 
   Chemotherapy and 
radiotherapy 
<50 (<2%) 44 (1%) <10 (<1%) 95 (1%) 
   Radiotherapy and HT <10 (<1%) <40 (<1%) 35 (2%) 73 (<1%) 
   All (chemo, radio, HT) <30 (<1%) 38 (1%) <10 (<1%) 66 (<1%) 
*Frequencies and %s amongst women who had neoadjuvant therapy, n=8,249 (12% of the total). HT=hormone 
therapy.  
Treatment differences were observed between age groups (Table 4.22). Older women 
aged 70 years or more were less likely to have surgery, radiation and chemotherapy and 




greatest differences between age groups were observed for chemotherapy, with 73% of 
women aged less than 50 years receiving this treatment, in contrast to 40% and 8% 
receiving chemotherapy if aged 50 to 69 years and 70 years or older respectively. The use 
of HT and neoadjuvant therapy increased with age and chemotherapy was the most used 
neoadjuvant therapy for women younger than 50 years and HT the most used in women 
aged 70 years or older.  
Given the importance of ER status in treatment decisions, Figure 4.14 presents trends of 
the treatments for BC given to Scottish women diagnosed with BC from 1997 to 2016 by 
ER status and age group. In Scotland, the percentage of women who had surgery to treat 
BC was very high (approximately 95%) regardless of ER status and remained constant 
over time for women aged less than 70 years. In older women aged 70 years or more, the 
proportion having surgery was lower at approximately 80% in 1998 for both ER+ and ER- 
tumours. This percentage remained constant in older women with ER- tumours but 
decreased over time for older women with ER+ tumours (62% in 2016).  
HT use was high for all women with ER+ tumours and remained constant over time. 
Women with ER- tumours still received HT in the late 90s, especially if they were aged 
70 years or more but the use of HT among women with an ER- tumour declined sharply 
over time and only 3-6% of them received HT in 2016.  
Chemotherapy treatment was consistently more widely used in women with ER- tumours 
than in women with ER+ tumours of the same age. The proportion of women receiving 
chemotherapy remained constant over time for ER+ tumours, whereas it increased in 
women with ER- tumours, especially in women aged 50 to 69 years and women aged 70 
years or older. Radiotherapy use was slightly higher for ER- tumours than for ER+ 
tumours in the late 1990s, but greater increases in the use of radiotherapy in women with 
ER+ tumours (especially if they were younger than 70 years) were observed during the 
study period. These increases have made the proportions receiving radiotherapy slightly 
higher in women with ER+ tumours than in women with ER- tumours, with the exception 
of women with ER+ tumours aged 70 years or more that are less treated with radiotherapy 













































































































Figure 4.14 Trends over time of the percentage of Scottish women diagnosed with BC who were treated with A) surgery and B) 

































































































































Figure 4. 14 (continued) Trends over time of the percentage of Scottish women diagnosed with BC who were treated with A) 







4.5.1 Summary of key findings 
4.5.1.1 Survival differences between subtypes 
In this large study in over 70,000 women diagnosed with BC in Scotland between 1997 
and 2016, prognosis differed between molecular subtypes. Scottish women with ER- 
tumours had considerably lower survival at 5 years compared to women with ER+ 
tumours (70.6% vs 87.4%) and an overall 44% higher risk of BCD after adjusting for other 
individual and tumour characteristics, treatments and comorbidities. The largest previous 
similar study conducted using SEER data for over 150,000 women found an increased 
mortality (adjusted HR=2.3, 95% CI: 2.2 to 2.4) in ER-/PR- tumours when compared to 
ER+/PR+ tumours. In comparison with this study, I found a smaller effect size for the 
comparison of ER+ and ER- tumours, which might be due to the use of a single hormone 
marker (only ER instead of ER/PR) and to further adjusting for screening, comorbidities 
and deprivation. The effect size for the TVE models (adjusted HR at 1 year=2.39, 95% 
CI: 2.08 to 2.80 and adjusted HR at 3 years=1.63, 95% CI: 1.23 to 2. 30) or for the model 
with follow-up restricted to 3 years (adjusted HR=2.26, 95% CI: 2.02 to 2.52) in my study 
shows similar HR for BCD in women with ER- compared to that observed in the US study 
that is restricted to early follow-up years. This highlights the potential for generating 
misleading estimates if non-constant hazards are ignored. 
The analysis of IHC defined molecular subtypes showed that Scottish women with luminal 
A subtype had the best survival (91% at 5 years), whereas women with TNBC subtypes 
had the worst survival (73% at 5 years). Although surrogate IHC definitions have been 
used in most previous studies there was heterogeneity in the definition of each molecular 
subtype and also in the outcome assessed between studies. In contrast to other studies, I 
used grade to further differentiate between luminal A and luminal B tumours and did not 
differentiate between luminal B HER2- and luminal B HER2+ tumours. Further, I use 
BCSS as outcome instead of relative survival estimates, DFS or local recurrence rate, as 
recurrence data are not available in routine cancer data in Scotland. Despite study 




[268], Italy [228], Germany [269], Spain [233], Switzerland [270] and Norway [230]. 
Scottish women with TNBC subtypes were 4 times more likely to die from BC than 
women with luminal A tumours which was in the higher end of HRs obtained in other 
studies that ranged from HR=1.6 in the US [226] to HR=4.2 in Switzerland [270]. The 
risk of BCD was very similar for Scottish women who expressed HER2 (luminal B and 
HER2-enriched tumours) regardless of ER status. Our data is consistent with an Italian 
study (HR=1.7 for luminal B and HER2-enriched subtypes when compared to women 
with luminal A tumours) [228]. In contrast, a large population-based study in the US found 
lower BC-specific mortality for luminal B tumours but higher risk for HER2-enriched 
tumours compared to luminal A tumours [225]. International comparisons are challenging 
due to the different health care systems and access to targeted therapy drugs. Furthermore, 
the rare subtypes (HER2-enriched and TNBC) have lack of power and definition of the 
molecular subtypes differed between countries. However, the highest mortality in women 
with TNBC subtypes was consistent across studies. This finding might be related to the 
lack of targeted therapy for TNBC in contrast to hormone positive subtypes or HER2-
enriched subtypes for which targeted treatments, Tamoxifen [117] and Trastuzumab 
[271], have been available since the late 1990s and early 2000s respectively.  
Apart from BCSS estimates, secondary analysis of OS at 5 and 10 years showed a similar 
pattern across the molecular subtypes to that observed for BCSS but with lower estimates 
of survival, particularly in older women aged 70 years or more with aggressive subtypes 
(ER-, HER2-enriched or TNBC). Assessment of other underlying causes of death showed 
that over half of Scottish women diagnosed with BC at 70 years or older died from other 
causes of death with CVDs contributing to 22% of the total deaths. A recent review 
estimated that the absolute risk of death from CVDs after BC diagnosis ranges from 1.6% 
to 10.4%  with older age being an important RF [272]. The mechanisms contributing to 
the increase risk of CVD death amongst BC survivors are not fully understood but shared 
aetiology such as increased obesity and diabetes prevalence [273] and the toxicity of BC 




4.5.1.2 Association of other prognostic factors with breast cancer death for the different 
subtypes 
A handful of studies have examined the prognostic value of different individual, tumour 
and treatment covariates stratified by BC subtypes [225, 268]. This analysis is the first in 
Scotland and the UK using population-based data.  
Age 
Older age at diagnosis was found to be associated with worse survival for all subtypes. 
Young age (<40 years) has previously been associated with poorer prognosis of luminal 
A and TNBC [241-243] when compared to women older than 40 years. However, our 
results suggest that after adjusting for potential confounders women aged less than 50 
years were less likely to die from BC than women aged 50 to 69 years for ER+, ER-, 
luminal A and HER2-enriched subtypes. In contrast, luminal B and TNBC had a slightly 
increased mortality but was not statistically significant after adjustment for other 
covariates. Differences with previous studies might be due to the different age groups used 
for the analysis and to the inclusion of additional covariates, such as, comorbidities and 
deprivation in our analysis.  
Other tumour characteristics 
Histological grade and tumour stage are key prognostic factors for clinical practice and 
they are important for treatment decisions. In this study, grade and stage were independent 
prognostic factors for all subtypes and a dose- response effect was observed with higher 
grade and stage associated with increased BC-specific mortality. Women with poorly 
differentiated (grade III) tumours had lower survival than women with grade I tumours 
irrespective of the tumour subtype but the association was stronger for ER- and HER2-
enriched tumours. Higher stage was also associated with poorer outcome for all subtypes 
and had the greatest effect on BCD of all factors. Women with stage IV tumours had an 
increased BC-specific mortality that ranged from HR=10.7 for luminal A tumours to 
HR=19.4 for HER2-enriched tumours compared to mortality in women with stage I 




Screening advances the time of tumour detection and tumours detected through screening 
have been associated with favourable characteristics, such as, low grade, early stage, 
hormone positive and HER2 negative, hence have better prognosis than symptomatic 
tumours [246, 275]. In our study, method of detection was associated with BC prognosis 
irrespective of tumour subtype. Women with tumours that were not screen detected had 
60-70% increased BC-specific mortality compared to women with screen detected 
tumours (for both ER+ and ER- tumours). Slightly different HRs were found between 
molecular subtypes with luminal A and TNBC non-screen detected tumours having the 
highest HRs (HR=2.7 and HR=2.3 respectively) and luminal B and HER2-enriched 
having 1.7 and 1.8 times the HR for a screen detected tumour of the same subtype. The 
estimate for HER2-enriched subtype did not reach significance after adjusting for all other 
tumour characteristics and treatments and comorbidities. 
Treatments 
Surgery was the most important treatment prognostic factor, and women who did not have 
surgery were more likely to die from BC for all subtypes compared to women with the 
same subtype receiving surgery. The highest beneficial effect of surgery was seeing in 
women with luminal A and HER2-enriched tumours. HT also had a beneficial effect on 
BC mortality in hormone positive tumours.  
The effect of radiotherapy and chemotherapy differ between subtypes. Radiotherapy had 
a beneficial effect on women with HER2-enriched and TNBC subtypes. However, for 
women with ER+ and luminal A tumours, adjusted models showed no benefit or even a 
detrimental effect of radiotherapy on luminal A tumours which is unlikely and might have 
been due to confounding by indication. TVE models seemed to correct, at least partially, 
this bias.  
Similar results were observed for chemotherapy that had a beneficial effect for women 
with ER-, luminal B and HER2-enriched subtypes but opposite effect (higher death risk) 




Treatment data had limitations as they are usually first treatment and more comprehensive 
and detailed datasets would be needed to assess the benefits of the different treatments on 
BCSS and recurrence. Further, treatment effects might have been biased due to 
confounding by indication. An explanation of this type of bias is presented in section 
4.5.3.1. 
Deprivation and comorbidities 
Previous studies from Scotland and other countries have found a clear association between 
SES (at both individual and neighbourhood level) and BC mortality, with women with 
low SES having a higher BC mortality [276-278]. Further, women with low SES are more 
likely to be diagnosed with more aggressive BC subtypes, particularly ER- and TNBC 
subtypes [278-280]. However, evidence of the extent to which the distinct prevalence of 
subtypes within deprived and non-deprived areas contribute to the worse prognosis 
observed for women with low SES is inconsistent. In the current analysis, deprivation was 
associated with a higher BCD with those women living in the most deprived areas of 
Scotland having a higher BC-specific mortality than those in the least deprived areas and 
this association was observed for all tumours subtypes except for TNBC. After adjusting 
for other covariates the association was no longer statistically significant for luminal B 
tumours, probably due to smaller sample sizes (as for TNBC). HER2-enriched tumours 
had the highest increase in mortality which was almost double for women in the most 
deprived areas vs women in the least deprived areas but with wider CI. Given that 
associations were still significant for this subtype after adjustment for other tumour 
characteristics (including screening) and treatments, future studies should focus on 
unmeasured lifestyle factors such as obesity or alcohol consumption which might further 
explain the differences in BCD observed by SES.  
Comorbidities, measured using a continuous comorbidity index, were associated with 
increased BC-specific mortality for all tumour subtypes (except luminal A), with women 
with HER2-enriched tumours and a higher comorbidity index having the highest BC-




index). In contrast, in women with luminal A tumours, having comorbidities did not 
significantly increased mortality after adjusting for all other covariates.  
4.5.1.3 Improvements in survival over time 
In Scotland, BCSS improved over the study period from 1997 to 2016, however 
improvements differed by age and tumour characteristics which might be related to 
differences in treatment and the effect of screening. The greatest improvements in BCSS 
were observed for women in the screening age group (50 to 69 years) and particularly in 
those with high grade and/or stage III-IV tumours. These improvements were observed 
both for ER+ and ER- tumours but were slightly higher for the ER- tumours which are 
generally less likely to be screen detected, hence, suggesting an important role of 
treatments in the improvements of this subtype that might be related to the increases 
observed in radiotherapy use. 
Although younger women of less than 50 years are not routinely invited for 
mammographic screening, trends over time also showed consistent statistically significant 
improvements in BCSS for ER+ and ER- high grade tumours and stage II tumours which 
might be due to increased use of neoadjuvant treatments. Data suggest that younger 
women were more likely to receive chemotherapy, especially if they had ER- tumours. 
However the proportion of women who received this treatment did not change over time 
so improvements might be due to other factors, such as increases in radiotherapy use. 
Younger women with stage III-IV tumours had an increasing survival trend but 
improvements did not reach statistical significance possibly due to limited power. 
BCSS observed in older women (aged 70 years or more) remained approximately constant 
over time with no statistically significant increases in survival found, except a slight 
improvement for ER+ high grade or stage II tumours, with undertreatment being a possible 
factor. Our analysis shows that the percentage of women aged 70 years that were treated 
with surgery was considerably lower than that observed for women younger than 70 years. 
This is in concordance with recent RCT in the UK that report undertreatment in women 
older than 70 years. Also, almost half of women aged 70+ years diagnosed with BC had 




indicated the potential role of some BC treatments on CVD risk [281, 282], however the 
relationship is still unclear and further research would be needed to elucidate whether this 
might be affecting survival trends in Scotland. 
Further stratification by method of detection in the age group of women who are invited 
for mammographic screening in Scotland (aged 50 to 69 years) showed improved BCSS 
for both screen detected and non-screen detected tumours although generally screen 
detected tumours had much better survival. Caution must be given to the interpretation of 
the trends given the presence of competing risks and possible bias.  
4.5.2 Strengths 
To my knowledge, this is the first population-based study in Scotland and the UK to assess 
BCSS by molecular subtypes and investigate trends based on important prognostic factors 
to assess whether BCSS has improved in recent years. This study expands our 
understanding of the evolution of BCSS in Scotland. This study has several strengths: 
4.5.2.1 Data quality and availability 
The Scottish cancer registry data quality has been previously described [157] and linkage 
to mortality records provides the opportunity to assess trends over time by subtypes (with 
data on ER collected from 1997 and PR and HER2 from 2009) providing one of the 
longest follow-up periods of cohorts from any European country. Further, either through 
data linkage to other national datasets or within the minimal dataset for the registry, 
possible confounders not usually recorded in other European and North American cancer 
registries, such as, method of detection, comorbidities and deprivation measures were used 
to assess the effect of these covariates in BCSS trends.  
4.5.2.2 Statistical analysis 
Another major strength of this study is the use of the extended Cox PH models and the 
use of MI.  
The Cox PH model is the preferred method to estimate survival in cancer patients when 
adjusting for multiple covariates. However, the PH assumption is key to obtain correct 




hazards, HR estimates are averaged across time and, for that, reason might mask 
differences at different time points. This analysis used extended Cox models that introduce 
interactions between time and those covariates that had non-proportional hazards over 
time. The TVE results highlighted the importance of correctly estimating HRs, especially 
for the molecular characteristics and treatment effects.  
Most previous studies have failed to account for missing tumour markers, and their results 
have been based on CCA. However, missing receptor data can biased the results as those 
without these markers are likely to have worse prognosis and be more frail and less likely 
to receive certain treatments [267]. In contrast to those studies, I compared findings from 
MIA to CCA findings for the traditional Cox model with ER and the subtypes as the main 
exposures. Estimates were found to be similar but slightly attenuated for the MIA and 
with narrower CIs which was consistent with findings of a previous study with SEER data 
that used MI to correct for missing molecular marker data  
4.5.3 Limitations 
4.5.3.1 Bias in observational studies 
Observational studies using population- based cancer registry data provide high quality 
data in which to assess cancer outcomes. However, the validity of their results must be 
assessed as they can be prone to confounding and biases.  
Unmeasured confounders 
Unmeasured confounders or measurement errors on the measured confounders might have 
biased the results. Although our analysis controlled for potential confounders, such as age, 
deprivation, tumour characteristics, treatments and comorbidities, other factors, such as 
lifestyle factors (alcohol and tobacco consumption, physical activity), reproductive factors 
or anthropometric factors (BMI) might have had an effect on the observed trends. For 
example, the higher risk of BCD observed in women living in the most deprived areas 
compared to women in the least deprived areas consistent across all subtypes might be 
further explained by different obesity prevalence and lifestyle factors, such as, alcohol and 




previous studies and that results were consistent across studies, it is unlikely that 
unmeasured confounders will explain the observed survival differences. However, future 
research should aim to explain the effect of tumour, treatment and other 
confounders/mediators in the differences in survival observed between women in most 
and least deprived areas through causal mediation analysis.  
Selection bias 
Confounding by indication is a particular form of selection bias in observational studies 
that estimate the benefit of treatments in cancer mortality [283]. In our study, confounding 
by indication might have been present, as women with BC receiving treatments such as 
chemotherapy and radiotherapy are likely to have more aggressive subtypes, whereas 
those receiving surgery or HT might be more likely to have early stage/low grade cancers 
and hormone positive subtypes. Similarly it is not surprising that women who are unfit for 
surgery have poorer outcomes. For that reason, the effect of treatments that are given to 
women with less severe diseases could show larger improvements in survival while the 
effect of chemotherapy and radiotherapy could appear to be associated with an increased 
risk in BCD. Further, selection bias can also affect comparisons of individuals that went 
through screening and those who did not. In our analysis, using TVE models seemed to 
correct, at least partially, the selection bias for the treatment effects. Further, the use of 
multiple covariates within the models might have also corrected part of this bias.  
Lead and length bias 
Survival rates can be affected by lead time and length biases [284] usually caused by the 
introduction of a national screening programme during the period of study. Screening 
inflates survival by advancing the time at which a tumour is diagnosed (lead time bias), 
by identifying early stage tumours that have a slow progression (length bias) and also by 
identifying tumours that may not have been identified otherwise as their progression is so 
slow that they would not affect survival (overdiagnosis). These three biases can explain 
survival improvements that are related to screening and not to an increase in the number 
of deaths that are prevented or delayed. Most cancer registries do not record data about 




trends for the different molecular subtypes can be assessed by method of detection 
providing a clearer image of the effect of screening in BCSS.  
In order to (partially) correct for these biases, I adjusted for possible confounders in all 
analysis and used 5 year survival estimates that might reduce the impact of lead time bias 
(estimated to be 3 years). Data in Scottish women suggest that screening is important for 
BC prognosis regardless of molecular subtype. These results are in line with a recent study 
in Sweden reporting that women who participated in screening had a 41% reduction in the 
risk of BCD in the 10 years following diagnosis [285]. However the potential for residual 
confounding remains as women who accept invitations to screening are likely to differ 
from women that do not attend screening in ways that may influence survival. 
4.5.3.2 Data and Statistical Analysis 
As previously stated, cancer registry data presents some limitations inherent to the 
difficulties of cancer registration (section 3.5.4.1 of the incidence chapter). Survival 
statistics derived from population-based cancer registries are key to estimate progress 
against BC. However, the validity of BC specific survival analysis depends on the 
accuracy of cause of death as recorded in the registry which assumes that the underlying 
cause of death has been accurately determined for each patient. In Scotland, underlying 
cause of death is based on death certificate records along with additional information 
provided by other official sources (pathologists, doctor who certified the death, 
Procurators Fiscal or the Crown office) and certification is completed by a registered 
medical practitioner following strict guidelines [286] developed by NRS that cross-checks 
all data sources in order to improve its coding of death. Despite guidelines and data 
chequing procedures, the death certification review service which aims to improve the 
quality and accuracy of Medical Certificates of Cause of Death (MCCD) have reported 
inaccuracies in 7% of all MCCDs with 43% found to have a cause of death considered too 
vague and 28% to have an incorrect cause of death. Further, the definition of neoplasms 
was the most common error (8% of all) identified for those that were considered too vague 
[287]. For that reason, we cannot rule out that our cause- specific analysis might be biased. 




lifetables for the BC molecular subtypes in order to calculate the expected survival which 
are currently not available. Further, relative survival can also be prone to bias if the 
lifetables are not representative of the cancer population, for example if the cancer patients 
are healthier on average than the population as could be the case for BC patients, or if 
other causes of death shared risk factors, such as obesity (risk factor for both BC and 
CVDs) [288, 289].  
Treatment data were very limited and there was no data available about recurrence. 
Further, other possible covariates such as reproductive factors or lifestyle factors were not 
available. However, the Scottish cancer registry can be linked to other national datasets 
such as maternity records from 1981 and there is scope to further investigate the effect of 
these factors in molecular subtypes in future research.  
Deprivation and comorbidity data used to estimate the effect of these confounders in BC 
mortality present some limitations [290]. The SIMD is an area-based measure of 
deprivation rather than an individual-based measure so it can miss some of the people who 
experience deprivation but do not live in deprived areas [291]. Hence, an association 
between deprivation and increased BC mortality for some of the subtypes might not be 
related to individual deprivation. This is particularly true for rural areas where the index 
domains, particularly the ‘access’ domain fails to capture important singularities of the 
rural areas, such as, frequency and cost of public transport [292]. Therefore, deprivation 
in rural areas is usually underweighted and they are less likely to be ranked as most 
deprived.  
The Charlson comorbidity index depends on the recording of all individual comorbidities 
included in the index. In Scotland, the score is derived from hospital admission records 
dating back to 5 years prior to the index admission, for that reason, if the patient was not 
hospitalised during those 5 years or if the condition was not recorded that comorbidity 
might be omitted and not included in the index. Further, one could argue that combining 
all comorbidities into a single index precludes to investigate the effect of individual 




was beyond the scope of this PhD but future research should aim to investigate the 
association of CVDs and BC mortality. 
Our analysis included women who were diagnosed with more than one tumour but only 
the tumour with higher grade/nodal status was kept and is included in the analysis which 
might have had an effect on the survival estimates. However, further adjusting for the 
presence of multiple tumours had little effect on the HR estimates for the main comparison 
of ER- vs ER+ tumours. Statistical power was an issue for some of the stratified analysis, 
especially for the rare subtypes of BC (power calculations reported in Appendix Table 
C.15). For example, the effect of some of the covariates in the analysis of luminal B and 
TNBC subtypes did not reach statistically significance probably due to small 
numbers.Also, the short follow-up (9 years) for the IHC define subtypes precluded 
estimation of survival trends over long periods of time.  
4.6 Conclusion 
This analysis using high quality population- based data in Scotland shows for the first time 
in the UK differences in prognosis between molecular subtypes of BC that are consistent 
with previous literature. Further, important prognostic factors for each molecular subtype 
were identified and groups of women for which probability of BCD was highest were also 
identified, such as women living in the most deprived areas of Scotland and women with 
comorbidities. Survival trends over time suggested improvements in BCSS and OS in 
recent years, particularly for women with more aggressive subtypes with high grade or 





Chapter 5 Discussion 
5.1 Introduction 
BC is a model disease for personalised medicine with different subtypes for which specific 
treatments have been developed over the years, such as the tamoxifen for hormone 
sensitive tumours or trastuzumab for the treatment of HER2+ tumours. Although BC 
heterogeneity has been widely recognised, cancer surveillance at the population level is 
still based on the evaluation of incidence, mortality and survival trends for all BC tumours, 
irrespective of their subtype.  
Previous research has shown that molecular subtypes differ aetiologically and in prognosis 
and other countries have reported distinct incidence and mortality trends by molecular 
subtypes. Using data from the Scottish cancer registry, this PhD described incidence and 
survival trends by molecular subtypes in Scotland and identified individual and tumour 
characteristics of women that are experiencing increasing incidence and lower survival 
after a BC diagnosis.  
My systematic review of incidence trends by ER status in European ancestry populations 
identified that only a few cancer registries collect molecular marker data. This represents 
a gap in the literature for the last decade given that new markers have been introduced and 
distinct trends in incidence by ER status have been identified from the limited number of 
studies. Further, in the UK the single study that assessed incidence trends by ER status 
was published in 2010 and was limited to women over 50 years of age. I used linked 
Scottish cancer registry and mortality data for 1997-2016 to describe incidence and 
survival trends in a wider range of BC subtypes to extend our existing knowledge. The 
strengths and limitations of those analyses are discussed in detail in each specific chapter.  
This chapter provides a general discussion for the PhD with the following parts: a 
summary of the results from the PhD focused on the contribution to our understanding of 
BC subtype incidence and survival trends, and its implications for research and clinical 
practice. There is also a discussion of the general strengths and limitations and a section 




5.2 Contribution of this project to our understanding of BC incidence and 
survival trends  
This project has contributed to our knowledge of secular trends of BC and highlights the 
feasibility of assessing BC heterogeneity using population-based data. For the first time 
in the UK, this study shows distinct temporal trends of BC incidence and survival by 
molecular subtypes for women diagnosed with BC between 1997 and 2016 in Scotland.  
5.2.1 Incidence trends by molecular subtypes 
Expanding on the only previous study reporting BC incidence trends by ER status in 
postmenopausal women, after correcting for missing ER status and for multiple tumours 
per woman, I investigated BC incidence trends by ER for all women diagnosed in Scotland 
from 1997 to 2016. I found that ER+ tumour incidence continued to increase until 2011 
while ER- tumour incidence decreased for the whole study period. Increases in incidence 
of ER+ tumours were mainly observed for women aged 50 to 69 years old, who are those 
invited for mammographic screening in Scotland, indicating a probable contribution of 
screening to the increasing trends in incidence of ER+ tumours. An important contribution 
of this analysis was the ability to study the potential impact of screening on the incidence 
rates, which were investigated by looking at incidence trends by method of detection and 
ER status. Findings suggested that the observed overall ER+ increasing trends were driven 
by increases of screen detected ER+ tumours, whereas incidence of non-screen detected 
tumours remained constant over time. Joinpoint and APC models showed consistent 
results in incidence trends by ER status. The use of APC models also led to the 
identification not only of age and period effects (probably related to screening) but of a 
cohort effect in ER+ tumours that could be related to changes in reproductive factors 
and/or differences in obesity prevalence between birth cohorts of Scottish women. The 
declines observed for ER+ tumour incidence since 2011 are likely to be multi-factorial. 
The consistent declines in incidence of ER- tumours over the whole study period since 
1997 for women of all ages, which have also been observed in other countries, represent 
an important finding as these subtypes have considerably worse prognosis than ER+ 




driving these declines which could lead to future interventions aimed at reducing the 
incidence and/or improving the prognosis of these more aggressive subtypes.  
The measurement of PR and HER status in BC patients and the collection of these markers 
in the Scottish cancer registry, allowed me to investigate trends using combinations of 
these three IHC markers as surrogates for the four intrinsic molecular subtypes defined by 
Perou et al. Limited follow-up, with data available from 2009 to 2016 contributed to the 
absence of statistically significant overall trends in incidence of luminal A, HER2-
enriched and TNBC tumours. Joinpoint regression analysis showed decreasing incidence 
of luminal B tumours that was driven by declines in incidence in women aged 50 years or 
older. APC models confirmed this result and further identified a cohort effect in women 
aged 60 years or older which highlights the value of using different methods that can pick 
up signals that would otherwise be missed. Another important finding from this thesis is 
the increasing incidence trend of TNBC observed in women younger than 50 years. 
TNBCs have the worst prognosis of all subtypes, as there is no targeted therapy that can 
be used in their treatment and aggressive chemotherapy is the only treatment option. 
Future trends in incidence of TNBC in young women need to be monitored and research 
on the association of modifiable RFs with this subtype would inform future prevention 
programmes.  
 
5.2.2 Breast cancer prognosis by molecular subtypes 
Univariate KM and multivariate Cox regression models were used to investigate survival 
by molecular subtypes and trends over time. ER+ and luminal A tumours have the best 
prognosis and ER- and TNBC the worst, consistent with the findings from previous studies 
[226, 228, 230, 231, 233, 268, 269]. Five-year survival trends of the most important 
prognostic factors were assessed to look for survival improvements over time. The most 




5.2.2.1 The role of age 
As expected, age was an independent prognostic factor for survival in all subtypes and 
increased age was associated with increased likelihood of BCD. Although ER+, luminal 
A tumours have been associated with better prognosis, several previous studies have found 
an increased BC-specific mortality in young women (aged <40 years) with these subtypes 
[230, 240, 241, 293] compared to older women. In our analysis, this association was not 
observed and women with ER+ and luminal A tumours younger than 50 years had lower 
risk of BCD than women aged 50 to 69 years with the same subtype after adjusting for 
tumour characteristics, treatments, deprivation and comorbidities. These discrepancies in 
findings are likely due to study heterogeneity with different definitions of age groups and 
luminal subtypes and different covariates used for the adjusted models. Further analysis 
is needed to investigate whether the increased risk of BCD amongst young compared to 
older women with luminal A and ER+ tumours observed in other countries is also 
observed in Scotland using similar age groups and IHC subtypes definitions.  
The analysis of 5-year BCSS trends showed improvements over time for women aged less 
than 50 years of age at BC diagnosis regardless of ER status, especially in women with 
high grade tumours and stage II tumours. Improvements in BCSS in Scottish women 
younger than 50 years of age are not likely to be related to screening as only 2% of all 
tumours are diagnosed through screening in this age group in Scotland. Improvements in 
BCSS in younger age women might be related to use of more aggressive chemotherapy 
treatments in recent years. Our data for Scotland showed that the proportion of women 
receiving chemotherapy remained constant over the study period in women younger than 
50 years but information on type of chemotherapy is not available within the registry. 
Future research should focused on linkage of the registry to detailed treatment data, such 
as that in cancer audit data, to further investigate treatment pathways for improved 
survival.  
In contrast to younger women, women aged 70 years or older at the time of diagnosis of 
BC showed consistently worse BCSS regardless of tumour subtype when compared to 




causes of death highlighted the importance of competing risks of death from other causes 
for this age group, and the important contribution of CVD as a cause of death in this 
population. Further, there were no significant improvements in survival for Scottish 
women aged 70 years or older that have also been reported in previous studies [294-296] 
that could be related to poorer health conditions and the omission of treatment [297, 298] 
and low adherence to standard treatment in older women [299]. In our study, the 
proportion of women aged 70 years or older with less aggressive ER+ tumours who 
received BC surgery declined over the study period, proportions receiving chemotherapy 
remained low but increased for ER- tumours and proportions treated with radiotherapy 
increased for both ER+ and ER- tumours. A recent study in the UK in women aged 70 
years or older showed that BC surgery is safe for this age group with no increased risk of 
death but that surgery might affect quality of life in this group of women [300]. Future 
research should aim to identify women with BC that may benefit from additional 
treatments.  
5.2.2.2 The role of method of detection (screening) 
These analyses extended the previous work on BC incidence in Scotland, not just by 
extending the age range of the study population and the study period but also by 
considering the role of screening in time trends in both BC incidence and survival. The 
beneficial effect of screening on BC prognosis in other settings has been previously 
estimated [301, 302] . In our study, the risk of BCD was higher amongst women with non-
screen detected tumours compared to women with screen detected tumours for all tumour 
subtypes and after adjusting for other individual and tumour characteristics, treatments 
and deprivation and comorbidities. Furthermore, the effect of screening was observed in 
improvements of 5-year BCSS and OS in women of screening age (50 to 69 years). 
Although both survival analyses were adjusted for molecular subtype, grade and stage 
which might be partly responsible for increasing survival due to detection of less 
aggressive early stage/grade tumours, the effect of length and lead time bias (explained in 




5.2.2.3 The role of deprivation  
A further important additional contribution of this study was the investigation of the 
association of neighbourhood deprivation with BC prognosis for the different subtypes. 
Deprivation was associated with higher risk of BCD for all molecular subtypes. Statistical 
power (Appendix Table C.15) was limited for the rarest subtypes (TNBC and luminal B) 
for which the association with deprivation was no longer statistically significant after 
adjusting for age, tumour characteristics, treatments and comorbidities. HER2-enriched 
tumours had the highest level of inequality, with women in the most deprived areas of 
Scotland diagnosed with this subtype having double the risk of BCD when compared to 
women in the least deprived areas with HER2-enriched tumours after adjusting for other 
tumour characteristics, screening, treatments and comorbidities. Future research should 
investigate to what extent access to and uptake of screening and treatment, alcohol 
consumption, smoking, obesity and other lifestyle factors might contribute to these 
inequalities.  
5.3 Strengths and limitations 
5.3.1 The use of the Scottish Cancer registry 
The use of Scottish cancer registry data for this PhD has provided an excellent opportunity 
to investigate BC incidence and survival trends by molecular subtypes in Scotland. The 
high quality of the data and the availability of molecular marker data, especially for ER 
status (available from 1997) makes it one of the largest cohorts in Europe (over 70,000 
women) in which to investigate heterogeneity of incidence and survival trends in BC 
subtypes. Further, linkage of death records and comorbidity records has provided the 
opportunity to investigate survival trends by subtype while adjusting for important 
covariates and identify subgroups of women with higher incidence and worse survival that 
would benefit from targeted treatments and prevention programmes.  
Moreover, the findings from this PhD are representative of the Scottish female population 
as the cancer registry ascertains 98% [157] of BC cases and might be generalizable to 




BC are similar between the UK nations. However, regional differences would need to be 
further investigated once other cancer registries have sufficient molecular marker data. 
Findings in the trends were also similar to previous studies for other countries [135, 136, 
146] adding to the existing literature and providing evidence of the distinct aetiology and 
prognosis of the BC subtypes.  
The use of population-based cancer registry data had also some limitations inherent to 
cancer registrations, such as changes in the disease classification, reporting delays and the 
arbitrary definition of a primary incident invasive cancer which is subject to the 
examination of histological specimens by a pathologist [303]. Furthermore, treatment data 
within the registry is very limited and there is no information on recurrence. Since TNBC 
and HER2-enriched subtypes have been associated with increased recurrence risk 
compared to other BC subtypes [304, 305], linkage of the registry to available audit data 
with information on recurrence could help investigate the patterns to recurrence within 
subtypes. Another limitation of the data is the lack of interval cancer data. Although 
method of detection is available in the registry, information is very limited (tumour 
recorded as screen detected vs symptomatic) and, without linkage to screening data it is 
not possible to identify interval cancers. Furthermore, other tumour markers such as ki67 
are not available within the Scottish registry. As cancer heterogeneity is an evolving 
research area, data on new molecular markers that can be used to assess secular trends and 
identify subgroups of women in need of additional treatments and prevention 
interventions will either need to be incorporated into the registry of available through data 
linkage. Finally, the role of RFs, such as reproductive factors and lifestyle factors, in 
secular trends in BC incidence and survival by molecular subtypes needs further research. 
This information could be used to estimate the number of BC that could be prevented for 
each subtype [155] and, inform cancer surveillance and resource allocation for prevention 






5.3.2 The use of robust statistical methods 
Cancer registries record cancer cases and not individual patients’ data, therefore, a woman 
can have multiple cancer records and hence appear multiple times in the registry. Using 
cancer records can therefor overestimate incidence rates which should be computed using 
population estimates at the individual (person) level. In order to correct for multiple 
tumours per woman being included in the rates, I used a single incident case per woman 
instead of multiple tumours.  
The use of joinpoint regression and APC models to assess incidence trends provided 
further evidence of the distinct trends as results were consistent regardless of the method. 
APC models not only estimated the overall trend by subtype but provided additional 
information and found cohort effects on ER+ tumour incidence, hence generating the 
hypothesis that such effects women born in particular periods might be related to changes 
in reproductive factors or obesity patterns.  
The methods used for the survival analysis expanded the traditional Cox PH model for 
which the PH assumption has largely been ignored in the cancer literature [260]. Using 
extended Cox models with TVE, my analysis highlights the importance of checking the 
PH assumption and of providing alternative methods to estimate the effect of certain 
tumour characteristics and treatments on BCSS at different time points after diagnosis. 
Further, the extended Cox model seemed to partially correct confounding by indication 
for the effects of radiotherapy and chemotherapy on BCSS.  
As previously described, missing data for molecular markers can bias the incidence and 
survival trends if ignored [135]. During this PhD, incidence and survival trends were 
corrected for missing molecular markers using simple and MI techniques previously 






5.4 Recommendations for future research 
Molecular markers are likely to continue to inform approaches to prevention and treatment 
of breast and other cancers. This thesis shows the importance of studying BC 
heterogeneity and of the use of molecular markers for cancer surveillance. As 
heterogeneity is also displayed for primary tumours in other locations, the study of 
molecular subtypes can be extended to other tumour types which could lead to the 
discovery of new molecular markers to target for treatment and hence, improved survival 
in cancer patients. Linkage of national population-based datasets with high quality 
pathology and RF could further inform prediction, especially for rare subtypes for which 
information on established RFs is limited. Risk prediction models are used to identify 
women at high risk, for treatment decisions and to inform patients about their prognosis 
in clinical practice [306] but these models might need further stratification by subtype, 
given the heterogeneity observed for BC subtypes in both aetiology and prognosis. There 
is also the need to establish risk-stratified screening programmes to help identify women 
at highest risk of aggressive subtypes that would benefit from earlier or more frequent 
screening and potentially reduce screening frequency for low-risk women.  
The novel coronavirus (COVID-19) pandemic and lockdown are a global public health 
concern and time trends in cancer incidence and survival will be affected by the current 
pandemic. Cancer patients are at high risk to develop severe complications from COVID-
19, including invasive ventilation and death [307, 308]. In Scotland and in most countries 
in the world, the pandemic has resulted in cessation of routine cancer screening which will 
result in delayed diagnosis and treatment for many people with cancer. Cancer referrals 
from primary to secondary care are also being affected and many patients diagnosed with 
cancer prior to lockdown are currently waiting to receive treatment which could have an 
effect on their chances of survival. The work presented in this thesis provides a foundation 
for pre-pandemic BC incidence and survival patterns and assessing future cancer trends 
will help estimate the effect of the pandemic in patients with BC in Scotland and beyond, 







Chapter 6 Conclusion 
 
Although heterogeneity of BC has been established for years, cancer progression is still 
assessed in many countries overall and not by subtype. Further, few cancer registries in 
the world collect molecular marker data that could be used to assess incidence and survival 
trends by the molecular subtypes to further our understanding of BC epidemiology.  
Using the excellent data resources within Scotland, this PhD has improved our 
understanding of the current incidence and survival trends observed in Scotland. The 
results from this study suggest that molecular subtypes are different diseases with different 
aetiology and prognosis and that divergent trends currently exist. While decreasing 
incidence of ER- tumours are cause for celebration, the increases in incidence of ER+ 
tumours suggest an important effect of screening and possibly other RFs as obesity and 
changes in reproductive factors. Additionally, this analysis found two important trends 
that should be carefully monitored in the future: the recent declines observed for ER+ 
tumours and the increases in TNBC in young women.  
This PhD has also identified clear prognostic differences between BC subtypes and 
highlights the importance of not only molecular markers, but also age, grade, stage and 
deprivation. Although, survival trends improved in the last two decades, improvements 
were higher for women of screening age. In contrast, survival in older women did not 
seem to improve and undertreatment might have been one of the reasons. The adoption of 
new treatments might have also played a role but more detailed data would be required to 
assess this contribution.  
Considering the importance of BC for public health, this PhD recommends looking at 
incidence and survival trends by molecular subtypes and future research should focused 
on the development of targeted screening for women with more aggressive tumours and 
in improving outcomes in older women and in women living in the most deprived areas 
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Appendix A Systematic Review 
Appendix A.1 List of countries included in the systematic review 
Europe: Albania, Andorra, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, 
Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, 
Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Macedonia, Malta, Moldova, 
Monaco, Montenegro, The Netherlands, Norway, Poland, Portugal, Romania, Russian 
Federation, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK, Ukraine.  
North America: the USA and Canada.  




Appendix A.2 Systematic review search terms  
List for Pubmed 
#1 *Breast Neoplasms/ 
#2 breast neoplasm$ OR breast cancer$ OR breast tumor$ OR breast tumour$ OR breast 
carcinoma$ 
#3 incidence.mp OR Incidence/ 
#4 trend$.mp  
#5 Receptors, Estrogen/  
#6 hormone replacement therapy/ or estrogen replacement therapy/  
#7 1 OR 2 
#8 3 OR 4 
#9 5 OR 6 
#10 7 AND 8 AND 9  
#11 limit 10 to (English language and humans) 
 
List for Embase 
#1 breast cancer/ OR breast tumor/ 
#2 breast neoplasm$ OR breast cancer$ OR breast tumor$ OR breast tumour$ OR breast 
carcinoma$ 
#3 incidence/ 
#4 trend study/ OR trend$.mp 
#5 estrogen receptor/ 
#6 hormone substitution/ OR estrogen therapy/ 
#7 1 OR 2 
#8 3 OR 4 
#9 5 OR 6 
#10 7 AND 8 AND 9 






List for Web of Science  
#1 breast 
#2 cancer OR tumor OR tumour OR neoplasm 
#3 incidence OR trend$ 
#4 estrogen receptor OR hormone replacement therapy OR estrogen replacement therapy  
#5 1 AND 2 
#6 5 AND 3 AND 4 
#7 su=oncology 
#8 ti=breast cancer 








Appendix A.3 Inclusion and exclusion criteria for systematic review 
 
INCLUSION CRITERIA: 
Types of studies  
- English language. 
- Studies from European ancestry majority countries, i.e. Europe, the US, Canada, 
Australia and New Zealand. 
Studies using data from cancer registries or population-based studies. 
Types of participants  
- Female adults (>18 years)  
Diagnosed with invasive breast cancer 
Types of outcome measures  
Incidence of invasive breast cancer stratified by ER status. 
 
EXCLUSION CRITERIA: 
Types of studies 
- Non English language. 
- Studies from Non-European ancestry majority countries, i.e. Africa, Asia, South 
America.  
- Quantitative studies without population-based data. 
- Reviews (systematic, narrative or qualitative). 
- Editorial comments with no research or additional data reported. 
- Conference or meeting abstracts.  
- Qualitative studies. 
Duplicate studies (with the same population data). 
Types of participants 
- Children (<18 years) and males. 
No breast cancer diagnosis or rare types of breast cancer. 
Types of outcome measures  
Any other than incidence rates in any of its forms OR without stratification by ER status and 




Appendix A.4 National screening programmes in the countries included in the 
systematic review 
 
Appendix Table A.1 Characteristics of screening programmes in the countries 
included in the systematic review 













time interval for 
screening 
Denmark YES 1991 Mammography 50 to 69 2 years 
Ireland YES 2000 Mammography 50 to 64 2 years 
France YES 1989 Mammography and 
clinical breast exam 
50 to 74 2 years 
Germany YES 2002 Mammography 50 to 69 2 years 
Norway YES 1996 Mammography 50 to 69 2 years 
Scotland YES 1988 Mammography 50 to 70 3 years 
Sweden YES 1986 Mammography 40 to 74 18 months (age 
40 to 49) and 2 
years (age 50+) 
United 
States 
NO 1995 Mammography and 
clinical breast exam 











Appendix B Incidence Chapter 
Appendix B.1 Classification of breast cancer molecular subtypes based on IHC 
markers ER, PR and HER2 in Scotland from 2009 to 2016 that would be used during 
the dissertation 
Appendix Table B.1 Intrinsic molecular subtypes as defined by IHC markers 















Positive Positive Positive Negative 13,344 
Positive Negative Positive Negative 2,173 
Positive Unknown Positive Negative 4,812 
Negative Positive Positive Negative <200 








Positive Positive Positive Positive 1,599 
Positive Negative Positive Positive 678 
Positive Unknown Positive Positive 567 
Negative Positive Positive Positive <100 






Negative Negative Negative Positive 1,077 
Negative Unknown Negative Positive 211 





Negative Negative Negative Negative 2,557 
Negative Unknown Negative Negative 342 













Positive Positive Positive Unknown 926 
Positive Negative Positive Unknown 185 
Positive Unknown Positive Unknown 1,110 
Negative Positive Positive Unknown <10 
Negative Negative Negative Unknown 169 
Negative Unknown Negative Unknown 211 
Unknown Positive Positive Unknown <10 
Unknown Negative Negative Unknown <10 
Unknown Unknown Unknown Positive 0 
Unknown Unknown Unknown Negative 0 
Unknown Unknown Unknown Unknown 901 
ER=oestrogen receptor, PR=progesterone receptor, HR=hormone receptor, HER2= human epidermal growth 




Appendix B.2 Algorithm to derive final TNM stage  
If pT = X or blank but pathological tumour size is recorded, derive pT as follows: 
If pathological tumour size ≤ 20mm, pT = 1 
If pathological tumour size >20mm ≤ 50mm, pT = 2 
If pathological tumour size > 50mm, pT = 3 
 
If pN = X or blank but number (of nodes) positive is recorded, derive pN as follows: 
If numbers positive = 0, pN = 0 
If numbers positive = 1–3, pN = 1 
If numbers positive = 4–9, pN = 2 
If numbers positive ≥ 10, pN = 3 
 
Construct Final TNM based on cTNM and pTNM as follows: 
Assume MX = M0 
T4 takes precedence whether from cT or pT 
M1 takes precedence whether from cM or pM 
If patient had radiotherapy, chemotherapy, biological therapy, or hormone therapy starting 
at least 4 weeks before surgery: 
 use cT unless pT is greater than or equal to cT. If cTX assume TX, unless pT4 
 use cN unless pN is greater than or equal to cN. If cNX assume NX, unless pN3 
 use cM unless pM is greater than or equal to cM. If cMX or cM0 assume M0, unless 
pM1 
Otherwise, use pTNM values in preference to cTNM values, unless pTNM values are blank or 
recorded as X. 
 
Once final TNM has been derived, convert to Stage Grouping I–IV as follows: 
 
Stage T N M 
IA T1* N0 M0 
IB T0, T1* N1mi M0 
IIA T0, T1* N1 M0 
IIA T2 N0 M0 
IIB T2 N1 M0 
IIB T3 N0 M0 
IIIA T0, T1*, T2 N2 M0 
IIIA T3 N1, N2 M0 
IIIB T4 N0, N1, N2 M0 
IIIC Any T N3 M0 
IV Any T Any N M1 
*T1 includes T1mi 
 
Note: pT = pathological T stage, pN= pathological N stage, pM=pathological M stage, cT = 





Appendix B.3 Selection of a single invasive tumour in women with two invasive tumours diagnosed within 6 months 
Appendix Figure B.1 Flowchart of the selection of one invasive tumour per woman based on grade and nodal status 
 
 
Grade and nodal 
status score
Same score
Same ER status Take the first
Different ER status
Take the ER 
positive, 
One ER status 
missing
Take the one with 
data
Both ER status 
missing
Take the first
Different score Take the highest
One score missing
Take the one with 
data
Both scores missing Look at grade Grade
Same grade
Same ER status Take the first
Different ER status
Take the ER 
positive
One ER missing
Take the one with 
data




Take the  one with 
highest grade
One grade missing








Same ER status Take the first
Different ER status




Take the one with 
positive nodes
One nodal status 
missing
Take the one with 
data
Both nodal status 
missing
Look at ER status ER status
Same ER status Take the first
Different ER status
Take the ER 
positive
One ER status 
missing
Take the one with 
data






Appendix B.4 Comparison of incidence trends by ER status with and without 
imputation of missing ER status 
 
Appendix Figure B.2 ASiR for ER+ and ER- tumours with imputation of missing ER 













Appendix B.5 Additional results and graphs obtained from Joinpoint regression 
























                                      ^indicates statistically significant EAPC (p<0.05) 
ER positive a) 
ER negative b) 
Appendix Figure B.3 Graph of breast cancer incidence trends for ER+ (a) and ER- (b) 




Appendix Table B.2 Modelled age adjusted incidence rates from joinpoint analysis for 
ER+ and ER- tumours and joinpoint location in the selected final model 





















1997 97.7 103.9 2.0  
1998 105.3 105.1 2.1  
1999 109.1 106.4 2.1  
2000 111.0 107.6 2.1  
2001 106.4 108.8 2.1  
2002 107.3 110.1 2.1  
2003 112.4 111.4 2.1  
2004 116.9 112.7 2.2  
2005 118.0 114.0 2.2  
2006 119.0 115.3 2.2  
2007 112.8 116.7 2.1  
2008 115.8 118.0 2.1  
2009 117.7 119.4 2.1  
2010 119.5 120.8 2.1  
2011 124.1 122.2 2.2  
2012 122.4 123.6 2.1 Joinpoint 1 
2013 121.8 120.9 2.1  
2014 115.3 118.2 2.0  
2015 117.5 115.6 2.0  












1997 35.5 35.3 1.2  
1998 30.2 31.3 1.1  
1999 29.5 27.8 1.1  
2000 25.0 24.6 1.0 Joinpoint 1 
2001 25.3 24.5 1.0  
2002 24.2 24.3 1.0  
2003 24.5 24.1 1.0  
2004 23.0 23.9 0.9  
2005 21.4 23.8 0.9  
2006 21.8 23.6 0.9  
2007 25.6 23.4 1.0  
2008 23.7 23.3 1.0  
2009 24.8 23.1 1.0  
2010 23.4 22.9 0.9  
2011 19.4 22.8 0.9  
2012 21.7 22.6 0.9  
2013 22.3 22.4 0.9  
2014 21.6 22.3 0.9  
2015 23.3 22.1 0.9  
2016 23.1 21.9 0.9  





Appendix Table B.3 Estimated regression coefficients with general parameterization 
for the final model fitted with joinpoint regression for trends in incidence of ER+ and 
ER- tumours in Scotland between 1997 and 2016 









Intercept 1 -18.43 3.51 -5.26 <0.0001 
Intercept 2 49.57 24.50 2.02 0.06 
Slope 1 0.01 <0.01 6.61 <0.0001 
Slope 2 -0.02 0.01 -1.83 0.09 
 
Negative 
Intercept 1 243.14 83.76 2.90 0.01 
Intercept 2 17.67 7.26 2.43 0.03 
Slope 1 -0.12 0.04 -2.86 0.01 
Slope 2 -0.01 <0.01 -2.00 0.06 
Bold results indicate the test was significant at the 5% level. ER= oestrogen receptor. 
 
Appendix Table B.4 Model selection, permutation hypothesis and tests results for ER+ 
and ER- tumours in joinpoint regression 
ER status Test 
Number 
Null Hypothesis Alternate 
Hypothesis 




#1 0 Joinpoint(s) 3 Joinpoint(s) * <0.01 0.02 
#2 1 Joinpoint(s) * 3 Joinpoint(s) 0.18 0.03 
#3 1 Joinpoint(s) * 2 Joinpoint(s) 0.09 0.03 
 
Negative 
#1 0 Joinpoint(s) 3 Joinpoint(s) * <0.01 0.02 
#2 1 Joinpoint(s) * 3 Joinpoint(s) 0.28 0.03 
#3 1 Joinpoint(s) * 2 Joinpoint(s) 0.48 0.03 












Appendix B.6 Sensitivity Analysis for joinpoint regression 
I used ER+ tumours as an example for the sensitivity analysis. The default methods and 
parameters are: 
 Modeling method: the grid search method with two constraints on the location of 
the joinpoints (a minimum of 2 observations from a joinpoint to either end of the 
data, and a minimum of 2 observations between two joinpoints). 
 Model selection method: Permutation Test with 4,499 permutations performed and 
overall significance level of 5%.  
 Number of joinpoints: the default number of joinpoints depend on the number of 
data points. Our data contains 20 consecutive years, therefore, the default maximum 
number of joinpoints is 3.  
 Errors options: Uncorrelated errors model 
 Estimation of AAPC and EAPC confidence intervals: Parametric method 
 
Appendix Table B.5 Sensitivity analysis of joinpoint regression with uncorrelated and 











EAPC (95% CI) 




1 Joinpoint 2012 1.2% (0.8, 1.5) -2.2 (-4.7, 0.4) 
Autocorrelated 
model based on 
the data 
















1 Joinpoint 2011 1.3% (0.8, 1.9) -1.7 (-3.7, 0.3) 



















#1 0 Joinpoint(s) 20 2 18 87.40 1.77 
#2 1 Joinpoint(s) 20 4 16 36.71 1.21 
#3 2 Joinpoint(s) * 20 6 14 26.34 1.17 




#1 0 Joinpoint(s) 20 2 18 87.40 1.77 
#2 1 Joinpoint(s) * 20 4 16 36.71 1.36 
#3 2 Joinpoint(s) 20 6 14 26.34 1.47 




#1 0 Joinpoint(s) * 20 2 18 87.40 1.12 
#2 1 Joinpoint(s) 20 4 16 36.71 1.14 
#3 2 Joinpoint(s) 20 6 14 26.34 1.56 
#4 3 Joinpoint(s) 20 8 12 23.83 2.29 
BIC in bold corresponds to smallest BIC value and *selected model. BIC= Bayesian Information Criterion, df= degrees of freedom, SSE= Sum of standard errors.  
 















EAPC (95% CI) 
 
Permutation test 1 Joinpoint 1997-2012 1.2% (0.8, 1.5) 2012-2016 -2.2 (-4.7, 0.4)   
BIC 2 Joinpoints 1997-1999 4.7% (-4.3, 14.6) 1999-2012 1% (0.5, 1.5) 2012-2016 -2 (-4.3, 0.5) 
BIC3 1 Joinpoint 1997-2012 1.2% (0.8, 1.5) 2012-2016 -2.2 (-4.7, 0.4)   
Modified BIC 0 Joinpoint 1997-2016 0.7% (0.4, 1)     




Appendix B.7 Additional graphs and results from APC models for ER+ tumours 
 
Appendix Figure B.4 Graphs for trends in breast cancer incidence for ER+ tumours by age, 






Appendix Figure B.5 Graphs for trends in breast cancer incidence for ER+ tumours by age, 
period and cohort effects for the curvature parameters 
 





Appendix Table B.8 Estimates with 95% CI for all the parameters of the final APC model 
for ER+ tumours 
Parameter Estimate SD Lower CI Upper CI 
Intercept  -6.56727 0.00764 -6.58224 -6.55229 
LAT        0.05360 0.00122 0.05121 0.05598 
Net Drift    0.00800 0.00106 0.00592 0.01008 
CAT         0.04560 0.00063 0.04436 0.04683 
Age curvature -0.00191 0.00006 -0.00203 -0.00179 
Period curvature -0.00083 0.00020 -0.00122 -0.00044 
Cohort curvature 0.00003 0.00005 -0.00006 0.00012 
Bold results indicate significant estimates. CI=Confidence interval, CAT=Cross-sectional age trend, LAT=Longitudinal 
age trend, SD=Standard deviation. 
Appendix Table B.9 Wald tests results for all key hypotheses on the APC model of ER+ 
tumours 
Hypothesis test Chi-square df P value 
Net Drift = 0                             56.75 1 <0.00000000001 
Age curvature = 0                               954.37 1 <0.00000000001 
All Higher-Order Age Deviations = 0      689.03 25 <0.00000000001 
All Age Deviations = 0                  1539.17 26 <0.00000000001 
Period curvature = 0                                17.02 1 0.00003694340 
All Higher-Order Period Deviations = 0    18.59 7 0.00956066800 
All Period Deviations = 0                 36.33 8 0.00001526035 
Cohort curvature = 0                                 0.53 1 0.46596760000 
All Higher-Order Cohort Deviations = 0    98.76 34 0.00000003130 
All Cohort Deviations = 0                99.24 35 0.00000004633 
All Period RR = 1                         85.82 9 <0.00000000001 
All Cohort RR = 1                        151.71 36 <0.00000000001 
All Local Drifts = Net Drift              93.59 28 0.00000000540 
All Gradient Shifts = CAT                 12.56 10 0.24924410000 
Bold results indicate the test was significant at the 5% level. CAT= Cross-sectional age trend, df= degrees of freedom, 
RR=rate ratio 
Appendix Table B.10 Combination tests for the APC model of ER+ tumours 
Combination tests P value 
All Period Deviations = 0       0.00007388679 
All PRR = 1 <=> FTT = constant  <0.00000000001 
All Cohort Deviations = 0       0.00000006260 
All CRR = 1 <=> FCP = constant  <0.00000000001 
Bold results indicate the test was significant at the 5% level. CRR=Cohort rate ratio, FCP=Fitted cohort pattern, 




Appendix Figure B.6 Graphs of the deviance residuals for APC models of ER+ tumours 
 










Appendix B.8  Additional graphs and results from APC models for ER- tumours 
Appendix Figure B.7 Graphs for trends in breast cancer incidence for ER- tumours by 


































Appendix Figure B.8 Graphs for trends in breast cancer incidence for ER- tumours by age, 




Appendix Table B.11 Estimates with 95% CI for all the parameters of the final APC model 
for ER- tumours 
Parameter Estimate SD Lower CI Upper CI 
Intercept  -7.98823 0.01112 -8.01003 -7.96642 
LAT        0.01105 0.00186 0.00740 0.01470 
NetDrift    -0.01438 0.00170 -0.01771 -0.01106 
CAT         0.02543 0.00084 0.02378 0.02708 
Age curvature -0.00117 0.00008 -0.00134 -0.00101 
Period curvature 0.00184 0.00034 0.00117 0.00250 
Cohort curvature -0.00006 0.00007 -0.00018 0.00007 
Bold results indicate significant estimates. CAT=Cross-sectional age trend, CI=Confidence interval, LAT=Longitudinal 
age trend, SD=Standard deviation. 
Appendix Table B.12 Wald tests results for all key hypotheses on the APC model of ER- 
tumours 
Hypothesis test Chi-square df P-Value 
Net Drift = 0                             71.84 1 <0.00000000001 
Age curvature = 0                               191.60 1 <0.00000000001 
All Higher-Order Age Deviations = 0      117.63 25 <0.00000000001 
All Age Deviations = 0                  293.49 26 <0.00000000001 
Period curvature = 0                                29.22 1 0.00000006449 
All Higher-Order Period Deviations = 0    34.59 7 0.00001334335 
All Period Deviations = 0                 63.85 8 0.00000000008 
Cohort curvature = 0                                 0.74 1 0.38923730000 
All Higher-Order Cohort Deviations = 0    46.87 34 0.06987975000 
All Cohort Deviations = 0                48.05 35 0.06978012000 
All Period RR = 1                         140.96 9 <0.00000000001 
All Cohort RR = 1                        125.33 36 0.00000000001 
All Local Drifts = Net Drift              40.28 28 0.06243669000 
All Gradient Shifts = CAT                 4.56 10 0.91834280000 
Bold results indicate the test was significant at the 5% level. CAT= Cross-sectional age trend, df= degrees of freedom. 
RR=rate ratio. 
Appendix Table B.13 Combination tests for the APC model of ER- tumours 
Combination tests P value 
All Period Deviations = 0       0.00000012898 
All PRR = 1 <=> FTT = constant  <0.00000000001 
All Cohort Deviations = 0       0.13975950000 
All CRR = 1 <=> FCP = constant  <0.00000000001 
Bold results indicate the test was significant at the 5% level. CRR=Cohort rate ratio, FCP=Fitted cohort pattern, 





























Appendix B.9 Comparison of incidence trends by HER2 status with and without 
imputation of missing HER2 status 
 
Appendix Figure B.10 ASiR for HER2- and HER2+ tumours with imputation of missing 












Appendix B.10 Additional graphs and results from APC models for HER2- 
tumours 
 
Appendix Figure B.11 Graphs for trends in breast cancer incidence for HER2- tumours by 






Appendix Figure B.12 Graphs for trends in breast cancer incidence for HER2- tumours by 









Appendix Table B.14 Estimates with 95% CI for all the parameters of the final APC model 
for HER2- tumours 
Parameter Estimate SD Lower CI Upper CI 
Intercept  -6.51271 0.00933 -6.53100 -6.49443 
LAT        0.04517 0.00322 0.03885 0.05149 
Net Drift    0.00136 0.00311 -0.00474 0.00745 
CAT         0.04381 0.00077 0.04231 0.04532 
Age curvature -0.00218 0.00015 -0.00247 -0.00188 
Period curvature -0.00487 0.00145 -0.00772 -0.00202 
Cohort curvature 0.00029 0.00014 0.00003 0.00056 
Bold results indicate significant estimates. CAT=Cross-sectional age trend, CI=Confidence interval, LAT=Longitudinal 
age trend, SD=Standard deviation. 
Appendix Table B.15 Wald tests results for all key hypotheses on the APC model of HER2- 
tumours 
Hypothesis test Chi-square df P value 
Net Drift = 0                             0.19 1 0.06629474 
Age curvature = 0                               213.79 1 <0.00000000001 
All Higher-Order Age Deviations = 0      388.92 53 <0.00000000001 
All Age Deviations = 0                  549.00 54 <0.00000000001 
Period curvature = 0                                11.24 1 0.0008001488 
All Higher-Order Period Deviations = 0    2.02 5 0.8468523 
All Period Deviations = 0                 13.32 6 0.03826178 
Cohort curvature = 0                                 4.65 1 0.03096644 
All Higher-Order Cohort Deviations = 0    92.96 60 0.004087221 
All Cohort Deviations = 0                94.92 61 0.003530879 
All Period RR = 1                         13.40 7 0.06285477 
All Cohort RR = 1                        94.92 62 0.004528519 
All Local Drifts = Net Drift              93.41 56 0.001267230 
All Gradient Shifts = CAT                 14.57 8 0.06798652 
Bold results indicate the test was significant at the 5% level. CAT= Cross-sectional age trend, df= degrees of freedom, 
RR=rate ratio. 
Appendix Table B.16 Combination tests for the APC model of HER2- tumours 
Combination tests P value 
All Period Deviations = 0       0.001600298 
All PRR = 1 <=> FTT = constant  0.002400447 
All Cohort Deviations = 0       0.008174443 
All CRR = 1 <=> FCP = constant  0.012261664 
Bold results indicate the test was significant at the 5% level. CRR=Cohort rate ratio, FCP=Fitted cohort pattern, 




Appendix B.11 Additional graphs and results from APC models for HER2+ 
tumours 
 
Appendix Figure B.13 Graphs for trends in breast cancer incidence for HER2+ tumours by 






Appendix Figure B.14 Graphs for trends in breast cancer incidence for HER2+ tumours by 









Appendix Table B.17 Estimates with 95% CI for all the parameters of the final APC model 
for HER2+ tumours 
Parameter Estimate SD Lower CI Upper CI 
Intercept  -8.08055 0.01922 -8.11822 -8.04288 
LAT        -0.00807 0.00718 -0.02214 0.00600 
Net Drift    -0.03412 0.00699 -0.04783 -0.02041 
CAT         0.02605 0.00150 0.02312 0.02898 
Age curvature -0.00187 0.00030 -0.00247 -0.00128 
Period curvature 0.01150 0.00348 0.00468 0.01831 
Cohort curvature 0.00052 0.00028 -0.00003 0.00107 
Bold results indicate significant estimates. CI=Confidence interval, LAT=Longitudinal age trend, CAT=Cross-sectional 
age trend, SD=Standard deviation. 
Appendix Table B.18 Wald tests results for all key hypotheses on the APC model of HER2+ 
tumours 
Hypothesis test Chi-square df P-Value 
Net Drift = 0                             23.80 1 0.00000106989 
Age curvature = 0                               37.72 1 0.00000000082 
All Higher-Order Age Deviations = 0      68.66 53 0.07267159 
All Age Deviations = 0                  97.61 54 0.0002577371 
Period curvature = 0                                10.94 1 0.0009418230 
All Higher-Order Period Deviations = 0    12.80 5 0.02528583 
All Period Deviations = 0                 22.74 6 0.0008894106 
Cohort curvature = 0                                 3.40 1 0.06529817 
All Higher-Order Cohort Deviations = 0    46.43 60 0.9006389 
All Cohort Deviations = 0                50.45 61 0.8301537 
All Period RR = 1                         46.81 7 0.00000006076 
All Cohort RR = 1                        79.82 62 0.06335441 
All Local Drifts = Net Drift              47.97 56 0.7685697 
All Gradient Shifts = CAT                 8.40 8 0.3957113 
Bold results indicate the test was significant at the 5% level. CAT= Cross-sectional age trend, df= degrees of freedom, 
RR=rate ratio. 
Appendix Table B.19 Combination tests for the APC model of HER2+tumours 
Combination tests P value 
All Period Deviations = 0       0.001883646 
All PRR = 1 <=> FTT = constant  0.000003209675 
All Cohort Deviations = 0       0.1305963 
All CRR = 1 <=> FCP = constant  0.000003209675 
Bold results indicate the test was significant at the 5% level. CRR=Cohort rate ratio, FCP=Fitted cohort pattern, 





Appendix B.12 Incidence rates of luminal B, HER2-enriched and Triple Negative 
tumours by age group 
Appendix Figure B.15 ASiR for luminal B, HER2-enriched and TNBC tumours by age group 


















Appendix B.13 Additional graphs and results from APC models for the IHC 
defined molecular subtypes of breast cancer 
 
Appendix Figure B.16 Cross-sectional age curve for each molecular subtype 
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Appendix Figure B.17 Longitudinal vs. cross-sectional rate ratio for each molecular 
subtype 
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Appendix Figure B.18 Fitted temporal trends for each molecular subtype 
      Luminal A 
 
         Luminal B 
 
          HER2-enriched 
 
         Triple Negative 
 












Appendix Figure B.20 Period deviations for each molecular subtype 
           Luminal A 
 
         Luminal B 
 
          HER2-enriched 
 
         Triple Negative 
 












Appendix Table B.20 Estimates with 95% CI for all the parameters of the final APC model 
for each molecular subtype 
Molecular 
subtype 







-6.67943 0.01048 -6.69997 -6.65889 
LAT        
0.04742 0.00347 0.04061 0.05422 
Net Drift    
-0.00040 0.00335 -0.00695 0.00616 
CAT         
0.04781 0.00088 0.04609 0.04953 
Age curvature 
-0.00224 0.00016 -0.00256 -0.00192 
Period curvature 
-0.00662 0.00153 -0.00963 -0.00362 
Cohort curvature 






Intercept  -8.42779 0.02233 -8.47157 -8.38402 
LAT        -0.01872 0.00846 -0.03530 -0.00215 
Net Drift    -0.04275 0.00822 -0.05886 -0.02665 
CAT         0.02403 0.00173 0.02063 0.02743 
Age curvature -0.00220 0.00036 -0.00291 -0.00150 
Period curvature 0.00651 0.00404 -0.00142 0.01443 







Intercept  -9.18175 0.03668 -9.25364 -9.10985 
LAT        0.01497 0.01235 -0.00923 0.03917 
Net Drift    -0.01327 0.01207 -0.03693 0.01039 
CAT         0.02824 0.00298 0.02239 0.03409 
Age curvature -0.00128 0.00053 -0.00233 -0.00023 
Period curvature 0.01920 0.00608 0.00729 0.03112 







Intercept  -8.41950 0.02277 -8.46413 -8.37486 
LAT        0.02694 0.00871 0.00987 0.04401 
Net Drift    0.00200 0.00847 -0.01460 0.01860 
CAT         0.02494 0.00175 0.02151 0.02837 
Age curvature -0.00166 0.00037 -0.00238 -0.00094 
Period curvature 0.00822 0.00037 -0.00016 0.01660 
Cohort curvature 0.00056 0.00034 -0.00011 0.00122 
Bold results indicate significant estimates. CAT=Cross-sectional age trend, CI=Confidence interval, LAT=Longitudinal 




Appendix Table B.21 Wald tests results for all key hypotheses on the APC model for each 
molecular subtype (page 1 of 2) 
Molecular 
subtype 











Net Drift = 0 0.01 1 0.9057431 
Age curvature = 0     185.70 1 <0.0000000001 
All Higher-Order Age Deviations = 0  381.80 53 <0.0000000001 
All Age Deviations = 0  524.92 54 <0.0000000001 
Period curvature = 0                                18.72 1 0.00001513379 
All Higher-Order Period Deviations = 0 2.54 5 0.7698591 
All Period Deviations = 0                 21.11 6 0.001756117 
Cohort curvature = 0                                 1.31 1 0.2515856 
All Higher-Order Cohort Deviations = 0 86.96 60 0.01301720 
All Cohort Deviations = 0                87.36 61 0.01506458 
All Period RR = 1                         21.22 7 0.003455566 
All Cohort RR = 1                        87.47 62 0.01828156 
All Local Drifts = Net Drift              83.83 56 0.009400891 











Net Drift = 0                             27.08 1 0.0000001953671 
Age curvature = 0                               37.64 1 0.000000000852 
All Higher-Order Age Deviations = 0 87.01 53 0.002232215 
All Age Deviations = 0                  114.95 54 0.0000026983 
Period curvature = 0                                2.59 1 0.1075124 
All Higher-Order Period Deviations = 0 11.45 5 0.04314690 
All Period Deviations = 0                 13.34 6 0.03790295 
Cohort curvature = 0                                 8.63 1 0.003298665 
All Higher-Order Cohort Deviations = 0 53.44 60 0.7126586 
All Cohort Deviations = 0                61.76 61 0.4486984 
All Period RR = 1                         40.63 7 0.0000009524 
All Cohort RR = 1                        96.57 62 0.003252102 
All Local Drifts = Net Drift              56.86 56 0.4427515 





Appendix Table B.21 (continued) Wald tests results for all key hypotheses on the APC 
model for each molecular subtype (page 2 of 2) 
Molecular 
subtype 











Net Drift = 0                             1.21 1 0.271668649 
Age curvature = 0                               5.76 1 0.016413910 
All Higher-Order Age Deviations = 0 44.64 53 0.786206109 
All Age Deviations = 0                  48.53 54 0.684664247 
Period curvature = 0                                9.97 1 0.001587857 
All Higher-Order Period Deviations = 0 5.18 5 0.394113156 
All Period Deviations = 0                 15.15 6 0.019157671 
Cohort curvature = 0                                 <0.01 1 0.943676832 
All Higher-Order Cohort Deviations = 0 44.40 60 0.934195258 
All Cohort Deviations = 0                44.79 61 0.940723990 
All Period RR = 1                         16.36 7 0.021984728 
All Cohort RR = 1                        47.52 62 0.91256242 
All Local Drifts = Net Drift              42.63 56 0.906051798 











Net Drift = 0                             0.06 1 0.8130395 
Age curvature = 0                               20.50 1 0.000005950883 
All Higher-Order Age Deviations = 0  70.72 53 0.005225893 
All Age Deviations = 0                  83.80 54 0.005778583 
Period curvature = 0                                3.70 1 0.05452570 
All Higher-Order Period Deviations = 0 8.21 5 0.1448488 
All Period Deviations = 0                 11.37 6 0.07761607 
Cohort curvature = 0                                 2.71 1 0.09985863 
All Higher-Order Cohort Deviations = 0 65.58 60 0.2893884 
All Cohort Deviations = 0                68.34 61 0.2421994 
All Period RR = 1                         11.39 7 0.1223193 
All Cohort RR = 1                        68.37 62 0.2700082 
All Local Drifts = Net Drift              62.52 56 0.2557501 
All Gradient Shifts = CAT                 13.43 8 0.09795575 
Bold results indicate the test was statistically significant at the 5% level. CAT= Cross-sectional age trend, df= degrees 




Appendix Table B.22 Combination tests for the APC model for each molecular subtype 
Molecular subtype Combination tests P value 
 
Luminal A 
All Period Deviations = 0       0.00003026758 
All PRR = 1 <=> FTT = constant  0.00004540137 
All Cohort Deviations = 0       0.02603439 
All CRR = 1 <=> FCP = constant  0.03905159 
 
Luminal B 
All Period Deviations = 0       0.08629380 
All PRR = 1 <=> FTT = constant  0.000000586101 
All Cohort Deviations = 0       0.006597330 
All CRR = 1 <=> FCP = constant  0.000000586101 
 
HER2-enriched 
All Period Deviations = 0       0.003175715 
All PRR = 1 <=> FTT = constant  0.004763572 
All Cohort Deviations = 0       1.0000000 
All CRR = 1 <=> FCP = constant  0.815005948 
 
Triple Negative 
All Period Deviations = 0       0.1090514 
All PRR = 1 <=> FTT = constant  0.1635771 
All Cohort Deviations = 0       0.1997173 
All CRR = 1 <=> FCP = constant  0.2995759 
Bold results indicate the test was statistically significant at the 5% level. CRR=Cohort rate ratio, FCP=Fitted cohort 












































Appendix C Survival Chapter 
 
Appendix C.1 Overall survival at 5 and 10 years by ER status and age group 
 
Appendix Table C.1 Overall survival derived from subtraction of proportions of deaths 
from all causes following a diagnosis of breast cancer among women in Scotland at 5 and 
10 years by ER status and age group 
OVERALL SURVIVAL <50 YEARS 50-69 YEARS 70 YEARS OR 
OLDER 
TOTAL 
ER+     
cases/deaths 6,691/947 17,511/2,348 6,566/4,412 30,768/7,707 
5-year OS (95% CI) 88.1 (87.4, 88.8) 88.0 (87.6, 88.5) 56.9 (56.0, 57.7) 78.9 (78.5, 79.3) 
ER-     
cases/deaths 1,774/616 2,963/1,098 865/894 5,602/2,608 
5-year OS (95% CI) 74.0 (72.3, 75.5) 71.4 (70.1, 72.6) 41.6 (39.7, 43.6) 64.9 (63.9, 65.8) 
% difference at 5 years 









ER+     
cases/deaths 3,678/624 9,165/1,890 2,330/2,380 15,173/4,894 
10-year OS (95% CI) 78.1 (77.1, 79.1) 76.1 (75.4, 76.7) 31.8 (30.9, 32.7) 63.3 (62.8, 63.8) 
ER-     
cases/deaths 1,063/152 1,604/335 327/308 2,994/795 
10-year OS (95% CI) 66.6 (64.7, 68.4) 61.7 (60.2, 63.1) 24.4 (22.6, 26.3) 54.0 (52.9, 55.0) 
% difference at 10 years 















Appendix C.2 Assessing the PH assumption for the fully adjusted model 4 with ER status as the main exposure 
Appendix Figure C.1 Log minus log plots to visually inspect the PH assumption for all individual and tumour characteristics and treatment 
regimes (page 1 of 2) 
   




Appendix Figure C.1 (continued) Log minus log plots to visually inspect the PH assumption for all individual and tumour characteristics 
and treatment regimes (page 2 of 2) 






Appendix Table C.2 Proportional hazards assumption test for fully adjusted Cox 
model with ER status as an exposure 
Variable Rho Chi-square P value 
ER status Negative (VS positive)  -0.1381 170 <0.001 
Age <50 years (vs 50 -69 years)         0.0026 5.23 0.819 
Age 70+ years (vs 50 -69 years)         -0.0174 2.41 0.121 
North region (vs West) -0.0055 0.230 0.632 
South East region (vs West) -0.0076 0.432 0.511 
Incidence year 2002-2006 (vs 1997-2001) 0.0214 3.50 0.061 
Incidence year 2007-2011 (vs 1997-2001) 0.0286 6.32 0.019 
Incidence year 2012-2016 (vs 1997-2001) 0.0076 0.434 0.510 
Tumour grade II (vs I) -0.0076 0.446 0.504 
Tumour grade III (vs I) -0.06282 30.7 <0.001 
TNM stage II (vs I) -0.0384 11.6 <0.001 
TNM stage III (vs I) -0.0870 59.3 <0.001 
TNM stage IV (vs I) -0.1230 115.0 <0.001 
Not screen detected (vs screen detected) -0.0425 14.0 <0.001 
No surgery (vs Yes) -0.0262 5.17 0.023 
No radiotherapy (vs Yes) -0.0639 31.5 <0.001 
No chemotherapy (vs Yes) -0.0643 34.6 <0.001 
No hormone therapy (vs Yes) -0.0635 35.5 <0.001 
SIMD quintile 2 (vs least deprived) -0.0179 2.43 0.119 
SIMD quintile 3 (vs least deprived) -0.0241 4.39 0.036 
SIMD quintile 4 (vs least deprived) -0.0002 0.0003 0.985 
Most deprived SIMD quintile (vs least deprived) -0.0119 1.07 0.301 
Charlson score of comorbidity -0.0175 2.16 0.141 
GLOBAL TEST  1340 <0.001 




Appendix C.3 Sensitivity analysis to investigate the PH assumption using extended Cox models with time-varying effects and two 
independent stratified models by time period  
Appendix Table C.3 Comparison of fully adjusted Cox model with model with time-varying effects and independent Cox models stratified 
by time period (0 to 3 years of follow-up and more than 3 years to the end of the follow-up) (page 1 of 2)  
 Fully adjusted Cox model 
N=51,140, deaths=7,592 
Cox model with time by covariate interactions 
N=51,140, deaths=7,592 
Independent Cox models for two time periods 
 
 
HR (95%CI, P value) 
 
 
HR (95%CI, P value) 
Main effect 
HR (95%CI, P value) 
Time-varying effect 
0-3 years follow-up 
N=51,140, deaths=3,535 
HR (95%CI, P value) 
+3 years to end of follow-up 
N=36,679, deaths=4,041 
HR (95%CI, P value) 
ER Status   ER Status*time   
Positive Ref Ref Ref Ref Ref 
Negative 1.44 (1.33-1.56) 2.89 (2.55-3.29) 0.83 (0.81-0.85) 2.26 (2.02-2.52) 0.85 (0.76-0.96, p=0.009) 
Age      
<50 years 0.89 (0.84-0.95) 0.89 (0.84-0.95)  0.88 (0.80-0.97) 0.89 (0.82-0.97, p=0.005) 
50-69 years Ref Ref  Ref Ref 
70 years or older 1.36 (1.27-1.45) 1.35 (1.27-1.44)  1.44 (1.32-1.58) 1.25 (1.14-1.38) 
NHS region      
West Ref Ref  Ref Ref 
North 1.12 (1.06-1.19) 1.11 (1.05-1.17)  1.09 (1.00-1.19, p=0.048) 1.13 (1.05-1.23, p=0.002) 
South East 1.01 (0.96-1.07, p=0.665) 0.99 (0.94-1.05, p=0.847)  1.01 (0.92-1.09, p=0.897) 1.00 (0.92-1.08, p=0.901) 
Year of diagnosis      
1997-2001 Ref Ref  Ref Ref 
2002-2006 0.79 (0.75-0.84) 0.79 (0.74-0.84)  0.75 (0.68-0.82) 0.81 (0.75-0.87) 
2007-2011 0.68 (0.64-0.73) 0.68 (0.64-0.73)  0.61 (0.56-0.67) 0.73 (0.67-0.80) 
2012-2016 0.73 (0.67-0.79) 0.74 (0.68-0.79)  0.71 (0.64-0.78) 0.74 (0.61-0.89) 
Grade   Grade*time   
Grade I-(Well) 
differentiated 
Ref Ref Ref Ref Ref 
Grade II- Moderately 
(well) differentiated 
1.84 (1.64-2.06) 2.10 (1.72-2.57) 0.99 (0.96-1.01, p=0.369) 1.88 (1.51-2.34) 1.93 (1.69-2.20) 





Appendix Table C.3 (continued) Comparison of fully adjusted Cox model with model with time-varying effects and independent Cox 
models stratified by time period (0 to 3 years of follow-up and more than 3 years to the end of the follow-up) (page 2 of 2) 
 Fully adjusted Cox model 
N=51,140, deaths=7,592 
Cox model with time by covariate interactions 
N=51,140, deaths=7,592 
Independent Cox models for two time periods 
 
 
HR (95%CI, P value) 
 
 
HR (95%CI, P value) 
Main effect 
HR (95%CI, P value) 
Time-varying effect 
0-3 years follow-up 
N=51,140, deaths=3,535 
HR (95%CI, P value) 
+3 years to end of follow-up 
N=36,679, deaths=4,041 
HR (95%CI, P value) 
TNM stage   TNM stage*time   
I Ref Ref Ref Ref Ref 
II 2.11 (1.95-2.28) 2.61 (2.28-2.99) 0.96 (0.94-0.98) 2.54 (2.20-2.93) 1.94 (1.76-2.13) 
III 5.90 (5.44-6.40) 9.13 (7.94-10.50) 0.91 (0.89-0.93) 8.33 (7.21-9.62) 4.64 (4.18-5.14) 
IV 11.09 (10.00-12.30) 23.54 (19.74-28.08) 0.80 (0.77-0.83) 18.67 (15.89-21.95) 5.99 (5.08-7.06) 
Screening                  Yes Ref Ref Screening*time Ref Ref 
No 1.62 (1.50-1.75) 2.07 (1.82-2.36) 0.96 (0.94-0.98) 2.02 (1.76-2.34) 1.52 (1.38-1.67) 
Surgery   Surgery*time   
Yes Ref Ref Ref Ref Ref 
No 4.01 (3.70-4.33) 5.10 (4.49-5.78) 0.90 (0.87-0.94) 4.11 (3.72-4.54) 3.69 (3.22-4.23) 
Radiotherapy   Radiotherapy*time   
Yes   Ref   
No 1.03 (0.98-1.09, p=0.201) 1.24 (1.15-1.34) 0.96 (0.95-0.97) 1.18 (1.09-1.26) 0.94 (0.88-1.01, p=117) 
Chemotherapy   Chemotherapy*time   
Yes Ref Ref Ref Ref Ref 
No 0.96 (0.90-1.02, p=0.218) 1.25 (1.14-1.36) 0.94 (0.93-0.96) 1.16 (1.06-1.28) 0.82 (0.75-0.89) 
Hormone therapy   Hormone therapy*time   
Yes Ref Ref Ref Ref Ref 
No 1.31 (1.21-1.41) 1.69 (1.50-1.92) 0.93 (0.91-0.96) 1.64 (1.47-1.83) 1.07 (0.95-1.19) 
SIMD quintile      
Most deprived 1.24 (1.15-1.34) 1.23 (1.14-1.33)  1.25 (1.12-1.40) 1.23 (1.11-1.36) 
2 1.19 (1.11-1.28) 1.18 (1.10-1.27)  1.27 (1.15-1.42) 1.12 (1.02-1.24) 
3 1.12 (1.04-1.20, p=0.002) 1.12 (1.04-1.20, p=0.002)  1.21 (1.09-1.35, p=0.002) 1.05 (0.95-1.15, p=0.349) 
4 1.03 (0.96-1.11, p=0.371) 1.03 (0.95-1.10, p=0.371)  1.05 (0.94-1.17, p=0.371) 1.02 (0.93-1.12, p=0.702) 
Least deprived Ref Ref  Ref Ref 
Charlson Score      
Mean (SD) 1.23 (1.13-1.33) 1.20 (1.11-1.30)  1.23 (1.11-1.36) 1.13 (0.98-1.30, p=0.084) 
Models include age, incidence year, NHS region, grade, TNM stage, method of detection, surgery, radiotherapy, chemotherapy, hormone therapy, SIMD and Charlson score index. 
All HRs were statistically significant at the 0.1% level unless stated otherwise.  CI= confidence interval, HR= hazard ratio, NHS= National Health Service, SD= standard deviation, SIMD= 




Appendix Table C.4 Estimates of hazard ratio at 1, 3, 5 and 10 years predicted from Cox 
model with time-varying covariates 
 
HR at 1 year HR at 3 years HR at 5 years HR at 10 years 
ER Status     
Positive Ref Ref Ref Ref 
Negative 2.39 (2.08, 2.80) 1.63 (1.23, 2.03) 1.12 (0.90, 1.48) 0.43 (0.31, 0.66) 
Grade     
Grade I-(Well) 
differentiated 
Ref Ref Ref Ref 
Grade II- Moderately 
(well) differentiated 
2.08 (1.65, 2.59) 2.03 (1.52, 2.48) 1.99 (1.40, 2.69) 1.90 (1.15, 2.32) 
Poorly differentiated 4.53 (3.60, 5.75) 3.78 (2.83, 5.10) 3.16 (2.23, 4.53) 2.01 (1.22, 3.35) 
TNM stage     
I Ref Ref Ref Ref 
II 2.51 (2.27, 2.94) 2.32 (1.90, 2.83) 2.14 (1.68, 2.72) 1.75 (1.25, 2.46) 
III 8.33 (7.03, 9.78) 6.96 (5.53, 8.50) 5.81 (4.35, 7.39) 3.71 (2.39, 5.21) 




7.85 (5.37, 10.91) 2.61 (1.46, 4.22) 
Screening     
Yes Ref Ref Ref Ref 
No 1.99 (1.72, 2.32) 1.84 (1.52, 2.23) 1.70 (1.35, 2.14) 1.39 (1.01, 1.93) 
Surgery     
Yes Ref Ref Ref Ref 
No 4.57 (3.90, 5.42) 3.67 (2.94, 4.81) 2.94 (2.26, 4.26) 1.70 (1.11, 3.16) 
Radiotherapy     
Yes Ref Ref Ref Ref 
No 1.20 (1.09, 1.30) 1.11 (0.99, 1.22) 1.02 (0.90, 1.15) 0.84 (0.70, 0.99) 
Chemotherapy     
Yes Ref Ref Ref Ref 
No 1.17 (1.06, 1.31) 1.04 (0.92, 1.21) 0.92 (0.80, 1.12) 0.68 (0.57,0.91) 
Hormone therapy     
Yes Ref Ref Ref Ref 
No 1.57 (1.38, 1.84) 1.36 (1.15, 1.70) 1.19 (0.96, 1.57) 0.84 (0.61, 1.28) 
ER= oestrogen receptor, HR= hazard ratio, Ref= reference category, TNM= tumour, nodes, metastases. 
The estimated hazard ratio of each covariate as a function of time t is given by: HR(t)=exp(α+βt) 
where α is the coefficient for the main effect for each specific covariate, β is the coefficient of 




Appendix C.4 Overall (all cause) survival at 5 years by IHC defined molecular subtypes 
and age groups in women diagnosed with invasive breast cancer from 2009 to 2016 in 
Scotland, N=30,965 
Appendix Table C.5 Overall survival estimates at 5 years (with 95% CI) by IHC defined 
molecular subtypes and age for women diagnosed from 2009 to 2016 
MOLECULAR 
SUBTYPE 
<50 YEARS 50- 69 YEARS 70 YEARS OR 
OLDER 
TOTAL 
Luminal A     
cases/deaths 749/90 2,413/334 888/889 4,050/1,313 
5-year OS (95% CI) 92.4 (90.8, 93.7) 91.7 (90.9, 92.5) 58.5 (56.6, 60.4) 81.8 (81.0, 82.6) 
Luminal B     
cases/deaths 679/185 1,176/297 379/421 2,234/903 
5-year OS (95% CI) 84.9 (82.8, 86.7) 85.4 (83.9, 86.8) 57.6 (54.7, 60.4) 78.6 (77.4, 79.7) 
HER2-enriched     
cases/deaths 89/29 173/57 49/77 311/163 
5-year OS (95% CI) 81.2 (74.6, 86.3) 79.6 (75.2, 83.3) 45.1 (38.0, 51.9) 71.3 (67.9, 74.3) 
Triple Negative     
cases/deaths 187/117 327/193 95/176 609/486 
5-year OS (95% CI) 72.9 (68.7, 76.6) 73.1 (70.0, 76.0) 41.8 (37.1, 46.5) 65.5 (63.2, 67.6) 








Appendix C.5 KM curves by individual, tumour characteristics and treatment regimens 
for women diagnosed in Scotland from 1997 to 2016 
Appendix Figure C.2 KM curves by age 
 
 





Appendix Figure C.4 KM curves by Scottish index of multiple deprivation 
 
 




Appendix Figure C.6 KM curves by tumour characteristics: a) tumour grade, b) tumour 






























Appendix Figure C.7 KM curves by tumour characteristics: a) nodal status, b) method 








Appendix Figure C.8 KM curves by treatments: a) surgery, b) radiotherapy, c) 








Appendix C.6 Sensitivity analysis: traditional and extended Cox models with TVE stratified by ER (1997-2016)  
Appendix Table C.6 Comparison of traditional and extended Cox models with TVE for ER+ and ER- tumours (separately) diagnosed from 
1997 to 2016 (page 1 of 3) 
 ER+ no. cases=42,146 no. failures=5,238 ER- no. cases=9,105 no. failures=2,378 
 
Traditional Cox model 
HR (95%CI) 
Extended Cox model 
with TVE 
HR (95%CI) 
Traditional Cox model 
HR (95%CI) 
Extended Cox model with 
TVE 
HR (95%CI) 
Age     
<50 years 0.89 (0.82-0.96) 0.89 (0.82-0.95) 0.92 (0.83-1.02) 0.92 (0.83-1.02) 
50-69 years Ref Ref Ref Ref 
70 years or older 1.34 (1.24-1.45) 1.36 (1.25-1.46) 1.30 (1.16-1.46) 1.26 (1.12-1.42) 
NHS region     
West Ref Ref Ref Ref 
North 1.11 (1.03-1.19) 1.11 (1.03-1.19) 1.13 (1.02-1.25) 1.11 (1.01-1.23) 
South East 1.00 (0.93-1.07) 0.99 (0.92-1.06) 1.04 (0.93-1.15) 1.02 (0.91-1.13) 
Year of diagnosis     
1997-2001 Ref Ref Ref Ref 
2002-2006 0.80 (0.74-0.85,) 0.79 (0.74-0.85) 0.83 (0.75-0.92) 0.83 (0.75-0.93) 
2007-2011 0.69 (0.64-0.74) 0.69 (0.64-0.74) 0.71 (0.63-0.79) 0.71 (0.63-0.79) 
2012-2016 0.73 (0.66-0.81) 0.73 (0.66-0.81) 0.83 (0.73-0.94) 0.83 (0.73-0.95) 
Grade     
Grade I-(Well) differentiated Ref Ref Ref Ref 
Grade II- Moderately (well) differentiated 1.80 (1.61-2.02) 1.95 (1.58-2.41) 3.08 (1.77-5.37) 2.91 (1.67-5.08) 
Poorly differentiated 3.14 (2.79-3.53) 4.94 (3.99-6.11) 4.03 (2.33-6.98) 3.76 (2.17-6.52) 
TNM stage     
I Ref Ref Ref Ref 
II 2.20 (2.00-2.42) 2.70 (2.27-3.22) 1.88 (1.63-2.16) 2.86 (2.29-3.57) 
III 5.51 (4.99-6.08) 8.44 (7.05-10.10) 6.03 (5.23-6.96) 12.07 (9.59-15.18) 




Appendix Table C.6 (continued) Comparison of traditional and extended Cox models with TVE for ER+ and ER- tumours (separately) 
diagnosed from 1997 to 2016 (page 2 of 3) 
 ER+ no. cases=42,146 no. failures=5,238 ER- no. cases=9,105 no. failures=2,378 
 
Traditional Cox model 
HR (95%CI) 
Extended Cox model 
with TVE 
HR (95%CI) 
Traditional Cox model 
HR (95%CI) 
Extended Cox model with 
TVE 
HR (95%CI) 
Screening     
Yes Ref Ref Ref Ref 
No 1.66 (1.51-1.82) 2.33 (1.98-2.74) 1.60 (1.37-1.86) 1.60 (1.37-1.86) 
Surgery     
Yes Ref Ref Ref Ref 
No 4.55 (4.14-5.00) 4.09 (3.71-4.51) 4.41 (3.81-5.10) 3.98 (3.42-4.62) 
Radiotherapy     
Yes Ref Ref Ref Ref 
No 0.97 (0.91-1.03) 1.15 (1.04, 1.27) 1.19 (1.09-1.30) 1.51 (1.32-1.73) 
Chemotherapy     
Yes Ref Ref Ref Ref 
No 0.87 (0.81-0.94) 1.08 (0.96-1.21) 1.28 (1.14-1.43) 1.58 (1.35-1.85) 
Hormone therapy     
Yes Ref Ref   
No 1.50 (1.36-1.64) 2.20 (1.90-2.56)   
SIMD quintile     
Least deprived Ref Ref Ref Ref 
4 1.03 (0.95-1.12) 1.03 (0.94-1.12) 1.04 (0.91-1.18) 1.04 (0.91-1.19) 
3 1.07 (0.99-1.17) 1.08 (0.99-1.17) 1.21 (1.07-1.38) 1.21 (1.07-1.38) 
2 1.18 (1.08-1.28) 1.17 (1.08-1.28) 1.23 (1.08-1.41) 1.23 (1.08-1.40) 
Most deprived 1.26 (1.15-1.38) 1.26 (1.15-1.38) 1.20 (1.04-1.38) 1.19 (1.04-1.37) 
Charlson Score     





Appendix Table C.6 (continued) Comparison of traditional and extended Cox models with TVE for ER+ and ER- tumours (separately) 
diagnosed from 1997 to 2016 (page 3 of 3) 
 ER+ no. cases=42,146 no. failures=5,238 ER- no. cases=9,105 no. failures=2,378 
 
Traditional Cox model 
HR (95%CI) 
Extended Cox model 
with TVE 
HR (95%CI) 
Traditional Cox model 
HR (95%CI) 
Extended Cox model with 
TVE 
HR (95%CI) 
TIME-VARYING EFFECTS     
Screening*time     
No  0.95 (0.93-0.97)   
TNM stage*time     
II  0.97 (0.95-0.99)  0.90 (0.86-0.94) 
III  0.93 (0.90-0.95)  0.82 (0.77-0.86) 
IV  0.76 (0.73-0.80)  0.69 (0.62-0.77) 
Grade*time     
Grade II- Moderately (well) differentiated  0.99 (0.96-1.02)   
Poorly differentiated  0.91 (0.89-0.94)   
Radiotherapy*time     
No  0.97 (0.95, 0.98)  0.91 (0.88-0.95) 
Chemotherapy*time     
No  0.96 (0.94-0.97)  0.93 (0.89-0.97) 
Hormone therapy*time     
No  0.92 (0.89-0.95)   
Footnote: Models are adjusted for age, incidence year, NHS region, grade, TNM stage, method of detection, surgery, radiotherapy, chemotherapy, hormone therapy (only for ER+ 
model), SIMD and Charlson score index. Models carried out in the complete case dataset separately by ER status. All HRs were statistically significant at the 0.1% level unless 
stated otherwise. CI= confidence interval, ER= oestrogen receptor, HR= hazard ratio, NHS= National Health Service, Ref= reference category, SD= standard deviation, SIMD= 




Appendix C.7 Sensitivity analysis: traditional and extended Cox models with TVE for luminal A and luminal B subtypes (2009-2016)  
Appendix Table C.7 Comparison of traditional Cox model and extended Cox models with time-varying covariates effects for luminal A 
and luminal B tumours (page 1 of 3) 
 Luminal A no. cases=13,755 no. failures=723 Luminal B no. cases=9,105 no. failures=2,378 
 
Traditional Cox model 
HR (95%CI) 
Extended Cox model 
with TVE 
HR (95%CI) 
Traditional Cox model 
HR (95%CI) 
Extended Cox model with 
TVE 
HR (95%CI) 
Age     
<50 years 0.65 (0.53-1.01) 0.75 (0.55-1.03) 1.06 (0.87-1.30) 1.03 (0.84-1.26) 
50-69 years Ref Ref Ref Ref 
70 years or older 1.48 (1.28-2.16) 1.67 (1.29-2.16) 1.41 (1.15-1.74) 1.39 (1.13-1.71) 
NHS region     
West Ref Ref Ref Ref 
North 1.13 (0.94-1.65) 1.26 (0.95-1.67) 1.33 (1.11-1.61) 1.29 (1.07-1.56) 
South East 0.90 (0.73-1.28) 0.96 (0.73-1.27) 1.06 (0.88-1.28) 1.06 (0.88-1.28) 
     
Year of diagnosis     
2009-2011 Ref Ref Ref Ref 
2012-2016 1.05 (0.99-1.12) 1.06 (0.99-1.13) 1.05 (1.00-1.11) 1.06 (1.01-1.11) 
TNM stage     
I Ref Ref Ref Ref 
II 2.02 (1.41-2.88) 2.03 (1.42-2.91) 3.10 (2.23-4.30) 5.96 (2.87-12.34) 
III 4.78 (3.25-7.02,) 4.83 (3.29-7.11) 7.53 (5.38-10.54) 22.16 (10.63-46.19) 
IV 11.33 (7.62-16.85) 11.45 (7.69-17.04) 17.50 (11.88-25.77) 66.70 (30.68-145.01) 
Screening     
Yes Ref Ref Ref Ref 






Appendix Table C.7 (continued) Comparison of traditional Cox model and extended Cox models with time-varying covariates effects for 
luminal A and luminal B tumours (page 2 of 3) 
 Luminal A no. cases=13,755 no. failures=723 Luminal B no. cases=9,105 no. failures=2,378 
 
Traditional Cox model 
HR (95%CI) 
Extended Cox model 
with TVE 
HR (95%CI) 
Traditional Cox model 
HR (95%CI) 
Extended Cox model with 
TVE 
HR (95%CI) 
Surgery     
Yes Ref Ref Ref Ref 
No 7.60 (5.72-10.11) 7.78 (5.85-10.34) 3.94 (3.09-5.01) 3.73 (2.91-4.78) 
Radiotherapy     
Yes   Ref Ref 
No - - 1.42 (1.16-1.73) 2.61 (1.88-3.63) 
Chemotherapy     
Yes Ref Ref Ref Ref 
No 0.67 (0.51-0.88) 0.68 (0.52-0.89) 1.90 (1.54-2.33) 4.29 (2.95-6.24) 
Hormone therapy     
Yes Ref Ref   
No 1.63 (1.14-2.32) 3.72 (2.13-6.47)   
SIMD quintile     
Least deprived Ref Ref Ref Ref 
4 0.97 (0.71-1.32) 0.97 (0.71-1.33) 0.97 (0.76-1.23) 0.95 (0.75-1.22) 
3 0.92 (0.68-1.25) 0.94 (0.70-1.27) 1.16 (0.92-1.48) 1.14 (1.07-1.45) 
2 1.27 (0.96-1.70) 1.30 (0.98-1.73) 1.17 (0.92-1.48) 1.15 (0.08-1.46) 
Most deprived 1.41 (1.03-1.92) 1.43 (1.05-1.95) 1.25 (0.98-1.61) 1.26 (0.98-1.62) 
Charlson Score     







Appendix Table C.7 (continued) Comparison of traditional Cox model and extended Cox models with time-varying covariates effects for 
luminal A and luminal B tumours (page 3 of 3) 
 Luminal A no. cases=13,755 no. failures=723 Luminal B no. cases=9,105 no. failures=2,378 
 
Traditional Cox model 
HR (95%CI) 
Extended Cox model 
with TVE 
HR (95%CI) 
Traditional Cox model 
HR (95%CI) 
Extended Cox model with 
TVE 
HR (95%CI) 
TIME-VARYING EFFECTS     
Screening*time     
No     
TNM stage*time     
II    0.81 (0.68-0.98) 
III    0.70 (0.58-0.85) 
IV    0.60 (0.48-0.75) 
Grade*time     
Grade II- Moderately (well) 
differentiated 
    
Poorly differentiated     
Radiotherapy*time     
No     
Chemotherapy*time     
No    0.80 (0.72-0.88) 
Hormone therapy*time     
No  0.73 (0.60-0.89)  0.73 (0.63-0.83) 
Footnote: Models are adjusted for age, incidence year, NHS region, grade, TNM stage, method of detection, surgery, radiotherapy (only for luminal B model), chemotherapy, 
hormone therapy (only for luminal A model), SIMD and Charlson score index. Models carried out in the complete case dataset separately by molecular subtype. CI= confidence 
interval, ER= oestrogen receptor, HR= hazard ratio, NHS= National Health Service, Ref= reference category, SD= standard deviation, SIMD= Scottish Index of Multiple Deprivation, 




Appendix C.8 Comparison of complete case analysis and multiple imputation 
results for IHC defined subtypes 
Appendix Table C.8 Traditional Cox model results from CCA and MIA with IHC defined 
subtypes as main exposure. Models in women diagnosed from 2009 to 2016 
 




 HR (95%CI) HR (95%CI) 
IHC defined subtype             Luminal A Ref Ref 
Luminal B 2.04 (1.83-2.28) 1.98 (1.79-2.19) 
HER2-enriched 1.95 (1.58-2.41) 1.73 (1.44-2.08) 
Triple Negative 3.93 (3.29-4.70) 2.86 (2.46-3.33) 
Age                                           <50 years 0.94 (0.83-1.07, p=0.350) 0.95 (0.85-1.05, p=0.304) 
50-69 years Ref Ref 
70 years or older 1.49 (1.33-1.67) 1.37 (1.24-1.51) 
NHS region   
West Ref Ref 
North 1.26 (1.13-1.40) 1.30 (1.19-1.42) 
South East 1.04 (0.94-1.16, p=0.462) 1.06 (0.97-1.16, p=0.170) 







TNM stage                                               I Ref Ref 
II 2.51 (2.10-3.00) 2.63 (2.25-3.09) 
III 7.26 (6.06-8.71) 6.97 (5.90-8.23) 
IV 14.72 (12.05-17.97) 14.29 (11.99-17.02) 
Screening   
Yes Ref Ref 
No 2.13 (1.78-2.53) 2.14 (1.84-2.49) 
Surgery   
Yes Ref Ref 
No 4.98 (4.37-5.68) 4.08 (3.67-4.53) 
Radiotherapy   
Yes   
No 1.05 (0.95-1.16, p=0.310) 1.07 (0.96-1.16, p=0.106) 
Chemotherapy   
Yes Ref Ref 
No 1.25 (1.11-1.40) 1.28 (1.15-1.42) 
Hormone therapy   
Yes Ref Ref 
No 1.85 (1.59-2.14) 2.28 (2.04-2.54) 
SIMD quintile   
Least deprived Ref Ref 
4 0.96 (0.83-1.10, p=0.536) 0.98 (0.87-1.10, p=0.718) 
3 1.11 (0.97-1.27, p=0.136) 1.13 (1.01-1.26, p=0.036) 
2 1.16 (1.01-1.32, p=0.035) 1.12 (0.99-1.25, p=0.051) 
Most deprived 1.29 (1.12-1.48) 1.34 (1.20-1.51) 
Charlson Score   
Mean (SD) 1.23 (1.08-1.40, p=0.001) 1.12 (1.01-1.25, p=0.031) 
Models are adjusted for age, incidence year, NHS region, grade, TNM stage, method of detection, surgery, 
radiotherapy, chemotherapy, hormone therapy, SIMD and Charlson score index. All HRs were statistically 
significant at the 0.1% level unless stated otherwise CI= confidence interval, ER= oestrogen receptor, HR= hazard 
ratio, NHS= National Health Service, Ref= reference category, SD= standard deviation, SIMD= Scottish Index of 




Appendix C.9 Overall survival estimates by ER-grade and ER-stage combinations for all women diagnosed in Scotland from 1997 to 
2009 and by age groups 
Appendix Table C.9 Five and 10-year overall survival by ER status and grade for all women diagnosed in Scotland from 1997 to 2016 and 
by age groups 
 
ER STATUS GRADE <50 YEARS 50-69 YEARS 70 YEARS OR 
OLDER 
TOTAL 
5-year OS (95% CI) ER+ Low 94.0 (93.2, 94.6) 92.2 (91.8, 92.6) 67.7 (66.7, 68.8) 86.0 (85.6, 86.4) 
  
High 83.2 (81.9, 84.4) 81.7 (80.7, 82.7) 56.2 (54.2, 57.8) 75.8 (75.0, 76.5) 
 
ER- Low 81.2 (76.6, 85.0) 79.2 (76.3, 81.8) 54.4 (49.8, 58.8) 72.6 (70.4, 74.7) 
  
High 74.1 (72.2, 75.9) 71.6 (70.1, 73.1) 43.8 (41.3, 46.3) 66.4 (65.3, 67.5) 
10-year OS (95% CI) ER+ Low 85.9 (84.7, 87.0) 81.5 (80.7, 82.2) 40.1 (38.7, 41.4) 71.1 (70.5, 71.7) 
  
High 70.6 (68.8, 72.3) 66.9 (65.5, 68.3) 31.2 (29.3, 33.1) 59.1 (58.1, 60.1) 
 
ER- Low 71.3 (65.8, 76.2) 68.0 (64.4, 71.3) 33.6 (28.9, 38.4) 58.9 (56.2, 61.4) 
  
High 66.9 (64.7, 68.9) 62.2 (60.4, 63.9) 26.1 (23.6, 28.6) 55.9 (54.6, 57.1) 








Appendix Table C.10 Five and 10-year overall survival by ER status and stage for all women diagnosed in Scotland from 1997 to 2016 and 
by age groups 
 
ER STATUS STAGE <50 YEARS 50-69 YEARS 70 YEARS OR 
OLDER 
TOTAL 
5-year OS (95% CI) ER+ I 97.2 (96.5, 97.8) 95.0 (94.6, 95.4) 78.5 (77.0, 79.9) 92.2 (91.8, 92.6) 
  
II 92.2 (91.3, 93.1) 90.2 (89.5, 90.9) 66.1 (64.7, 67.5) 83.7 (83.1, 84.2) 
  III-IV 70.9 (68.9, 72.9) 65.5 (63.9, 67.1) 39.7 (38.0, 41.4) 57.2 (56.2, 58.2) 
 
ER- I 87.9 (85.1, 90.3) 88.9 (87.2, 90.4) 74.6 (70.0, 78.6) 86.4 (85.0, 87.7) 
  
II 82.6 (80.4, 84.6) 77.8 (75.9, 79.6) 52.6 (49.4, 55.7) 73.5 (72.1, 74.8) 
  III-IV 45.6 (41.7, 49.4) 40.1 (37.2, 43.0) 20.4 (17.6, 23.3) 35.5 (33.6, 37.3) 
10-year OS (95% CI) ER+ I 92.4 (91.2, 93.5) 86.7 (85.9, 87.4) 52.8 (50.7, 54.9) 81.2 (80.5, 81.9) 
  
II 82.0 (80.6, 83.4) 77.5 (76.4, 78.5) 37.5 (35.9, 39.1) 66.8 (65.9, 67.6) 
  III-IV 55.3 (52.8, 57.6) 45.4 (43.6, 47.3) 17.7 (16.2, 19.2) 37.3 (36.2, 38.5) 
 
ER- I 81.7 (78.2, 84.7) 78.8 (76.3, 81.0) 48.9 (43.1, 54.6) 75.0 (73.0, 76.8) 
  II 74.6 (72.0, 77.1) 67.8 (65.5, 70.0) 31.6 (28.3, 34.8) 61.5 (59.9, 63.1) 
  
III-IV 38.5 (34.6, 42.4) 31.0 (28.1, 34.0) 10.1 (7.8, 12.6) 26.5 (24.7, 28.3) 




Appendix C.10 Results from Joinpoint regression for ER-grade and ER-stage combinations for the three age groups 
Appendix Table C.11 Estimates of 5-year breast cancer specific survival trends from joinpoint regression results by age, ER and grade 
combinations for all women diagnosed in Scotland from 1997 to 2011 






BCSS 1997 to 2011 
Period AAPC (95%CI) P value 
<50 years ER+ Low 93% 95% -2% Full period 0.1 (0.0, 0.3) 0.1318 
 
 
High 80% 88% 8% Full period 0.7 (0.4, 1) 0.0003* 
 
ER- High 72% 80% 8% Full period 0.4 (0.1, 0.8) 0.0186 
50-69 years ER+ Low 94% 98% 4% Full period 0.3 (0.2, 0.3) <0.0001* 
 
 
High 75% 90% 5% Full period 0.7 (0.5, 0.9) <0.0001* 
 
ER- High 69% 81% 12% Full period 1.1 (0.7, 1.5) 0.0001* 
70+ years ER+ Low 84% 89% 5% Full period 0.1 (-0.1, 0.3) 0.3500 
 
 
High 67% 71% 4% Full period 0.5 (0.1, 0.9) 0.0278 
 
ER- High 58% 66% 8% Full period 0.4 (-0.3, 1.1) 0.2445 
Bold results indicate the test was statistically significant at the 5% level. * Indicates that the p value is significant after correcting for multiple testing using Bonferroni correction, 
     𝛼 =
0.05
9




Appendix Table C.12 Estimates of 5-year breast cancer specific survival trends from joinpoint regression results by age, ER and stage 
combinations for all women diagnosed in Scotland from 1997 to 2011 






BCSS 1997 to 2011 
Period AAPC (95%CI) P value 
<50 years ER+ I 99% 98% -1% Full period 0.0 (-0.1, 0.1) 0.9186 
 
 
II 90% 93% 3% Full period 0.3 (0.1, 0.5) 0.0048 
 
 III-IV 70% 81% 11% Full period 0.4 (-0.1, 0.9) 0.1243 
 ER- I 88% 80% -8% Full period -0.1(-0.7, 0.6) 0.8341 
 
 
II 80% 90% 10% Full period 0.8 (0.4, 1.2) 0.0033 
 
 III-IV 53% 42% -9% Full period 0.3 (-1.1, 1.7) 0.7109 
50-69 years ER+ I 97% 99% 2% Full period 0.1 (0.0, 0.1) 0.0053 
 
 
II 90% 95% 5% Full period 0.4 (0.2, 0.5) 0.0001* 
 
 III-IV 61% 70% 9% 1997-2000 2.8 (1.2, 4.4) 0.0063 
 
     2000-2011 -0.2 (-0.8, 0.4) 0.4672 
 ER- I 87% 95% 8% 1997-2006 1.3 (0.7, 1.8) 0.0009* 
 
     2000-2011 -0.6 (-1.5, 0.3) 0.2335 
 
 
II 75% 85% 10% Full period 0.7 (0.3, 1.2) 0.0089 
 
 III-IV 38% 50% 12% Full period 1.4 (0.9, 1.9) 0.0002* 
70+ years ER+ I 97% 97% 0% Full period 0.2 (-0.1, 0.5) 0.1705 
 
 
II 82% 86% 4% Full period 0.3 (0.0, 0.5) 0.0434 
 
 III-IV 54% 52% 2% Full period -0.2 (-0.8, 0.5) 0.6222 
 ER- I 85% 86% 1% Full period 0.6 (-0.1, 1.3) 0.1291 
 
 
II 77% 77% 0% Full period 0.3 (-0.3, 0.9) 0.4010 
 
 III-IV 24% 37% 7% Full period 0.1 (-1.1, 1.2) 0.9323 








Appendix C.11  Five-year OS and BCSS probabilities (with 95% CI) by ER and 
grade combinations and by age group 
Appendix Figure C.9 Comparison of OS (left column) and BCSS (right column) by age, 
ER and grade combinations in women diagnosed from 1997 to 2011 in Scotland 
 
 
Shaded area represents the 95% CI around the estimate. Year of diagnosis in the graphs represents the middle 









Appendix C.12  Five-year OS probabilities (with 95% CI) by ER and stage 
combinations and by age group 
 
Appendix Figure C.10 Five-year OS by age, ER and stage combinations in women 
diagnosed from 1997 to 2011 in Scotland 
 
 
Shaded area represents the 95% CI around the OS estimate. Year of diagnosis in the graphs represents the 





Appendix C.13 Results from Joinpoint regression for ER-grade and ER-stage combinations for the three age groups 
Appendix Table C.13 Estimates of 5-year breast cancer specific survival trends from joinpoint regression results by screening, ER and grade 










BCSS 1997 to 2011 
Period AAPC (95%CI) P value 
Yes ER+ Low 96% 99% 3% Full period 0.1 (0.1, 0.2) 0.0009* 
 
 
High 82% 96% 14% Full period 0.3 (0.1, 0.5) 0.0207 
 




 2000-2011 0.0 (-0.5, 0.5) 0.9711 
 








 2004-2011 -0.2 (-1.0, 0.6) 0.6316 
No ER+ Low 93% 95% 2% Full period 0.2 (0.0, 0.4) 0.1439 
 
 
High 73% 84% 11% Full period 0.6 (0.4, 0.9) 0.0001* 
 
ER- Low 73% 89% 16% Full period 0.2 (-0.7, 1.2) 0.6488 
  
High 65% 77% 12% Full period 0.8 (0.3, 1.3) 0.0051* 








Appendix Table C.14 Estimates of 5-year breast cancer specific survival trends from joinpoint regression results by screening, ER and stage 
combinations for women aged 50 to 69 years (screening age) diagnosed in Scotland from 1997 to 2011 
Screening ER status Stage 
5-year BCSS 
in 1997 
5-year BCSS  
in 2011 
Difference 5-year 
BCSS 1997 to 2011 
Period AAPC (95%CI) P value 
Yes ER+ I 98% 100% 2% Full period 0.1 (0.0, 0.1) 0.0315 
 
 
II 88% 96% 8% Full period 0.2 (0.0, 0.4) 0.0410 
 
 III-IV 67% 89% 22% Full period 1.1 (0.4, 1.8) 0.0104 
 
ER- I 83% 97% 14% 1997-2004 1.8 (0.9, 2.8) 0.0042* 
 
     2004-2011 -0.0 (-0.5, 0.4) 0.8936 
 
 
II 91% 84% -6% Full period 0.4 (-0.4, 1.3) 0.3487 
 
 III-IV 56% 80% 24% Full period 3.2 (2.0, 4.3) 0.0001 
No ER+ I 96% 98% 2% Full period 0.2 (0.0, 0.3) 0.0443 
 
 
II 90% 95% 5% Full period 0.4 (0.2, 0.6) 0.0034* 
 
 III-IV 59% 64% 5% 1997-2002 3.2 (1.0, 5.3) 0.0182 
 
     2002-2011 -0.9 (-1.8, 0.0) 0.0671 
 
ER- I 91% 91% 0% Full period 0.4 (0.0, 0.8) 0.0918 
 
 
II 71% 85% 14% Full period 0.6 (0.1, 1.1) 0.0259 
 
 III-IV 35% 46% 11% Full period 1.0 (0.5, 1.6) 0.0019* 








Appendix C.14 Power and sample size calculations for Cox proportional hazards models. 
Appendix Table C.15 Power calculations for the proportional hazards models with BC survival for the rare subtypes as the outcome and 
deprivation or screening as the main exposure. 







dying from BC 
Postulated 
Hazard ratio 






(most vs least 
deprived) 
3103 521 0.45 0.17 1.2 0.05 0.54 
5000 840 0.45 0.17 1.2 0.05 0.75 
7500 1259 0.45 0.17 1.2 0.05 0.90 
TNBC SIMD quintile  
(most vs least 
deprived) 
1120 292 0.52 0.26 1.1 0.05 0.13 
5000 1303 0.52 0.26 1.1 0.05 0.40 
15000 3911 0.52 0.26 1.1 0.05 0.85 
HER2-enriched Mode of detection 
(non-screen vs screen 
detected) 
1285 283 0.81 0.22 1.8 0.05 0.97 
Numbers in bold represent the original sample sizes in the analysis. Numbers in red represent the estimates number of deaths that would be required to obtain the estimated power 
(also in red). Power calculations have been performed using ‘powerSurvEpi’ package [309] in R studio [310] which are based on the sample size formulas for the proportional hazards 




Appendix D Published article 
Link to access the article: https://www.nature.com/articles/s41416-020-0938-z 
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